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ABSTRACT 
 
Biochemistry textbooks define enzymes as being efficient and highly specific. However, 
these characteristics are usually associated with a lack of versatility, and therefore, an 
inability to evolve new functions. In spite of this, it is known that new enzymes can arise 
rapidly (such as when bacteria evolve antibiotic resistance). One hypothesis proposes that 
enzymes are actually promiscuous (Jensen, 1976); that is, they are able to carry out 
secondary reactions, in addition to the one they evolved to catalyze. The goal of this 
research was to explore the role that promiscuity plays in the origins and evolution of 
enzyme functions, using Escherichia coli as a model organism.  
 In the first part of this thesis, I report the discovery of two enzymes (alanine racemase 
and cystathionine ?-lyase) that are reciprocally promiscuous, and are dependent on the 
cofactor pyridoxal 5’-phosphate (PLP) for activity. In vivo, the cofactor-mediated 
promiscuous activities of alanine racemase and cystathionine ?-lyase were each successfully 
improved to near wildtype levels using directed evolution experiments. These results 
extend Jensen’s hypothesis, and led me to propose that PLP played a significant role in the 
evolution of new enzymes, in the primordial world.  
 In the second part of the thesis, I developed a comprehensive library-on-library screen 
to search for E. coli proteins that could mediate improved growth in environments 
containing either a foreign nutrient or a toxin. Proteins were over-expressed in an attempt 
to increase their weak, promiscuous activities, and to mimic the common genetic 
phenomenon of gene amplification. Over-expression of individual proteins conferred 
improved growth to the host cell in 35% of ~2,000 environments. The findings have 
important implications for understanding bacterial adaptation to new environments, such 
as when antibiotic resistance emerges. The ability of promiscuous proteins to drive the 
emergence of new phenotypes, when their expression is increased, validates the feasibility 
of the Innovation, Amplification and Divergence (IAD) model for the evolution of new 
genes (Bergthorsson et al., 2007). 
 Overall, the work described in this thesis demonstrates that protein promiscuity is 
common, though difficult to predict a priori. My experimental results are consistent with the 
work of others, in suggesting that promiscuous activities are evolvable. Together, the high 
frequency and evolvability of promiscuous proteins appear to underpin many different 
cellular innovations. 
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?
Introduction 
Life is shaped by networks of chemical reactions. Protein molecules called enzymes are 
responsible for accelerating thousands of these reactions, under biologically relevant 
conditions (e.g. in an aqueous environment with a near-neutral pH, at atmospheric pressure 
and temperatures below 100°C). In the absence of enzymes, these chemical reactions are 
unlikely to happen due to their unfavourable thermodynamics and/or kinetics. For 
example, orotidine 5’-phosphate (OMP) decarboxylase enhances the uncatalyzed rate of 
OMP decarboxylation by a factor of 1017 (Radzicka & Wolfenden, 1995; Callahan & Miller, 
2007). However, the evolutionary processes that give rise to, and optimize, such remarkable 
catalysts remain poorly understood.  
 New enzyme activities must arise as species adapt to changing environments. At the 
molecular level, the presence of novel nutrients or toxins can drive the evolution of new 
functions by imparting selection for enzymes that can recognize or metabolize these 
compounds (Hegeman & Rosenberg, 1970; Mortlock, 1984). Understanding the emergence 
of enzymes and metabolic pathways is important for learning about the past; that is, how 
extant organisms evolved to be what they are. Further, lessons from the past can allow 
predictions to be made about the future, such as predicting the routes by which antibiotic 
resistance may emerge in disease-causing bacteria. These “looking back” and “looking 
forward” perspectives on enzyme evolution will be explored in this thesis.  
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1.1 ORIGINS OF NEW FUNCTIONS AND METABOLIC PATHWAYS 
An early attempt to explain how new enzymes could evolve was provided by Norman 
Horowitz. He proposed a model of retrograde evolution, in which the depletion of a 
metabolite is the selection pressure for evolution of a new enzyme (Horowitz, 1945). 
Selection for this new enzyme is based on its ability to use an available precursor(s) to 
catalyze the formation of the required metabolite. For instance, once product A is exhausted 
(as the organism grows), it can be replenished from a closely related compound (precursor 
B) if a suitable enzyme E1 evolves (Figure 1.1). The depletion of precursor B will further 
drive the evolution of enzyme E2, which can synthesize compound B from precursor C. 
Hence, metabolic pathways evolve backwards. This evolutionary model surmises that both 
new and old enzymes must have similar binding specificities, as chemically related 
compounds are continuously being recruited into the pathway. Horowitz and Metzenberg 
(1965) further postulated that all enzymes involved in the same multi-step biosynthetic 
pathway are homologous — each enzyme located upstream in the pathway is most likely to 
have arisen by duplication and divergence from the immediate progenitor downstream in 
the pathway [enzyme E2 from E1; enzyme E3 from E2 in Figure 1.1]. 
 
      
Figure 1.1:  Horowitz’s model of retrogade evolution. 
A new enzyme (E1) emerges when a metabolite (product A) is exhausted by cellular consumption. The enzyme E1 
catalyzes the formation of the metabolite by recruiting a chemically-related compound (precursor B) as a substrate. 
The iterative process further suggests that the last enzyme (E1) in a metabolic pathway is the first to appear, and 
the first enzyme (E3) is the last to appear.  Figure adapted from Holliday et al. (2007). 
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 An example that appears to follow the retrogade evolution model is the enzymes from 
tryptophan biosynthesis. In bacteria, the enzymes phosphoribosylanthranilate isomerase 
(TrpF), indole-3-glycerol phosphate synthase (TrpC) and the ?-subunit of tryptophan 
synthase (TrpA) catalyze three sequential reactions to yield indole, the precursor for 
synthesizing tryptophan. The (?/?)8-barrel structures of the three enzymes are very similar 
to one another (Wilmanns et al., 1992), with an RMSD of ~1.0 Å for their superimposed main 
chains (Wilmanns et al., 1991). However, neither the enzymes before TrpF in the pathway 
(TrpE, TrpG and TrpD), nor the final enzyme (TrpB) are homologous (?/?)8-barrels. This 
suggests that Horowitz’s model may be an over-simplification.  
 In 1976, Roy Jensen pointed out that Horowitz’s hypothesis depended on the 
availability of chemically related metabolites in primordial cells (Jensen, 1976). 
Hypothetically, the cell would have to obtain each metabolic intermediate from its 
environment. This seemed highly unlikely, given the “extreme chemical lability of many 
intermediary metabolites, as well as by the barriers to their transport that may have existed 
in the absence of specialized transport systems” (Jensen, 1976). Instead, an alternative 
hypothesis of enzyme evolution was proposed, after taking the minimal gene contents in 
primordial cells into account (Y?as, 1974; Jensen, 1976). This hypothesis assumes that 
primitive enzymes possessed broad specificities for multiple substrates. Many pathways for 
synthesizing key metabolites could therefore exist in a patchwork fashion, albeit at a low 
level (Figure 1.2A). Genes for advantageous enzymes could be duplicated and then 
accumulate mutations that enabled them to provide increased levels of key metabolites 
(Figure 1.2B). The combination of broad-specificity enzymes and fortuitous chemical 
reactions could allow the production of key metabolites from novel intermediates, even if 
several enzymatic steps were required simultaneously (Jensen, 1976; Rison & Thornton, 
2002). This model is appealing, because such a “multitasking” strategy would allow the cell 
to cope with as many fluctuations as possible with a minimal number of enzymes (and 
therefore the smallest possible genome). 
 With its emphasis on enzymes with secondary activities, this model of patchwork 
evolution has also proven useful for explaining the on-going evolution of modern enzyme 
activities. A classic example is the emergence of a phosphotriesterase (PTE) enzyme in 
Pseudomonas diminuta (Lewis et al., 1988). PTE catalyzes the hydrolysis of synthetic 
organophosphate pesticides, particularly paraoxon. Although the bacterium first 
encountered these human-made compounds in the mid-20th century, PTE has evolved to 
have a catalytic efficiency (kcat/KM) for paraoxon hydrolysis that approaches diffusion-
limited ‘catalytic perfection’ [?107 s-1.M-1] (Omburo et al., 1992). The evolution of such an 
efficient catalyst took less than fifty years, as organophosphates were synthesized for the 
first time in the 1930s and the paraoxonase activity was discovered in the 1980s (Lewis et al., 
1988). Further studies suggested that PTE has evolved from an ancestor with lactonase 
activity, which might have been involved in quorum quenching (Afriat et al., 2006; Chow et 
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al., 2009). Consistent with Jensen’s model, it seems likely that this ancestor possessed a weak 
affinity for phosphotriesters such as paraoxon, even before this activity was selected for 
(Roodveldt & Tawfik, 2005; Afriat et al., 2006). Optimization of the enzyme’s affinity and 
activity towards a new substrate — paraoxon — became rapid after organophosphates were 
introduced into the environment. 
 
   
Figure 1.2:  Jensen’s model of patchwork evolution. 
(A) Primordial enzymes may favour one substrate and/or catalytic mechanism (solid arrows), but are capable of 
promiscuously catalyzing other reactions (dotted arrows). Therefore, many metabolite chains synthesizing key 
metabolites may have existed. (B) Duplication of any of these primordial enzymes would increase the production 
of key metabolites, thereby increasing the fitness of the cell. (C) Further enzyme specialization would account for 
extant pathways.  Figure taken from Holliday et al. (2007). 
 Similar to primordial enzymes, including the recent lactonase ancestor of PTE, many 
extant enzymes are now known to be promiscuous (see Section 1.3). O’Brien and Herschlag 
(1999) were the first to coin the term “catalytic promiscuity” to refer to enzymes that are 
able to catalyze different reactions. Another term, “substrate ambiguity” is used to describe 
the ability of enzymes to catalyze similar reactions on a range of different substrates 
(Khersonsky et al., 2006). However, for the sake of convenience, in this thesis I broadly 
define “promiscuity” as the ability of proteins (including enzymes) to perform any 
secondary functions that have not been selected for during their evolution to date. The key 
feature of promiscuous proteins is that they are not completely specific. Instead, they 
possess “hidden talents” (Copley, 2003), that manifest in the form of broad substrate 
specificities or weak secondary activities. As explained in Jensen’s model, these secondary 
activities or affinities are thought to act as starting points for the evolution of new functions 
(O'Brien & Herschlag, 1999; Copley, 2003; Khersonsky et al., 2006; Khersonsky & Tawfik, 
2010). 
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1.2 EVOLUTION OF NEW FUNCTIONS, FROM THE GENETIC PERSPECTIVE 
Jensen’s explanation for the evolution of new functions appears to be biochemically 
plausible. Yet, how can this model of enzyme evolution be reconciled with genetic 
mechanisms for the birth of new genes?  
 Fundamentally, new enzymes are the products of new genes. The primary source of 
novel genes is gene duplication and divergence from pre-existing ones (Lewis, 1951; Ohno, 
1970). Duplication supplies a redundant copy of the gene that is free from selective pressure 
for its original function. This allows previously “forbidden” mutations to accumulate, 
potentially leading to a new function. Kimura and Ohta (1974) went as far as to state that 
gene duplication must always precede the emergence of a new gene with a new function. 
This evolutionary route to functionally novel proteins is referred to as the classic neo-
functionalization model, or the model of Mutation During Non-functionality (MDN), and 
has been proposed as a fundamental process in adaptive evolution (Hughes, 1994).  
 The MDN model assumes that the newly duplicated gene is neutral until it acquires 
beneficial mutations or compensatory mutations that allow it to be selected (Ohta, 1988; 
Wagner, 2008). However, in the absence of selection, loss of the duplicate gene’s function is 
expected to be much more frequent than gain of a new function (Hughes, 1994; Wagner, 
1998). Common fates for the extra duplicate are loss via drift, inactivating mutations or 
recombinational segregation, and gene conversion, thereby resulting in the formation of 
pseudogenes (Walsh, 1995; Wagner, 1998). Hence, Force et al. (1999) proposed a 
subfunctionalization model that offers an alternative explanation for the maintenance of 
gene duplicates during the off-selection period. In this model, duplicate copies accumulate 
degenerate mutations, which partially damage the ancestral function of both genes to a 
point that neither could perform the original function well. This creates a selection pressure 
to maintain both subfunctionalized copies. While this strategy can buy time for the 
duplicated genes to remain in the population until selection starts to act on them, the 
likelihood of evolving a novel function is not clear. The reason is that the subfunctionalized 
(ancestral) function of the duplicates is still being selected, and therefore, neither of the 
genes is entirely free to acquire a new function.  
 Without selection, it seems unlikely that a duplicate gene could be maintained intact, 
at a high frequency in a population, until mutations accumulate and give it a new and 
selectable function. One way to maintain the duplicated gene is to assume that it remains 
under selection for its original function. However, by definition, this would limit its ability 
to lose its old function, as it gained a new one. This contradiction of the MDN model has 
been referred to as “Ohno’s dilemma” (Bergthorsson et al., 2007). 
 To address Ohno’s dilemma, Bergthorsson and his colleagues (2007) proposed the 
Innovation, Amplification and Divergence (IAD) model for the evolution of new genes. This 
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IAD model emphasizes a role for secondary functions (i.e., protein promiscuity), and 
invokes continuous selection during all processes from gene duplication and higher-order 
amplifications, to maintenance of the gene copies, to divergence of their functions. The 
model also predicts that gene amplification (as a means to increase gene dosage) is 
common, and this has been observed experimentally (Anderson & Roth, 1981; Andersson et 
al., 1998; Hendrickson et al., 2002). The three steps described by the model are as follows: 
 
(i) Innovation 
The parent gene encodes a primary activity that is being selected as well as a handful of 
minor activities that are neither under selection nor deleterious (Figure 1.3A). When the 
environment changes (e.g. by the introduction of a novel nutrient or toxin), one of the 
secondary activities becomes important and selection will favour an increase in its levels. 
(ii) Amplification 
Gene duplication and amplification events are at least four orders of magnitude more likely 
than point mutations (Bergthorsson et al., 2007). Amplification increases gene dosage, and 
therefore, the level of the secondary activity that is under selection. Since the secondary 
activity is valuable under the selective condition, there is selection pressure to maintain the 
extra gene copies in the population (Figure 1.3B). Under continuous selection, gene 
amplification relieves the new gene copies from having to retain their original function 
(provided at least one copy retains it). This amplification step solves the basic problem of 
Ohno’s dilemma.   
(iii) Divergence 
An increase in gene copies provides a higher number of targets for mutation and 
recombinational reassortment (Figure 1.3B). This increases the probability of improving the 
secondary activity of at least one gene copy, thereby relaxing the selection pressure on other 
copies. These extra copies can now be lost from the population via drift and inactivating 
mutations. On the other hand, the improved copy remains under selection for increasing its 
new activity. The original activity of the parental gene may (or may not) be maintained if it 
does not incur a fitness cost.    
 
 This IAD model is a testable hypothesis for the mechanism by which promiscuous 
activities drive the evolution of new genes. Its plausibility remains to be seen; yet, evidence 
that supports the different steps of the IAD model is emerging. This will be discussed in the 
following section. 
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Figure 1.3:  The IAD model of the evolution of new gene. 
See text for details. (A) The Innovation step. (B) The Amplification and Divergence steps.  Figure adapted from 
Bergthorsson et al. (2007). 
1.3 EXPERIMENTAL VALIDATION OF THE IAD MODEL 
Consistent with both Jensen’s model and the IAD model, a growing number of studies 
suggest that secondary activities are common in extant enzymes. Multicopy suppression 
studies are a powerful and tractable way of uncovering these promiscuous activities (Berg et 
al., 1988), and further demonstrating that adaptation can begin with the increased 
expression of promiscuous proteins. The latter is analogous to the gene amplification step 
described in the IAD model. Under selective conditions, elevated levels of promiscuous 
activities caused by increased gene dosage can provide a selective advantage to the cells. In 
multicopy suppression experiments, conditionally auxotrophic bacterial strains are typically 
transformed with plasmid-encoded open reading frames (ORFs) of interest, or plasmid-
encoded genomic libraries. The resulting clones, with each harbouring different plasmid 
constructs, are screened for genes that can suppress the phenotype of the original mutation. 
At the outset of this thesis, a handful of promiscuous proteins had been identified from 
these suppression screens, including four transaminases with overlapping substrate 
specificities (Berg et al., 1988), and an uncharacterized YjbQ protein that showed thiamine 
phosphate synthase activity (Morett et al., 2008). 
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 Many promiscuous activities are latent, and thus, they are not detectable unless their 
expression has been increased by using a strong promoter. To search for these latent 
activities, Miller and Raines (2004) constructed an E. coli genomic library in a plasmid with 
the T7 promoter. The authors then over-expressed the ORFs of the library in an auxotrophic 
E. coli strain that lacked the enzyme glucokinase, and was therefore a glucose auxotroph. 
Three suppressors were found: nanK, yajF and ycfX. Their gene products possessed weak 
glucokinase activity, although their activities were more than 104-fold lower than the 
endogenous bacterial glucokinase. Despite their ability to catalyze the glucokinase reaction, 
NanK, YajF and YcfX show only insignificant sequence identity (~7%) with E. coli 
glucokinase. This suggests that extant proteins with overlapping functions are not 
necessarily descendants of a single ancestral protein. 
 Non-homology-based promiscuity was further demonstrated by Patrick and his 
colleagues (2007). In their suppression screens, the authors made use of the E. coli ASKA 
and Keio libraries in an attempt to assess the prevalence of promiscuity, on a proteome-
wide scale. The ASKA library consists of a plasmid collection all E. coli ORFs cloned into an 
over-expression vector [pCA24N] (Kitagawa et al., 2005), whereas the Keio collection 
represents an E. coli mutant library consisting of all viable single-gene deletions (Baba et al., 
2006). The plasmids of the ASKA library were pooled, and used to transform 104 
conditionally auxotrophic, single-gene deletion strains from the Keio collection. Twenty-one 
of the auxotrophies were specifically suppressed by the over-expression of non-cognate E. 
coli proteins (Patrick et al., 2007). Among these, eight strains were rescued by non-
homologous suppressor enzymes that appeared to have weak activity, or affinities for the 
substrate, of the deleted enzyme. The overall implication from this study and that of Miller 
and Raines (2004) is that protein promiscuity is a feature of not only primordial enzymes, 
but also extant enzymes. This fulfils the innovation step of the IAD model, for the evolution 
of new functions from pre-existing activities. 
 In some cases, promiscuous enzymes do not simply replace the functions of deleted 
enzymes. They can catalyze unrelated reactions, provided these reactions bypass the step 
that is blocked by gene deletion (Desai & Miller, 2008). A recent suppression study showed 
that several proteins with promiscuous activities could be patched together to form a new 
bypass pathway for synthesizing the vitamin B6 cofactor (Kim et al., 2010). Promiscuous 
activities from three enzymes (and a non-enzymatic activity) diverted an intermediate from 
the serine biosynthetic pathway to a product that was subsequently incorporated in the 
cofactor biosynthesis pathway. The elegance of this work is two-fold: (i) promiscuous 
activities from extant enzymes are clearly contributing to metabolic and phenotypic 
robustness by providing an alternative pathway bypassing a blocked reaction; and more 
importantly, (ii) the patching of promiscuous activities typifies the evolution of new 
pathway as described by Jensen (1976). 
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 Finally, the IAD model assumes that secondary activities are evolvable, i.e., they can be 
readily improved by point mutations. In vitro evolution studies reveal that this is often the 
case. For example, the promiscuous lactonase and esterase activities of a PTE variant (also 
described previously in Section 1.1) could be improved with as few as one critical mutation 
[H254R] (Roodveldt & Tawfik, 2005). Two additional mutations (F306C and P342A) 
improved the esterase activity of PTE by two orders of magnitude, while decreasing the 
enzyme’s native paraoxonase activity only by a factor of three (Aharoni et al., 2005).  
 In a separate study, the in vivo TrpF (also described previously in Section 1.1) activity 
of E. coli PurF (glutamine phosphoribosylpyrophosphate amidotransferase) could be 
improved to almost wildtype levels using random mutagenesis (Patrick & Matsumura, 
2008). Yet, the in vitro TrpF activity of the evolved PurF variant was >107-fold less than 
wildtype TrpF. These results implied that even very weak promiscuous activities could 
provide immediate selective advantages for the cells.  
 The emerging consensus from in vitro evolution studies is that promiscuity is readily 
improved by incorporating a few mutations (and often, without compensating the native 
activity). Along with Jensen’s model, the IAD model appears to be a plausible route for the 
evolution of new enzymes. The models also suggest that protein promiscuity continues to 
play critical roles in the evolution of new enzymes. A comprehension of where and how 
new enzyme activities emerge will provide us with a better understanding of adaptive 
processes at the organismal level, as well as insights for biotechnological applications. 
1.4 AIMS OF THIS STUDY 
The goals of this research were to investigate how enzymes evolve, and where new 
enzymes originate from. The specific aims were:  
 
1. To explore patterns of overlapping promiscuity in non-homologous enzymes.  
Jensen’s model predicts that two proteins with overlapping patterns of promiscuous 
activities are likely to be homologues (i.e., descended from a common ancestor). However, 
there is an increasing number of examples in which a specialist enzyme (e.g. Glk, TrpF) and 
its promiscuous suppressor (Nan/YajF/YcfX, PurF) are not homologues (Miller & Raines, 
2004; Patrick & Matsumura, 2008). In Chapters 2 and 3, I will describe a novel case in which 
two non-homologous enzymes are reciprocally promiscuous. Biochemical studies and 
directed evolution experiments extend Jensen’s model, and confirm that cofactors can play 
a critical role in driving enzyme evolution. 
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2. To screen for promiscuous proteins that allow cells to adapt to novel environments.   
Current efforts are focused on discovering promiscuous proteins that can complement 
auxotrophies when other pre-existing enzymes are deleted (see Section 1.3). It has been 
hypothesized that promiscuous activities can also serve as the evolutionary starting points 
for the emergence of entirely new biochemical functions (Bergthorsson et al., 2007). 
However, the plausibility of this model has not been demonstrated experimentally, on a 
proteome-wide scale. In Chapters 4 and 5, the development of a comprehensive screen for 
promiscuous proteins is described. This screen was used to identify proteins that can enable 
improved growth when E. coli cells are exposed to novel nutrients and toxins. The results 
are presented in the context of the IAD model (Bergthorsson et al., 2007). 
 
 On the whole, the first part of this thesis (Chapters 2 and 3) is analogous to “looking 
backwards in enzyme evolution”, where I unravel the way evolution has shaped and 
optimized extant enzyme activities. The second part (Chapters 4 and 5) is about “looking 
forwards in enzyme evolution” — exploring the possible routes by which new functions 
may emerge in the future. These two themes (looking backwards and forwards in enzyme 
evolution) sum up this thesis.  
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CHAPTER 2 
?
Cofactor-mediated promiscuity in 
alanine racemase 
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2.1 INTRODUCTION 
Jensen (1976) has proposed that new catalytic functions can evolve from the secondary 
activities of pre-existing proteins. Enzymes that perform similar catalytic transformations 
therefore share significant sequence or structural homology because they have evolved 
from a shared ancestral scaffold. Examples include enzymes belonging to the same enzyme 
superfamily, such as those from the enolase and amidohydrolase superfamilies (Babbitt & 
Gerlt, 1997; Gerlt & Babbitt, 2001; Glasner et al., 2006). Despite catalyzing different overall 
reactions, members from the same superfamily share a common structural fold, and a 
common partial reaction, intermediate or transition state. 
 However, several studies have also shown that proteins with no significant homology 
can catalyze the same reaction. For example, James and Tawfik (2001) found that human 
serum albumin and a catalytic antibody (that had been raised against a diketone hapten) 
were able to catalyze the Kemp elimination of benzisoxazole. The affinity and activity for 
benzisoxazole appeared to stem from a reactive lysine and apolar patches in the active sites 
of both non-homologous proteins. In a separate study, the affinity for similarly 
phosphoribosylated substrates allowed E. coli PurF (glutamine 
phosphoribosylpyrophosphate amidotransferase) to catalyze the isomerization of 
phosphoribosylanthranilate, which is the reaction ordinarily catalyzed by TrpF 
(phosphoribosylanthranilate isomerase) (Patrick & Matsumura, 2008). In spite of the 
sequence and structural dissimilarities, E. coli ?trpF was rescued by the over-expression of 
PurF. This indicates that, unlike the Kemp elimination activity shown by the serum albumin 
and antibody (James & Tawfik, 2001), the promiscuous activity of PurF can be 
physiologically relevant in the absence of TrpF.  
 The TrpF activity of PurF is not a one-off example of molecular promiscuity by non-
homologous enzymes. A proteome-wide screen for promiscuous enzymes revealed that 21 
out of 104 single-gene deletion strains of E. coli were successfully rescued by one or more 
non-cognate E. coli genes (Patrick et al. 2007). In 30 of 41 cases, the suppressor gene and the 
deleted gene were unrelated. One particularly interesting case was the Alr/MetC 
combination — over-expression of Alr rescued E. coli ?metC on minimal medium 
supplemented with glucose. The expression of MetC, or cystathionine ?-lyase, is essential 
for E. coli growth on minimal media (Kim & Copley, 2007; Patrick et al., 2007), due to its role 
in cleaving C?-S bonds during methionine biosynthesis. On the other hand, Alr (alanine 
racemase) is involved in alanine biosynthesis and is not known to possess any C?-S bond 
cleavage activity. Alr is not a sequence or structural homolog of MetC, although both MetC 
and Alr are dependent upon the cofactor, pyridoxal 5’-phosphate (PLP), to be catalytically 
active. The implication was that the promiscuous MetC activity of Alr was mediated by 
PLP. However, at the outset of this study, it was unclear how this PLP-mediated chemistry 
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gave rise to promiscuous activity in non-homologous scaffolds. The aim of this study was to 
investigate the basis for the PLP-mediated promiscuity in Alr. 
2.1.1 THE PYRIDOXAL 5’-PHOSPHATE-DEPENDENT ENZYMES 
Pyridoxal 5’-phosphate (PLP; Figure 2.1) is the biologically active form of the vitamin B6 
cofactor. It has been dubbed the most versatile organic cofactor due to the catalytic and 
structural diversities associated with PLP-dependent enzymes (Schneider et al., 2000; 
Percudani & Peracchi, 2003). Generally, PLP-dependent enzymes catalyze reactions 
involving the C?, C? and C? atoms of amino acids, or compounds with an amino group. 
Examples of reactions catalyzed include transamination, ?,?-elimination, ?,?-elimination, ?-
decarboxylation, ?-replacement, ?-replacement, racemization and retro aldol cleavage. Since 
PLP-dependent enzymes are heavily involved in amino acid metabolism, it is not surprising 
that these enzymes are widespread among bacteria, archaea and eukaryotes. In prokaryotes 
alone, Percudani and Peracchi (2003) estimated that as many as 1.5% of all genes code for 
PLP-dependent enzymes. The same authors also reported that there were about 140 distinct 
PLP-dependent activities documented by the Enzyme Commission (EC), corresponding to 
~4% of all classified catalytic activities at that time.  
 
    
Figure 2.1:  The structure of PLP, and the carbon numbering used throughout the thesis. 
In the resting state, the PLP is bound to an active site lysine through an imine bond, forming an internal aldimine. 
 All PLP enzymes are classified according to their fold. It is widely accepted that there 
are five fold groups (Figure 2.2; Schneider et al., 2000), although a recent study has proposed 
two additional groups, as new structures have been reported that are unlike any other PLP-
dependent enzymes (Percudani & Peracchi, 2009). In this thesis, fold types I (MetC) and III 
(Alr) are of particular interest, and they will be discussed further throughout Chapters 2 
and 3. Overall, there is no correlation between the fold type and the reaction catalyzed (Eliot 
& Kirsch, 2004). The prevalence of different reaction types within each fold group suggests 
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that extant PLP-dependent enzymes have evolved multiple times over history (Christen & 
Mehta, 2001). However, despite the structural dissimilarities, all five scaffolds harbour a 
similar “phosphate-binding cup” subdomain for anchoring the PLP molecule in the active 
site (Denesyuk et al., 2002). 
 
    
Figure 2.2:  The five commonly accepted PLP-binding folds. 
Circles represented ?-helices, whereas triangles represented ?-strands. The ?-strands in indigo and ?-helices in 
yellow depicted the PLP-interacting domains. The ?-strands in blue and ?-helices in orange depicted other 
domains. The PLP cofactor bound to the catalytic lysine was shown in red. (A) Fold type I. (B) Fold type II. (C) Fold 
type III. (D) Fold type IV. (E) Fold type V.  Figure taken from Schneider et al. (2000). 
 The mechanistic features of catalysis are very similar in most PLP-dependent enzymes 
(except for glycogen phosphorylase from fold type V). This similarity is important in 
accounting for the diversity of PLP-dependent activities. Using serine as an example of a 
typical substrate, the possible outcomes catalyzed by PLP-dependent enzymes are 
illustrated in Figure 2.3. During the resting state, a PLP molecule is bound covalently to the 
?-amino group of a catalytic lysine in the active site as an internal aldimine (Figures 2.1 and 
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2.3). The amine group of an incoming substrate then replaces lysine to form an external 
aldimine. From this point onwards, the reaction routes diverge depending on the 
conformation of the imine complex that is formed (Figure 2.3). Generally, the bond 
perpendicular to the planar PLP-imine-?-system will be broken (Dunathan, 1966). For 
instance, the substrate is deprotonated if the C-H bond (coloured in red, Figure 2.3) is 
perpendicular to the PLP-imine-?-system. The resulting negative charge on the carbanion 
intermediate is delocalized throughout the conjugated ?-bonding system of PLP (Richard et 
al., 2009). Following this, two outcomes are possible for the deprotonated carbanion 
intermediate. In a racemization step, the intermediate is reprotonated at C?, on the opposite 
plane from which the initial proton was removed. Otherwise, a transamination reaction 
results from the protonation of the C4’ of the intermediate.  
 The substrate and reaction outcome for a PLP-dependent enzyme is largely dependent 
on the types of catalytic residues in the active site. As all PLP-dependent enzymes (except 
glycogen phosphorylase from fold type V) share the initial mechanistic steps (i.e., the 
formation of internal and external aldimines), the imperfect control of the reaction and 
substrate selectivities occasionally result in side reactions (Eliot & Kirsch, 2004).   
 
  
Figure 2.3:  The possible catalytic routes taken by PLP-dependent enzymes. 
A substrate example is serine, which is depicted on the left. In the first step of catalysis, the substrate displaces the 
catalytic lysine to form an external aldimine with PLP. The formation of the external aldimine is common in all 
PLP-dependent catalyses. Depending on the bond conformation and leaving groups (which are coloured 
differently), the possible catalytic routes are shown (in matching colours).  Figure taken from Toney (2011). 
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2.1.2 CYSTATHIONINE ?-LYASE (METC) 
MetC (EC 4.4.1.8) produces L-homocysteine from L-cystathionine in the penultimate step of 
methionine biosynthesis (Figure 2.4A). MetC has been identified as a potential antibiotic 
target, as its inhibition impacts overall protein synthesis and DNA synthesis (via the methyl 
donor, S-adenosylmethionine) in bacteria (Ejim et al., 2007). Unlike human MetC, 
prokaryotic MetC (and MetB, cystathionine ?-synthase) are parts of the reverse 
transsulfuration pathway that synthesizes methionine from cysteine (Wada & Takagi, 2006). 
In contrast, the transsulfuration pathway in humans converts methionine to cysteine. In E. 
coli, MetC is dispensable for growth on rich medium such as LB. In contrast, MetC is 
essential for growth on minimal medium supplemented with either glycerol or glucose as 
the carbon source (Joyce et al., 2006; Kim & Copley, 2007; Patrick et al., 2007). Similar to 
other methionine biosynthetic genes, the MetC expression in E. coli is negatively co-
regulated by the MetJ repressor and S-adenosylmethionine (Weissbach & Brot, 1991). 
 E. coli MetC is a tetrameric protein, with each monomer consisting of 395 amino acids 
(Figure 2.4B). Each monomer adopts a type I PLP-binding fold (Clausen et al., 1996) [also 
refer to Figure 2.2 in Section 2.1.1 for PLP-binding folds]. Within the active site of each 
monomer, one PLP molecule is bound to Lys210 (Belfaiza et al., 1986; Clausen et al., 1996). 
As with other enzymes of fold type I, the MetC enzyme has three functional domains. The 
N-terminal domain contributes to tetramerization, whereas the C-terminal domain consists 
of an anti-parallel ?-sheet with ?-helices on the solvent side. The middle domain harbours 
the PLP cofactor, which is found in a parallel seven-stranded ?-sheet covered by adjacent ?-
helices.  
 In addition to L-cystathionine, MetC also recognizes alternative substrates such as L-
cystine, L-cysteine, L-djenkolic acid, L-homolanthionine and L-meso-lanthionine (Uren, 1987). 
Degradation of L-cysteine to pyruvate, ammonia and hydrogen sulfite by MetC has been 
demonstrated using a crude cell extract (Awano et al., 2003), but kinetic measurements of L-
cysteine by purified MetC have remained a challenge so far. This is because the free thiol 
group of L-cysteine reacts with the coupling agent of the MetC assay (the assay details will 
be described in Sections 2.2.4.1 and 2.4.7.2). In the presence of a mild reducing agent 
(dithioerythritol), MetC was inhibited by excess L-cystine, and the maximal velocity with L-
cystine is only 1% of that with L-cystathionine (Uren, 1987). Although the intracellular level 
of cysteine must be carefully regulated to prevent cytotoxicity (Sørensen & Pedersen, 1991; 
Ohtsu et al., 2010), cysteine degradation in E. coli is also catalyzed by four other enzymes in 
addition to MetC, namely CysK (cysteine synthase A), CysM (cysteine synthase B), MalY (?-
cystathionase/negative regulator of maltose regulon) and TnaA (L-cysteine 
desulfhydrase/tryptophanase) (Awano et al., 2003; Awano et al., 2005). Thus, cysteine 
degradation by MetC is much less likely to be physiologically relevant than its role in 
methionine biosynthesis.  
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Figure 2.4:  The function and structure of MetC. 
(A) A simplified version of the methionine biosynthetic pathway in E. coli. MetC catalyzes the ?-elimination of 
cystathionine, producing homocysteine, pyruvate and ammonia. Homocysteine is then methylated to form 
methionine. (B) The ribbon diagram of MetC’s structure (PDB code: 1cl1), as reported by Clausen et al. (1996). Each 
monomer is shown in a different colour. Within each monomer, the PLP molecule bound to Lys210 is shown as 
sticks. Loops have been smoothed for clarity. 
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2.1.3 ALANINE RACEMASE (ALR) 
Alr (EC 5.1.1.1) is an important enzyme in a bacterial cell, due to its role in synthesizing cell 
wall components. Alr mainly isomerizes L-alanine to D-alanine [Figure 2.6A; (Lambert & 
Neuhaus, 1972)], although the enzyme also catalyzes the reverse reaction. Both alanine 
isomers are constituents of the tetrapeptide linker found in the peptidoglycan layer of 
bacterial cell wall (Figure 2.5). D-alanine is a critical component of the tetrapeptide chain 
due to its role in interpeptide crosslinking within the peptidoglycan layer. The absence of D-
alanine leads to a defective bacterial cell wall.  
 
    
Figure 2.5:  The peptidoglycan layer of E. coli.  
The sugar backbone consists of repeating units of N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM), 
which are linked by ?(1,4)-glycosidic bonds. Attached to every NAM residue is a tetrapeptide, which varies in 
different bacterial species. In E. coli, the tetrapeptide is L-Ala, D-Glu, meso-diaminopimelic acid (DAP) and D-Ala. 
An interpeptide bond links a DAP of one chain to D-Ala of the other chain.  Figure adapted from Cooper (2000). 
 Unlike L-alanine, the only biosynthetic source of D-alanine in bacteria comes from the 
catalytic activity of alanine racemase(s). In E. coli, there is an extra alanine racemase, DadX, 
in addition to Alr. While both Alr and DadX catalyze the same reaction, the regulation of 
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their expression is different. Alr is expressed constitutively in the cell, whereas DadX is 
repressible by glucose. E. coli cells with both their alr and dadX genes deleted can not 
survive, unless D-alanine is supplied exogenously (Strych et al., 2001). Similarly, Alr is 
essential for growth of mycobacterial species such as Mycobacterium tuberculosis, because 
they possess only one alanine racemase (Strych et al., 2001; Milligan et al., 2007). The 
essentiality of Alr in the biosynthesis of the bacterial cell wall renders it an attractive 
antibiotic target (Lambert & Neuhaus, 1972; LeMagueres et al., 2005). The absence of Alr 
homologues in humans also indicates that Alr inhibitors should have minimal clinical side 
effects (Strych et al., 2001). One of the clinical antibiotics used to treat tuberculosis is an Alr 
inhibitor, D-cycloserine (Koul et al., 2011). However, the use of D-cycloserine causes 
neurotoxicities, which appear to stem from non-specific binding of the drug to other PLP-
dependent enzymes in humans (Burman et al., 1999; Di Perri & Bonora, 2004). This has led 
to the call for new Alr inhibitors (Anthony et al., 2011), which are more specific to the 
enzyme but less toxic to patients. 
 
   
Figure 2.6:  The function and structure of Alr. 
(A) Alr catalyzes the interconversion of L-alanine and D-alanine. (B) The ribbon diagram of Alr’s structure (PDB 
code: 2rjg), as reported by Wu et al. (2008). The monomers are shown in blue and red. Within each monomer, the 
PLP molecule bound to Lys34 is shown as sticks. Loops have been smoothed for clarity. 
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 The native E. coli Alr protein is a dimer [Figure 2.6B; (Wu et al., 2008)]. Each monomer 
is composed of 359 amino acids, and its overall structure adopts a type III PLP-binding fold 
(refer to Figure 2.2 in Section 2.1.1 for PLP-binding folds). Two domains are found in each 
monomer: a N-terminal domain consisting of a (?/?)8-barrel, and a C-terminal domain 
consisting mainly of ?-strands. The core of the (?/?)8-barrel houses the active site, where 
the PLP cofactor binds covalently to Lys34. Proton transfer during alanine racemization is 
typically achieved by a catalytic lysine and a catalytic tyrosine (Watanabe et al., 1999). In E. 
coli Alr, Lys34 and Tyr255’ (primed number denotes a residue from the other monomer) 
were identified as the catalytic pair (Wu et al., 2008).  
 Similar to MetC, Alr is also known to catalyze secondary reactions. E. coli Alr can 
catalyze ?,?-elimination, as evident from the elimination of halide from suicide substrates 
such as ?-fluoroalanine, ?,?-difluoroalanine, ?,?,?-trifluoroalanine, ?-chloroalanine, ?,?-
dichloroalanine and 3-halovinylglycine (Wang & Walsh, 1978; Wang & Walsh, 1981; 
Thornberry et al., 1991). Alr from Geobacillus stearothermophilus was found to catalyze the 
transamination of both alanine isomers, albeit only once every 107 turnovers (Kurokawa et 
al., 1998). The rate of transamination activity was increased by ~7-fold when two conserved 
residues (Tyr265’ and Arg219) were mutated (Yow et al., 2003). In another study, Seebeck 
and Hilvert (2003) mutated Tyr265’ to Ala, and reported an increase of 105-fold increase in 
phenylserine aldolase activity. Taken together, these studies underline the intrinsic 
promiscuity of Alr, which can be easily accessed by non-synonymous mutations. However, 
the physiological and evolutionary implications of these promiscuous activities remain to 
be studied. 
2.1.4 FOCUS OF THIS CHAPTER 
I hypothesized that the promiscuous activity of Alr is responsible for rescuing the ?metC 
strain of E. coli. This promiscuous activity has not been demonstrated previously. Alr and 
MetC enzymes are unrelated in terms of their sequence, structure, reaction type, substrate 
choice and participation in biosynthetic pathways. In this chapter, I offer genetic and 
biochemical evidence to confirm the promiscuous MetC activity of Alr. I also show that this 
promiscuous activity of Alr can be improved by directed evolution. This substantiates the 
notion that promiscuous activities from non-homologous protein scaffolds are evolvable 
(Patrick & Matsumura, 2008). 
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2.2 RESULTS 
2.2.1 ALR OVER-EXPESSION RESCUED E. COLI ?metC 
All the results described in this chapter were built on the results reported by Patrick and his 
colleagues (2007). According to their results, the growth of E. coli ?metC mutant on glucose-
supplemented M9 medium was complemented by the over-expression of Alr. As this 
experiment was performed a while ago, and in a different laboratory, I set out to verify this 
phenotype. The growth complementation assays were set up based on the described 
methods (Patrick et al., 2007; Section 2.4.4). Instead of using their negative control plasmid 
(pCA24N-lacZ), a new negative control plasmid was constructed for this assay (pCA24N-
NoIns; Section 2.4.1). The pCA24N-NoIns plasmid does not carry any gene insert, and its 
vector backbone is essentially identical to all other ASKA plasmids (pCA24N).  
 First, E. coli ?metC cells were transformed with pCA24N-metC, pCA24N-alr and 
pCA24N-NoIns to form the positive control clone, test clone and negative control clone, 
respectively. It has been known that E. coli ?metC cells alone were unable to grow on 
glucose-supplemented M9 medium (Kim & Copley, 2007; Patrick et al., 2007). Likewise, no 
growth was observed for the negative control clone (E. coli ?metC harbouring pCA24N-
NoIns) plated on the IPTG-supplemented M9/glucose agar, even after 3 weeks of 
incubation at 28°C. The positive control clone (E. coli ?metC harbouring pCA24N-metC) took 
2 days to form full-sized colonies on the IPTG-supplemented M9/glucose agar. Full-sized 
colonies were defined as colonies with a diameter of at least 1 mm. Similar to the reported 
results (Patrick et al., 2007), the Alr-over-expressing clone took 5–6 days to form full-sized 
colonies. Although the cells were incubated at a lowered temperature [28°C instead of 30°C 
as reported by Patrick and co-workers (2007)], the growth patterns of the MetC- and Alr-
over-expressing clones, as well as the negative control clones were comparable to those 
previously reported (Patrick et al., 2007). All clones were grown on separate M9 agar plates 
to ensure that there was no cross-feeding. For every complementation assay, approximately 
103–104 cfu of each clone were plated on the selective M9 agar. The complementation assays 
were individually repeated to ascertain that the growth results were reproducible. An 
example of growth complementation assay is illustrated in Figure 2.7.  
  Every gene insert in the ASKA plasmids is fused to a (His)6 tag at the 5’ end, and a GFP 
tag at the 3’ end. As the GFP is a considerably large fusion protein (243 amino acids), it was 
not known if the promiscuous activity shown by the Alr-expressing clone (during growth 
complementation assays) was due to the Alr-GFP fusion. For this reason, the GFP tag was 
eliminated from pCA24N-alr, and the resulting plasmid was termed as pCA24N-alr(GFP?) 
[Section 2.4.2]. E. coli ?metC cells over-expressing the Alr(GFP?) protein took 3 days to form 
colonies, and by the fourth day of incubation, full-sized colonies were formed. The reduced 
amount of time for the formation of colonies suggested that the plasmid-encoded GFP fused 
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to the C-terminus of Alr had reduced the latter’s activity, possibly because the GFP hinders 
the access of the substrate to the active site. It was concluded that the GFP fusion tag did not 
endow promiscuous activity to Alr.  
 
      
Figure 2.7:  The growth of E. coli ?metC clones on IPTG-supplemented M9/glucose agar after 4 days of 
incubation at 28°C.  
Different clones were normally plated or streaked on separate agar plates. In this figure, different clones were 
streaked on the same agar plate for a comparative purpose. Each quadrant of the agar plate was streaked with the 
clone over-expressing the following plasmids (clockwise, from top left): (1) pCA24N-metC; (2) pCA24N-alr; (3) 
pCA24N-alr(GFP?); (4) pCA24N-NoIns. 
 For comparative purposes with the pCA24N-alr(GFP?) in subsequent growth 
complementation and enzyme activity assays, the GFP tag of the pCA24N-metC was 
eventually removed (Section 2.4.3). The resulting plasmid, pCA24N-metC(GFP?), was 
electroporated into E. coli ?metC to form the new positive control clone. Cells over-
expressing the MetC(GFP?) protein took only 1 day to form full-sized colonies on the IPTG-
supplemented M9/glucose agar. Similar to Alr, the removal of GFP tag from the MetC 
protein also reduced the incubation period required (from 2 days to 1 day) for colony 
formation. To facilitate subsequent protein purification via the immobilized metal affinity 
purification approach (Section 2.4.5), the (His)6 tags of both MetC and Alr proteins were 
retained. 
 No mutations were found in the alr inserts after sequencing the pCA24N-alr and 
pCA24N-alr(GFP?) plamids. This confirmed that the native Alr was sufficient to 
complement E. coli ?metC on M9/glucose agar. A summary of the growth patterns of 
different E. coli ?metC clones is presented in Table 2.1. 
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Table 2.1:  Summary of the growth complementation of E. coli ?metC and ?metE clones on M9/glucose 
supplemented with IPTG (50 μM). 
Over-expressed protein ?metC ?metC + L-methionine ?metE ?metE + L-methionine 
MetC 2 NT NT NT 
MetC(GFP?) 1–2 1–2 NT NT 
NoIns No growth 1–2 No growth 2 
Alr 5–6 NT NT NT 
Alr(GFP?) 3–4 1–2 No growth 2 
MetE NT NT 2 2 
 
Each value represents the number of days that each clone took to form colonies on the agar medium. NT, Not 
tested. 
2.2.2 E. COLI ?metC CELLS WERE STARVED FOR METHIONINE 
E. coli MetC has been shown to catalyze two reactions in vitro, depending on the substrates 
(Figure 2.8). MetC can catalyze either the degradation of cysteine (Awano et al., 2003), or the 
C?-S bond breakage of cystathionine to generate homocysteine, a precursor for synthesizing 
methionine (Uren, 1987). However, the physiological importance of both activities was 
unclear. In other words, it was not known whether the growth of E. coli ?metC on 
M9/glucose was limited by the accumulation of cysteine, or the lack of methionine, in the 
cells. My hypothesis was that the MetC deletion had impacted the methionine biosynthesis 
more than cysteine accumulation in E. coli. Therefore, the growth of E. coli ?metC on 
M9/glucose was likely to be limited by the lack of methionine in the cells. Understanding 
the growth limitation of the ?metC strain was important for determining whether Alr is 
involved in the methionine biosynthetic pathway, or the degradation pathway of L-cysteine. 
 To test the methionine auxotrophic state of the strain, the growth complementation 
assay was repeated with the M9/glucose agar that had been supplemented with L-
methionine (100 μM). Three clones of E. coli ?metC were tested: the positive control clone 
[pCA24N-metC(GFP?)], the test clone [pCA24N-alr(GFP?)] and the negative control clone 
(pCA24N-NoIns). As shown in Figure 2.9 (and also summarized in Table 2.1 in Section 
2.2.1), all three ?metC clones were able to grow on the methionine-supplemented 
M9/glucose agar. The rate of colony formation appeared to be identical among the clones, 
with full-sized colonies appearing after 1–2 days of incubation at 28°C. The confluent 
growth of the E. coli ?metC clones, especially the negative control (Plate 2 in Figure 2.9), 
appeared to be consistent with the initial assumption that methionine starvation was the 
limiting factor in the growth of the ?metC strain. In contrast, if cysteine accumulation were 
the factor that limited the growth of E. coli ?metC, the negative control clone would not have 
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been able to grow, even in the presence of exogenous methionine. These results confirmed 
my hypothesis that the in vivo promiscuous activity of Alr is likely to be involved in the 
methionine biosynthesis (e.g. the formation of homocysteine from cystathionine), instead of 
the breakdown of cysteine. 
 
   
Figure 2.8:  The catalytic activities of MetC with two different substrates, cysteine and cystathionine. 
In the first reaction, the MetC-catalyzed cysteine degradation is shown. In the second reaction, MetC converts 
cystathionine into homocysteine during the biosynthesis of methionine. 
 
Figure 2.9:  The growth of E. coli ?metC clones on M9/glucose agar containing 100 μM L-methionine and 50 μM 
IPTG after 2 days of incubation at 28°C.  
The numbered agar plates were streaked with E. coli ?metC harbouring the following plasmids: (1) pCA24N-
metC(GFP?); (2) pCA24N-NoIns; (3) pCA24N-alr(GFP?). 
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2.2.3  ALR OVER-EXPRESSION DID NOT RESCUE E. COLI ?metE 
I also considered another possibility, in which the promiscuous activity of Alr might 
produce the methionine via a novel metabolic bypass. In this case, over-expression of Alr 
would still be able to rescue the ?metC auxotroph on M9/glucose medium. In the final step 
of de novo methionine biosynthesis, a methyl group is transferred to the MetC-generated 
homocysteine via the activity of either the cobalamin-dependent MetH (homocysteine 
transmethylase) or the cobalamin-independent MetE (methionine synthase) [Figure 2.10]. If 
alr had encoded a bypass pathway for methionine biosynthesis, over-expression of the Alr 
would also rescue E. coli deleted for enzymes that catalyze the final step of the biosynthetic 
pathway.  
 
   
Figure 2.10:  The final step of de novo methionine biosynthesis in E. coli. 
The transfer of a methyl group to homocysteine can be catalyzed by either MetH or MetE. Both 5-methyl-THF and 
5-methyl-THG are methyl donors. THF, tetrahydrofolate; THG, tetrahydropteroyltri-L-glutamate. 
 Previous studies have shown that E. coli ?metH is able to grow on glucose (Kim & 
Copley, 2007; Patrick et al., 2007), due to a functional copy of metE in the cells. In contrast, 
the cobalamin-dependent MetH in the ?metE strain is unlikely to be functional due to the 
absence of cobalamin in the minimal medium. Hence, E. coli ?metE is unable to grow on the 
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M9/glucose medium, unless a plasmid-encoded MetE protein was provided (Patrick et al., 
2007). 
 Therefore, the ?metE strain (from the Keio collection) was transformed with pCA24N-
metE, pCA24N-NoIns and pCA24N-alr(GFP?) to form the positive control clone, the 
negative control clone and the test clone, respectively. The growth of the various ?metE 
clones was assessed on M9/glucose medium supplemented with IPTG. Figure 2.11A 
depicted the growth of different E. coli ?metE clones on M9/glucose medium containing 
IPTG. The ?metE strain was rescued by over-expressing the plasmid-encoded MetE, but not 
by the plasmid-encoded Alr or the empty vector. The agar plates were incubated at 28°C for 
up to one week, but no growth was observed for the Alr-expressing and the negative 
control clone by the end of incubation. The lack of growth for the ?metE clone harbouring 
the pCA24N-alr(GFP?) was also consistent with the previous observation — the ?metE 
mutation was not suppressed by other gene, except metE (Patrick et al., 2007). When the 
same set of the ?metE clones were plated on M9/glucose agar supplemented with 
methionine (and IPTG), full-sized colonies were observed for all clones after 2 days of 
incubation at 28°C (Figure 2.11B). Overall, the growth complementation results (tabulated 
in Table 2.1 of Section 2.2.1) supported the hypothesis that the in vivo promiscuous activity 
of Alr is the cystathionine ?-lyase activity that is normally catalyzed by MetC. 
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Figure 2.11:  The growth of E. coli ?metE clones on (A) M9/glucose alone; and (B) M9/glucose with L-methionine 
(100 μM) after 2 days of incubation at 28°C.  
All M9/glucose agar plates were supplemented with 50 μM IPTG. The numbered agar plates were streaked with E. 
coli ?metE harbouring the following plasmids: (1) pCA24N-metE; (2) pCA24N-NoIns; (3) pCA24N-alr(GFP?). 
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2.2.4 CYSTATHIONINE ?-LYASE ACTIVITIES OF METC AND ALR 
2.2.4.1 KINETIC ACTIVITIES OF CYSTATHIONINE ?-LYASE 
Throughout Sections 2.2.1 to 2.2.3, I present genetic evidence for the in vivo cystathionine ?-
lyase activity in E. coli Alr. The in vitro cystathionine ?-lyase activities of MetC and Alr are 
tested in this section.  
 E. coli ?metC was used as the host strain to over-express the MetC enzyme from 
pCA24N-metC(GFP?). For the Alr enzyme, E. coli MB2795 (?alr ?dadX; see Section I.3 in 
Appendix I) was used as the host strain. Each MetC subunit was fused to a 17-amino acids 
linker, including the (His)6 tag, at the N-terminus. Similarly, each Alr subunit was fused to 
the same linker at the N-terminus. Both MetC and Alr were largely soluble, and were (His)6-
tagged purified to >95% purity (see Section 2.4.5 for more details), as judged by SDS-PAGE 
(Figure 2.12). The molecular sizes of both MetC and Alr subunits were also verified by SDS-
PAGE (MetC, 45 kDa; Alr, 41 kDa). 
 
  
Figure 2.12:  SDS-PAGE analyses of the purified (A) MetC and (B) Alr. 
Each lane was loaded with a 6-μL aliquot from the corresponding fractions. Lane 1, Crude cell lysate after 6 hours 
of protein over-expression. Lane 2, Soluble lysate. Lane 3, Insoluble fraction. Lane 4, Proteins not bound to the 
Talon® metal affinity resin. Lanes 5 and 12, Bio-Rad Precision Plus protein All Blue standard. Lanes 6–7, Batch 
washes. Lane 8, Flow-through from the enzyme-bound resin in the gravity flow column. Lanes 9–10, Column 
washes with low imidazole concentration (3 mM). Lane 11, Column wash with high imidazole concentration (15 
mM). Lanes 13–18, Elution fractions 1–6. 
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 Both enzymes were dialyzed extensively to remove the reducing agent, ?-
mercaptoethanol, from the elution buffer (see Section 2.4.5 for the recipe of elution buffer). 
Thiol-containing compounds (such as ?-mercaptoethanol) interfere with the cystathionine 
?-lyase activity assay (see Figure 2.13 and Section 2.4.7.2 for details). After dialysis, the 
enzymes were quantified as described in Section 2.4.6. The yield of purified MetC always 
exceeded 18 mg/L of culture, whereas purified Alr always yielded more than 20 mg/L of 
culture. Throughout this study, at least 70% of either MetC or Alr were catalytically active, 
as defined by the ratio of the concentration of PLP-bound enzymes to the total enzyme 
concentrations (see Section 2.4.6 for details).  
 The continuous assay system that was described by Uren (1987) was modified and 
used to measure the cystathionine ?-lyase activity (refer to Section 2.4.7.2 for details). In this 
assay, a coupling agent [DTNB; 5,5’-dithiobis(2-nitrobenzoic acid); (Ellman, 1959)] is added 
to react with the product of the reaction, homocysteine [Figure 2.13]. One mole of TNB2- (2-
nitro-5-thiobenzoate dianion) is generated for every mole of homocysteine reacted with 
DTNB. Since the TNB2- ion absorbs strongly at A412, the increase of A412 can be used as a 
proxy to measure the rate of homocysteine formation. 
 
   
Figure 2.13:  The DTNB assay used to measure the in vitro cystathionine ?-lyase activity. 
The homocysteine produced by the cystathionine ?-lyase catalysis is reacted with DTNB, to form TNB2- (in blue). 
The TNB2- anion was measured spectrophotometrically at 412 nm, using an extinction coefficient of 14,150 M-1.cm-1. 
DTNB, 5,5’-dithiobis(2-nitrobenzoic acid); TNB, nitro-thiobenzoate. 
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 First, the kinetic parameters were determined for E. coli MetC. The KM for 
cystathionine was 39 ± 7 μM, whereas the kcat was 90 ± 14 s-1. The final values were the mean 
of three repeats, and each repeat was obtained from the average of duplicate assays. While 
the KM value was very close to that obtained by Uren (1987) [39 μM versus 40 μM], the kcat 
was approximately 2.5-fold higher than that reported by Lodha and Aitken (2011). Overall, 
the catalytic efficiency (kcat/KM) of MetC was 2.3 ? 10
6 s-1.M-1, which is about 10-fold higher 
than the catalytic efficiency reported by Lodha and Aitken (2011). The slight difference in 
the kcat and kcat/KM values between this study and Lodha and Aitken (2011) is likely due to 
the the higher temperature (37°C, instead of 25°C) used to assay the activity in this study.  
 No cystathionine ?-lyase activity was detected for Alr up to 10 mM L-cystathionine. 
The use of higher L-cystathionine concentration was not possible due to low solubility of L-
cystathionine (~5.6 mg/mL in 0.04 N HCl). The activity assays of Alr were also monitored at 
different temperatures (25°C, 30°C, and 37°C) for prolonged duration (30 min), but there 
was still no detectable cystathionine ?-lyase activity. The native activity of Alr (alanine 
racemization) was detectable (refer to Table 2.7 in Section 2.2.6.5), hence confirming that the 
purified Alr was not inactive. Throughout this study, the in vitro cystathionine ?-lyase 
activity of Alr could not be detected even with Alr aliquots purified from different batches. 
Overall, the kinetic parameters of the cystathionine ?-lyase activity in Alr could not be 
established using the steady state enzyme kinetics approach.  
2.2.4.2 ENDPOINT ASSAYS AND MASS SPECTROMETRY 
The undetectable cystathionine ?-lyase activity of Alr in the spectrophotometric assay was 
possibly due to an overall low catalytic turnover of L-cystathionine. The low substrate 
turnover could be explained by two scenarios: (i) the enzyme was assayed under non-
physiological conditions [Tris-HCl buffer (pH 8.8), lack of intracellular reducing agents, 
diluted enzyme and substrate concentrations, etc.]; and (ii) the enzyme’s activity and/or 
affinity for L-cystathionine was very low. Instead of measuring the rate of the cystathionine 
?-lyase activity in Alr within a short period of time (~30 min), I attempted to demonstrate 
the catalytic turnover of cystathionine by Alr using endpoint assays. 
 In the first instance, MetC (0.8 μM, final concentration) and Alr (5.1 μM, final 
concentration) were reacted with 5 mM L-cystathionine in 50 mM Tris-HCl assay buffer (pH 
8.8) for 16 h. A blank control containing no enzyme was also included. All reactions 
contained DTNB for detection of the product, homocysteine. The reactions were incubated 
in the dark, at 37°C. At the end of the incubation, MetC and Alr were removed from the 
reactions (see Section 2.4.8 for details).  
 Figure 2.14A shows the absorbance spectra of the enzyme-free reaction products. After 
a 16-h incubation, it was evident that the homocysteine produced by MetC had formed 
mixed disulfides with DTNB, and hence, generated TNB2- ions in the reaction. The TNB2- 
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ions gave a strong absorbance peak at 410 nm (purple line, Figure 2.14A). In contrast, no 
peaks at 410 nm were observed for Alr and the blank control. Instead, both reactions 
displayed an absorbance peak at 325 nm, which was attributed to unreacted DTNB (Figure 
2.14B). The in vitro cystathionine ?-lyase activity of Alr was still undetectable by endpoint 
assays alone.  
 
   
Figure 2.14:  The absorbance spectra of the endpoint reactions, and different components of the reactions. 
(A) The peak at 410 nm in the MetC reaction (purple line) was ascribed to the TNB2- ions, which had been 
generated from the sulfide interchange of DTNB by homocysteine, the product of the cystathionine ?-lyase activity. 
The peak at 325 nm in the Blank and Alr reactions was attributed to unreacted DTNB. (B) Freshly prepared DTNB 
generated a peak at 325 nm, which was similar to those observed previously in the Blank and Alr reactions. The 
assay buffer and L-cystathionine did not yield any absorbance peak from 220–600 nm wavelengths.  
 To determine whether Alr could turnover cystathionine in endpoint assays, the next 
logical step was to employ a more sensitive method of detecting the reaction products. 
Electrospray mass spectrometry was chosen for this purpose. For mass spectrometry 
analyses, the endpoint assays were repeated without DTNB. The Tris-HCl assay buffer was 
replaced with a NH4HCO3 buffer (see Section 2.4.8 for details). The reason was that the 
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NH4HCO3 buffer would evaporate as NH3 and CO2 when the samples were concentrated 
under vacuum, and hence, no buffer components would be detected in the mass 
spectrometer. Preliminary assays indicated that the use of NH4HCO3 buffer had no effect on 
the cystathionine ?-elimination activity — the initial rates (V0) of MetC activity with various 
concentrations of L-cystathionine in the NH4HCO3 buffer were similar to those performed in 
the Tris-HCl buffer (results not shown).  
 The mass spectra of the reaction products are shown in Figure 2.15. For the positive 
control in which MetC was added, homocysteine (observed mass, 135.04 Da; predicted 
mass, 135.18 g/mol) was observed as a dominant species (Figure 2.15B). No cystathionine 
(222.07 Da) was detected, thereby confirming that all cystathionine had been turned over by 
MetC. Zoomed-in areas of the spectra revealed that there was a small peak at 135 Da that 
corresponded to the mass of homocysteine, in the Blank, Alr and Alr+PLP reactions (Gill 
Norris, personal communication). However, the size of this peak in these reactions was 
similar, implying that no significant amount of homocysteine was formed in the reactions 
containing Alr and Alr+PLP. As the detection threshold of the mass spectrometer is in the 
range of femtomoles (Gill Norris, personal communication), and the amount of Alr was ~1 
nmole per reaction, the upper limit for Alr’s turnover of L-cystathionine was estimated to be 
<6.1 ? 10-8 per h per Alr molecule. This turnover rate seems too low to be physiologically 
relevant. It was possible that the in vitro assay conditions were too far from the in vivo 
conditions to accurately estimate the activity of Alr in vivo. 
 For the Alr reaction, two peaks were observed (Figure 2.15C). The peak at 222.07 Da 
corresponded to cystathionine (predicted mass, 222.26 g/mol), while the identity of the 
other peak at 133.02 Da remains unknown. These two peaks were also present in the Blank 
control and Alr reaction supplemented with 50 μM PLP (Figures 2.15A and D). The 
implications were: (i) the 133-Da species was related to the substrate (L-cystathionine) used 
in the reaction; and (ii) that adding excess PLP to the reaction did not increase the 
cystathionine ?-lyase activity of Alr. The appearance of the 133-Da species is intriguing, 
because no biological compound involved in either methionine or cysteine metabolism has 
a molecular mass of 133 Da. Several compounds related to methionine and cysteine 
metabolism in E. coli are O-succinyl-L-homocysteine (218 g/mol), succinate (118 g/mol), 
pyruvate (88 g/mol), methionine (149 g/mol), cysteine (121 g/mol) and homoserine (119 
g/mol). Due to the fact that the 133-Da compound was also present in the Blank, the 133-Da 
compound was likely a decomposed product, or an impurity, of L-cystathionine. The L-
cystathionine stock in our lab was of TLC-grade, and a reported purity of ~90% (Sigma). 
The 133-Da compound might have originated from the remaining 10% impurity. Curiously, 
this peak (at 133.02 Da) was reduced by ? in the MetC reaction, thereby suggesting that 
MetC could turnover this 133-Da impurity (Gill Norris, personal communication).  
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Figure 2.15:  Mass spectra of the reaction products from endpoint assays. 
(A) Blank control. (B) MetC. (C) Alr. (D) Alr + 50 μM PLP. The species with a m/z value of 135.04 corresponded to 
homocysteine (blue-boxed; panel B). The species with a m/z value of 222.07 corresponded to cystathionine (green-
boxed; panels A, C and D). The identity of the species with a m/z value of 133.02 (red-boxed; panels A, C and D) is 
not known.  
 Two compounds with a mass of 133 Da were inferred (Figure 2.16), based on logic and 
species searches from the National Institute of Standards and Technology (NIST) database 
(2011). The compounds were ?-keto-?-thiobutyric acid and aspartic acid, although it is not 
known if the former is of biological origin. Efforts in determining the identity of the 133-Da 
compound, and confirming whether it has been originated from L-cystathionine, are under 
way (Gill Norris, personal communication). 
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Figure 2.16:  Inferred compounds with a molecular mass of 133 Da.  
 
2.2.4.3 pH EFFECT ON THE CYSTATHIONINE ?-LYASE ACTIVITY OF ALR 
The in vitro cystathionine ?-lyase activity was assayed at alkaline pH, because the coupling 
reagent (DTNB) is highly stable in mildly alkaline conditions (Ellman, 1959; Riddles et al., 
1979). Furthermore, MetC and Alr are known to function optimally between pH 8–9 
(Dwivedi et al., 1982), and 8.5–11 (Esaki & Walsh, 1986; Kurokawa et al., 1998), respectively. 
Yet, the pH conditions where the promiscuous activity of Alr was observed during the 
growth complementation assays (Section 2.2.1) were likely to be near neutral or slightly 
acidic (due to accumulation of metabolic waste from cell growth). The disparity of the pH 
conditions between in vivo and in vitro assays prompted a preliminary study on the effect of 
pH on the promiscuous activity of Alr.       
 Figure 2.17 shows the effect of low pH on the in vitro activity assays for Alr. Each 
reaction was initiated by the addition of L-cystathionine (5 mM, final concentration) at t = 
0.5–0.8 min. Although the cystathionine ?-lyase activities were low (as depicted by the 
increasing slope of the activity curves), the overall trend suggested that they were 
detectable at low pHs. The biphasic curves also hinted at burst phase kinetics for the 
enzymes under these conditions. The amount of product that was produced during the 
putative burst phase was calculated from the total increase in absorbance over the range t = 
0.8–1.2 min (pH 6.0), and t = 0.85–1.4 min (pH 5.5). A total of 1.4 μM of product formed at 
pH 6.0, and 1.0 μM of product formed at pH 5.5. As expected for a burst phase, this is 
approximately the same as the total of Alr concentration (0.8 μM) in each assay; that is, ?c ? 
[E]T. The implication was that release of the spectrophotometrically active product 
(homocysteine) from the Alr active site was more rapid than the turnover of the enzyme. 
While preliminary, this interpretation is consistent with the hypothesis that the second 
reaction product, pyruvate, is released from the MetC active site after homocysteine 
(Clausen et al., 1996). However, the kinetics of Alr catalyzing the MetC reaction at low pH 
need to be investigated further, due to the instability of the enzyme in acidic conditions.  
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Figure 2.17:  The cystathionine ?-lyase activity of Alr assayed at pH 5.5 and 6.0. 
      
2.2.5 ENZYME ACTIVITIES OF ALR(R209E) 
The preliminary results in the previous section (see Figure 2.17) suggested that a low pH 
environment might be favourable to the cystathionine ?-lyase activity of Alr. This begged 
the question whether the protonation state of PLP was affected by pH changes. Therefore, I 
used site-directed mutagenesis to change a key residue in Alr that might alter the 
protonation state of PLP.  
 In Alr, the pyridine nitrogen of PLP has been regarded as a mechanistic determinant 
for the alanine racemase activity (Sun & Toney, 1999; Yow et al., 2003; Rubinstein & Major, 
2010; Griswold & Toney, 2011). Under physiological conditions, the L- to D-alanine 
racemization in E. coli Alr is achieved by the actions of a pair of catalytic base (Lys34 and 
Tyr255’) located at the opposite sides of the PLP-conjugated plane (Figure 2.18A). In 
principle, the substrate (L-Ala) displaces Lys34 to form an external aldimine with the PLP, 
and Tyr255’ abstracts a proton from the substrate. The resulting carbanion intermediate was 
then reprotonated by Lys34 on the opposite side to form D-Ala. The D-Ala product was 
subsequently released after being displaced by Lys34 to reform the internal aldimine with 
PLP.  
 In MetC, the negatively charged aspartic acid within the vicinity of the pyridine 
nitrogen ensures that the PLP is fully protonated (Figure 2.18C). The protonated pyridine 
ring plays a key role in stabilizing the negative charge developed at the C? after the 
formation of external aldimine (Figure 2.18B). However, the aspartic acid was replaced by a 
positively charged arginine in Alr. The arginine residue prevents full protonation of the PLP 
(Figure 2.18C), thereby negating the electrophilicity of the ?-bonding system. As a result, 
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after proton abstraction of the external aldimine, the carbanion intermediates (including the 
quinonoid species) are assumed to be highly unstable in Alr (Eliot & Kirsch, 2004). Yet, the 
unprotonated PLP feature has been proposed to aid in the control of reaction specificity in 
Alr by having intermediates with limited lifetime (Sun & Toney, 1999; Yow et al., 2003; 
Toney, 2005; Rubinstein & Major, 2010; Griswold & Toney, 2011). Computational 
simulations and pre-steady state studies have demonstrated that Alr mutants with 
relatively stable intermediates were likely to catalyze transamination, instead of 
racemization (Sun & Toney, 1999; Yow et al, 2003; Rubinstein & Major, 2010). 
 At the outset of this study, it was not known if the protonation state of the PLP was 
important for the cystathionine ?-lyase activity in Alr. Previously, an Arg219Glu mutation 
in G. stearothermophilus Alr resulted in protonated PLP, and consequently increased its 
transamination activity (Sun & Toney, 1999; Yow et al., 2003). To investigate the potential 
role of protonated PLP in increasing the cystathionine ?-lyase activity in E. coli Alr, the 
Arg209 residue (that interacts with the pyridine nitrogen) was similarly mutated to Glu. The 
alr insert with the R209E mutation was cloned into the GFP-deleted over-expression vector, 
pCA24N (Section 2.4.9), to form pCA24N-alr(R209E). In the first instance, the in vivo enzyme 
activities of Alr(R209E) were assessed prior to in vitro studies. 
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Figure 2.18:  The alanine racemization mechanism of Alr.  
(A) Proton abstraction and donation in alanine racemization are achieved by a pair of catalytic Lys and Tyr in the 
active site. (B) The formation of carbanion intermediates after the C? of the external aldimine is deprotonated. 
Species shown in brackets are resonance structures of carbanion intermediates. (C) The protonation state of the 
pyridine nitrogen of PLP in MetC, and the lack thereof in Alr.  Figure A was taken from Griswold and Toney 
(2011). Figures B and C were adapted from Eliot and Kirsch (2004). 
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2.2.5.1 THE IN VIVO ALANINE RACEMASE ACTIVITY OF ALR(R209E) 
Previous studies have reported that protonated PLP in G. stearothermophilus Alr led to a 
~1,000-fold decrease in its in vitro alanine racemase activity (Sun & Toney, 1999; Yow et al., 
2003), but its in vivo effect has not been demonstrated. In this section, I will evaluate the in 
vivo alanine racemase activity of Alr(R209E). 
  E. coli MB2795 (?alr ?dadX) is a D-alanine auxotroph (see Section I.3 in Appendix I), 
and its growth must be supplemented with D-alanine. This strain was transformed with 
pCA24N-NoIns, pCA24N-alr(GFP?) and pCA24N-alr(R209E) formed the negative control, 
positive control and test clone, respectively. As expected, the negative control did not grow 
on LB-chloramphenicol-IPTG agar (Plate 1 in Figure 2.19), even after 12 days of incubation 
at 28°C. In contrast, the positive control took 1 day to form full-sized colonies (Plate 3 in 
Figure 2.19). The growth of the Alr(R209E)-expressing clone, however, was worse than the 
positive control. Cells over-expressing Alr(R209E) grew only after 2–3 days of incubation 
(Plate 2 in Figure 2.19). Overall, the growth of the Alr(R209E)-expressing clone presented 
here is consistent with the previous, in vitro findings (Sun & Toney, 1999; Yow et al., 2003). 
The results also appeared to suggest that the R209E mutation had resulted in protonation of 
PLP, thereby reducing the racemization activity in Alr (Sun & Toney, 1999; Yow et al., 2003; 
Rubinstein & Major, 2010; Griswold & Toney, 2011). 
 
     
Figure 2.19:  Growth complementation assays of E. coli MB2795 clones on LB-chloramphenicol-IPTG after 5 
days of incubation at 28°C. 
The agar plates were streaked with E. coli MB2795 expressing [1] the empty vector (pCA24N-NoIns); [2] pCA24N-
alr(R209E) and [3] pCA24N-alr(GFP?).  
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2.2.5.2 THE IN VIVO CYSTATHIONINE ?-LYASE ACTIVITY OF ALR(R209E) 
Next, the in vivo cystathionine ?-lyase activity of Alr(R209E) was assessed, to determine if 
the activity was increased by the R209E mutation. The plasmids (pCA24N-NoIns, pCA24N-
alr(GFP?) and pCA24N-alr(R209E)] were introduced into E. coli ?metC to form the negative 
control, parental clone and test clone, respectively. The strain was also transformed with 
pCA24N-metC(GFP?) to form the positive control.  Similar to the results presented in 
Section 2.2.1, the MetC-expressing clone grew on M9/glucose-IPTG medium after 2 days of 
incubation at 28°C (Plate 2 of Figure 2.20A). The negative control did not grow, even up to 
12 days of incubation (Plate 1 of Figure 2.20A). While the Alr-expressing clone grew as 
expected (4–5 days; Plate 4 of Figure 2.20A), the Alr(R209E)-expressing clone barely grew 
after 6 days of incubation (Plate 3 of Figure 2.20A). This implied that the R209E mutation 
did not increase the cystathionine ?-lyase in Alr. Overall, the growth patterns of the 
Alr(R209E)-expressing clone indicated that the R209E mutation impeded both alanine 
racemase (Section 2.2.5.1) and cystathionine ?-lyase activity in Alr. 
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Figure 2.20:  Growth complementation assays of E. coli ?metC clones on M9/glucose-IPTG after 7 days of 
incubation at 28°C. 
All agar plates were supplemented with kanamycin and chloramphenicol. (A) The agar plates were streaked with 
E. coli ?metC expressing [1] the empty vector, pCA24N-NoIns; [2] pCA24N-metC(GFP?); [3] pCA24N-alr(R209E) 
and [4] pCA24N-alr(GFP?). (B) The M9/glucose agar supplemented with 100 μM L-methionine was streaked with 
E. coli ?metC expressing pCA24N-alr(R209E). 
2.2.5.3 THE IN VITRO ACTIVITY OF ALR(R209E) 
Results from the growth complementation assays (Section 2.2.5.2) demonstrated that the in 
vivo cystathionine ?-lyase activity of the Alr(R209E) mutant was worse than wildtype Alr. 
Hence, the possibility of detecting any cystathionine ?-lyase activity in Alr(R209E) using in 
vitro assay was very low. This is confirmed further in this section by the lack of activity in 
the purified Alr(R209E). 
 The Alr(R209E) was purified from E. coli MB2795 (?alr ?dadX), as previously described 
(Sections 2.2.4 and 2.4.5). The enzyme was largely soluble, and was purified to >95% purity, 
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as judged by SDS-PAGE (Figure 2.21). Consistent with the thick protein bands on the SDS-
PAGE, the yield of purified Alr(R209E) was high (~31 mg/L of culture). However, the 
absorbance spectrum of Alr(R209E) revealed that no peak was observed at 420 nm (where 
PLP absorbs strongly) [Figure 2.22], thus indicating that the purified enzyme was not PLP-
bound. In comparison, wildtype Alr [which had been purified simulatenously with 
Alr(R209E)] showed a peak at 420 nm (Figure 2.22) that corresponded to ~70% of PLP-
bound enzyme.  
 Nevertheless, the purified Alr(R209E) was added to in vitro assays in an attempt to 
measure its cystathionine ?-lyase activity. PLP was also added to the assays to reconstitute 
the apoenzymes. No activity was detected for Alr(R209E), with up to 10 mM L-cystathionine 
(results not shown). The lack of in vitro activity of Alr(R209E) was consistent with the low in 
vivo cystathionine ?-lyase activity of the Alr(R209E)-expressing clone (Section 2.2.5.2). The 
overall implication was that the R209E mutation might have prevented strong anchoring of 
the PLP in the active site, thereby resulting in the loss of the cofactor from the enzyme upon 
purification. Due to the lack of PLP, it was likely that a majority of the Alr(R209E) enzymes 
were catalytically inactive. 
 
    
Figure 2.21:  SDS-PAGE analyses of the purified Alr(R209E). 
Each lane was loaded with a 6-μL aliquot from the corresponding fractions. Lane 1, Insoluble fraction. Lane 2, 
Soluble lysate. Lane 3, Proteins not bound to the Talon® metal affinity resin. Lanes 4 and 11, Bio-Rad Precision Plus 
protein All Blue standard. Lanes 5–6, Batch washes. Lane 7, Flow-through from the enzyme-bound resin in the 
gravity flow column. Lanes 8–9, Column washes with low imidazole concentration (3 mM). Lane 10, Column wash 
with high imidazole concentration (15 mM). Lanes 12–19, Elution fractions 1–8. 
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Figure 2.22:  The absorbance spectra of purified Alr and Alr(R209E). 
The peak at 280 nm represents the total protein absorbance, whereas the peak at 420 nm represents the absorbance 
of PLP in the sample. 
2.2.6 IMPROVING THE CYSTATHIONINE ?-LYASE ACTIVITY OF ALR VIA 
DIRECTED EVOLUTION 
Since the in vitro cystathionine ?-lyase activity was undetectable in wildtype Alr and the 
R209E variant, in this section I will attempt to improve this activity to a level that can be 
detected spectrophotometrically. This approach can demonstrate the existence of the weak 
cystathionine ?-lyase activity in Alr (because enzyme activity can not be improved if there is 
no activity at all), and that this promiscuous activity is evolvable. 
 Random mutations were introduced into the alr gene using error-prone PCR (epPCR) 
(Cadwell & Joyce, 1992). Mutated alr genes were cloned into the pCA24N vector, and the 
ligated plasmids were subsequently introduced into E. coli ?metC. The mutant clones with 
higher in vivo cystathionine ?-lyase activity were selected based on their ability to grow 
faster on the M9/glucose medium than the parental clone with unmutated Alr.  
2.2.6.1 AN ALR LIBRARY GENERATED BY ERROR-PRONE PCR 
A library consisting of 3.4 ? 107 clones was constructed (see Section 2.4.10.1 for more 
details). A PCR screen of twenty unselected clones confirmed that the plasmid-encoded alr 
was present in each clone. These alr gene inserts were sequenced to obtain a general view 
on the mutational spectrum of the library (Table 2.2). A total of (20 sequences ? 1,077 bp) = 
21,540 bp were analyzed. Among these, 16 point mutations and 0 indel were found. The 
number of mutations found in each gene ranged from 0–4. In Table 2.2, it was apparent that 
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the mutational spectrum of the alr library biased towards G?N and C?N mutations. The 
number of G?N and C?N mutations was approximately twice as many as the number of 
A?N and T?N mutations. Overall, the average mutation rate was low (0.8 mutation per 
gene). This was advantageous for identifying beneficial mutations needed to improve low 
enzyme activity (Tracewell & Arnold, 2009). As most mutations are either deleterious or 
neutral, a high mutation rate would be more likely to yield false positives. 
 
Table 2.2:  The mutational spectrum of the error-prone alr library. 
Types of mutation Frequency Proportion of total 
Transitions   
A?G, T?C 1  6.3% 
G?A, C?T 8 50.0% 
Transversions   
A?T, T?A 3 18.8% 
A?C, T?G 1  6.3% 
G?C, C?G 2 12.5% 
G?T, C?A 1 6.3% 
Summary of bias   
Transitions/Transversions 1.3  N/A 
AT?GC/GC?AT 0.2 N/A 
A?N, T?N 5 31.5% 
G?N, C?N 11 68.8% 
Mutation per kb 0.7 N/A 
Mutation per alr gene (1,077 bp) 0.8 N/A 
 
N/A = not applicable. 
 PEDEL-AA was used to estimate the mutational diversity on an amino acid level of the 
alr library based on the DNA mutational spectrum (Firth & Patrick, 2008). The key 
characteristics of the library are summarized in Table 2.3. While it was previously calculated 
that the DNA mutation rate was 0.8 per gene, PEDEL-AA predicted an even lower amino 
acid substitution rate per protein (0.6 per variant). Therefore, it was estimated that up to 
~62% of the library consisted of unmutated Alr sequences. However, the Alr library was 
still considerably large (~1.3 ? 107 mutated variants), after the unmutated variants had been 
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subtracted from the total library size. Despite the low amino acid substitution rate per 
variant, the overall large library size rendered this Alr library suitable for subsequent 
experiment (Section 2.2.6.2).  
 
Table 2.3:  Summary of the key characteristics of the Alr library based on its DNA mutational spectrum. 
Property Estimate 
Total library size 3.4 ? 107 
Number of variants with no indels or stop codons 3.3 ? 107 
Mean number of amino acid substitutions per variant 0.6 
#Unmutated (wildtype) sequences (% of library) 61.8% 
#Number of distinct full-length proteins in the library 2.4 ? 106 
                
2.2.6.2 SELECTION OF ALR VARIANTS WITH IMPROVED IN VIVO METC ACTIVITY 
Having deemed the Alr library suitable for selection experiments, the library variants were 
selected using a more stringent growth complementation assay. Previously, all growth 
complementation assays were performed on M9/glucose medium supplemented with 50 
μM IPTG. When the IPTG concentration was reduced to 5 μM, the duration required for the 
parental clone [E. coli ?metC harbouring pCA24N-alr(GFP?)] to form colonies was extended 
to 12–13 days, instead of 3–4 days. Therefore, Alr variants with improved cystathionine ?-
lyase activity should form colonies faster than the parental clone.  
 E. coli ?metC was transformed with the pooled plasmids of the Alr library. A total of 
1.0 ? 108 clones were then plated on the selective medium and incubated at 28°C. The 
number of clones plated represented a ~3-fold over-sampling of the initial Alr library 
(which consisted of 3.4 ? 107 clones). This also corresponded to a sampling of 95.3% of the 
clones from the initial library [calculated by the library diversity and completeness 
programme, GLUE (Patrick et al., 2003)].  
 As expected, no growth was observed for the negative control (E. coli ?metC expressing 
pCA24N-NoIns) throughout the selection experiment. For the Alr library, approximately 
3,400 colonies had formed on the selective medium after only 2 days of incubation. In 
comparison to the parental clone (12-day growers), these Alr variants (2-day growers) 
represented a ~6-fold improvement in growth. Given that a total of 1.0 ? 108 clones were 
initially spread on the agar, the number of surviving Alr variants represented a survival 
rate of 0.003%. The growth rate of these Alr variants was also comparable with that of the 
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positive control (the MetC-expressing clone), which also took 2 days to form colonies. The 
growth of all E. coli ?metC clones on the selective medium (M9/glucose supplemented with 
5 μM IPTG) is tabulated in Table 2.4. Since the number of surviving clones was large, 48 
colonies were randomly picked for sequencing, in order to identify the mutations in their 
plasmid-encoded alr.  
 DNA sequences were obtained for 34 out of 48 clones. The sequencing chromatograms 
of the remaining 14 clones had overlapping peaks, which suggests the presence of mixed 
templates (i.e., mixed clones). Among these 34 clones, 32 clones harboured mutated alr, 
which could be classified into eight mutated variants (Table 2.4). The number of amino acid 
mutations ranged from 1–3 substitutions per clone. In particular, every clone harboured the 
Y274F substitution. The Alr-3 variant with a single Y274F mutation dominated the pool 
with a frequency of (25/32) = 78%. Other clones possessed 1–2 substitutions, in addition to 
Y274F. The prevalence of the Y274F mutation in all 32 clones suggested that it was likely to 
be a beneficial, rather than a neutral, mutation. Furthermore, I later showed in Section 
2.2.6.3 that the 2-day growth phenotype of these 32 clones was reproducible.  
 No DNA mutation was found in the plasmid-encoded alr in two clones, Alr-1 and Alr-
2 (results not shown). The rapid growth of Alr-1 and Alr-2 was likely to be caused by 
regulatory mutations, such as those in the T5-lacO promoter of the pCA24N vector (Patrick 
& Matsumura, 2008). I tested this possibility by recloning the unmutated alr insert of Alr-1 
and Alr-2 into fresh pCA24N vector (see Section 2.4.10.3 for details). Fresh E. coli ?metC was 
then used to retransform the newly ligated plasmids. Cells over-expressing the newly 
recloned, unmutated alr insert were unable to form colonies after 2 days of incubation at 
28°C (results not shown); instead, they grew only after 12 days of incubation, which was 
reminiscent of the growth of the parental Alr variant. This demonstrates that regulatory 
mutations were present in the original plasmid backbone of the Alr-1 and Alr-2 variants.  
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Table 2.4:  Summary of the selected Alr variants and their amino acid mutations. 
Variant Frequency Days to form colonies Mutation(s) 
Alr [Template] 12–13 None 
Alr-1* 1 2 None 
Alr-2* 1 2 None 
Alr-3 25 2 Y274F 
Alr-11  1 2 Y274F, A335T 
Alr-14  1 2 R266S, Y274F 
Alr-19  1 2 M29I, Y274F 
Alr-22  1 2 L241M, R263H, Y274F 
Alr-24  1 2 T97S, P252R, Y274F 
Alr-28  1 2 I242V, Y274F 
Alr-41  1 2 V150I, Y274F 
MetC [Positive control] 2 None 
NoIns [Negative control] No growth None 
 
*The growth phenotype of these clones was not reproducible upon recloning and retransformation tests. 
 A total of 10 amino acid substitutions were identified from the eight Alr variants 
described in Table 2.4. In seven of the mutated residues, the chemical property of the side 
chains remained similar. Examples include the T97S mutation, where both threonine and 
serine have a polar, uncharged side chain; as well as the V150I mutation, where both valine 
and isoleucine have a hydrophobic side chain. The three mutations with altered chemical 
property of the side chain were P252R (from hydrophobic to positively charged), R266S 
(from positively charged to polar and uncharged) and A335T (from hydrophobic to polar 
and uncharged). 
 The location of the mutated residues was mapped to the tertiary and quaternary 
structures of E. coli Alr (Figure 2.23). Of the 10 mutated residues, seven were located in the 
?-strands that populate the C-terminal domain (residues 232–359; Figure 2.23A). The 
remaining three mutated residues were buried in the core of the (?/?)8-barrel of the N-
terminal domain (residues 1–231; Figure 2.23A). Y274 is the only residue located within the 
vicinity of the active site, which is a cleft formed between the N-terminal and C-terminal 
domains from opposite monomers. Along with P252, Y274 was also likely to be on the 
dimerization surface. Other residues were located on the surface of the protein.  
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Figure 2.23:  The position of the mutated residues in the Alr structure. 
The mutated residues are mapped to the structure of E. coli Alr (PDB code: 2rjg). Each PLP molecule is coloured 
according to its elements, whereas each residue is coloured differently. (A) Ribbon diagram of an Alr monomer 
and the position of the mutated residues. Loops have been smoothed for clarity. (B) Surface diagram of an Alr 
dimer. The residues of both monomers are shown, and the residue numbering is given in the left panel. 
2.2.6.3 CONFIRMATION OF THE IMPROVED GROWTH PHENOTYPE OF ALR MUTANTS 
Retransformation and restreaking tests (see Section 2.4.10.3 for details) were used to confirm 
the growth phenotypes of the eight mutated clones (Alr-3, Alr-11, Alr-14, Alr-19, Alr-22, 
Alr-24, Alr-28 and Alr-41) that had been selected previously (Section 2.2.6.2). These tests can 
demonstrate that chromosomal mutations are not responsible for the rapid growth of the 
mutant clones. 
 Plasmids were isolated from these clones, and reintroduced into fresh E. coli ?metC 
cells. The retransformed clones were then grown on the same selective medium, 
M9/glucose supplemented with 5 μM IPTG. To further identify the most active Alr 
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variant(s) among the eight clones, the clones were also streaked on M9/glucose agar 
without IPTG.  
 All eight retransformed clones formed colonies on the IPTG-supplemented 
M9/glucose agar after 2 days of incubation. These phenotypes were consistent with the 2-
day growth phenotypes observed in the selection experiment (Section 2.2.6.2). By the third 
day, confluent growth was observed for all Alr variants on IPTG-supplemented 
M9/glucose agar, except for Alr-41 (Table 2.5; Figure 2.24). In particular, the Alr-41 variant 
did not manage to grow on the M9/glucose agar without IPTG. The growth of other clones 
varied greatly on the IPTG-less agar (Table 2.5; Figure 2.24). Therefore, the order of the in 
vivo cystathionine ?-lyase activity in these Alr variants was established as follows: Alr-3 > 
Alr-11, Alr-14, Alr-19, Alr-24 > Alr-22, Alr-28 > Alr-41. 
 Overall, these results confirmed that all eight Alr mutants could rescue the E. coli MetC 
auxotroph faster than the parental Alr clone. The implication was that these Alr variants 
expressed higher in vivo cystathionine ?-lyase activity.   
 
Table 2.5:  Summary of the growth of retransformed Alr mutant clones on selective media after 3 days of 
incubation. 
Variant Growth on M9/glucose agar + 5 μM IPTG 
Growth on M9/glucose 
agar alone 
Alr-3 ++++ ++++ 
Alr-11 ++++ +++ 
Alr-14 ++++ +++ 
Alr-19 ++++ +++ 
Alr-22 ++++ ++ 
Alr-24 ++++ +++ 
Alr-28 ++++ ++ 
Alr-41 ++ ? 
 
Key for scoring growth: (?) No growth; (+) Little growth. Colony size was <0.1 mm; (++) Considerable growth. 
Colony size was ~0.1 mm; (+++) Good growth. Colony size was 0.1–0.5 mm; (++++) Confluent growth. Colony size 
was >0.5 mm. 
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Figure 2.24:  The growth of retransformed Alr mutant clones on M9/glucose agar with and without 5 μM IPTG, 
after 3 days of incubation at 28°C. 
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2.2.6.4 THE PARENTAL ACTIVITY OF THE ALR MUTANTS  
In this section, I will test the in vivo alanine racemase activity of the eight Alr mutants. 
Previously, Alr variants with improved promiscuous activity have shown lower native 
activity (Seebeck & Hilvert, 2003; Yow et al., 2003). As a preliminary test to probe the degree 
of activity trade-off, I expressed each of the eight Alr variants in the D-Ala auxotroph, E. coli 
MB2795 (?alr ?dadX). The cells were grown on the selective medium, LB-chloramphenicol 
agar without D-Ala. No growth difference was noted for all eight Alr variants, regardless of 
the presence of IPTG (Table 2.6; Figure 2.25). Similar to the Alr-expressing clone, all clones 
expressing the mutated Alr variants formed full-sized colonies after 2 days of incubation at 
28°C. The results suggested that in vivo activity trade-off was minimal in these mutated Alr 
variants. 
 
Table 2.6:  Summary of the growth of E. coli MB2795 that expressed mutated Alr variants, on selective media 
after 2 days of incubation. 
Variant Growth on LB agar + 50 μM IPTG 
Growth on LB 
agar alone 
Alr-3 ++++ ++++ 
Alr-11 ++++ ++++ 
Alr-14 ++++ ++++ 
Alr-19 ++++ ++++ 
Alr-22 ++++ ++++ 
Alr-24 ++++ ++++ 
Alr-28 ++++ ++++ 
Alr-41 ++++ ++++ 
 
Key for scoring growth: (?) No growth; (+) Little growth. Colony size was <0.1 mm; (++) Considerable growth. 
Colony size was ~0.1 mm; (+++) Good growth. Colony size was 0.1–0.5 mm; (++++) Confluent growth. Colony size 
was >0.5 mm.  
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Figure 2.25:  The growth of E. coli MB2795 that expressed mutated Alr variants, on LB medium with and 
without 50 μM IPTG, after 2 days of incubation at 28°C. 
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2.2.6.5 KINETIC CHARACTERIZATION OF ALR-3 
After confirming the in vivo activities of the eight Alr mutants (Sections 2.2.6.3 and 2.2.6.4), I 
will test the in vitro activities in this section. Based on the growth complementation results 
(Section 2.2.6.3), the Alr variant with the highest in vivo cystathionine ?-lyase activity was 
Alr-3, which was followed by Alr-11, Alr-14, Alr-19, Alr-24. Thus, Alr-3 and Alr-19 were 
initially selected for protein purification and kinetic characterizations. 
 The Alr-3 and Alr-19 variants were over-expressed in E. coli ?metC strain. These 
enzymes were (His)6-tagged purified to >95% purity, as judged by SDS-PAGE (Figure 2.26). 
Similar to wildtype Alr, both Alr-3 and Alr-19 were highly soluble despite having 1–2 
amino acid substitution (Y274 for Alr-3; M29I and Y274F for Alr-19). The enzyme yields for 
Alr-3 and Alr-19 were 49 mg/L of culture and 68 mg/L of culture, respectively. The 
absorbance spectra of both enzyme variants revealed that ~82% of the Alr-3 enzymes, and 
75% of the Alr-19 enzymes, were bound to PLP. 
  
???? ??
Figure 2.26:  SDS-PAGE analyses of the purified (A) Alr-3 and (B) Alr-19. 
Each lane was loaded with a 6-μL aliquot from the corresponding fractions. Lane 1, Crude cell lysate before IPTG 
induction. Lane 2, Crude cell lysate after 6 hours of protein over-expression. Lane 3, Insoluble fraction. Lane 4, 
Soluble lysate. Lanes 5 and 13, Bio-Rad Precision Plus protein All Blue standard. Lane 6, Proteins not bound to the 
Talon® metal affinity resin. Lanes 7–8, Batch washes. Lane 9, Flow-through from the enzyme-bound resin in the 
gravity flow column. Lanes 10–11, Column washes with low imidazole concentration (3 mM). Lane 12, Column 
wash with high imidazole concentration (15 mM). Lanes 14–19, Elution fractions 1–6. 
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 Since Alr-3 displayed higher in vivo cystathionine ?-lyase activity than Alr-19 (Section 
2.2.6.3), the in vitro activities of Alr-3 were assayed in the first instance. Purified Alr-3 
showed detectable cystathionine ?-lyase activity, but the overall activity was low (<0.025 
turnover/s at 10 mM L-cystathionine for all six repeats, which were assayed on different 
days; Figure 2.27). The overall catalytic efficiency (kcat/KM) was 0.85 s
-1.M-1 (Table 2.7), which 
was ~2.7 ? 106-fold lower than that of MetC. The low kcat/KM value of Alr-3 was largely due 
to poor kcat (~10 turnover/h), rather than KM. In particular, the KM of Alr-3 for L-
cystathionine was only 85-fold higher than MetC (Table 2.7). In contrast, the kcat of Alr-3 was 
~32,000-fold lower than MetC. Although the E. coli ?metC clone that expressed Alr-3 was 
able to grow at the same rate as MetC-expressing clone (i.e., 2 days to form colonies on 
M9/glucose agar), the low in vitro activity of Alr-3 did not seem to reflect its in vivo activity. 
 As evident in Figure 2.27, the error bars from each pooled data points were rather 
large. Previously, I had considered a possibility that the data points might be better fitted 
with a linear regression, instead of a hyperbolic regression. Linear regression analyses have 
been used previously to determine the kcat/KM of low promiscuous activities in enzymes, 
which could not be saturated with substrates during in vitro assays (Patrick & Matsumura, 
2008; McLoughlin & Copley, 2008). When the data points of Figure 2.27 were fitted with a 
linear regression, the estimated kcat/KM of Alr-3 was 0.24 M s
-1.M-1, with a R2 value of 0.9283 
(not shown). The kcat/KM value produced by linear regression was rather close to the kcat/KM 
produced by hyperbolic regression (~3.5-fold difference). However, the R2 value of the 
linear fitting was slightly lower than that of the hyperbolic fitting (R2 = 0.9636, as shown in 
Figure 2.27). Therefore, it was deemed that the hyperbolic regression fitted better than the 
linear fitting, and the final kinetic parameters were derived from hyperbolic regression. 
 Since the in vitro cystathionine ?-lyase activity of Alr-3 was barely detectable, I did not 
proceed to assay the activities of Alr-19. Given that the in vivo cystathionine ?-lyase activity 
of Alr-19 was lower than Alr-3 (Section 2.2.6.3), the in vitro activity of Alr-19 was expected 
to be lower, and hence, more difficult to be detected than Alr-3.  
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Figure 2.27:  The cystathionine ?-lyase activity of Alr-3. 
The Michaelis-Menten plot was constructed using the mean ± S.E.M. from six data sets. L-Cth, L-cystathionine.  
 In addition, the native activity of Alr-3 and wildtype Alr was assayed 
spectrophotometrically to determine the degree of activity trade-off. The working principles 
of the racemase assay will be described in Section 3.2.3 (Chapter 3), and further details can 
be found in Section 2.4.7.1. Briefly, each racemase assay was coupled with NADH, which 
was oxidized by a coupled enzyme. The substrate for the coupled enzyme originated from 
the racemization of alanine. NADH oxidation was measured as a decrease in A340 over time.  
 In this study, the kcat and KM of the alanine racemization activity of Alr (see Table 2.7) 
were reasonably close to those of published data — Wu et al. (2008) has reported a kcat of 53 
s-1 and a KM of 1.0 mM for E. coli Alr. In comparison to Alr, a subtle decrease in kcat (~1.4-
fold) and a subtle increase in KM (~1.7-fold) were observed for Alr-3, thereby resulting in an 
overall ~2.5-fold decrease in kcat/KM (Table 2.7). The kinetic parameters of the alanine 
racemization activity of Alr-3 appeared to suggest that its Y274F mutation had minimal in 
vivo (Section 2.2.6.4) and in vitro activity trade-off. 
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 Table 2.7:  Kinetic parameters of MetC, Alr-3 and Alr. 
Cystathionine ?  Homocysteine + Pyruvate + NH3 L-Ala ?  D-Ala 
Enzyme 
kcat (s-1) KM (M) kcat/KM (s-1.M-1) kcat (s-1) KM (M) kcat/KM (s-1.M-1) 
MetC 89.5 ± 13.9 (3.9 ± 0.7) ? 10-5 2.3 ? 106 Presented in Chapter 3 
Alr-3 #(2.8 ± 0.3) ? 10-3 #(3.3 ± 1.0) ? 10-3 0.85 39.6 ± 4.7 (1.5 ± 0.6) ? 10-3 2.6 ? 104 
Alr †n.d. n.d. <0.85 55.3 ± 3.7 (8.7 ± 1.5) ? 10-4 6.4 ? 104 
 
Each value represented the mean ± S.E.M. (n = 3), and each value was the mean of duplicate assays.              
#The values represented the mean ± S.E.M. of six repeats.                    
†n.d., not determined. 
2.3 DISCUSSION 
2.3.1 PROMISCUITY IN NON-HOMOLOGOUS ENZYMES 
In this chapter, I demonstrated that the promiscuous activity of Alr was responsible for 
rescuing a methionine auxotroph, E. coli ?metC. In vitro characterization of Alr-3 (an 
evolved Alr variant) revealed that the enzyme was able to catalyze the cystathionine ?-lyase 
activity, the native function of MetC. Unlike other promiscuous activities of Alr such as 
transamination, aldol cleavage and ?,?-elimination (Wang & Walsh, 1978; Wang & Walsh, 
1981, Thornberry et al., 1991; Kurokawa et al., 1998; Seebeck & Hilvert, 2003; Yow et al., 
2003), the weak cystathionine ?-lyase activity was physiologically relevant in cells lacking 
MetC. This finding further emphasizes that promiscuous, pre-existing enzymes such as Alr 
can be recruited to catalyze functions in different metabolic pathways (Patrick & 
Matsumura, 2008; Kim et al., 2010). 
 Enzymes capable of catalyzing similar chemical transformations are usually 
descendants from a generalist ancestral enzyme, and hence, are sequence or structure 
homologues (Khersonsky & Tawfik, 2010). However, recent findings revealed that enzyme 
promiscuity could also exist in non-homologous enzymes (James & Tawfik, 2001; 
McLoughlin & Copley, 2008; Patrick & Matsumura, 2008; Kim et al., 2010). Results from this 
chapter further extend this line of reasoning. The lack of evolutionary relationship between 
Alr and MetC was evident from their minimal sequence and structural homologies. 
Pairwise alignment of protein sequences of E. coli Alr and MetC showed 9% sequence 
identity, whereas pairwise structural alignment of the Alr (input chain: 1sftA) and MetC 
(input chain: 1cl1A) using the DBAli algorithm (Martí-Renom et al., 2001) yielded a RMSD 
of 3.91Å over 54 residues. The overall structural alignment was interpreted as a lack of 
significant homology (P-value = 3.3; P-value >5.2 represents significant homology according 
to the algorithm).  
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 Although the tertiary and quaternary structures of Alr and MetC are non-homologous, 
I further compared the active sites of both enzymes to identify any overlapping regions. 
Using a ligand-based structural alignment approach (Heifets & Lilien, 2010), the PLP 
molecules were aligned with a RMSD of 2.67Å over 15 atoms. As shown in Figure 2.28C, the 
internal aldimines formed between the PLP and the catalytic Lys residues were pointed at 
opposite directions in the aligned active sites. Within the vicinity of the PLP molecules, the 
residues from both enzymes could not be superimposed. Despite sharing the same PLP 
cofactor, the active site structure of Alr was spatially different from that of MetC. It seems 
reasonable to argue that the promiscuous cystathionine ?-lyase activity of Alr could not 
have been predicted a priori based on sequence and structural comparisons alone.   
 
 
Figure 2.28:  Poor superimposition of the active site of E. coli Alr and MetC. 
The PLP molecules are illustrated in sticks, whereas the residues making up the active site are shown as lines. The 
catalytic Tyr is coloured purple in the active site of Alr (Tyr255’), and brown in the active site of MetC (Tyr111), 
respectively. (A) The active site of E. coli Alr. (B) The active site of E. coli MetC. (C) Structural alignment of the 
active site of Alr and MetC. Residues shown in the diagram are within 3.5Å of the internal aldimine. The alignment 
was performed using LigAlign, which aligns protein structures based on the ligand in the active site. The LigAlign 
software was interfaced to MacPymol to allow visualization of the alignment.  
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 The different active site structure of Alr also indicated that the mechanism of the 
cystathionine ?-lyase activity is likely to be different from the mechanism occuring in the 
active site of MetC. For instance, the pyridine ring of the PLP molecule in MetC was fully 
protonated by Asp185. To mimic the protonated state of PLP in MetC, a R209E mutation 
was introduced to protonate the pyridine ring of Alr. Instead of increasing the cystathionine 
?-lyase activity in Alr, growth complementation results indicated that the in vivo 
cystathionine ?-lyase activity of Alr(R209E) was worse than Alr (Section 2.2.5.2). The 
reduced in vivo activity might have been a result of the Alr(R209E) favouring the 
transamination activity. As demonstrated previously (Sun & Toney, 1999; Yow et al., 2003; 
Rubinstein & Major, 2010), a protonated PLP in Alr stabilized the quinonoid intermediate, 
which was otherwise highly unstable during alanine racemization. The stabilized quinonoid 
intermediate has been proposed to be critical for opening up possibilities for side activity 
such as alanine and ?-ketoglutarate transamination to produce pyruvate and glutamate 
(Toney, 2005; Rubinstein & Major, 2010).  
2.3.2 DIRECTED EVOLUTION OF ALR  
Promiscuous activities are barely detectable in vitro because they are often orders of 
magnitude lower than native activities (Copley, 2012). A simple approach to circumvent the 
low activity level is to improve the activity by directed evolution. The underlying principle 
of a directed evolution experiment is “you get what you select for”, and more importantly, 
it is unlikely to evolve an activity that is not already there (You & Arnold, 1996; Peisajovich 
& Tawfik, 2007). For instance, a previous study has shown that a 25-fold improvement of a 
promiscuous activity was sufficient to render the activity detectable using conventional 
spectrophotometric methods (Patrick & Matsumura, 2008). 
 The best-evolved Alr variant, Alr-3, was also the dominant variant from the selected 
pool. Cells expressing Alr with a single Y274F mutation grew most rapidly on the selective 
medium, thereby implying that its in vivo cystathionine ?-lyase activity was the highest 
among the Alr mutants (Section 2.2.6.3). The Y274F mutation was not only found in Alr-3, 
but also in the rest of the selected variants that carried 1–2 additional amino acid 
substitutions. The prevalence of the Y274F mutation suggested that Y274’ (primed number 
denotes a residue from the other monomer) is an important determinant for the 
cystathionine ?-lyase activity in Alr. Y274’ is located in the inner layer of the substrate 
entranceway of Alr, and is part of the active site (Figure 2.29). The residue is not known for 
taking part in the catalytic cycle of Alr, but it has been shown to interact with a stable 
aromatic adduct of D-cycloserine, a suicide inhibitor (Fenn et al., 2003; Wu et al., 2008). The 
aromatic adduct was a derivative of 3-hydroxyisoxazole pyridoxamine 5’-phosphate (PMP), 
of which its hydroxyimine formed a hydrogen bond with Y274’ in E. coli Alr (Figure 2.29A). 
This hydrogen bond hinted that Y274’ might interact with the substrate or product in the 
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active site. However, this hydrogen bond was likely to be abolished by a Y274F mutation, 
due to the lack of hydroxyl group in the side chain of F274’ (Figure 2.29B).  
 Therefore, the lack of a hydrogen bond between F274’ and the substrate or product 
was the likely factor in improving the overall cystathionine ?-lyase activity in Alr. It is not 
possible to determine if the catalytic improvement was due to changed substrate specificity 
or higher product turnover because no individual kinetic parameters (KM and kcat) were 
obtained for the cystathionine ?-lyase activity of Alr (Table 2.7 In Section 2.2.6.5). 
Hypothetically, if F274’ was responsible for altering the substrate preference of Alr-3, the KM 
for alanine (the substrate for the native activity) would be drastically increased. However, 
the KM for alanine shown by the Y274F variant was reduced by a mere 1.7-fold in 
comparison to wildtype Alr. In fact, the Y274F mutation did not seem to be too detrimental 
to the native activity of Alr, as the kcat/KM of the Y274F variant was only 2.5-fold lower than 
that of Alr.  
 
 
Figure 2.29:  The surface diagram of the active site of E. coli Alr. 
The 3-hydroxyisoxazole PMP and the catalytic pair (Lys34 and Tyr255’) are shown as sticks. The E. coli Alr bound 
to D-cycloserine (PDB code: 2rjh) was used as the template for modelling. (A) The Y274’ residue is highlighted in 
magenta. The distance between Y274’ and the hydroxyimine of the 3-hydroxyisoxazole PMP is 3.2Å. (B) The 
modelled mutated residue, F274’, is highlighted in grey. The distance between F274’ and the hydroxyimine of the 
3-hydroxyisoxazole PMP is 4.1Å. 
 Instead, I speculate that the inability of F274’ to form hydrogen bond is likely to 
facilitate higher product turnover in the active site. Clausen and his colleagues (1996) have 
proposed that homocysteine and iminopropionate (the products of cystathionine ?-lyase 
activity) were released in a two-step process. The details of the catalytic mechanism of MetC 
will be discussed in Section 3.3.2 (Chapter 3). Briefly, homocysteine is released after the 
protonation of S? of L-cystathionine by K210 in the MetC’s active site (Figure 3.15 in Section 
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3.3.2, of Chapter 3). The resulting intermediate (a PLP derivative of aminoacrylate) is 
reprotonated to release iminopropionate. Iminopropionate is then hydrolyzed to pyruvate 
and ammonia outside the active site. The same authors also proposed that either the C?-S 
bond cleavage (of homocysteine), or the second transaldimination step (to release 
iminopropionate) is rate limiting based on unpublished results. Therefore, it was possible 
that product release and the internal aldimine regeneration were faster in the Y274F variant 
due to the loss of hydrogen bond in anchoring the products. This speculation is also 
consistent with the in vitro cystathionine ?-lyase activity curves of Alr performed under 
near neutral pH conditions (Figure 2.17). Following the apparent burst phase, the plateau of 
each activity curve possibly reflects the rate-limiting step caused by iminopropionate 
release.   
 Although the Y274F variant was deemed the best-evolved variant based on growth 
complementation results, its in vitro cystathionine ?-lyase activity was barely detectable. 
The kcat/KM of the Y274F variant (0.85 s
-1.M-1) was slightly higher than that of the 
phosphoribosylanthranilate isomerase (TrpF)  activity (kcat/KM ~0.3 s
-1.M-1) reported for an 
evolved glutamine phosphoribosylpyrophosphate amidotransferase, PurF (Patrick & 
Matsumura, 2008). Such inefficient enzyme activity was also reported in another study, 
where the kcat/KM of the 3-phosphohydroxypyruvate phosphatase activity of an unevolved 
YeaB (predicted NUDIX hydrolase) was estimated to be >0.024 s-1.M-1 (Kim et al., 2010). 
Clearly, promiscuous activities are often low.  
 Yet, inefficient enzyme activities can be physiologically relevant in a “life-or-death” 
situation. In this study, Alr-3 (carrying the Y274F mutation) managed to complement the 
methionine auxotrophy of E. coli ?metC after 2 days. Since MetC also rescued the strain after 
2 days, one could easily assume that the in vitro cystathionine ?-lyase activity of Alr-3 was 
comparable to that of MetC. However, the superior in vivo activity of Alr-3 was not reflected 
in the in vitro activity, which was very low. This disconnect between the in vitro 
promiscuous activity and organismal fitness is an emerging theme in the literature. 
Previously, PurF was able to rescue E. coli ?trpF at a rate similar to wildtype TrpF, but the in 
vitro kinetic activity was very low (see previous paragraph for the kcat/KM of the TrpF 
activity of PurF). In another study, the N-acetylglutamylphosphate reductase (ArgC) 
activity of glutamyl phosphate reductase (ProA) showed a kcat/KM of 0.4 M
-1.s-1, which was 
approximately half of the cystathionine ?-lyase activity of Alr-3. However, over-production 
of ProA did not rescue E. coli ?argC, unless ProA carried a structural and a regulatory 
mutations (McLoughlin & Copley, 2008; Copley, 2012). Taken together, this suggests that 
there is no direct relationship between in vitro activity and in vivo fitness. A possible 
explanation for this phenomenon is related to the in vivo expression of the promiscuous 
protein. For instance, in this study, and that of Patrick and Matsumura (2008), a strong T5-
lacO promoter was responsible for driving the expression of the pCA24N-encoded 
promiscuous proteins. Furthermore, the copy number of pCA24N was likely to be 300–400 
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per cell (Qiagen, 2011). Therefore, the amount of the promiscuous protein in a cell was 
likely to be very high, although the precise amount has not been investigated. Alternatively, 
regulatory mutations, such as that of ProA (McLoughlin & Copley, 2008), can also increase 
the amount of promiscuous protein in a cell. This high amount of protein could compensate 
for its low promiscuous activity in the course of effecting physiologically relevant activities 
(i.e., rescuing conditionally auxotrophic strains). However, in vitro studies often showed 
that the promiscuous activities were low, because these in vitro assays measured the 
promiscuous activity itself, without taking the enzyme’s in vivo expression into account. To 
what degree does the in vivo expression of the promiscuous proteins effect a selectable 
phenotype will require further investigation. 
2.3.3 PROMISCUITY IS DRIVEN BY CHEMISTRY  
The existence of promiscuous activities catalyzed by non-homologous enzymes poses 
important evolutionary implications. In particular, results from this study and those from 
Patrick et al. (2008) suggested that promiscuous activities from non-homologous scaffolds 
are evolvable under selection. Current knowledge of promiscuous activities was largely 
derived from biochemical characterization of enzyme superfamilies, of which their 
members share similar structural folds and/or sequence homologies but may catalyze 
different overall activities (Babbitt & Gerlt, 1997; Gerlt & Babbitt, 2001; Glasner et al., 2006). 
The promiscuous activities found in extant members of enzyme superfamilies are thus 
believed to be catalytic vestiges from the ancestral enzymes. However, this cannot be said 
for Alr and MetC (as well as PurF and TrpF), because the enzymes did not have a common 
ancestral enzyme. Promiscuity appears to be inherent in enzymes, and remains difficult to 
predict based on protein sequence and structures.  
 Overall, results from this chapter support the notion that cofactor-mediated 
promiscuity (Dimitrov & Vassilev, 2009; Babtie et al., 2010) can represent a plausible starting 
point in the course of evolving new biochemical functions. Of all the cofactors, PLP is 
known to be the most catalytically versatile (Eliot & Kirsch, 2004). It will not be surprising if 
there are more physiologically relevant, promiscuous activities yet to be discovered in other 
PLP-dependent enzymes. This theme will be explored further in Chapter 3, in which I 
searched for promiscuous alanine racemase activity in the E. coli proteome. 
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2.4 MATERIALS AND METHODS 
All reagents were purchased from Sigma unless specifically noted. Common molecular 
biology materials, techniques and primer sequences are described in Appendix I. Specific 
materials and methods used in this chapter are described in the following subsections. 
 Lysozyme (20 mg/mL) was dissolved in 10 mM Tris-HCl (pH 8.0). One mg of DNase I 
(2000 U/mg; Roche) was dissolved in 1 mL Buffer A [20 mM Tris-HCl (pH 7.5), 1 mM 
MgCl2, 50% (v/v) glycerol]. L-Cystathionine was dissolved in 0.04 N HCl and prepared as a 
25 mM stock. PLP stock (100 mM) was prepared by dissolving the powder in 1 N HCl. 
NADH (Merck) was dissolved in 10 mM NaOH, and it was always prepared as 5 mM 
stocks. DTNB was prepared as a 10 mM stock, by dissolving the powder in 100 mM 
potassium phosphate buffer (pH 7.0). The NH4HCO3 buffer was dissolved in water without 
adjusting its pH (~8.1 at 20°C). 
2.4.1 CONSTRUCTION OF AN EMPTY ASKA VECTOR (pCA24N-NoIns) 
The backbone of the empty ASKA vector, pCA24N-NoIns, was derived from pCA24N-tS1-
corr (Section I.4 in Appendix I). The 5.2-kb vector backbone was amplified using a pair of 
outward-facing primers, pCA24N-NoIns.for and pCA24N-NoIns.rev, which contained 
phosphorylated 5’ termini (Section I.6 in Appendix I; Figure 2.30). The forward primer was 
designed to bind to the 5’ start of the GFP region, and the reverse primer binds to the 3’ end 
of the (His)6 tag. The 20-μL PCR reaction contained 1? iProof™ HF master mix (BioRad; also 
contained 0.4 U of DNA polymerase), 0.5 μM of each primer and 10 ng of the template 
(pCA24N-tS1-corr). The thermocycling conditions were 98°C for 30 s, 35 cycles of 98°C for 
10 s, 67°C for 30 s, 72°C for 3 min, and 72°C for 5 min.  
 After purifying the PCR products using commercial spin columns (see Section I.8 in 
Appendix I for details), residual plasmid template was eliminated by DpnI-digestion for 2 h. 
The 4-base cutter DpnI only cleaves methylated restriction site (i.e., DNA that has been 
originated from a dam+ strain). Without cleaning up the digestion, the phosphorylated ends 
of the PCR products were ligated to form a circular plasmid, pCA24N-NoIns (Figure 2.30). 
The plasmid was then used to transform E. coli DH5?-E. After an overnight incubation, the 
plasmid was re-purified from a single transformed colony. The absence of a gene insert in 
pCA24N-NoIns was confirmed by sequencing, using a forward primer that anneals 
upstream of the 6?His region (pCA24N.for; Section 1.6 in Appendix I) and a reverse primer 
that anneals downstream of the GFP region (pCA24N.rev2; Section 1.6 in Appendix I). The 
molecular size of pCA24N-NoIns was also confirmed by a NotI-digestion. In addition, E. coli 
colonies carrying pCA24N-NoIns also appeared as fluorescing green when viewed using a 
UV transilluminator, indicating that the orientation of the GFP had not been altered during 
the cloning process. 
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Figure 2.30:  Schematic diagram of pCA24N-NoIns construction. 
The 5.2-kb vector backbone was amplified from pCA24N-tS1-corr using a pair of 5’-phophorylated, outward-facing 
primers (brown rectangles). Brown arrows denoted the direction of PCR amplification. The phosphorylated ends 
of the linear PCR product were ligated to form a circular plasmid, pCA24N-NoIns. 
2.4.2 CONSTRUCTION OF pCA24N-alr(GFP?) 
Similar to other plasmids from the ASKA collection, the alr gene of pCA24N-alr had been 
fused to a GFP. To remove the GFP, the alr gene was isolated and cloned into a pCA24N 
vector that lacks the GFP gene. 
 The oligonucleotides, pCA24N.for and Alr.rev, were used to amplify the alr gene insert 
from pCA24N-alr. As explained earlier (Section 2.4.1), pCA24N.for anneals upstream of the 
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6?His region. The reverse primer, Alr.rev, anneals to the 3’ of the alr gene. A stop codon 
and an SfiI recognition site were also incorporated at the 3’ end of Alr.rev. The PCR reaction 
was set up with 1? Thermopol buffer, 1 U VentR
® DNA polymerase (both from New 
England Biolabs), 0.2 mM dNTPs, 0.5 μM of each primer and ~20 ng of pCA24N-alr. The 
thermocycling conditions were 98°C for 30 s, 35 cycles of 98°C (30 s), 58°C (30 s), 75°C (90 s), 
and finally 75°C for 1 min. The amplified product was purified using commercial spin 
column. 
 The plasmid pCA24N-trpD(GFP?) was used to prepare the vector backbone since the 
GFP had been eliminated previously (see Section I.4 in Appendix I). The alr insert and 
pCA24N-trpD(GFP?) were SfiI-digested to generate compatible sticky ends. The 4.5-kb 
linearized vector and 1.1-kb insert were then ligated to form pCA24N-alr(GFP?), and the 
plasmid was electroporated into E. coli ?metC. Transformed colonies were PCR-screened for 
the presence of the plasmid using vector-specific primers, pCA24N.for and pCA24N.rev2. 
The plasmid purified from a single clone was also checked with SfiI digestion. Sequencing 
of the alr insert (using pCA24N.for and pCA24N.rev2) confirmed that no mutation had been 
introduced into alr during the cloning process. 
2.4.3 CONSTRUCTION OF pCA24N-metC(GFP?) 
To remove the GFP tag fused to the pCA24N-metC (from the ASKA collection), the 
pCA24N-trpD(GFP?) was used as the host vector (see Section 2.4.2 for details). 
 The metC gene insert was amplified from pCA24N-metC using the oligonucleotides, 
pCA24N.for and MetC(GFP?).rev. The reverse primer, MetC(GFP?).rev, anneals to the 3’ of 
the metC gene. The primer also has a stop codon and an SfiI recognition site incorporated at 
the 3’ end of the sequence. The PCR reaction was set up with 1? GoTaq buffer (Promega), 1 
U Phusion® DNA polymerase (Finnzymes), 0.2 mM dNTPs, 0.5 μM of each primer and ~20 
ng of pCA24N-metC. The thermocycling conditions were 95°C for 1 min, 30 cycles of 95°C 
(30 s), 53°C (30 s), 72°C (60 s), and finally 72°C for 2 min. The amplified product was 
purified using commercial spin column. 
 The purified metC insert DpnI-digested for 2.5 h to eliminate residual plasmid template 
that had been carried over from the PCR reaction. SfiI was then added to the reaction to 
produce compatible sticky ends, and the reaction was further incubated for 3 h. The 
digested 1.2-kb fragment was gel-purified, and ligated into a SfiI-digested vector to form 
pCA24N-metC(GFP?). E. coli MB2795 was transformed with the ligated plasmid and 
transformed cells were grown on LB-chloramphenicol supplemented with 0.5 mM D-Ala. A 
single colony that appeared the next day was inoculated in 3 mL LB-chloramphenicol with 
0.5 mM D-Ala. The culture was grown overnight at 37°C. A 1-μL aliquot of the saturated 
culture was used for PCR screening with pCA24N-specific primers (pCA24N.for and 
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pCA24N.rev2) were used to detect the presence of the plasmid-encoded metC. The 
amplified metC insert was purified and sequenced to confirm that no mutation had been 
introduced during the cloning process. The remaining culture was used to make freezer 
stock, and stored at ?80°C.  
2.4.4 GROWTH COMPLEMENTATION ASSAYS 
2.4.4.1 COMPLEMENTATION OF METC DELETION 
A saturated culture of each E. coli ?metC clone was prepared by inoculating 0.5 mL LB-
chloramphenicol-kanamycin with the strain’s glycerol stock. The culture was grown 
overnight, and pelleted at 12,000 ?g for 4 min on a microcentrifuge. After discarding the 
supernatant, the cell pellet was resuspended with 1 mL of 1? M9 medium, and re-pelleted. 
This pellet-washing step was repeated twice. The final cell resuspension was diluted to an 
OD600 ~0.1 using 1? M9 medium. A 2.5-μL aliquot was streaked or spread on the selective 
M9 agar plates. Cell count was obtained by plating appropriate dilutions of the culture on 
(non-selective) LB-chloramphenicol-kanamycin agar plates. The M9 agar plates were 
incubated at 28°C for at least 1 week, whereas the LB agar plates were incubated overnight 
at 37°C. All agar plates were placed in plastic containers lined with moistened paper towels. 
 The M9 agar plates were made up of 1? M9 medium, 2 mM MgSO4, 0.1 mM CaCl2 
(Merck), 0.4% (w/v) glucose, 34 μg/mL chloramphenicol and 30 μg/mL kanamycin. A final 
concentration of 50 μM IPTG (GBT GoldBio) was added if protein over-expression was 
desired. The 1? M9 medium was diluted from a 5? M9 stock (Sigma; 33.9 g/L Na2HPO4, 15 
g/L KH2PO4, 2.5 g/L NaCl and 5 g/L NH4Cl). 
2.4.4.2 COMPLEMENTATION OF ALR (AND DADX) DELETION 
The glycerol stock of each E. coli MB2795 (?alr ?dadX) clone was used to inoculate 0.5 mL 
LB-chloramphenicol supplemented with 0.5 mM D-Ala. The culture was grown overnight to 
saturation, and harvested by centrifuging at 12,000 ?g for 4 min. The supernatant was 
discarded, and the cell pellet was resuspended with 1 mL of LB. The cell resuspension was 
re-pelleted. This pellet-washing step was repeated twice. LB was used to resuspend the final 
cell pellet to an OD600 ~0.1. A 2.5-μL aliquot was streaked or spread on the selective LB-
chloramphenicol agar plates supplemented with 50 μM IPTG to allow protein over-
expression. Appropriate dilutions of the cell resuspension were plated on non-selective LB-
chloramphenicol plates supplemented with 0.5 mM D-Ala to obtain cell counts. The 
selective agar plates were incubated at 28°C for at least 1 week, whereas the non-selective 
agar plates were incubated overnight at 37°C. All agar plates were incubated in plastic 
containers lined with moistened paper towels. 
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2.4.5 ENZYME OVER-EXPRESSION, PURIFICATION & DIALYSIS 
Unless otherwise specified, all enzyme variants described in this chapter were over-
expressed, purified and dialyzed according to the following protocol. Metal affinity 
chromatography was used to purify all enzyme variants, as the N-terminus of all enzyme 
variants in this thesis were fused to a (His)6 tag. 
 A 4-mL overnight culture was used to inoculate 250 mL LB supplemented with 
appropriate antibiotics. For the MB2795 strain, D-Ala (0.5 mM, final concentration) was also 
added to the media. The culture was incubated at 37°C until its OD600 reached ~0.5. IPTG 
(0.5 mM, final concentration) was added to the culture to induce enzyme over-expression. 
The culture was then incubated at 28°C for another 5–16 h. At the end of incubation, the 
cells were pelleted at 5,700 rpm and 4°C for 20 min. After discarding the supernatant, the 
pellet was stored overnight at ?80°C. 
 A 4-mL aliquot of Column Buffer [50 mM potassium phosphate buffer (pH 8.0), 300 
mM NaCl, 3 mM imidazole, 1 mM ?-mercaptoethanol, 10% (v/v) glycerol, 10 μM PLP] was 
used to resuspend every 1 g of the thawed cell pellet. Next, the cell suspension was 
incubated with lysozyme (0.5 mg/mL, final concentration), DNase I (4 U, final amount) and 
50 μL protease inhibitor cocktail (Sigma) on ice for 30–45 min. The cells were lysed by 10 
cycles of sonication (amplitude 45%; Ultrasonic processor S-4000, Misonix) on ice. The lysate 
was clarified by centrifugation at 13,000 rpm for 35 min, at 4°C. The resulting supernatant 
was filtered through a 0.22-μm filter unit to remove possible aggregates. Filtered 
supernatant was incubated with 1 mL of Talon® metal affinity resin (bed volume, 0.5 mL; 
Clontech) at 4°C for 2 h with agitation, to allow the soluble (His)6-tagged enzyme to bind to 
the resin. Prior to the incubation, the resin had been pre-washed twice with 8 mL of Column 
Buffer. At the end of the incubation, the resin was pelleted (800 ?g, 5 min, 4°C), and washed 
twice with 5 mL of Column Buffer. Then, the resin was suspended using 1 mL of Column 
Buffer, and transferred to a gravity flow column (Bio-Rad). The resin in the column was 
washed twice with 3 mL of Column Buffer and lastly, once with 3 mL of Column Buffer 
with a higher imidazole concentration (15 mM). The purified enzyme was eluted in 3 mL 
Elution Buffer [50 mM potassium phosphate buffer (pH 8.0), 300 mM NaCl, 150 mM 
imidazole, 1 mM ?-mercaptoethanol, 10% (v/v) glycerol]. Eluted fractions usually appeared 
yellow due to the presence of PLP bound to enzymes. 
 Each enzyme was dialyzed overnight against Dialysis Buffer [50 mM potassium 
phosphate (pH 8.0), 150 mM NaCl, 10% (v/v) glycerol) at 4°C before being quantified 
(Section 2.4.5) and used for activity assays (Sections 2.4.7 and 2.4.8). Enzyme dialysis was 
performed in SpectraPor2 cellulose tubing (MWCO 12–14 kDa; SpectrumLabs) according to 
the manufacturer’s instruction. Recovered enzyme was usually concentrated using a 
centrifugal filtration concentrator (Vivaspin 6; GE Healthcare) to 1–2 mL. The enzyme was 
finally passed through a 0.22-μm filter unit to remove any possible aggregates, and the 
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filtrate was aliquoted into microcentrifuge tubes. These enzyme aliquots were stored at 
either 4°C or ?80°C. All enzymes were used within 2 weeks of being purified. 
2.4.6 ENZYME QUANTIFICATION 
Either a 10-fold or 20-fold dilution of each enzyme sample (prepared in a total volume of 
100 μL) was scanned across the 220–600 nm wavelengths in a Cary 100 UV-Vis 
spectrophotometer (Agilent). The peaks at A280 and A420 corresponded to the amount of total 
enzyme and the amount of PLP-bound enzyme, respectively. 
 The background-corrected A280 of the enzyme sample was used to calculate the total 
enzyme concentration. The molar extinction coefficient of each enzyme variant was 
determined as previously described (Pace et al., 1995). The ?280 used for each Trp residue 
was 5,500 M-1.cm-1, Tyr 1,490 M-1.cm-1 and Cystine 125 M-1.cm-1. 
 The background-corrected A420 of the enzyme sample was used to calculate the 
concentration of PLP-bound enzymes. The molar extinction coefficient of PLP used was 
8,450 M-1.cm-1 (Inagaki et al., 1986). A comparison of the concentrations of PLP-bound 
enzymes versus the total enzymes would reveal the fraction of catalytically active enzymes 
in the sample. 
2.4.7 STEADY STATE KINETIC ASSAYS  
All enzyme activity assays were performed using a thermostatically controlled Cary 100 
UV-Vis spectrophotometer (Agilent). All reactions were measured in quartz cuvettes with 
1-cm path length. All initial rates (V0) were corrected for the background rate of 
spontaneous reaction (NADH oxidation for L-Ala racemization; DTNB decomposition for 
cystathionine ?-elimination) in the absence of enzyme. Non-linear regression analyses of all 
V0s and Michaelis-Menten curve fittings were performed using the Origin software 
(OriginLab). Unless specifically noted, all Michaelis-Menten plots were constructed with 7–
9 data points of varying substrate concentrations. 
2.4.7.1 ALANINE RACEMIZATION 
A continuous coupled assay was set up for the racemization of L-Ala to D-Ala based on two 
previously reported assay systems (Esaki & Walsh, 1986; Patrick et al., 2002). A 1-mL 
reaction mixture contained 100 mM N-cyclohexyl-2-aminoethanesulfonic acid (CHES, pH 
9.0), various L-Ala concentrations (Merck), 0.2 mM NADH, 1 U D-amino acid oxidase and 
120 U lactate dehydrogenase. Each mixture was pre-incubated at 37°C for about 2 min, and 
a purified Alr (8.4 nM, final concentration) aliquot was added to initiate the reaction. 
NADH was oxidized to NAD+ during the reaction, and this could be monitored by a 
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decrease in A340. The molar extinction coefficient of NADH (6,220 M
-1.cm-1) was used to 
calculate the amount of NAD+ formation. The substrate (L-Ala) concentrations used for all 
racemization assays typically ranged from (0.3–10) ? KM. In the absence of enzyme, the rate 
of spontaneous NADH oxidation measured throughout this study was ?0.48 μM per min 
(which was approximately ?2.0% of the maximal rate of Alr-catalyzed NAD+ formation).  
 2.4.7.2 CYSTATHIONINE ?-ELIMINATION 
The continuous assay for cystathionine ?-elimination was modified from the protocol 
described by Uren (1987). Every reaction mixture contained 50 mM Tris-HCl (pH 8.8), a 
fixed amount of purified enzyme and 0.4 mM DTNB. The final concentration of MetC used 
was 11 nM in 1 mL assays, whereas the concentration of Alr variants ranged from 0.8–7 μM 
in 0.5 mL assays. The reaction mixture was pre-incubated at 37°C for about 2 min, and L-
cystathionine was added to initiate the reaction. The enzyme-catalyzed reaction produced 
homocysteine, of which its free thiol group would stoichiometrically react with DTNB to 
form 2-nitro-5-thiobenzoate dianion (TNB2-). The formation of TNB2- was monitored as an 
increase of A412, and was calculated using its molar extinction coefficient of 14,150 M
-1.cm-1 
(Riddles et al., 1979). For MetC assays, the substrate (L-cystathionine) concentrations 
typically ranged from (0.25–3) ? KM. Meanwhile, assays added with the Alr variants usually 
contained 0.5–10 mM L-cystathionine, which corresponded to (0.6–3) ? KM. Due to the low 
solubility of L-cystathionine (~5.6 mg/mL in 0.04 N HCl, which corresponded to a 
concentration of 25 mM), it was not possible to use >10 mM. To measure the cystathionine 
?-lyase activity of Alr-3, all reactions were performed in 0.5 mL assays, and the buffer was 
100 mM Tris-HCl (pH 8.8). In the absence of enzyme, the rate of spontaneous DTNB 
decomposition oxidation measured throughout this study was ?0.35 μM per min (which 
was approximately ?0.6% of the maximal rate of MetC-catalyzed TNB2- formation).  
2.4.8 ENDPOINT ASSAYS AND ELECTROSPRAY MASS SPECTROMETRY 
Endpoint activity assays and mass spectrometry were used to detect the reaction products 
of cystathionine ?-elimination. A typical reaction mixture (total volume, 200 μL) contained 
50 mM NH4HCO3 as the assay buffer, 5 mM L-cystathionine and a purified aliquot of MetC 
or Alr. A positive control containing 0.8 μM MetC, and a negative control without any 
enzyme, were prepared. The Alr was assayed at a concentration of 5.1 μM, and PLP (50 μM, 
final concentration) was optionally added. All reactions were foil-wrapped, and incubated 
at 37°C for 16 h in thin-walled, low-binding 0.5 mL tubes (Axygen).  
 At the end of incubation, 60 μL of Talon® metal affinity resin (bed volume, 30 μL) was 
added to each reaction. The resin was pre-washed twice with 200 μL assay buffer (50 mM 
NH4HCO3) prior use. The assays were further incubated at room temperature (~20°C) for    
1 h to allow the (His)6-tagged enzyme to bind to the resin. To remove the enzyme/resin 
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from the reactions, the tubes were pelleted at 12,000 ?g for 2 min. The supernatants lacking 
the enzyme/resin were transferred to new low-binding 0.5 mL tubes. The components in 
each supernatant fraction were then concentrated by evaporating all NH4HCO3 buffer in a 
vacuum concentrator (Concentrator 5301, Eppendorf), until no solution was observed at the 
bottom of the tube. The tubes were finally sent to the Norris Lab (Institute of Molecular 
Biosciences, Massey University, Palmerston North) for mass spectrometry analyses.  
 Briefly, the components in each tube were dissolved in 50 μL of 50% 
acetonitrile/water/0.1% formic acid. The tubes were incubated in a sonication bath (Elma 
S15H) for 3 min to assist component solubilization.  Insoluble particulates were removed by 
pelleting at 16,300 ?g for 15 min. A 5-μL aliquot of the supernatant was injected into an 
Agilent 6520 Q-TOF mass spectrometer, using an Agilent 1200 LC system with a bypass run 
of 50% acetonitrile/water/0.1% formic acid at 0.1 mL/min. The samples were analyzed in 
positive mode and the collected spectra were examined using Mass Hunter Qualitative 
Analysis software (Rev B.03.01). Mass spectrometry conditions were set at: VCap = 3800 V, 
Fragmentor Voltage = 125 V, Skimmer Voltage = 65 V, OCT RF Voltage = 750 V, Gas 
Temperature = 325°C, Drying Gas = 5 L/min, Nebulizer = 40 psig, Acquisition Rate = 3 
spectra/s, TOF spectra mass range = 100–4,500 m/z. 
2.4.9 CONSTRUCTION OF ALR(R209E) 
A single codon mutation (R209E) was introduced to Alr by overlap extension PCR (Ho et al., 
1989). A pair of complementary primers, Alr-R290E.for and Alr-R209E.rev (Section I.6 in 
Appendix I), was designed to mutate the CGC codon to GAA. The mutagenic codon was in 
the middle of the 22-bp primer sequence, and was flanked by 10 and 9 nucleotides 
homologous to the upstream and downstream regions, respectively.  
 The plasmid carrying the alr gene [pCA24N-alr(GFP?)] was used as the DNA template 
for two separate PCR amplifications. First amplification involved using the vector-specific 
forward primer (pCA24N.for) and Alr-R209E.rev to produce a 718-bp DNA fragment. 
Second amplification involved using Alr-R209E.rev and the vector-specific reverse primer 
(pCA24N.rev2) to produce a 571-bp DNA fragment. Both PCR reactions were carried out in 
1? Thermopol buffer, 2 U VentR
® DNA polymerase, 0.2 mM dNTPs, 0.5 μM of each primer 
and ~20 ng of plasmid template. The thermocycling protocol for both reactions was 95°C for 
1.5 min, 35 cycles of 95°C (30 s), 52°C (30 s), 72°C (1 min), and finally, 72°C for 30 s. Both 
amplified fragments were gel-purified. 
 The pair of mutagenic primers was used to produce two fragments with overlapping 
3’ ends. The overlapping ends were annealed in a second PCR reaction. After the 3’ ends of 
both fragments were annealed, each strand could act as a primer for the 3’ extension of the 
complementary strand. Therefore, equal amount of purified overlapping fragments (10 ng 
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of each 718-bp and 571-bp fragments) was added to a PCR mix containing 1? Thermopol 
buffer, 2 U VentR
® DNA polymerase, 0.2 mM dNTPs and 0.5 μM pCA24N.for and 0.5 μM 
pCA24N.rev2. The pCA24N-specific primers were used to amplify the entire 1.3-kb DNA 
product that had been reassembled from the two overlapping fragments. The PCR cycling 
conditions were as follows: 1 cycle of 95°C for 1 min, 35 cycles of 95°C (30 s), 54°C (20 s), 
72°C (70 s), and finally 1 cycle of 72°C for 30 s.  
 The resulting 1.3-kb product (containing a codon mutation R209E) was digested with 
SfiI. The fragment was then ligated to a SfiI-digested 4.5-kb pCA24N(GFP?) vector (Section 
2.4.2). E. coli MB2795 transformed with the ligated product was grown on LB-
chloramphenicol supplemented with 0.5 mM D-Ala. The transformed colonies were PCR-
screened using pCA24N-specific primers, and a 1.3-kb amplified product was sequenced. 
Nucleotide sequence of the fragment validated that the Arg209 codon had been changed to 
Glu209. 
2.4.10 RANDOM MUTAGENESIS OF ALR 
2.4.10.1 CONSTRUCTION OF RANDOMIZED ALR LIBRARY 
The GeneMorph II Random Mutagenesis kit (Stratagene) was used to introduce random 
mutations into the alr gene during PCR. An epPCR reaction mixture (total volume, 100 μL) 
contained 1? Stratagene Mutazyme buffer, 2.5 U Mutazyme DNA polymerase, 0.8 mM 
dNTPs, 0.5 μM of pCA24N.for primer, 0.5 μM of Alr.rev primer and 567 ng of plasmid 
template [pCA24N-alr(GFP?)]. That amount of plasmid template corresponded to 100 ng of 
initial target DNA (alr), which was recommended (by the manufacturer) to achieve a 
mutation rate of 1–4 amino acid mutations per gene. The thermocycling conditions were 1 
cycle of 95°C for 2 min, 35 cycles of 95°C (30 s), 58°C (30 s), 72°C (70 s), and 1 final cycle of 
72°C for 2 min.  
 The yield of the PCR product was estimated to be 1 μg by running a 1-μL aliquot of the 
product on an agarose gel. Given that the initial target template was 100 ng, the final yield 
reflected a 10-fold amplification of the initial target template and an overall duplication 
number of 3.3 (2duplication = amplification fold). The PCR efficiency (i.e., the probability that 
any particular sequence is duplicated in a given PCR cycle) was therefore 0.068 (Patrick et 
al., 2003). 
 Next, the 1.2-kb PCR product was purified using spin columns. Since a significant 
amount of plasmid template was co-purified with the PCR product, the sample was treated 
with DpnI so that the plasmid template would be fragmented. SfiI was also added to the 
reaction to generate compatible 3’ sticky ends with those of the pCA24N-tS1(no-ext) vector 
(Section I.4 in Appendix I), which also had been SfiI-digested. The digested 1.1-kb fragment 
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(containing the randomized alr gene) and the linearized 4.5-kb vector backbone were gel-
purified using the QIAEXII Gel Extraction kit (Qiagen). The purified alr insert (365 ng) was 
ligated to the vector (500 ng) at a 3 : 1 molar ratio. A “vector only” control was also set up 
using the same ligation components but without any gene insert. The ligation reaction was 
incubated for 16 h before being heat-inactivated. Then, the ligated products were cleaned 
up using the MinElute columns (Qiagen). A 1-μL aliquot of the ligated product was used to 
transform a fresh 50-μL aliquot of E. coli ?metC. A total of 14 electroporations were 
performed for the alr library, and the time constant for each electroporation was >5.10 ms. 
The ?metC cells were also transformed with the “vector only” control and pUC19 (a 
standard plasmid control used to determine transformation efficiency), respectively. 
Different dilutions of the recovered cells were plated on LB-kanamycin-chloramphenicol 
plates, and allowed to grow at 37°C for 15 h. 
 Based on the colony counts, the transformation efficiency of the ?metC strain was 
found to be 2.5 ? 109 cfu/μg of pUC19. After subtracting from the “vector only” background 
(~0.0014%), the total number of transformed clones for the alr library was 3.4 ? 107 cfu. To 
check for the presence of the randomly mutated alr gene cloned in the pCA24N plasmid, 20 
colonies were randomly picked from the library plates. The colonies were grown in 0.2 mL 
LB-kanamycin-chloramphenicol for 8 h. One μL of each saturated culture was used as the 
template for PCR screen. Vector-specific primers, pCA24N.for and pCA24N.rev2, were 
used. PCR results from all 20 clones showed the presence of the alr insert (carried in the 
plasmid), as indicated by a 1.3-kb fragment. After purifying these PCR products using 
commercial spin columns, they were sequenced in order to obtain the number and type of 
mutations introduced during epPCR. 
 Meanwhile, a spreader glass rod pre-wetted with LB-kanamycin-chloramphenicol was 
used to scrape the remaining colonies on the library agar plates. The ~45 mL cell suspension 
was concentrated by pelleting the cells at 3,500 ?g for 30 min, at 4°C. The LB supernatant 
was discarded, and the cell pellet was resuspended in 8 mL LB-kanamycin-chloramphenicol 
supplemented with 12.5% (v/v) glycerol. The OD600 of the final cell suspension was 512, 
which corresponded to ~1.3 ? 1011 cfu/mL [assuming that OD600 ~1.0 is roughly equivalent 
to 2.5 ? 108 cfu/mL (Sambrook & Russell, 2001)]. The cell suspension was evenly divided 
into 8 aliquots, and finally stored at ?80°C. 
2.4.10.2 SELECTION FOR ALR VARIANTS WITH HIGHER LYASE ACTIVITY  
A frozen aliquot of the E. coli ?metC library harbouring the randomly mutated alr gene 
(pCA24N-epAlr) was thawed. Ten μL of the library was used to inoculate 50 mL LB-
kanamycin-chloramphenicol, and grown at 37°C until OD600 reached ~0.8. The cells were 
harvested by centrifuging at 2,200 ?g for 16 min, at 4°C. After discarding the LB 
supernatant, the cell pellet was resuspended twice in 50 mL of 1? M9, and re-pelleted 
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similarly after each resuspension. The final pellet was resuspended in 50 mL of 1? M9. One 
mL of the cell suspension (~1.04 ? 108 cfu; calculated based cells grown on non-selective 
medium) was plated on a selective medium (24.5 cm ? 24.5 cm), M9-kanamycin-
chloramphenicol supplemented with 0.4% (w/v) glucose and 5 μM IPTG.  
 For side-by-side comparison, the same E. coli strain carrying the parental alr gene 
[pCA24N-alr(GFP?)] was included in the selection experiment. In addition, the same E. coli 
cells harbouring the empty ASKA vector (pCA24N-NoIns) were used as a negative control, 
whereas those harbouring the pCA24N-metC(GFP?) [Section 3.4.2] was used as a positive 
control. Overnight cultures of these 3 clones were subjected to the same routine of 1? M9 
washes as previously described. Cell densities were standardized by adjusting their OD600 
to ~0.1, and a further 100-fold dilution was performed for each strain. A 2-μL aliquot of each 
diluted cell suspension was plated on separate M9-kanamycin-chloramphenicol agar plates 
supplemented with 0.4% (w/v) glucose and 5 μM IPTG. All M9 agar plates, including those 
plated with the alr library, were incubated at 28°C for at least 3 days. To enumerate the 
number of cells plated on M9 agar plates, appropriate dilutions were made for each strain, 
and plated on non-selective LB-kanamycin-chloramphenicol. The LB agar plates were 
grown overnight at 37°C. 
 After 2.5 days of incubation, the alr library plate was divided into 4 equal sections. 
Twelve colonies were randomly picked from each section, and inoculated in 0.2 mL LB-
kanamycin-chloramphenicol. A total of 48 cultures were incubated overnight at 37°C. The 
next day, 1 μL from each saturated culture was used as the template for PCR screen. The 
remaining cultures were stored at ?80°C after adding each with 50 μL of 50% (v/v) glycerol. 
The use of the vector-specific primers (pCA24N.for and pCA24N.rev2) in the PCR screen 
would ensure amplification of only pCA24N-encoded alr genes. The resulting PCR products 
were purified and sequenced to reveal the number and type of mutations in found in the alr 
gene that had allowed rapid colony formation on the selective medium. 
2.4.10.3 RETRANSFORMATION/RECLONING AND RESTREAKING TESTS 
The growth phenotypes of each alr variant from the epPCR library section (Section 2.4.10.2) 
were confirmed by retransformation/recloning and restreaking tests.  
 Plasmid was purified from all the mutated variants using commercial spin columns.  A 
new batch of electrocompetent E. coli ?metC cells was transformed with the purified 
plasmids, respectively. For each plasmid variant, one retransformed clone was picked and 
grown to saturation in 2 mL LB-kanamycin-chloramphenicol at 37°C. The cultures were 
PCR-screened using pCA24N-specific primers (pCA24N.for and pCA24N.rev2) to confirm 
the presence of the plasmid before being made as freezer stocks.  
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 For (two) variants in which no mutation was been detected in the alr gene, the plasmid 
was similarly purified from the original clones (which had been maintained as freezer 
stocks). The plasmids were digested overnight with SfiI, and the excised alr gene was gel-
purified. The alr insert was ligated to the SfiI-treated pCA24N vector in a molar ratio of 3 : 1. 
After heat-inactivating the ligation reaction, it was diluted 5 fold using sterile dH2O. A 2-μL 
aliquot of each ligated product was used to transform freshly prepared electrocompetent E. 
coli ?metC cells. One retransformed clone was selected and grown overnight in 2 mL LB-
kanamycin-chloramphenicol at 37°C. The cultures were PCR-screened using pCA24N-
specific primers (pCA24N.for and pCA24N.rev2) to confirm the presence of the plasmid 
before being made as freezer stocks.  
 For the restreaking experiments, 1 mL LB-kanamycin-chloramphenicol was inoculated 
with the freezer stock of either a retransformed or a recloned alr variant. After an overnight 
incubation at 37°C, the culture was pelleted at 12,000 ?g for 4 min in a benchtop 
microcentrifuge. The cell pellet was resuspended thrice in 1 mL of 1? M9 medium, and re-
pelleted similarly after each resuspension. The final cell pellet was resuspended in 1 mL of 
1? M9. A 20-fold dilution was performed for the cell suspension, and a 2.5-μL aliquot of the 
diluted suspension was streaked on two sets of agar, M9-kanamycin-chloramphenicol-
glucose agar plates with and without 5 μM IPTG. All M9 agar plates were incubated at 
28°C, in sealed container lined with moistened paper towels. Colony formation was 
monitored for at least 1 week. 
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3.1 INTRODUCTION 
The catalytic diversity of PLP-dependent enzymes is evident from the number of enzyme 
classes they belong to: PLP-dependent enzymes are found in five out of six enzyme classes, 
according to the Enzyme Commission classification (Christen & Mehta, 2001). In addition to 
their native functions, many PLP-dependent enzymes are known to catalyze side reactions 
in vitro (Eliot & Kirsch, 2004). However, the in vivo relevance of these side activities is 
largely unexplored. Given that the PLP-dependent enzymes occupy a central role in carbon 
and nitrogen metabolism (by catalyzing a variety of reactions involving amino acids and 
their derivatives), the ability of these PLP-dependent promiscuous activities to alter the 
cell’s metabolic flux, via changes in their activity or expression levels, is not clear. 
  In Chapter 2, the promiscuous activity of alanine racemase (Alr) was shown to rescue 
an E. coli strain with its cystathionine ?-lyase (MetC) gene deleted. Both enzymes are PLP-
dependent although they are not homologous. The results had two implications: (1) 
promiscuous activities mediated by PLP can be physiologically valuable under certain 
selective conditions; and (2) the native function of a PLP enzyme can be a promiscuous 
function of another non-homologous PLP enzyme. Enzyme promiscuity in non-homologous 
enzymes has gained attention in recent years because these enzymes did not diverge from a 
common ancestor, and thus, their promiscuous activities did not originate from a 
multifunctional ancestral protein (Jensen, 1976; also refer to Chapter 2 for details of this 
reasoning). Instead, their promiscuous activities have been described as a form of molecular 
contingency (Patrick & Matsumura, 2008). To date, only a handful of groups have explored 
protein promiscuity in non structural homologues (James & Tawfik, 2001; McLoughlin & 
Copley, 2008; Patrick & Matsumura, 2008; Kim et al., 2010). 
 In this regard, I considered the PLP-dependent enzyme family a good system to 
explore promiscuous activities in evolutionarily unrelated enzymes. Seven structural 
scaffolds are adopted by modern PLP-dependent enzymes (Percudani & Peracchi, 2009), 
and enzymes belonging to each fold group are likely to represent an independent 
evolutionary lineage (Christen & Mehta, 2001). The very first ancestral PLP-dependent 
enzymes were probably multifunctional due to the innate catalytic potential of the cofactor. 
In the absence of an apoenzyme, the electrophilic PLP is believed to catalyze many reactions 
— which are normally catalyzed by PLP-dependent holoenzymes — very slowly (Eliot & 
Kirsch, 2004; Vacca et al., 2008). This argument is based on the fact that almost all PLP-
dependent enzymes (except glycogen phosphorylase) share the initial mechanistic steps 
during catalysis (i.e., the formation of internal and external aldimine in the active site). 
However, as each lineage evolved, the reaction and substrate specificities of the enzymes 
narrowed. The enzymes became more specific for a certain type of catalysis and/or 
substrate due to the specialization of the protein scaffolds. In other words, the enzyme 
scaffolds may dictate the substrate choice as well as the type of catalysis possible for 
modern PLP-dependent enzymes. 
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 In the course of studying the promiscuous activity of Alr in Chapter 2, I acquired E. 
coli MB2795 from Prof. Kurt Krause (University of Otago). As the two homologous alanine 
racemase genes (alr and dadX) of this strain have been deleted, the cells are not able to 
racemize alanine isomers (Strych et al., 2001). The absence of D-Ala in this strain leads to the 
formation of a defective cell wall, which in turn effects cell death. Due to the potential for 
PLP-mediated promiscuity, I began searching for promiscuous alanine racemase activities 
that could complement the growth of E. coli MB2795. In this chapter, I describe the 
serendipitous discovery of a promiscuous alanine racemase activity shown by E. coli MetC 
(whose native activity is the promiscuous activity of Alr, as demonstrated in Chapter 2). 
The reciprocal activity profile shown by Alr and MetC is a novel finding, especially in light 
of their lack of structural homology. Overall, the findings from Chapter 2 and 3 support the 
notion that promiscuous activities can be found in non-homologous enzymes. Sequence or 
structural homology alone is not the only parameter to look for when predicting 
promiscuous activities.   
3.2 RESULTS 
3.2.1 SUPPRESSOR CLONES THAT RESCUE E. COLI MB2795 (?alr ?dadX) 
First, a multicopy suppression screen was set up in an attempt to search for promiscuous 
alanine racemase activity in the E. coli proteome. The E. coli MB2795 strain (?alr ?dadX) is 
auxotrophic for D-Ala. The strain will not grow unless D-Ala is exogenously supplied. 
Therefore, the pooled plasmids of the ASKA library (Patrick et al., 2007) were used to 
transform E. coli MB2795 to select for multicopy suppressors that could complement the 
growth of the strain. Transformed clones were selected on an IPTG-supplemented LB-
chloramphenicol agar plate (see Section 3.4.1 for details). A total of 36,000 cells were initially 
spread on the selective agar. This amount of cells corresponded to ~7-fold over-sampling of 
the ASKA library, which consisted of 5,272 clones. This over-sampling ensured that ~99% of 
all ASKA plasmids were present [as calculated by the library diversity and completeness 
programme, GLUE (Patrick et al., 2003)]. In the absence of exogenous D-Ala, ten clones 
survived and formed colonies on the agar plate after 1–4 days of incubation. No additional 
colonies were formed even after 2 weeks of incubation.  
 These ten clones were screened by PCR, in order to determine the identity of their 
plasmid-encoded ORF. Figure 3.1 shows the plasmid-encoded ORF amplified from each of 
the ten clones. The sizes of the ORFs varied between 1,000–1,650 bp, suggesting that more 
than one type of suppressor clone had been isolated. These ORFs were sequenced to reveal 
their identity. A total of five ORFs were identified from the ten clones: alr, dadX, cycA, metC 
and wcaL (Table 3.1).  
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Figure 3.1:  PCR product amplified from the ten suppressor clones using vector-specific primers. 
Lanes 1, 8 and 11, Invitrogen 1 kb plus DNA ladder. Lanes 2–7, clones 1–6. Lanes 9–10, clones 7–8. Lanes 11–12, 9–
10. 
 To confirm the rescuing activity of these ORFs, their individual ASKA plasmids were 
isolated and used to retransform fresh E. coli MB2795. The clones were grown on separate 
agar plates to verify that their growth phenotype was not a result of cross-feeding. Out of 
the five suppressor clones, only the WcaL-expressing clone did not grow after this 
retransformation test, indicating that this clone was likely to be a false positive. The 
remaining four clones formed colonies after 1–3 days of incubation, and this was consistent 
with the growth observed during the initial suppression test. In particular, the CycA-
expressing clone grew after only 1 day of incubation. Other clones expressing Alr, DadX or 
MetC grew after 2–3 days of incubation. Table 3.1 summarizes the growth complementation 
results of the suppressor clones.  
 
Table 3.1:  List of over-expressed proteins identified from the suppressor clones. 
Over-expressed protein Frequency Days to form 
colonies 
Size of 
colony 
Retransformed 
clone grew? 
CycA (Serine/alanine/glycine APC 
transporter) 2 1 2 mm Yes 
Alr (Alanine racemase 1) 4 2–3 3–4 mm Yes 
DadX (Alanine racemase 2) 2 2 3–4 mm Yes 
MetC (Cystathionine ?-lyase) 1 2 3–4 mm Yes 
WcaL (Predicted glycosyl transferase 
involved in colanic acid biosynthesis) 1 4 1 mm No 
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 As expected, over-expression of either Alr or DadX rescued the ?alr ?dadX strain, E. 
coli MB2795. The growth of the strain was also complemented by over-expression of CycA, 
a serine/alanine/glycine transporter (Keseler et al., 2009), which might have allowed the 
influx of residual D-Ala from LB. As explained in Chapter 2, MetC is neither a sequence nor 
structural homologue of Alr (or DadX). MetC is not known to racemize amino acids, nor to 
recognize alanine as a substrate. The native function of MetC is part of the methionine 
biosynthetic pathway, which has no direct relationship with alanine metabolism in cells. 
Therefore, the ability of MetC to rescue the D-Ala auxotroph implied that MetC might 
catalyze the formation of D-Ala. 
3.2.2 GROWTH COMPLEMENTATION TESTS 
3.2.2.1 METC(GFP?) COMPLEMENTS E. COLI (?alr ?dadX) 
To eliminate the possibility that the rescuing activity of MetC was due to the MetC-GFP 
fusion protein encoded by pCA24N-metC, the growth complementation test was repeated 
using a GFP-less MetC. E. coli ?alr ?dadX cells harbouring the pCA24N-alr(GFP?) [Section 
2.4.2], pCA24N-metC(GFP?) [Section 2.4.3] and pCA24N-NoIns [Section 2.4.1] were used as 
the positive control clone, test clone and negative control clone, respectively. Saturated 
cultures of all three clones were plated on the selective agar (LB-chloramphenicol 
supplemented with 50 μM IPTG). The incubation temperature was increased to 37°C (from 
30°C in the previous suppression test, described in Section 3.2.1) to provide optimal 
conditions for the growth of E. coli.  
 As expected, confluent growth was observed for the positive control after 1 day of 
incubation. The MetC-expressing clone also formed colonies at a similar rate. No mutation 
had been found in pCA24N-metC(GFP?) [Section 2.4.3], thus confirming that MetC, and not 
mutations in the plasmid, was responsible for the rescuing activity. No colonies were 
observed for the negative control clone, up to 1 week of incubation. Figure 3.2 shows an 
example of the growth results of the E. coli MB2795 clones on the selective agar.  
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Figure 3.2:  The growth of E. coli MB2795 clones on IPTG-supplemented LB-chloramphenicol agar after 1 day of 
incubation at 37°C. 
For comparative purpose, different clones were streaked on the same agar plate. Different clones were normally 
plated or streaked on separate agar plates. Each section of the agar plate corresponded to the growth of (or the lack 
thereof) E. coli ??2795 clone harbouring the following plasmids (clockwise, from left): (1) pCA24N-alr(GFP?); (2) 
pCA24N-metC(GFP?); (3) pCA24N-NoIns.  
3.2.2.2 GROWTH COMPLEMENTATION OF E. COLI (?alr ?dadX ?metC)  
I showed in Chapter 2 that cystathionine ?-lyase activity was a promiscuous function of E. 
coli Alr. In this study, the ability of MetC to rescue the ?alr ?dadX strain (Section 3.2.2.1) 
suggested that MetC could catalyze alanine racemization. Thus, the overall implication is 
that MetC and Alr can catalyze each other’s reaction, in addition to their native activity. 
However, it was not known whether both enzymes are bifunctional in vivo, i.e., both the 
native and promiscuous activities are required for growth. Enzyme bifunctionality is 
important for addressing issues such as activity trade-offs and phenotypic robustness in the 
course of evolving new function (Copley, 2012). In this section, the bifunctionality of MetC 
and Alr are tested using in vivo assays. 
 To select for both alanine racemase and cystathionine ?-lyase activities at the same 
time, a triple knockout strain, E. coli ?alr ?dadX ?metC, was constructed. The chromosomal 
metC gene of E. coli MB2795 (?alr ?dadX) was replaced with a kanamycin resistance cassette 
(refer to Section 3.4.2 for more details). This strain was transformed with pCA24N-NoIns to 
form the negative control. Cells that had been transformed with pCA24N-alr(GFP?) and 
pCA24N-metC(GFP?) formed the Alr-expressing and MetC-expressing clones, respectively. 
The growth of all three clones was tested on M9/glucose agar supplemented with 50 μM 
IPTG. The minimal medium selected for MetC activity, while the absence of D-Ala in the 
medium selected for Alr activity.  
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 As expected, no growth was observed for the negative control, up to 4 weeks of 
incubation. Two phenotypes were observed for the Alr-expressing and MetC-expressing 
clones: the faster-growing “pseudo-revertants” and the slower-growing colonies. These 
“pseudo-revertants” were individual colonies that usually grew faster than other colonies 
that carry the same plasmid (as evident from the appearance of big colonies in the primary 
inocula in Figure 3.3). For both Alr-expressing and MetC-expressing clones, two to ten 
pseudo-revertant colonies appeared after 2–3 days of incubation, while the slower-growing 
colonies took 12–14 days to grow into pinprick sizes (Figure 3.3). These two phenotypes 
were still observed in independent repeats of the growth complementation assay. The 
presence of the pCA24N-encoded alr or metC insert in these pseudo-revertants was 
confirmed by PCR screens, thereby confirming that these pseudo-revertants were not cross 
contaminants. The rapid growth of these pseudo-revertants was likely due to the presence 
of chromosomal or regulatory mutations that increased both alanine racemase and 
cystathionine ?-lyase activities in the cells.  
 
    
Figure 3.3:  The growth of E. coli ?alr ?dadX ?metC clones on IPTG-supplemented M9/glucose agar, after 14 
days of incubation at 37°C. 
For comparative purpose, different clones were streaked on the same agar plate. Different clones were normally 
streaked on separate agar plates. Each section of the agar plate corresponded to the growth of (or the lack thereof) 
E. coli ?alr ?dadX ?metC clone harbouring the following plasmids (clockwise, from left): (1) pCA24N-alr(GFP?); (2) 
pCA24N-metC(GFP?); (3) pCA24N-NoIns.  
 The slower-growing colonies of the Alr-expressing and MetC-expressing clones 
appeared to be rescued by the plasmid-encoded alr or metC, instead of chromosomal or 
regulatory mutations. In independent repeats of the growth complementation assays, the 
formation rate of these pinprick-sized colonies was consistent (12–14 days of incubation). 
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Furthermore, these colonies grew along the streaked lines (Figure 3.3), rather than 
clustering around the faster-growing pseudo-revertants. This implied that the pinprick-
sized colonies were not satellite colonies, which usually formed during a cross feeding 
phenomenon. Despite the appearance of the pseudo-revertants, the consistent growth of the 
pinprick-sized colonies provided a hint that Alr and MetC can be bifunctional in vivo.  
3.2.3 ALANINE RACEMASE ACTIVITY OF METC 
In vivo results shown in Sections 3.2.1 and 3.2.2 suggested that MetC could catalyze alanine 
racemization as its promiscuous function. In this section, the alanine racemase activity of 
MetC was demonstrated using in vitro assays. 
 The (His)6-tagged MetC was expressed and purified from E. coli ?metC, as described in 
Sections 2.2.4.1 and 2.4.5 (Chapter 2). Figure 2.12A (in Section 2.2.4.1) shows an example of a 
SDS-PAGE analysis of various MetC fractions from the purification process. As shown in 
the same figure, the purity of the eluted MetC fractions reached >95%. The eluted fractions 
were further dialyzed into a buffer without ?-mercaptoethanol, and the dialyzed enzyme 
fractions were used for in vitro assays. 
 The alanine racemase activity was measured using a coupled assay modified from 
previous protocols (Esaki & Walsh, 1986; Patrick et al., 2002). Two coupling enzymes, D-
amino acid oxidase (DAAO) and lactate dehydrogenase (LDH), were added to every 
reaction to convert D-Ala (the product of the alanine racemization reaction) to pyruvate and 
finally, lactate. During the conversion of pyruvate to lactate, LDH also oxidizes NADH to 
NAD+. Since NADH absorbs strongly at A340 but NAD
+ does not, the rate of NAD+ 
formation could be spectrophotometrically measured as a decrease of A340. A schematic 
diagram detailing the coupled assay system is illustrated in Figure 3.4. 
 Unlike the promiscuous activity of Alr (Section 2.2.4.1), the alanine racemase activity 
of MetC was detectable in vitro. This racemase activity was confirmed by the lack of activity 
in assay controls without one of the coupling enzymes, DAAO. In the absence of DAAO, no 
decrease in A340 was detected (after the background rate of NADH oxidation was corrected; 
Figure 3.5). DAAO only recognizes D-amino acids (such as D-Ala) as substrate. Hence, the 
omission of DAAO from the assay should result in no substrate being produced for LDH 
(Figure 3.4). Furthermore, the possibility that MetC might be acting as a deaminase (i.e., 
converting L-Ala into pyruvate) was eliminated, because in that case, a positive signal (i.e., a 
decrease in A340) would still be generated in the absence of DAAO. Instead, the signal was 
only detected when DAAO was present in the reaction, thereby confirming that D-Ala was 
produced from L-Ala via the activity of MetC. 
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Figure 3.4:  The in vitro coupled assay used to measure the alanine racemization activity.  
The racemization of L-Ala produces D-Ala, which is then used as a substrate for DAAO. In the presence of O2 and 
H2O, D-Ala is converted to pyruvate. LDH further converts pyruvate to lactate via the oxidation of NADH. The 
amount of NADH can be measured spectrophotometrically at 340 nm using a molar extinction coefficient of 6,220 
M-1.cm-1. Therefore, the formation of NAD+ is measured as a decrease of absorbance at 340 nm. DAAO, D-amino 
acid oxidase; LDH, lactate dehydrogenase; NAD+/NADH, oxidized/reduced form of ?-nicotinamide adenine 
dinucleotide. 
 
Figure 3.5:  The alanine racemase assay of MetC performed in the presence and absence of DAAO. 
The alanine racemase activity of MetC was measured in CHES buffer (pH 9.0) at 37°C. Each reaction contained 58 
nM MetC, 5 mM L-Ala, 0.2 mM NADH, 100 U lactate dehydrogenase. The MetC(+DAAO) assay also contained 1 U 
of D-amino acid oxidase (DAAO).  
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 The kinetic parameters of MetC for alanine racemization were derived from the mean 
of three repeats, with each repeat value representing the mean of duplicate assays. The KM 
for L-Ala was found to be 51.0 ± 4.3 mM, whereas the kcat was 3.3 ± 0.6 s
-1. Based on the 
catalytic efficiencies (kcat/KM), the alanine racemase activity of MetC was ~35,000-fold lower 
than the native activity of MetC (Table 3.2; data were also derived from Table 2.8 from 
Section 2.2.6.5, of Chapter 2). Although over-expression of MetC rescued E. coli MB2795 at a 
comparable rate with that of Alr (Section 3.2.2.1; both clones took 1 day to form colonies on 
the selective medium), the in vitro alanine racemase activity of MetC was still nearly 3 
orders of magnitude lower than the native activity of Alr (Table 3.2). The lack of correlation 
between the in vitro promiscuous activity level and the in vivo fitness has also been 
previously noted and discussed (Section 2.3.2 of Chapter 2).  
 
Table 3.2:  Kinetic parameters of the alanine racemization of MetC. 
Cystathionine ?  Homocysteine + Pyruvate + NH3 L-Ala ?  D-Ala 
Enzyme 
kcat (s-1) KM (M) kcat/KM (s-1.M-1) kcat (s-1) KM (M) kcat/KM (s-1.M-1) 
MetC 89.5 ± 13.9 (3.9 ± 0.7) ? 10-5 2.3 ? 106 3.3 ± 0.6 (5.1 ± 0.4) ? 10-2 65 
Alr †n.d. n.d. <0.85 55.3 ± 3.7 (8.7 ± 1.5) ? 10-4 6.4 ? 104 
 
The kinetic parameters of the alanine racemase activity of MetC are highlighted in blue.                  
†n.d., not determined. 
3.2.4 DIRECTED EVOLUTION OF METC (ROUND 1) 
Random mutagenesis and genetic selection can be used to improve very low promiscuous 
activities to detectable levels in the laboratory. These in vitro functional improvements have 
been demonstrated previously (Chapter 2; Patrick and Matsumura (2008)]. However, at the 
outset of this study, attempts to improve the alanine racemase activity in MetC were 
expected to be challenging, because the selection window for obtaining MetC variants with 
higher racemase activity was narrow — the starting racemase activity of MetC was only 
~103 fold lower than Alr (Table 3.2 in Section 3.2.3). In this section, I probed the evolvability 
of the alanine racemase activity of MetC using two rounds of low-mutation-rate 
mutagenesis (1.0–3.0 DNA substitutions per metC gene) and genetic selection experiments.  
3.2.4.1 FIRST-GENERATION LIBRARY  
EpPCR was used to introduce random mutations into the plasmid-encoded metC gene. For 
the first-generation library, the mutated metC gene was cloned into a pCA24N(KanR) vector, 
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which was a derivative of pCA24N with a kanamycin resistance cassette, instead of a 
chloramphenicol resistance cassette (courtesy of Dr. Monica Gerth). The change in 
resistance marker ensured that false positives arising from ASKA contaminants were 
avoided.  
 First, E. coli DH5?-E was used as a non-selective host to propagate the ligated 
plasmids. The reason for using the DH5?-E strain was its considerably higher 
transformation efficiency (?108 cfu/μg of pUC19) than that of the D-Ala auxotroph, E. coli 
MB2975 (<108 cfu/μg of pUC19). In a preliminary study, I transformed both the DH5?-E 
and MB2795 strains with the same amount of ligated products. The number of transformed 
DH5?-E clones was ~2.2-fold higher than the number of MB2795 clones (results not shown). 
Therefore, the ligated metC products were initially electroporated into DH5?-E to maximize 
the library size. Circular plasmids purified from the transformed clones were then 
introduced into the MB2795 strain.  
  A library consisting of 1.5 ? 105 distinct variants was constructed in E. coli DH5?-E 
(see Section 3.4.7.1 for more details). All 14 clones randomly chosen from the library were 
found to possess the plasmid-encoded metC. To estimate the overall mutation rate of the 
library, the metC genes from the 14 clones were sequenced. A total of (14 sequences ? 1,185 
bp) = 16,590 bp were analyzed. There were 42 point mutations and no indels in total, and 
each metC gene carried 1–5 mutations. As summarized in Table 3.3, the average DNA 
mutation rate was 3.0 substitutions per metC gene.  
 While the previous error-prone alr library was biased towards G?N and C?N 
mutations (Table 2.3 in Section 2.2.6.1), such bias was not observed for this metC library. In 
fact, the 42 mutations found in the metC library were almost evenly divided into A?N and 
T?N substitutions (47.6%), as well as G?N and C?N substitutions (52.4%). Yet, a slight 
bias towards DNA transitions (Ts; 59.5%), rather than transversions (Tv; 40.5%), was noted.  
 Table 3.4 summarized the key characteristics of the metC library, which had been 
analyzed by the programme that calculates the mutational diversity of an epPCR library on 
an amino acid level, PEDEL-AA (Firth & Patrick, 2008). On average, there were 2.0 amino 
acid substitutions per MetC variant. Less than 30% of the total library consisted of 
unmutated MetC variants, and thus, the estimated number of mutated MetC variants was 
?1.1 ? 105 cfu. Overall, up to 7.4 ? 104 cfu were estimated to carry distinct, full-length MetC 
variants. 
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Table 3.3:  The mutational spectrum of the first-generation metC library. 
Types of mutation Frequency Proportion of total 
Transitions   
A?G, T?C 11 26.2% 
G?A, C?T 14 33.3% 
Transversions   
A?T, T?A 5 11.9% 
A?C, T?G 4 9.5% 
G?C, C?G 6 14.3% 
G?T, C?A 2 4.8% 
Summary of bias   
Transitions/Transversions 1.5  N/A 
AT?GC/GC?AT 0.9 N/A 
A?N, T?N 20 47.6% 
G?N, C?N 22 52.4% 
Mutation per kb 2.5 N/A 
Mutation per metC gene (1,185 bp) 3.0 N/A 
 
N/A = not applicable. 
 
Table 3.4:  Summary of the key characteristics of the first-generation metC library based on its DNA mutational 
spectrum. 
Property Estimate 
Total library size 1.5 ? 105 
Number of variants with no indels or stop codons 1.4 ? 105 
Mean number of amino acid substitutions per variant 2.0 
Unmutated (wildtype) sequences (% of library) 27.3% 
Number of distinct full-length proteins in the library 7.4 ? 104 
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3.2.4.2 SELECTION OF FIRST-GENERATION METC VARIANTS 
The metC library (Section 3.2.4.1) was further introduced into the D-Ala auxotroph, E. coli 
MB2795, to select for MetC variants with higher alanine racemase activity on LB agar 
supplemented with 5 μM IPTG (see Section 3.4.7.2 for details). The 10-fold reduction in the 
IPTG concentration extended the duration taken for the MetC-expressing clone to form 
colonies at 28°C. Colonies of the MetC-expressing clone were usually observed after 1–2 
days of incubation on LB agar supplemented with 50 μM IPTG (Section 3.2.2.1). However, 
reducing the IPTG concentration to 5 μM led to colony formation in 5–7 days. The reduced 
IPTG concentration on the selective medium did not affect the rate of colony formation for 
the positive control clone and the negative control clone — the Alr-expressing clone still 
formed colonies after 1 day of incubation, whereas no colonies were observed for the clone 
expressing the empty pCA24N vector. 
 In the absence of D-Ala, mutant clones that grew faster than the MetC-expressing clone 
were selected as “winners”. A total of 1.0 ? 106 cfu were plated on the selective agar, as 
calculated from colony counts on non-selective medium. The number of plated clones 
represented a ~6.6? coverage of the initial library, which consisted of 1.5 ? 105 variants. The 
programme that calculates the library diversity and completeness, GLUE (Patrick et al., 
2003), suggested that 99.9% of the variants from the initial library were likely to be sampled 
during the selection experiment.  
 Pinprick-sized colonies were observed on the library plate after 1 day of incubation. By 
42 h, the colony sizes on the library plate reached 0.5–1.5 mm. An estimated 37,000 colonies 
were present, which corresponded to a survival rate of 3.7%. The growth of these mutant 
clones was nearly as good as that of the positive control (the Alr-expressing clone), which 
took 1 day to form colonies.  
3.2.4.3 RESELECTION OF FIRST-GENERATION METC VARIANTS  
The survival rate of the first-generation metC library on the IPTG-supplemented LB agar 
was high (3.7%), even though the IPTG concentration had been lowered to 5 μM (from the 
50 μM normally used for growth complementation assays). This implied that the selection 
system was not stringent enough to select for clear winners. The surviving MetC clones also 
showed a variety of colony sizes (0.5–1.5 mm) on the selective agar, which suggested that 
certain colonies grew faster than the rest. Therefore, the fastest-growing MetC clones were 
identified by another round of selection on LB-kanamycin agar alone. By omitting IPTG 
from the agar, it was hoped that only variants with high in vivo alanine racemase activities 
would be selected.  
 For the reselection test, I chose to focus on a subset of the 37,000 MetC clones that 
survived on the initial selective medium (Section 3.2.4.2), as it would be impractical to 
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screen all of them. Forty-eight colonies were randomly picked from the surviving 
populations, and restreaked on two sets of agar plates, LB with and without 5 μM IPTG. 
Consistent with the growth phenotypes described in the initial selection experiment 
(Section 3.2.4.2), all 48 clones grew on the IPTG-supplemented agar after 1 day of incubation 
(Figure 3.6). However, growth variations were observed for the clones in the absence of 
IPTG (Table 3.5; Figure 3.6). A general scale was used to rank the growth of each clone 
(Table 3.5), and clones that showed better growth (highlighted with red labels in Figure 3.6) 
were selected for further characterization.  
 
Table 3.5:  The growth phenotypes of the first-generation MetC clones after 1 day of incubation. 
Clone(s) Growth on LB-kanamycin 
agar + 5 μM IPTG  
Growth on LB-kanamycin 
agar alone  
A2, A4, A5, A6, A11, B1, B5, B6, B7, B9, B11, C2, 
C3, C7, C9, C11, C12, D1, D2, D4, D5, D6, D8, D9, 
D10, D11, D12 
++ ++ 
A1, A7, A9, A10, A12, B2, B3, B4, B8, B10, B12, C1, 
C4, C5, C6, C8, C10, D3, D7 ++ + 
A3, A8 ++ ? 
Template (MetC)  + ? 
Negative control (NoIns) ? ? 
 
Key for scoring growth: (?) No growth; (+) Little growth. Isolated colonies of <0.5 mm were observed; (++) 
Considerable growth. Isolated colonies of ~0.5 mm were observed. 
 A total of 27 clones were selected based on their better growth phenotype in the 
absence of IPTG (Table 3.5; Figure 3.6). Their plasmid-encoded metC genes were PCR-
amplified and sequenced to identify their mutations. DNA sequences were obtained for 24 
clones. Out of 24 clones, only clone A11 did not harbour any mutation in the metC gene. 
Instead, sequencing analysis of the lacIq gene and T5-lacO promoter region of the plasmid 
backbone revealed that a g?a DNA substitution was found in the lacO2 region. Since the 
lacO2 region is a binding site for LacIq, the g?a mutation was likely to disrupt the 
LacIq/lacO interaction, and led to leaky transcription. It seems likely that this leaky 
transcription had resulted in the increased levels of MetC in the cells, and further effected 
the improved growth of clone A11 in the absence of IPTG (Figure 3.6). 
 
- Chapter 3: Reciprocal promiscuity in two non-homologous enzymes - 
87
       
Figure 3.6:  The growth of selected first-generation MetC mutants on LB-kanamycin agar plates with and 
without 5 μM IPTG, after 1 day of incubation at 28°C. 
A general scale was used to rank the growth of each clone. Clones selected as “winners” based on their slightly 
better growth phenotype on LB agar without IPTG are labelled in red. 
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 The remaining 23 clones harboured 1–2 amino acid substitutions per clone. Notably, 
residue P113 of all 23 clones was mutated into either glutamine, alanine, threonine or serine 
(Table 3.6). The pool was dominated by the P113S mutation, which appeared in 17 out of 23 
clones. This was followed by the P113A mutation, which appeared in 4 clones. The 
remaining 2 clones carried the P113Q and P113T mutations, respectively. In total, only 8 
residues were mutated in the 23 clones. Overall, the 23 clones represented 12 distinct 
variants (Table 3.6), whose growth phenotypes were essentially indistinguishable in the 
absence of IPTG (Figure 3.6). 
 
Table 3.6:  Summary of the selected MetC variants from the reselection experiment. 
Variant Frequency Days to form colonies Mutation(s) 
MetC [Template] 5–7 None 
D11 10 1–2 P113S 
A6  2 1–2 P113S; 1 silent 
B7  2 1–2 P113A 
D12  1 1–2 P113A, D247E 
D2  1 1–2 L34M, P113A; 1 silent 
C12  1 1–2 P113T 
A4  1 1–2 P113Q; 1 silent 
B9  1 1–2 P113S, A237V 
A5  1 1–2 P113S, N321S 
C2  1 1–2 P113S, A325V 
D5  1 1–2 P113S, F331T 
B11  1 1–2 P113S, A246V; 1 silent 
A11*  1 1–2 None 
Alr [Positive control] 1 None 
NoIns [Negative control] No growth None 
 
*A regulatory mutation was found in clone A11. See text for details. 
 The 8 mutated residues were mapped to the tertiary and quaternary structures of E. 
coli MetC (Figure 3.7). A literature search confirmed that these mutated residues are not 
known to possess catalytic or substrate-binding roles. Only one residue (L34) is in the N-
terminal domain, which is important for tetramerization (Clausen et al., 1996). Residue L34 
- Chapter 3: Reciprocal promiscuity in two non-homologous enzymes - 
89
is located on the monomer-monomer interface, which is formed around a crystallographic 
2-fold axis (see Figure 3.7B for details). Four residues (P113, A237, A246, D247) are in the 
middle domain, where the active site and PLP are housed, but none of these residues are in 
the active site. The residue closest to the active site is P113, which was mutated in 23 out of 
24 winners. Similar to L34, residues A237 and D247 are also located on the monomer-
monomer interface. In particular, D247 is also located on the dimer-dimer interface, which 
is formed around a non-crystallographic diad axis (see Figure 3.7B for details). This puts 
D247 in a tetramer interface, where charged residues in this patch are known to interact 
with their symmetry mate from the opposite monomer (Clausen et al., 1996). The remaining 
three residues (N321, A325, F331) are in the C-terminal domain, and are physically located 
at the exposed surface area of the enzyme (Figure 3.7).  
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Figure 3.7:  Mutated residues from the first-generation MetC winner clones. 
The mutated residues from the first-generation MetC winner clones were mapped to the structure of E. coli MetC 
(PDB code: 1cl1). The biological unit of MetC is a tetramer, but the asymmetric unit in the PDB file is a dimer. The 
tetramer was recreated using the Sympexp command in MacPymol. Each PLP molecule is coloured according to its 
elements, while each residue is coloured differently. (A) Ribbon diagram of a MetC monomer and the position of 
the mutated residues. Loops have been smoothed for clarity. (B) Surface diagram of the quaternary structure of 
MetC. The mutated residues of each dimer are labelled in black and blue, respectively. The axis pointed by the red 
arrow is the monomer-monomer interface, whereas the axis pointed by the blue arrow is the dimer-dimer 
interface. 
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3.2.5 DIRECTED EVOLUTION OF METC (ROUND 2) 
Results from the first round of directed evolution revealed that P113 is potentially an 
important residue for the promiscuous alanine racemase activity of MetC. The majority of 
the winner clones harboured one of the following mutations: P113Q, P113A, P113T or 
P113S. Although all four P113 mutants and the positive control clone (Alr-expressing cells) 
took the same duration to form colonies on the selective medium (~1 day), I realized that 
the magnitude of in vivo improvements does not strictly correlate with in vitro 
improvements of a promiscuous activity (see previous discussion in Section 2.3.2 of Chapter 
2). For this reason, a second round of directed evolution was attempted to investigate if the 
in vivo and in vitro alanine racemase activity of the P113 mutants could be further improved.   
3.2.5.1 SECOND-GENERATION LIBRARIES 
All four P113 mutants (P113Q, P113A, P113T and P113S) were used as the templates for a 
second round of evolution. This would test whether the evolutionary trajectory of the 
various P113 mutants would differ in the course of evolving the alanine racemase activity. 
Random mutations were introduced into the metC inserts (from the P113 mutants) using 
epPCR. The inserts were then introduced into the pBAD vector (Invitrogen), which is a low-
copy number plasmid [its pBR322 origin of replication maintains 15–20 plasmid copies in a 
cell; (Qiagen, 2011)]. In addition, the PBAD promoter allows titratable, arabinose-inducible 
protein expression (Guzman et al., 1995). Such dose-dependent expression is in contrast 
with the all-or-nothing expression of the lac operon in the pCA24N vector of the first-
generation winners. In principle, the use of a tightly regulated, low-copy number vector 
allows further repression of the in vivo enzyme expression level. When the enzyme 
expression level is low, only variants with alanine racemase activity higher than the 
parental P113 clones would be selected. 
 Similar to the first-generation library, the second-generation libraries were initially 
constructed in E. coli DH5?-E. The number of distinct variants in the P113Q, P113A, P113T 
and P113S libraries were 1.3 ? 106 cfu, 9.1 ? 105 cfu, 6.6 ? 105 cfu and 2.2 ? 106 cfu, 
respectively. The mutation rate in each library was determined by sequencing 11–14 clones. 
In general, all second-generation libraries showed lower mutation rates (1.0–2.4 mutations 
per metC gene) than the first-generation library (3.0 mutations per metC gene). Table 3.7 
summarizes the type of mutations present in all four libraries, and their overall mutation 
rates. The variations in the mutational biases of the libraries emphasized the highly 
stochastic nature of epPCR, as these libraries were constructed simulatenously. For instance, 
the transition/transversion (Ts/Tv) ratios of the second-generation libraries ranged from 
0.8–2.0 (Table 3.7), while Stratagene (the manufacturer of the GeneMorph II kit) has 
expected a Ts/Tv ratio of 0.9 for every epPCR library constructed using the components 
from the kit.  
- Chapter 3: Reciprocal promiscuity in two non-homologous enzymes - 
92
 
Table 3.7:  The mutational spectrum of the second-generation metC libraries. 
Frequency (% proportion of total) 
Types of mutation 
MetC(P113Q) MetC(P113A) MetC(P113T) MetC(P113S) 
Number of clones sequenced 11 12 12 14 
Transitions     
A?G, T?C 3 (11.1%) 0 (0%) 4 (26.7%) 5 (29.4%) 
G?A, C?T 13 (48.1%) 6 (40%) 5 (33.3%) 5 (29.4%) 
Transversions     
A?T, T?A 3 (11.1%) 1 (6.7%) 0 (0%) 1 (5.9%) 
A?C, T?G 2 (7.4%) 0 (0%) 3 (20.0%) 0 (0%) 
G?C, C?G 2 (11.1%) 2 (13.3%) 2 (13.3%) 0 (0%) 
G?T, C?A 3 (7.4%) 5 (33.3%) 1 (6.7%) 4 (23.5%) 
Indels     
Insertion 1 (3.7%) 0 (0%) 0 (0%) 0 (0%) 
Deletion 0 (0%) 1 (6.7%) 0 (0%) 2 (11.8%) 
Summary of bias     
Transitions/Transversions 2.0 0.8 1.5 2.0 
AT?GC/GC?AT 0.2 0 1.2 0.6 
A?N, T?N 8 (29.6%) 1 (6.7%) 7 (46.7%) 6 (35.3%) 
G?N, C?N 18 (66.7%) 13 (86.7%) 8 (53.3%) 9 (52.9%) 
Mutation per kb 1.9 1.0 1.0 0.9 
Mutation per metC gene (1,227 bp) 2.4 1.2 1.3 1.0 
 
 PEDEL-AA (Firth & Patrick, 2008) was used to estimate the mutational diversity of 
each second-generation library on an amino acid level. The key characteristics of each 
library are tabulated in Table 3.8. As expected from the low DNA substitution rate per 
sequence, all libraries showed even lower average number of amino acid substitutions per 
variant. Nevertheless, all the second-generation libraries were predicted to contain >105 
distinct variants, which was greater than the number screened in the first-generation library 
(Table 3.4 in Section 3.2.4.1). 
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Table 3.8:  Summary of the key characteristics of the second-generation metC libraries based on their DNA 
mutational spectrum. 
Estimate 
Property 
MetC(P113Q) MetC(P113A) MetC(P113T) MetC(P113S) 
Vector background 3.1% 18.2% 10.7% 9.4% 
Total library size after subtracting vector 
background 1.3 ? 10
6 9.1 ? 105 6.6 ? 105 2.2 ? 106 
Number of variants with no indels or stop 
codons 1.1 ? 10
6 8.0 ? 105 6.4 ? 105 1.8 ? 106 
Mean number of amino acid substitutions 
per variant 1.6 0.8 0.9 0.7 
Unmutated (wildtype) sequences              
(% of library) 
36.5% 49.2% 51.8% 50.9% 
Number of distinct full-length proteins in 
the library 4.3 ? 10
5 1.7 ? 105 1.5 ? 105 2.9 ? 105 
 
3.2.5.2 SELECTION OF SECOND-GENERATION METC VARIANTS 
Plasmids from each of the second-generation libraries were pooled, and introduced into the 
selective host, E. coli MB2795. The four libraries were spread separately on LB-carbenicillin 
supplemented with different arabinose concentrations but without D-Ala (Table 3.9). The 
arabinose concentration chosen for each second-generation library represented the strongest 
selection stringency that could be applied. For every library, preliminary experiments were 
carried out to test the minimum arabinose concentration that permitted the growth of the 
parental clone (results not shown). When the arabinose concentrations were higher than the 
chosen concentration, the parental clones grew rapidly and thus, there was no room for 
selecting variants that outgrow the parental clones. In contrast, the parental clones did not 
grow if the arabinose concentrations were lower than the chosen concentration. 
 The arabinose concentration chosen for the P113Q, P113A, P113T and P113S libraries 
was 0.8 mM, 0.6 mM, 0.4 mM and 0.4 mM, respectively. Under these arabinose 
concentrations, the parental clones took 3–5 days to form full-sized colonies (i.e., colonies 
>0.5 mm in diameter). During the selection experiment, thousands of full-sized colonies 
were observed for each library after only 1 day of incubation. Given that each library was 
over-sampled by 9- to 18-fold, the survival rate for these libraries was <0.02% (Table 3.9). 
The low survival rates of the second-generation libraries indicated that the selection 
stringencies were considerably higher than the first-generation library, whose survival rate 
was 3.7% (Section 3.2.4.2).  
 
 
- Chapter 3: Reciprocal promiscuity in two non-homologous enzymes - 
94
Table 3.9:  Results summary of the selection of second-generation metC libraries on 0.4–0.8 mM arabinose. 
Second-generation libraries 
Summary 
MetC(P113Q) MetC(P113A) MetC(P113T) MetC(P113S) 
Arabinose concentration 0.8 mM 0.6 mM 0.4 mM 0.4 mM 
Coverage of the initial library 17.7?  8.5? 12? 9.8? 
Survival rate 0.005% 0.075% 0.014% 0.019% 
Growth improvements shown by 
winner clones ~3-fold ~3-fold ~4-fold ~4-fold 
 
3.2.5.3 RESELECTION OF SECOND-GENERATION METC VARIANTS 
Although the survival rates of the second-generation libraries were low, the large number 
of colonies in each library rendered further characterizations impractical within the time 
frame of this study. These large numbers of winners were likely due to the over-sampling of 
the libraries. For instance, the size of the P113Q library was 1.3 ? 106, but a total of 2.3 ? 107 
cfu were plated on the selective agar, and thus ensuring that the initial library was covered 
by almost 18-fold. In other words, there would be 18 clones of the same winner in the pool 
of surviving colonies. 
 To further increase the stringency of selection, the arabinose concentration was 
reduced to 0.1 mM for all four second-generation libraries. A smaller number of cells were 
plated, so that the final coverage of each library was less than 6 fold (Table 3.10). For each 
library, full-sized colonies still appeared after 1 day of incubation, although the arabinose 
concentration had been reduced to a concentration at which all parental clones barely grew 
at all (results not shown). Approximately 180 cfu was observed for the P113Q library, 700 
cfu for the P113T library, and 3,000 cfu for each of the P113A and P113S libraries. Despite 
the lower number of colonies appearing in each library, the survival rates did not change 
significantly (compare Table 3.9 and Table 3.10). 
 
Table 3.10:  Results summary of the reselection of second-generation metC libraries on 0.1 mM arabinose. 
Second-generation libraries 
Summary 
MetC(P113Q) MetC(P113A) MetC(P113T) MetC(P113S) 
Arabinose concentration 0.1 mM 0.1 mM 0.1 mM 0.1 mM 
Coverage of the initial library 2.9?  5.4? 3.9? 2.9? 
Survival rate 0.005% 0.059% 0.027% 0.049% 
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 The growth of the winner clones at such low arabinose concentration (0.1 mM) 
prompted me to investigate whether these clones would also grow in the absence of 
arabinose. Twenty-four colonies were randomly picked from each library and re-streaked 
on LB-carbenicillin agar alone. In the absence of arabinose (and D-Ala), all 24 clones from 
each library did indeed grow into full-sized colonies after 1 day of incubation (Figure 3.8). 
To test if the LB-carbenicillin agar plates were contaminated with D-Ala or arabinose (and 
hence, permitting the growth of all 96 winner clones), various parental and negative control 
clones were also streaked on the same batch of agar plates. However, no growth was 
observed for all the parental and negative control clones, even up to 1 week of incubation 
(Figure 3.9). Therefore, this confirmed that the growth of the winner clones (Figure 3.8) was 
not effected by arabinose or D-Ala contamination in the agar.  
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Figure 3.8:  The growth of the selected second-generation MetC mutants in the absence of arabinose and D-Ala, 
after 1 day of incubation at 28°C. 
The 24 winner clones were picked from the (A) P113Q library. (B) P113A library. (C) P113T library. (D) P113S 
library.  
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Figure 3.9:  The lack of growth of various parental and negative control clones in the absence of arabinose, even 
after 1 week of incubation. 
 
 After PCR-screening the 24 clones from each library, less than half was tested positive 
for a pBAD-encoded metC gene. A total of eight positive clones were identified for the 
P113Q library, three positive clones for the P113A library, five positive clones for the P113T 
library and ten positive clones for the P113S library. The plasmid-encoded metC genes 
amplified from these 26 clones were sequenced.  
 Table 3.11 summarizes the mutations (or the lack thereof) in the pBAD-encoded metC 
gene of the sequenced clones. Sequencing analysis revealed that seven out of eight variants 
from the P113Q library, and one variant from the P113A library, consisted of heterogeneous 
populations based on the presence of mixed DNA templates. The remaining variant from 
the P113Q library, all five variants from the P113T library as well as four variants from the 
P113S library, did not harbour additional mutation apart from their P113 mutation. For the 
two variants from the P113A library, an A113P substitution had reverted their MetC to the 
wildtype enzyme. Overall, no new mutations were found in the metC genes of the winner 
clones from the P113Q, P113A and P113T libraries, even though the winner clones grew in 
the absence of arabinose. 
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 On the contrary, additional mutations were found in the P113S-2, P113S-14 and P113-
16 variants from the P113S library. The three variants carried two new amino acid 
substitutions, in addition to their parental P113S mutation. Furthermore, four out of the ten 
sequenced clones from the P113S library were the P113S-14 variant, which suggested that 
mutation at I251 (in addition to P113) might be important for improving the alanine 
racemase activity of MetC. On the whole, only three mutated variants were selected from all 
the second-generation libraries, and all three variants were from the P113S library.  
 
Table 3.11:  Mutations found in the second-generation winners. 
Variant Frequency Day to form colonies in the absence of arabinose Mutation(s) 
The P113Q library   
MetC(P113Q) [Template] No growth up to 7 days P113Q 
P113Q-12  1 1 P113Q 
The P113A library   
MetC(P113A)  [Template] No growth up to 7 days P113A 
P113A-9 2 1 A113P; 2 silent 
The P113T library   
MetC(P113T)  [Template] No growth up to 7 days P113T 
P113T-20 5 1 P113T 
The P113S library   
MetC(P113S)  [Template] No growth up to 7 days P113S 
P113S-2  1 1 P113S, P156L, A227T 
P113S-14*  4 1 P113S, I251M 
P113S-16  1 1 P113S, K120N, P352A, 1 silent 
P113S-18 4 1 P113S 
 
*An R?W amino acid substitution was also found in the second residue of the linker sequence, which is located 
between the N-terminal (His)6-tag and the metC gene. 
 For the variants whose genotype was identical to their parental P113 clone, it was 
hypothesized that their growth in the absence of arabinose was due to the presence of 
chromosomal mutations or regulatory mutations on the plasmid. To test this possibility, 
recloning, retransformation and restreaking tests were carried out. The pBAD-encoded 
metC insert from these clones were isolated and re-ligated with freshly linearized pBAD 
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vector. After transforming the ligated product into a new batch of host (E. coli MB2795), the 
clones were restreaked on the same selective medium (LB-carbenicillin) and incubated 
under identical conditions. However, no growth was observed for any of the retransformed 
clones, for up to 19 days of incubation (results not shown). The results were in contrast to 
the 1-day growth phenotype exhibited by these clones during the initial selection 
experiment (Figure 3.8). Hence, results from these recloning, retransformation and 
restreaking tests suggested that the growth of the “unmutated” clones in the absence of 
arabinose was caused by either chromosomal or regulatory mutations.  
 Retransformation and restreaking tests were also used to validate the growth 
phenotypes of the mutated variants, namely P113S-2, P113S-14 and P113S-16. Plasmids 
were extracted from these clones, and used to transform a fresh batch of competent E. coli 
MB2795. Retransformed clones were restreaked on the LB-carbenicillin agar lacking 
arabinose. After 1 day of incubation, full-sized colonies were observed for all three 
retransformed clones (Figure 3.10). This observation was consistent with the 1-day growth 
phenotype shown by these mutated clones during the initial selection experiment (Figure 
3.8D). Thus, these mutated variants were deemed the winner clones of the entire second 
round of directed evolution. 
 
       
Figure 3.10:  The growth of the retransformed clones of P113S-2, P113S-14 and P113S-16, on LB-carbenicillin 
after 1 day of incubation at 28°C. 
The agar plates on the left did not contain any arabinose, whereas the agar plates on the right were supplemented 
with 0.1 mM arabinose. 
- Chapter 3: Reciprocal promiscuity in two non-homologous enzymes - 
100 
 The mutations found in the P113S-2, P113S-14 and P113S-16 variants were mapped to 
the tertiary and quaternary structures of E. coli MetC (Figure 3.11). A total of five new 
mutated residues were identified from these second-generation winners. Similar to the 
mutated residues found in the first-generation winners, little is known about the mutated 
residues of the P113S-2, P113S-14 and P113S-16 variants. Furthermore, the second-
generation mutated residues are different from those of the first-generation. Most of the 
second-generation mutated residues are located in the middle-domain of MetC, but the 
first-generation mutated residues are distributed almost evenly between the middle and C-
terminal domains. Specifically, four of the five mutated residues (K120, P156, A227 and 
I251) from the P113S-2, P113S-14 and P113S-16 variants are located in the middle-domain of 
MetC, while only 1 mutated residue (P352) is found in the C-terminal domain. 
 Yet, none of these five mutated residues is located near the active site — a trend that 
was also noted for the first-generation mutations. Three residues (K120, A227 and P352) 
were located on the exposed enzyme surface, with K120 close to the monomer-monomer 
interface (Figure 3.11). On the other hand, residue I251 is located near the tetramerization 
core of MetC. Along with mutations at A246 and D247 (found in the first-generation winner 
clones; Figure 3.7 in Section 3.2.4.3), mutation at I251 might therefore affect the 
oligomerization state of the protein.  
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Figure 3.11:  Mutated residues from the second-generation MetC winner clones. 
The mutated residues from the second-generation MetC winner clones were mapped to the structure of E. coli 
MetC (PDB code: 1cl1). The biological unit of MetC is a tetramer, but the asymmetric unit in the PDB file is a dimer. 
The tetramer was recreated using the Sympexp command in MacPymol. Each PLP molecule is coloured according 
to its elements, while each residue is coloured differently. (A) Ribbon diagram of a MetC monomer and the 
position of the mutated residues. Loops have been smoothed for clarity. (B) Surface diagram of the quaternary 
structure of MetC. The mutated residues of each dimer are labelled in black and blue, respectively. The axis 
pointed by the red arrow is the monomer-monomer interface, whereas the axis pointed by the blue arrow is the 
dimer-dimer interface. 
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3.2.6 THE IN VIVO NATIVE ACTIVITY OF THE SELECTED METC VARIANTS 
Two rounds of directed evolution yielded MetC variants that could efficiently rescue the D-
Ala auxotroph, E. coli MB2795. The implication was that the in vivo alanine racemase 
activity of these MetC variants was higher after each round of selection. However, it was 
not known if the in vivo alanine racemase activity was improved at the expense of the 
enzyme’s native activity. Hence, all four first-generation MetC variants (P113Q, P113A, 
P113T and P113S) and three second-generation MetC variants (P113S-2, P113S-14 and 
P113S-16) were expressed in E. coli ?metC to investigate their in vivo cystathionine ?-lyase 
activity. The clones were streaked on two sets of M9/glucose agar: one set with 50 μM 
arabinose and the other set without arabinose. Clone expressing the wildtype MetC served 
as the positive control, whereas a LacZ-expressing clone served as the negative control. 
 Table 3.12 summarizes the growth differences shown by various clones after 3 days of 
incubation at 28°C. Generally, the growth of the first-generation MetC variants was worse 
than the positive control on both sets of agar plates (Figure 3.12). In particular, the P113Q 
and P113T clones showed the poorest growth among all clones. This was followed by the 
P113A variant, whose growth was average in comparison to the confluent growth of the 
positive control clone. The growth of the P113S variant was reasonably good (although not 
as comparable to the growth of the positive control), and was considered the best among all 
first-generation MetC variants. These results suggested that the P113 mutations, which 
conferred improvements to the in vivo alanine racemase activity of MetC, were likely to be 
detrimental to the cystathionine ?-lyase activity of MetC. 
 However, clones expressing the second-generation MetC variants grew better than the 
clones expressing first-generation MetC variants (Table 3.12). Even in the absence of 
arabinose, the growth of the second-generation variants was comparable to that of the 
positive control (Figure 3.12). This implied that the mutations of the second-generation 
variants seemed to be able to confer in vivo improvements to both alanine racemase (Figure 
3.10) and cystathionine ?-lyase activities (Figure 3.12). This observation was rather 
unexpected because the native activity of MetC had not been selected throughout the two 
rounds of directed evolution.  
 One possible explanation for the confluent growth shown by the second-generation 
variants was that there were regulatory mutations, in addition to the structural mutations 
detected previously (Table 3.11). It was realized at a later time that previous 
retransformation and restreaking tests used to confirm the growth phenotype of the second-
generation winners (Figure 3.10) could not rule out the presence of regulatory mutations, 
because the metC inserts of the second-generation winners had not been recloned into fresh 
pBAD vectors. In vitro characterization of the activities of these MetC variants appeared to 
confirm this possibility (Section 3.2.7). 
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Table 3.12:  Growth summary of E. coli ?metC harbouring different MetC variants on selective medium after 3 
days of incubation. 
Variant Growth on M9/glucose 
agar + 50 μM arabinose 
Growth on M9/glucose 
agar alone 
LacZ ? ? 
MetC ++++ ++++ 
MetC(P113Q) + +/? 
MetC(P113A) ++ ++ 
MetC(P113T) + +/? 
MetC(P113S) +++ ++ 
MetC(P113S-2) ++++ ++++ 
MetC(P113S-14) ++++ ++++ 
MetC(P113S-16) ++++ ++++ 
 
Key for scoring growth: (?) No growth; (+/?) Poor growth. Colony size was <0.1 mm; (+) Little growth. Colony 
sizes ranged from 0.1–0.5 mm; (++) Average growth. Colony sizes ranged from 0.5–1.0 mm; (+++) Good growth. 
Colony sizes ranged from 0.5–1.5 mm; (++++) Confluent growth. Colonies ranged from 1.0–2.0 mm. 
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Figure 3.12:  The growth of E. coli ?metC clones harbouring different MetC variants on M9/glucose agar with 
and without 50 μM arabinose, after 3 days of incubation at 28°C. 
 
3.2.7 ENZYME ACTIVITIES OF METC MUTANTS 
For in vitro characterizations, all seven MetC mutants (P113Q, P113A, P113T, P113S, P113S-
2, P113S-14 and P113S-16) were expressed in E. coli MB2795, and purified to >95% purity, as 
previously described (Section 2.4.5 in Chapter 2). All enzyme variants appeared largely 
soluble, although their yields were lower than wildtype MetCs, as judged by SDS-PAGE 
(compare Figure 3.13 versus Figure 2.12A). This was likely to be caused by the lower 
expression, and copy number, of pBAD plasmids in the cell. The final enzyme yields for all 
MetC mutants were <10 mg/L of culture. The yield of the P113A variant was the highest 
(9.3 mg/L of culture), while the yield of the P113S-14 variant was the lowest (2.9 mg/L of 
culture). Overall, the proportion of PLP-bound enzymes in the MetC mutants (30% to 50%) 
was generally lower than that of wildtype MetC (>70%; Section 2.2.4.1 in Chapter 2).  
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Figure 3.13:  SDS-PAGE analyses of the purified MetC mutants.  
(A) Purification of MetC(P113Q). (B) Purification of MetC(P113A). (C) Purification of MetC(P113T). (D) Purification 
of MetC(P113S). (E) Purification of MetC(P113S-2). (F) Purification of MetC(P113S-14). (G) Purification of 
MetC(P113S-16). Each lane [except lanes 1 and 2 of panel (D)] was loaded with a 6-μL aliquot from the 
corresponding fractions. Lane 1, Crude cell lysate before arabinose induction. Lane 2, Crude cell lysate after 6 
hours of protein over-expression. Lane 3, Insoluble fraction. Lane 4, Soluble lysate. Lanes 5 and 13, Bio-Rad 
Precision Plus protein All Blue standard. Lane 6, Proteins not bound to the Talon® metal affinity resin. Lanes 7–8, 
Batch washes. Lane 9, Flow-through from the enzyme-bound resin in the gravity flow column. Lanes 10–11, 
Column washes with low imidazole concentration (3 mM). Lane 12, Column wash with high imidazole 
concentration (15 mM). Lanes 14–19, Elution fractions 1–6. The lanes 1 and 2 of panel (D) were empty due to 
accidental loss of samples. 
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 After dialyzing each MetC variant into a buffer without ?-mercaptoethanol, the 
dialyzed enzyme fractions were used for the in vitro assays. Both the alanine racemase and 
the cystathionine ?-lyase activities of each MetC variant were assayed 
spectrophotometrically as previously described (Section 2.4.7 in Chapter 2; and Section 
3.4.6). The kinetic parameters for all seven MetC variants are summarized in Table 3.13. The 
kinetic parameters were established from the mean of three repeats, with each repeat value 
representing the mean of duplicate assays.  
 
Table 3.13:  Kinetic parameters of MetC and selected variants from the first- and second-generation libraries. 
Cystathionine ?  Homocysteine + Pyruvate + NH3 L-Ala ?  D-Ala 
Enzyme 
kcat (s-1) KM (M) kcat/KM (s-1.M-1) kcat (s-1) KM (M) kcat/KM (s-1.M-1) 
Native enzymes     
MetC 89.5 ± 13.9 (3.9 ± 0.7) ? 10
-5 2.3 ? 106 3.3 ± 0.6 (5.1 ± 0.4) ? 10-2 65 
Alr †n.d. n.d. <0.85 55.3 ± 3.7 (8.7 ± 1.5) ? 10-4 6.4 ? 104 
First-generation mutants     
P113Q 95.6 ± 7.5 (1.2 ± 0.2) ? 10-4 8.0 ? 105 3.6 ± 0.6 (3.3 ± 1.0) ? 10-2 1.1 ? 102 
P113A 81.1 ± 10.8 (3.1 ± 0.7) ? 10-4 2.6 ? 105 4.6 ± 0.5 (2.3 ± 0.5) ? 10-2 2.0 ? 102 
P113T 30.4 ± 2.0 (2.1 ± 0.2) ? 10-4 1.4 ? 105 5.8 ± 0.5 (3.9 ± 0.4) ? 10-2 1.5 ? 102 
P113S 94.6 ± 3.2 (1.2 ± 0.2) ? 10-4 7.9 ? 105 21.6 ± 0.4 (5.8 ± 0.3) ? 10-2 3.7 ? 102 
Second-generation mutants   
P113S-2 76.0 ± 15.7 (2.0 ± 0.4) ? 10-4 3.8 ? 105 11.9 ± 0.1 (7.1 ± 1.0) ? 10-2 1.7 ? 102 
P113S-14 103.2 ± 16.2 (1.9 ± 0.6) ? 10-4 5.4 ? 105 20.5 ± 2.1 (5.6 ± 1.4) ? 10-2 3.7 ? 102 
P113S-16 76.0 ± 4 (1.4 ± 0.4) ? 10-4 5.4 ? 105 16.3 ± 3.4 (5.2 ± 0.7) ? 10-2 3.1 ? 102 
 
Each value represented the mean ± S.E.M. (n = 3), and each value was obtained as the mean of duplicate assays. 
†n.d., not determined. 
 The catalytic efficiency (kcat/KM) for alanine racemization by each of the first-generation 
MetC mutants ranged from 110 to 370 s-1.M-1, which corresponded to an increase of 1.7-fold 
to 5.7-fold over wildtype MetC (65 s-1.M-1). In comparison with wildtype MetC, the KM for L-
Ala was slightly decreased and the kcat values were largely unchanged for the P113Q, P113A 
and P113T variants. On the other hand, the kinetic changes in the P113S variant were 
opposite to the other P113 mutants. A modest 6.5-fold increase was observed for the kcat of 
P113S, while its KM was similar to the wildtype MetC. The P113S mutant was also the 
variant with the highest alanine racemase activity among the first-generation mutants, with 
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a 5.7-fold improvement over wildtype MetC based on their catalytic efficiencies. Overall, 
the alanine racemase activity of the P113S variant was only 170-fold lower than wildtype 
Alr.  
   All three second-generation MetC variants were expected to display higher in vitro 
alanine racemase activity than the P113S variant, since the latter was their parental variant. 
However, this trend was not observed. The catalytic efficiency, KM and kcat values of the 
P113S-14 and P113S-16 variants were comparable to those of the P113S variant. The P113S-2 
variant even showed a 2-fold lower kcat and a 1.2-fold higher KM than the P113S variant. 
Although these results appeared rather counter-intuitive, they appeared to support the 
hypothesis that additional regulatory mutations might be present in their plasmid backbone 
(see Section 3.2.6 for the discussion). These regulatory mutations might increase the 
expression, or even allow constitutive expression, of MetC in the cell. As a result, the 
second-generation MetC variants would rescue E. coli MB2795 (Figure 3.10) and E. coli 
?metC (Figure 3.12 in Section 3.2.6) better than the P113S variant. This elevated, or 
constitutive, expression of MetC could be apparent on the SDS-PAGE analyses, where the 
crude cell lyates at t = 0 (Lane 1 of Figure 3.13E, F and G) would show a heavy band that 
corresponded to the size of MetC. However, this was not observed. Further investigations 
are needed to confirm the presence of such regulatory mutations in the second-generation 
MetC variants, and to determine whether these regulatory mutations are solely responsible 
for the fitness-enhancing effects in growth complementation assays.  
 In comparison to wildtype MetC, the cystathionine ?-lyase activity of the first-
generation MetC variants was decreased by 3- to 16-fold (Table 3.13). The P113T variant 
showed the lowest cystathionine ?-lyase activity due to a kcat value that was 3-fold lower 
than that of wildtype MetC. The P113T variant was also the only one with a lowered kcat, 
while the kcat of the P113Q, P113A and P113S variants remained similar in comparison with 
the wildtype MetC. On the whole, the KM of all the first-generation variants was increased 
by 3- to 5-fold. For the second-generation variants, their cystathionine ?-lyase activity was 
lower than their parental P113S variant, albeit by a mere 1.4- to 2-fold (Table 3.13). Among 
these variants, the P113S-2 variant showed the lowest cystathionine ?-lyase activity, which 
was approximately 6-fold lower than wildtype MetC.  
 Activity trade-offs of the MetC variants are illustrated in Figure 3.14, where both of 
their cystathionine ?-lyase and alanine racemase activities were plotted. All P113 mutations 
appeared to decrease the enzyme’s cystathionine ?-lyase activity by ?3-fold, while only 
improving the alanine racemase activity by ?2-fold. Overall, the alanine racemase activity of 
these MetC variants appeared to be improved at the expense of their native activity.  
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Figure 3.14:  Activity trade-off in MetC variants. 
 
3.3 DISCUSSION 
3.3.1 ALANINE RACEMASE ACTIVITY OF METC 
At the outset of this work, I expected that the E. coli MB2795 strain could be rescued by 
promiscuous alanine racemase activity in the cells. I speculated that the in vivo alanine 
racemase activity could potentially stem from the following enzymes: 
(A) General racemases or epimerases. All racemases and epimerases, including E. coli Alr, 
interconvert L- and D-isomers in their active sites by having proton donors and acceptors 
arranged in opposite planes. The similar arrangements of proton donors and acceptors in 
the active sites would provide a favourable environment for alanine racemization. Besides, 
the chances that alanine will be recognized as a substrate in other racemases or epimerases 
are high because alanine is a relatively small substrate. Among the 4 racemases and 23 
epimerases in E. coli (Keseler et al., 2009), many isomerize amino acids and other small 
substrates. For instance, glutamate racemase isomerizes glutamate (Yoshimura et al., 1993; 
Lundqvist et al., 2007). It was appealing to hypothesize that the active site of glutamate 
racemase could also accommodate alanine at physiological levels since alanine is an even 
smaller amino acid than glutamate.  
(B) (? /?)8-barrel enzymes. E. coli Alr possesses a (?/?)8-barrel (also known as TIM-barrel) 
fold, and promiscuous activities arising from TIM-barrel enzymes have been well-
- Chapter 3: Reciprocal promiscuity in two non-homologous enzymes - 
110 
documented. For instance, TIM-barrel enzymes found in enzyme superfamilies such as the 
amidohydrolases (Roodveldt & Tawfik, 2005; Afriat et al., 2006)  and the enolases (Palmer et 
al., 1999; Thoden et al., 2004) are known to catalyze secondary functions. Specific examples 
include HisA [N’-(5’-phosphoribosyl)formimino-5-aminoimidazole-4-carboxamide 
ribonucleotide isomerase], which is able to catalyze the TrpF (phosphoribosylanthranilate 
isomerase) reaction, although both enzymes belong to different biosynthetic pathways 
(Jürgens et al., 2000; Henn-Sax et al., 2002). As the TIM-barrel fold is a common fold in 
prokaryotes (Wolf et al., 1999), I speculated that there could be TIM-barrel enzymes in E. coli 
that might catalyze alanine racemization.  
(C) Other PLP-dependent enzymes. Promiscuous activities are rather common in PLP-
dependent enzymes due to their shared mechanistic chemistry. It was possible that other 
PLP-dependent enzymes in E. coli, in addition to Alr, might be able to catalyze alanine 
racemization. One of the probable candidates was diaminopimelate decarboxylase (PDB 
code: 1KNW, Unpublished work by Levdikov et al.), as this also possesses a TIM-barrel 
domain. However, following the results from Chapter 2, I also expected that promiscuous 
alanine racemase activity could arise in other non-homologous, PLP-dependent enzymes.  
 
 Indeed, results from the ?alr ?dadX suppression screen revealed that the last 
speculation was right — one of the suppressors was found to express MetC, a PLP-
dependent enzyme that is non-homologous to Alr (Section 3.2.1). Even so, the discovery 
that MetC could rescue E. coli MB2795 was unexpected. Recall that, in Chapter 2, Alr was 
found to catalyze MetC’s activity in vivo and in vitro. In a reciprocal manner, the in vivo and 
in vitro alanine racemase activity of MetC were discovered and characterized in this chapter. 
Overall, the discovery of this reciprocal activity profiles shown by MetC and Alr was far 
from the initial predictions. 
 The in vitro alanine racemase activity of MetC was initially expected to be low, as 
promiscuous activities stemming from non-homologous scaffolds are generally low [Alr 
from Chapter 2; YeaB from Kim et al. (2010); PurF from Patrick & Matsumura (2008)]. 
However, the kcat/KM of MetC for alanine racemization (65 s
-1.M-1) was at least 80-fold higher 
than other promiscuous activities previously reported (0.85 s-1.M-1 for an evolved Alr 
variant; ~0.3 s-1.M-1 for an evolved PurF variant; >0.024 s-1.M-1 for YeaB). In particular, the 
kcat for L-Ala turnover by MetC (~3 s
-1) was less than 4-fold lower than the average “global” 
kcat of 10 s
-1, which was derived from several thousand enzymes (Bar-Even et al., 2011). 
Based on the kcat value, alanine racemization may occur in MetC at a rate of approximately 
200 turnovers per minute (or 12,000 turnovers per hour) — a rate that was clearly sufficient 
to sustain the growth of the D-Ala auxotroph, E. coli MB2795, in the absence of D-Ala. 
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 Another group has also recently discovered that upregulation of MetC in an E. coli 
BL21(DE3)/?alr ?dadX strain led to the formation of prototrophic revertants in the absence 
of D-Ala (Kang et al., 2011). Point mutations in the metJ repressor were ascribed to the 
increased MetC expression level in the revertants. Their results were analogous to the 
findings reported here, where the growth of E. coli MB2795 was effected by over-expression 
of the plasmid-encoded MetC. The overall implication is that MetC expression in E. coli 
could be up-regulated to physiologically relevant levels by regulatory mutations. These 
regulatory mutations can increase enzyme expression to compensate for the low 
promiscuous activity (see previous discussion in Section 2.3.2 of Chapter 2).  
3.3.2 IN VITRO EVOLUTION OF METC 
Despite the structural differences shown by MetC and Alr (see previous discussion in 
Section 2.3.1 of Chapter 2), I attempted to improve the alanine racemase activity on the 
MetC scaffold. After one round of directed evolution, mutations were observed for P113 in 
almost all selected MetC variants. The prevalence of P113 mutations implied that the 
residue was critical for the fitness improvements seen in MetC clones selected in the 
absence of D-Ala (Table 3.5 in Section 3.2.4.3). To my knowledge, the role of P113 has not 
been studied in any MetC enzyme.  
 Residue P113 is located in the vicinity of the active site of MetC (Figure 3.16), 
especially close to Y111. Two roles have been proposed for Y111 (Clausen et al., 1996; 
Clausen et al., 1997b): proton abstraction from the ?-amino group of cystathionine (the 
substrate) during the transaldimination step (Panel II of Figure 3.15), and re-protonation of 
the PLP derivative of aminoacrylate after the elimination of homocysteine (Panel IV of 
Figure 3.15). The re-protonated aminoacrylate forms iminopropionate, which would diffuse 
from the active site (and spontaneously hydrolyze into pyruvate and ammonia). As shown 
in Figures 3.16, the short distance (3.6 Å) between the phenolate ion of Y111 and the ?-
amino group of a MetC substrate analogue [aminoethoxyvinylglycine (AVG), which is also 
an inhibitor] may facilitate proton transfer. While P113 is not directly involved in the 
catalytic mechanism of MetC, the kinetic data suggested that mutations at P113 might 
mediate catalytic changes in an alternative manner. It was rather unlikely that the P113 
mutations altered the hydrophobicity or steric effects in the active site, because the side 
chains of all four P113 mutations are not of the same length, nor belong to the same 
chemical group. For example, the side chains of S113 and A113 are shorter in length than 
those of T113 and Q113. Also, S113, T113 and Q113 carry polar side chains, whereas A113 
harbours a hydrophobic side chain. There was also lack of evidence that the P113 mutations 
were changing the substrate preference of MetC from cystathionine to alanine (Table 3.13 in 
Section 3.2.7). The KM values of the P113 mutants for alanine were generally unchanged in 
comparison to wildtype MetC. 
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Figure 3.15:  The proposed cystathionine ?-elimination mechanism of MetC. 
Transaldimination occurs after cystathionine (Panel I) binds to the PLP, and results in the formation of an external 
aldimine (Panel II). The proton of cystathionine is abstracted to yield a resonance stabilized ketimine quinonoid 
intermediate (Panel III). Homocysteine (abbreviated as RSH) is then eliminated (as a result of protonation of S? by 
K210), and a PLP derivative of aminoacrylate is formed (Panel IV). Re-protonation of the aminoacrylate by Y111 
yields iminopropionate, and leads to regeneration of the enzyme-bound PLP. The iminopropionate is hydrolyzed 
to pyruvate and ammonia after it is released from the active site.  Figure taken from Clausen et al. (1997a). 
 The racemization activity in Alr requires a catalytic pair (K34 and Y255’) at opposite 
planes for proton transfers (Figure 2.28 in Section 2.3.1). A similar arrangement was also 
found in MetC — K210 and Y111 are arranged in such a way that alanine racemization 
appears spatially and chemically possible (Figures 3.16B and D). Based on the arrangement 
of K210 and Y111 in MetC, it was initially speculated that the P113 mutations might have 
caused a subtle rearrangement of Y111 in the active site. Since both P113 and Y111 are 
located at the start of helix 6, mutations at P113 might bring Y111 closer to the substrate 
(and PLP), thereby facilitating proton transfers. Consequently, the more efficient proton 
transfers would hypothetically lead to higher racemization activity, as evident from the 7-
fold improvement in kcat for the P113S mutant (Table 3.13 in Section 3.2.7). However, the 
unaffected kcat for alanine racemization in the P113Q, P113A and P113T mutants do not 
appear to support this speculation. Furthermore, the closer distance between Y111 and the 
substrate might also affect the turnover of cystathionine in MetC, since the cystathionine ?-
lyase activity also requires the protonation and deprotonation steps (Figure 3.15). Yet, the 
kcat for cystathionine turnover was largely unaffected for the P113 mutants (Table 3.13 in 
Section 3.27).  
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Figure 3.16:  Surface diagrams of the active site of E. coli MetC. 
The PLP-AVG complex, P113 and the catalytic pair (K210 and Y111) are shown as sticks. The E. coli MetC bound to 
AVG (PDB code: 1cl2) was used as the template for modelling. The distance between the phenolate ion of the Y111 
and the ?-amino group of the AVG is 3.6 Å. (A) & (C) The active site viewed from the substrate entranceway. 
Residue P113 is highlighted in magenta, whereas S113 is modelled as purple. (B) & (D) Side view of the active site.  
 Mutations that improve the promiscuous activity often compromise the native activity 
of the enzyme (Jürgens et al., 2000; Seebeck & Hilvert, 2003), because such mutations tend to 
disrupt the optimal catalytic or binding environments for the native substrate. Indeed, 
moderate activity trade-offs were observed for the first-generation MetC mutants (Figure 
3.14 in Section 3.2.7). However, the moderate reductions in the cystathionine ?-lyase activity 
(Table 3.13 in Section 3.2.7) may be pivotal for the overall improvements of the alanine 
racemase activity, because such reductions may divert the activity flux in MetC towards the 
alanine racemase activity (Copley, 2012). Activity flux, or catalytic preference, can be 
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defined as the ratio of activity A to activity B. Figure 3.17 illustrates the catalytic preference 
of each MetC variant as a ratio of its promiscuous (alanine racemase) activity to its native 
(cystathionine ?-lyase) activity. Wildtype MetC shows a low catalytic preference towards 
the alanine racemase activity, as its cystathionine ?-lyase activity is four orders of 
magnitude higher than the racemase activity (Table 3.13 in Section 3.2.7). In comparison to 
wildtype MetC, the MetC mutants showed significantly higher preference towards the 
alanine racemase activity due to moderate decreases in the cystathionine ?-lyase activity 
and modest increases in the alanine racemase activity. Among all the mutants, the P113T 
variant showed the highest catalytic preference towards the alanine racemase activity — its 
catalytic preference of 0.001 is 38-fold higher than the wildtype MetC. The high preference 
for alanine racemase activity in the P113T variant is attributed to its poor kcat/KM for its 
native activity (Table 3.13 in Section 3.2.7). On the other hand, the variants with the highest 
alanine racemase activity among all mutants, P113S and P113S-14, display a slight 
difference in their catalytic preferences. Due to a lower cystathionine ?-lyase activity, the 
catalytic preference of P113S-14 variant was 1.5-fold higher than P113S (Figure 3.17). Taken 
together, mutations at the residue P113 can either increase the promiscuous alanine 
racemase activity, or decrease the native cystathionine ?-lyase activity on the MetC scaffold. 
Based on the catalytic efficiencies, the P113S mutation seems to increase the promiscuous 
activity, while the P113T was responsible for the decrease in MetC’s native activity.  
 
 
Figure 3.17:  Catalytic preferences of MetC variants 
For each MetC variant, the catalytic preference was derived from the ratio of kcat/KM of the alanine racemase 
activity to kcat/KM of the cystathionine ?-lyase activity. 
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 To elucidate the roles of P113S and P113T mutations in altering the catalytic 
preferences on the MetC scaffold, the Squire group (University of Auckland) is attempting 
to solve the structures of both mutant enzymes. Crystal structures of the native and the 
inhibitor-bound P113S and P113T mutants will be solved. The inhibitor of the enzyme, (R)-
1-aminoethylphosphonic acid [L-Ala-P], is a synthetic L-Ala analogue that forms an external 
aldimine with alanine racemases (Stamper et al., 1998). As L-Ala-P is neither racemized nor 
hydrolyzed, the L-Ala-P-bound enzymes will be trapped in a non-reactive intermediate 
state. Although L-Ala-P is not known to inhibit MetC, crystals of the P113S variant saturated 
with L-Ala-P, have recently been obtained (Christopher Squire, personal communication). It 
is hoped that the native and the L-Ala-P-complexed structures of the P113 mutants will be 
informative, especially regarding the effects of P113 mutations and the residues required for 
the racemization activity in MetC. The mechanistic analysis of the alanine racemase activity 
in MetC may also help to resolve a conundrum about the role of Y111 as a proton carrier. 
While Clausen et al. (1996) initially proposed that Y111 is involved in proton transfers for 
the cystathionine ?-lyase activity, another group has recently argued that Y111 has no role 
in proton transfers, based on their relatively unchanged activity observed in the Y111F 
variant (Lodha & Aitken, 2011). 
3.3.3 RECIPROCAL PROMISCUITY IN NON-HOMOLOGOUS SCAFFOLDS 
The overall findings from Chapter 2 and 3 substantiate the hypothesis that promiscuous 
activities can arise in non-homologous enzymes. For E. coli MetC and Alr, the PLP cofactor 
and other catalytic residues in their active sites provide environments permissible for 
secondary activities. The abilities of MetC and Alr to catalyze each other’s reaction are 
particularly noteworthy, because to my knowledge, such reciprocal promiscuity has not 
been noted elsewhere.  
 From the literature, cross-reactivities, or overlapping activities among homologous 
enzymes is an occurrence that appears most similar to reciprocal promiscuity shown by 
MetC and Alr. Several groups have previously reported the overlapping activity profiles in 
enzyme homologues, such as the paraoxonase and dihydroorotase activities in P. diminuta 
phosphotriesterase (PTE) and E. coli dihydroorotase (DHO). The DHO enzyme catalyzed 
both its native dihydroorotase activity and paraoxonase activity, but the PTE enzyme only 
catalyzed its “native” paraoxonase activity (Roodveldt & Tawfik, 2005). Similarly, Jürgens et 
al. (2000) observed that an artificially evolved HisA of Thermotoga maritima shows low TrpF 
activity (46 s-1.M-1), while maintaining its native activity (4.6 ? 104 s-1.M-1). However, no 
HisA activity was detected on the TrpF scaffold.  
 Yet, the reciprocal promiscuity shown by MetC and Alr is different from these 
examples of enzyme cross-reactivities in three aspects. First, Met and Alr are not 
homologues, while the enzymes showing cross-reactivities are structural homologues 
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(Roodvelt & Tawfik, 2005; Jürgens et al., 2000). Second, the native and promiscuous 
activities of MetC are the promiscuous and native activities of Alr, respectively. In contrast, 
only one enzyme from either the PTE/DHO or HisA/TrpF combination is able to catalyze 
two activities. In particular, the paraoxonase activity of PTE is not even considered as the 
enzyme’s native activity, because the substrates for the activity are synthetic 
organophosphates, such as paraoxon (Roodvelt & Tawfik, 2005). Lastly, and perhaps most 
importantly, the promiscuous activities of both MetC and Alr are relevant for E. coli fitness, 
i.e., both enzymes rescued E. coli when either protein was absent. The ability of PTE to 
replace the function of DHO in the cell, and vice versa, has not been demonstrated. While 
the T. maritima HisA was previously shown to rescue an E. coli ?trpF strain (Jürgens et al., 
2000), no suppressor genes were able to rescue the E. coli ?hisA strain (Patrick et al., 2007). 
 For both MetC and Alr, mutations at a single residue were sufficient to improve their 
promiscuous activities. Mutations at the P113, such as P113S, on the MetC scaffold were 
particularly insightful. Based on the activities of the P113S variant, the high turnover rates 
for both cystathionine (~90 s-1) and alanine (~20 s-1) indicated that the MetC scaffold is 
capable of supporting both activities, since there is only a 4-fold difference between the two 
turnover rates. In contrast, the MetC scaffold does not appear to bind both cystathionine 
and alanine equally well. The difference between the KM values of both substrates is 1,500-
fold, and the P113S variant bound alanine as poorly as the wildtype MetC. On the whole, it 
seems that the barrier to switching the activity in the MetC scaffold lies with the constrained 
substrate specificity.  
 However, the kinetic changes of the P113S mutant appear to be consistent with the 
current arguments for the evolution of PLP-dependent enzymes. Due to the catalytic 
potential of PLP, the ancestral PLP-dependent enzymes were likely to be multifunctional 
after PLP was incorporated into the rudimentary active sites. Over time, the scaffolds 
evolved to optimize substrate binding and possibly, reaction specificity (Christen & Mehta, 
2001; Eliot & Kirsch, 2004). As a result, the substrate and reaction specificities of modern 
PLP-dependent enzymes are largely controlled by their protein scaffolds. Therefore, 
mutations on the protein scaffolds are likely to disrupt the optimal binding of the native 
substrate, but not the alternative substrate (as observed for the P113 mutants; see kinetic 
data in Table 3.13 of Section 3.2.7). In some cases such as the P113S mutant, the spatial 
changes in the binding of native substrate may remove the physical barrier for the catalysis 
of side reactions. This leads to an increase of product turnover, such as the significant 
increase of kcat in the P113S variant.  
3.3.4 INCREASED PROTEIN EXPRESSION AS A ROUTE TO FITNESS? 
Overall, weak promiscuous activities, such as the cystathionine ?-lyase activity of Alr 
(Chapter 2) and the alanine racemase activity of MetC (Chapter 3), could be physiologically 
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relevant when their expression is increased. This can be inchieved by over-expression from 
plasmids, regulatory mutations or gene duplications (or higher-order amplifications). The 
results from Chapters 2 and 3 implied that elevated protein expression is likely to be an 
important determinant in the evolution of new functions, and possibly, new phenotypes. 
This possibility will be investigated further in Chapter 4, in which over-expressed proteins 
from E. coli were screened for their ability to mediate the emergence of new phenotypes. 
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3.4 MATERIALS AND METHODS  
Materials and methods specific to this chapter are described in the following sections as 
well as Section 2.4 (of Chapter 2). Common molecular biology materials and techniques, as 
well as the primer sequences, can be found in Appendix I.  
3.4.1 IDENTIFICATION OF SUPPRESSOR GENES THAT COMPLEMENT 
ALANINE RACEMASE 
An aliquot of E. coli MB2795 (Section I.3 in Appendix I) was transformed with 3.2 ng of 
pooled ASKA plasmids (Patrick et al., 2007). The cells were recovered in 0.5 mL SOC 
supplemented with 0.5 mM D-Ala at 37°C for 1 h. The recovered cells were pelleted at 
10,000 ?g for 3 min in a benchtop microcentrifuge. After discarding the supernatant, the cell 
pellet was washed thrice with 1? M9 medium to eliminate residual D-Ala from the growth 
medium. During each wash, the cell pellet was resuspended in 0.5 mL of 1? M9 medium, 
and centrifuged at 10,000 ?g for 3 min. The cell pellet was finally resuspended in 0.5 mL of 
1? M9. A 50-μL aliquot of the cell suspension was plated on the selective agar (24.5 cm ? 
24.5 cm), LB-chloramphenicol supplemented with 50 μM IPTG. The selective agar plate was 
incubated in a sealed container lined with moistened paper towels, at 30°C for 7 days. 
Colony formation was observed throughout the incubation period. Appropriate dilutions of 
the cell suspension were also spread on non-selective medium, LB-chloramphenicol 
supplemented with 0.5 mM D-Ala, to enumerate the number of cells plated on the non-
selective medium. Non-selective agar plates were incubated overnight at 37°C. 
 Colonies that formed on the selective agar plate (LB-chloramphenicol-IPTG) were 
inoculated in 0.5 mL LB-chloramphenicol supplemented with 0.5 mM D-Ala. The cultures 
were incubated overnight at 37°C. One μL from each saturated culture was used as the 
template for a PCR screen. The universal pCA24N-specific primers, pCA24N.for and 
pCA24N.rev (Section I.6 in Appendix I), were added to the PCR reaction to amplify each 
pCA24N-encoded ORF. The resulting PCR products were analyzed by gel electrophoresis, 
and purified using commercial spin columns. The purified PCR products were sent for 
sequencing to reveal the identity of the ORFs. 
 Once the identity of the ORFs was revealed, the corresponding plasmid from the 
individual ASKA clone was isolated for retransformation test. The retransformation tests 
were carried out to confirm the rescuing phenotype displayed by cells over-expressing the 
pCA24N-encoded ORFs. The same host strain, E. coli MB2795, was transformed with the 
purified plasmid. The cells were recovered and washed with 1? M9 medium as previously 
described. A total of 250–1,000 transformed cells (calculated by the number of colonies 
grown on non-selective medium in parallel) were spread on the selective medium, LB-
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chloramphenicol supplemented with 50 μM IPTG. The agar plates were incubated at 30°C 
for at least 1 week. 
3.4.2 CONSTRUCTION OF E. COLI (?alr ?dadX ?metC) 
The protocol for in-frame deletion of the genomic metC gene in E. coli was modified from 
Datsenko and Wanner (2000). E. coli MB2795 was used as the target host since both the alr 
and dadX genes have been deleted from this strain (Strych et al., 2001). Using a homologous 
recombination approach mediated by ? Red recombination, the metC gene was replaced 
with a kanamycin resistance (KanR) cassette (Figure 3.18). 
3.4.2.1 AMPLIFICATION OF THE KANR CASSETTE 
The 1.4-kb KanR cassette was derived from the E. coli ?metC strain in the Keio collection 
(Baba et al., 2006). A 1-μL aliquot of a saturated culture of E. coli ?metC was added to a PCR 
reaction containing 1? Thermopol buffer, 1 U VentR
® DNA polymerase (both from New 
England Biolabs), 0.2 mM dNTPs and 0.5 μM of each forward and reverse primer (metC-
upstr.for and metC-dwnstr.rev; Section I.6 in Appendix I). The thermocycling conditions 
were 95°C for 6 min, 35 cycles of 95°C (30 s), 67°C (30 s), 75°C (45 s), and finally 75°C for 2 
min. The amplified KanR product was purified using a commercial spin column.  
3.4.2.2 INTRODUCTION OF THE KANR CASSETTE INTO MB2795  
Approximately 30 ng of the helper plasmid, pKD46 (Section I.4 in Appendix I), was used to 
transform E. coli MB2795. The electroporated cells were recovered in 0.5 mL LB 
supplemented with 0.5 mM D-Ala at 28°C for 90 min. The recovered cells were then spread 
on LB agar plates supplemented with 0.5 mM D-Ala and 10 μg/mL ampicillin (to select for 
clones transformed with pKD46). All agar plates were incubated overnight at 28°C. The 
next day, a colony was inoculated in 1 mL LB supplemented with 0.5 mM D-Ala and 10 
μg/mL ampicillin, and grown overnight at 28°C. The saturated culture was made as a 
freezer stock, and was stored at ?80°C. 
  This freezer stock (MB2795 cells harbouring the pKD46) was used to inoculate 0.1 mL 
LB supplemented with 0.5 mM D-Ala and 10 μg/mL ampicillin. The culture was inoculated 
overnight at 30°C. The next day, 2 mL LB supplemented with 0.5 mM D-Ala and 10 μg/mL 
ampicillin was added to the overnight culture, and the cells were incubated at 30°C for 
another 4 h. L-Arabinose (final concentration, 5 mM) was added to the culture to induce the 
expression of the recombinases from pKD46. Induction was allowed to proceed at 37°C for 
1.5 h. At the end of the induction, the culture was evenly divided into two aliquots, which 
were pelleted at 17,000 ?g for 1 min. The cell pellet in each aliquot was resuspended twice 
with 1 mL of pre-chilled 10% (v/v) glycerol, and pelleted similarly after each resuspension. 
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The final cell pellet was resuspended using 50 μL of the pre-chilled 10% (v/v) glycerol. The 
cells were transformed with ~100 ng of the purified KanR cassette (Section 3.4.3.1), and the 
cells were recovered in 0.5 mL SOC supplemented with D-Ala (0.5 mM) and L-Arabinose (1 
mM) at 37°C for 3.5 h. All the recovered cells were spread on LB agar plates supplemented 
with 0.5 mM D-Ala and 30 μg/mL kanamycin, which were then incubated overnight at 
37°C.  
 After the incubation, 16 colonies were selected for further screening. The colonies were 
grown to saturation in 0.15 mL LB-kanamycin supplemented with 0.5 mM D-Ala, at 37°C 
for 6.5 h. A 2-μL aliquot from each saturated culture was streaked on two different agar 
plates: LB-kanamycin-D-Ala alone and LB-kanamycin-D-Ala plus 50 μg/mL ampicillin. All 
agar plates were incubated overnight at 42°C to promote the loss of the helper plasmid, 
pKD46, from the cells. At the end of the incubation, 15 clones (out of 16 screened) grew only 
on LB-kanamycin-D-Ala and none on LB-kanamycin-D-Ala-ampicillin, indicating that 
pKD46 had been lost from these 15 clones. 
 
 
Figure 3.18:  Schematic diagram of gene replacement mediated by ?  Red recombination. 
(A) The 1.4-kb KanR cassette flanked with FRT sites at both ends was amplified from E. coli ?metC from the Keio 
collection using the metC-upstr.for and metC-dwnstr.rev primers (illustrated as brown arrows). The 54-nucleotide 
5’ extension of the amplified product is homologous to the 5’ end of the genomic metC gene. Similarly, the 47-
nucleotide 3’ extension of the product is homologous to the 3’ end of the genomic metC gene. The linear product 
was introduced to the host strain (MB2795), which expressed the ? Red recombinases from the helper plasmid 
(pKD46). The homologous ends of the linear product facilitated recombination (as shown by the double 
crossovers), resulting in the genomic metC gene being replaced by the linear product (KanR cassette). (B) In 
addition to a new selectable phenotype (kanamycin resistance), MB2795 cells with their metC gene replaced by the 
KanR cassette could be PCR-verified using the metC-upstr.for and metC-dwnstr.rev primers. In another similar 
PCR screen, the use of the metC-upstr.for and KeioKanR.out primers (brown arrows) yielded a 750-bp product, 
confirming the presence of the KanR cassette in the metC locus.  
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3.4.2.3 VERIFICATION OF THE RECOMBINED KANR CASSETTE IN MB2795 
Among those 15 clones that grew on LB-kanamycin-D-Ala agar plates, Clone 1 was grown 
overnight in 2 mL LB-kanamycin-D-Ala. A 300-μL aliquot of the saturated culture was then 
made as freezer stock, and kept at ?80°C. 
 The genomic DNA of the remaining culture was extracted using the Wizard® Genomic 
DNA Purification Kit (Promega). The purified genomic DNA of Clone 1 was used as the 
template for PCR screens. The PCR mixture contained 1? Green GoTaq® Reaction buffer, 1 
U i-Taq™ DNA polymerase, 0.2 mM dNTPs and 0.5 μM of each forward and reverse primer 
(metC-upstr.for and metC-dwnstr.rev). The thermocycling conditions were 95°C for 6 min, 
40 cycles of 95°C (60 s), 51°C (60 s), 72°C (45 s), and finally 72°C for 2 min. The size of the 
amplified PCR product was ~1.4 kb according to agarose gel electrophoresis. After 
purifying the PCR product using commercial spin columns, the PCR product was sent for 
sequencing using three primers (metC-upstr.for, metC-dwnstr.rev and KeioKanR.out). 
Sequencing results verified the presence of KanR cassette flanked by FRT sites at both ends. 
3.4.3 GROWTH COMPLEMENTATION ASSAYS 
All growth complementation assays were performed as previously described in Section 
2.4.4 (of Chapter 2). Selective and non-selective agar plates were supplemented with 
appropriate antibiotics depending on the antibiotic resistance marker present in the plasmid 
and the E. coli genome. Specifically, cells carrying the pBAD plasmid were always grown in 
50 μg/mL carbenicillin. E. coli ?alr ?dadX ?metC was always grown in 30 μg/mL 
kanamycin. Thiamine (final concentration, 5 μg/mL) was added to the M9/glucose agar 
used for the growth complementation assays with E. coli ?alr ?dadX ?metC clones. 
3.4.4 ENZYME OVER-EXPRESSION, PURIFICATION & DIALYSIS 
All enzyme variants in this study were purified according to the protocols described in 
Section 2.4.5 (of Chapter 2). 
3.4.5 ENZYME QUANTIFICATION 
All enzymes were quantified as previously described in Section 2.4.6 (of Chapter 2). 
3.4.6 STEADY STATE KINETIC ASSAYS 
Generally, all in vitro enzymatic activities were assayed as outlined in Section 2.4.7 (of 
Chapter 2).  
- Chapter 3: Reciprocal promiscuity in two non-homologous enzymes - 
122 
 The alanine racemization activity for all MetC variants was measured as described in 
Section 2.4.7.1 (of Chapter 2). The final concentration of each MetC variant ranged from 29–
158 nM. The L-Ala concentrations typically ranged from ?0.5 to ?2 ? KM. 
 The cystathionine ?-elimination activity for all evolved MetC variants was assayed as 
described in Section 2.4.7.2 (of Chapter 2). The final concentration of the evolved MetCs 
ranged from 6.5–20.2 nM. The L-cystathionine concentrations typically ranged from 0.1 to 
?1.6 ? KM. 
3.4.7 RANDOM MUTAGENESIS OF METC (ROUND 1) 
3.4.7.1 CONSTRUCTION OF FIRST-GENERATION METC LIBRARY 
The GeneMorph II Random Mutagenesis kit (Stratagene) was used to introduce random 
mutations into the plasmid-encoded metC gene. The components in a 100-μL epPCR 
reaction were 1? Stratagene Mutazyme buffer, 2.5 U Mutazyme DNA polymerase, 0.8 mM 
dNTPs, 0.5 μM of pCA24N.for primer, 0.5 μM of MetC(GFP?).rev primer and 1.325 μg of 
plasmid template [pCA24N-metC(GFP?)]. The amount of plasmid template corresponded to 
300 ng of initial target DNA (metC), which was recommended to achieve a mutation rate of 
4.5–9 mutations per kb (Stratagene). The thermocycling conditions were 1 cycle of 95°C for 
1.5 min, 30 cycles of 95°C (30 s), 54°C (30 s), 72°C (90 s), and a final cycle of 72°C for 1 min. 
The yield of the 1.3-kb PCR product was estimated to be 2 μg. Given that the amount of the 
initial DNA target was 300 ng, the final yield reflected a 6.67? amplification (and 2.74 
duplications) of the initial DNA target. The PCR efficiency was calculated as 0.065 (Firth & 
Patrick, 2005). 
 After the PCR product was purified using spin columns, it was restricted with DpnI for 
2 h to digest any plasmid template that had been carried over from the purification step. 
Next, SfiI was added to the reaction to produce 3’ sticky ends compatible with those of the 
SfiI-linearized pCA24N(KanR)-tS1 vector (Section I.4 in Appendix I). After verifying the size 
of the digested metC gene insert (1.2 kb) and the linearized vector (5.0 kb) on an agarose gel, 
the DNA bands containing the gene insert and vector were excised and purified using the 
QIAEXII Gel Extraction kit (Qiagen).  
 The purified metC insert was ligated to the linearized pCA24N(KanR) vector at a 3 : 1 
molar ratio. A total of 290 ng of metC insert and 400 ng of vector were added to the ligation 
reaction. A “vector only” control was also set up using the same components but without 
the metC insert. After 16 hours of incubation, the reactions were heat-inactivated and 
cleaned up using MinElute columns (Qiagen). Due to the low transformation efficiency of E. 
coli MB2795 (typically <108 cfu/μg of pUC19), the ligated products were first electroporated 
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into a fresh batch of E. coli DH5?-E (whose transformation efficiency was routinely higher 
than that of E. coli MB2795).  
 A 50-μL aliquot of E. coli DH5?-E was transformed with 1 μL of the ligated product by 
electroporation. A total of 22 electroporations were carried out, and the time constant for 
each electroporation was ?4.50 ms. Cells were also transformed with the “vector only” 
control and pUC19 (to determine transformation efficiency of the cells). Each aliquot of 
electroporated cells was recovered in 0.5 mL of SOC at 37°C for 1 h. The recovered cells 
were plated on LB-kanamycin agar plates (24.5 cm ? 24.5 cm), which were then incubated at 
37°C for 16 h. 
 Based on the colony counts, the transformation efficiency of the DH5?-E cells was 1.6 
? 108 cfu/μg of pUC19. After subtracting the “vector only” background (0.36%), the 
effective MetC library size was 1.5 ? 105 cfu. Sixteen colonies were randomly picked from 
the library and PCR-screened using the vector-specific primers, pCA24N.for and 
MetC(GFP?).rev. The PCR products were purified and sent for sequencing. All sequences 
were used for estimating the mutation rate and the overall type of mutations present in the 
library.  
 The remaining colonies were washed off the LB-kanamycin plates, and pooled in ~45 
mL of LB-kanamycin. The cell suspension was concentrated by centrifuging at 2,500 ?g for 
20 min, at 4°C. After discarding the supernatant, the cell pellet was resuspended in 7 mL 
LB-kanamycin. One mL of the cell suspension was stored at ?80°C for posterity, whereas 
the remaining cell suspension was evenly divided into 10 aliquots for plasmid extraction 
[using the QIAprep Spin Miniprep kit (Qiagen)]. The plasmids from each aliquot were 
eluted in 30 μL of Elution Buffer. All plasmid aliquots were pooled to form a 300 μL stock, 
at a concentration of 340 ng/μL. The pooled plasmids were used to transform fresh E. coli 
MB2795 cells. 
 For electroporation, a 20-fold dilution of the pooled plasmid was prepared. A 1-μL 
aliquot of the plasmid (~17 ng) was used to electroporate 50 μL of E. coli MB2795. A total of 
10 electroporations were carried out and the time constant for every electroporation 
exceeded 5.20 ms. An aliquot of the cells was transformed with pUC19 to estimate 
transformation efficiency. The electroporated cells were recovered in 0.5 mL SOC-D-Ala at 
37°C for 1 h. Recovered cells were grown on LB-kanamycin agar plates supplemented with 
0.5 mM D-Ala at 37°C for 16 h. 
 The transformation efficiency of E. coli MB2795 was 6.2 ? 107 cfu/μg of pUC19. The 
total number of transformed clones was 3.0 ? 107. The size of the library should theoretically 
ensure that 100% of the initial library (1.5 ? 105 cfu) was sampled. Using a spreader glass 
rod, all the colonies were washed off the library agar plates and pooled in 20 mL LB-
kanamycin-D-Ala. The cell suspension was further concentrated by pelleting at 2,500 ?g for 
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20 min, at 4°C. The cell pellet was finally resuspended in 5 mL LB-kanamycin-D-Ala 
supplemented with 12.5% (v/v) glycerol. The OD600 of the cell suspension was 350, which 
corresponded to ~8.8 ? 1010 cfu/mL. The cell suspension was evenly divided into 25 
aliquots, which were stored at ?80°C. 
3.4.7.2 SELECTION FOR METC VARIANTS WITH HIGHER RACEMASE ACTIVITY 
A 10-μL aliquot of the thawed E. coli M2795 cells harbouring the MetC epPCR library was 
used to inoculate 50 mL LB-kanamycin supplemented with 0.5 mM D-Ala. The culture was 
incubated at 37°C until an OD600 of 0.4 was reached. After diluting the culture 25-fold using 
LB, a 350-μL aliquot of the diluted culture was spread on the selective agar plate (24.5 cm ? 
24.5 cm), LB-kanamycin supplemented with 5 μM IPTG. Dilutions of the cultures were also 
spread on the non-selective agar plates, LB-kanamycin supplemented with 0.5 mM D-Ala. 
The selective agar plate was incubated at 28°C, whereas the non-selective agar plates were 
incubated overnight at 37°C. 
 It was estimated that a total of 1.0 ? 106 cfu was plated on the selective medium based 
on the colony counts of the non-selective medium. After 42 h of incubation, the library plate 
was divided into 4 equal sections. Twelve colonies were randomly picked from each 
section, and grown to saturation in 0.2 mL LB-kanamycin-D-Ala. The cultures were stored at 
?80°C for restreaking tests (Section 3.4.7.3).  
3.4.7.3 RESTREAKING TESTS 
The 48 clones isolated from the selection plate (Section 3.4.7.2) were individually restreaked 
on new selective plate to confirm the growth phenotype of the clones. 
 The freezer stock of the 48 clones was used to inoculate 0.2 mL LB-kanamycin 
supplemented with 0.5 mM D-Ala. After an overnight incubation at 37°C, the saturated 
cultures were pelleted at 12,000 ?g for 3 min. Cell pellets were resuspended and diluted to 
OD600 ~0.1 using LB. A 3-μL aliquot of each cell suspension was streaked on two sets of 
agar, LB-kanamycin with and without 5 μM IPTG. All agar plates were incubated at 28°C 
for at least 1 week. 
 To sequence the plasmid-encoded metC gene of the selected clones, a 1-μL aliquot of 
the saturated culture from the selected clones was used as the template for PCR screen. 
Vector-specific primers, pCA24N.for and pCA24N.rev2, were used to amplify the plasmid-
encoded metC gene. The resulting 1.4-kb PCR product was purified using spin columns, and 
sent for DNA sequencing. The following primers were used for sequencing the metC gene: 
pCA24N.for (N-terminus), pCA24N.rev2 (C-terminus) and metC877.rev (middle region). 
When no mutation was found in the metC gene, the Rev+270 and Univ-70 primers were 
used to sequence the lacIq repressor of the vector. The  pUCrev+120 primer was used to 
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sequence the promoter region and the (His)6 tag located upstream of the metC gene. All 
primer sequences are listed in Section I.6 of Appendix I. 
3.4.8 RANDOM MUTAGENESIS OF METC (ROUND 2) 
3.4.8.1 SUBCLONING metC INSERTS INTO pBAD VECTOR 
The wildtype metC gene and the four mutated variants selected from the first-generation 
library were subcloned into pBAD/Myc-His-B (Invitrogen) to test the expression of MetC 
under the PBAD promoter of the araBAD operon. The plan was to clone the metC gene 
inserts into the NcoI and XbaI sites of the pBAD plasmid. However, since there are multiple 
NcoI recognition sites in the metC gene, PciI was used to produce 3’ ends, which are 
compatible with those produced by NcoI on the 5’ end of the vector backbone.  
 All pCA24N-encoded metC gene inserts (wildtype, P113Q, P113A, P113T and P113S) 
were PCR-amplified using the primers, His-metC.for and His-metC.rev. The amplified 
product also included a (His)6 tag fused to the N-terminus of the metC insert via a 15-amino 
acid linker sequence (MSHHHHHHTDPALRA), which was produced after the MRG 
tripeptide was removed from the original 17-amino acid linker 
(MRGSHHHHHHTDPALRA). The first methionine codon was reintroduced into the linker 
sequence via the PciI recognition site (ACATGT) in the His-metC.for sequence. For the His-
metC.rev sequence, an XbaI recognition site was engineered on the C-terminus of the 
primer. 
 The E. coli clones harbouring the pCA24N-encoded metC variants were grown to 
saturation. A 1-μL aliquot of each saturated culture was added to a PCR reaction containing 
the 1? Phusion HF buffer, 1 U Phusion® High-Fidelity DNA polymerase (Finnzymes), 0.8 
mM dNTPs, 0.5 μM of His-metC.for, 0.5 μM of His-metC.rev. The thermocycling conditions 
were 1 cycle of 98°C for 1 min, 35 cycles of 98°C (15 s), 59°C (20 s), 72°C (30 s), and a final 
cycle of 72°C for 5 min. The 1.2-kb PCR products were cleaned up using commercial spin 
columns.  
 Next, the purified metC gene inserts were digested with PciI and XbaI for 7 h. The 
pBAD vector was treated with NcoI and XbaI for the same duration to generate sticky ends 
compatible with those of the metC gene inserts. After verifying the size of the DNA bands 
on an agarose gel, the 1.2-kb gene inserts and the 4.3-kb vector were gel-purified using 
MinElute columns. Each metC variant was then ligated to the linearized pBAD vector in a 
molar ratio of 3 : 1. The MinElute columns were used to clean up the ligation reactions. Two 
μL of the ligated products were used electroporate a 50-μL aliquot of E.coli MB2795. 
Recovered cells were grown on LB agar plates supplemented with 50 μg/mL carbenicillin 
and 0.5 mM D-Ala. Transformed colonies were PCR-screened for the presence of pBAD-
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encoded metC using vector-specific primers, pBAD-60 and pBAD.rev. The PCR products 
were purified and sequenced to confirm that no extra mutation had been introduced during 
the subcloning process.  
3.4.8.2 CONSTRUCTION OF SECOND-GENERATION METC LIBRARIES  
Similar to the first-generation library, random mutations were introduced to the metC gene 
using the GeneMorph II Random Mutagenesis kit. The pCA24N(KanR)-encoded metC 
variants (P113Q, P113A, P113T and P113S) selected from the first-generation library were 
used as DNA templates for constructing four separate second-generation libraries. 
 A 50-μL epPCR reaction was set up for each library. An epPCR reaction consisted of 1? 
Stratagene Mutazyme buffer, 2.5 U Mutazyme DNA polymerase, 0.8 mM dNTPs, 0.5 μM of 
His-metC.for primer, 0.5 μM of His-metC.rev primer and 1.5 μg of plasmid template. This 
amount of plasmid template corresponded to 300 ng of initial target DNA (metC). The 
thermocycling protocols were 1 cycle of 95°C for 1.5 min, 30 cycles of 95°C (30 s), 55°C (30 
s), 72°C (75 s), and a final cycle of 72°C for 1 min. The yield of the 1.2-kb PCR product was 
estimated to be 1 μg for all four reactions. Given that 300 ng of the initial DNA template was 
used, the final yield reflected a 3.33? amplification (and 1.74 duplications) of the initial 
DNA target. The PCR efficiency was calculated as 0.041 (Firth & Patrick, 2005). 
 After cleaning up the PCR reactions using spin columns, the PCR product was 
digested with DpnI for 2 h to eliminate the DNA template that had been carried over from 
the purification step. To generate the sticky ends for cloning into the pBAD vector, PciI and 
XbaI were added to the reaction, which was further incubated for another 6 h. At the same 
time, the pBAD/Myc-His-B vector was digested with NcoI and XbaI to linearize the vector. 
The QIAEXII Gel Extraction kit was used to purify the digested 1.2-kb metC insert and the 
4.3-kb linearized vector. Approximately 280 ng of the purified insert was ligated to 340 ng 
of the linearized pBAD vector at a molar ratio of 3 : 1. A ligation control was also set up 
using the same ligation components but without the metC insert. After 16 h of incubation, 
all ligation reactions were heat-inactivated, and cleaned up with MinElute columns. 
 Similar to the first-generation library, the ligated products were first electroporated 
into E. coli DH5?-E. A 1-μL aliquot of the ligated product was used to electroporate a 50-μL 
aliquot of E. coli DH5?-E. A total of 11 electroporations were performed for each of the four 
libraries. The time constants for all the electroporations exceeded 5.0 ms. After recovering 
the electroporated cells in 0.5 mL of SOC at 37°C for 1 h, the cells were spread and 
incubated overnight on LB-carbenicillin library plates (24.5 cm ? 24.5 cm). Based on the 
number of colonies grown on the agar plates, the library size could be estimated.  
 Twelve to seventeen colonies were randomly selected from each library and PCR-
screened using the vector-specific primers, pBAD-60 and pBAD.rev. The presence of a 1.3-
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kb PCR product indicated the presence of the pBAD-encoded metC gene. The PCR products 
were purified and sent for sequencing to allow determination of the mutation rate and bias 
of the libraries.  
 The remaining colonies on each library plate were separately pooled in 50 mL LB-
carbenicillin. The cell suspensions were pelleted at 2,300 ?g for 20 mins, at 4°C. Each cell 
pellet was resuspended thoroughly in 10 mL LB-carbenicillin. A 400-μL aliquot from each 
library suspension was stored at ?80°C for posterity. For each library, the remaining 
suspension was evenly divided to 10 aliquots for plasmid extraction (using QIAprep Spin 
Miniprep kit). After eluting the plasmids from the spin columns, a 300-μL plasmid stock 
was obtained for each library. The plasmid concentration for the MetC(P113Q), 
MetC(P113A), MetC(P113T) and MetC(P113S) were 43 ng/μL, 77 ng/μL, 77 ng/μL and 102 
ng/μL, respectively.  
 Next, the pooled plasmids were introduced to E. coli MB2795 for function selection. A 
50-μL aliquot of fresh E. coli MB2795 was transformed with 1 μL of the pooled plasmids. A 
total of 14 electroporations were performed for the MetC(P113Q) library, 13 electroporations 
for MetC(P113A) library, 10 electroporations for the MetC(P113T) library and 12 
electroporations for the MetC(P113S) library. The time constant for all electroporations were 
>5.30 ms. All electroporated cells were recovered in 0.5 mL SOC-D-Ala at 37°C for 1 h. 
Recovered cells were spread on LB-carbenicillin library plates (24.5 cm ? 24.5 cm) 
supplemented with 0.5 mM D-Ala, and grown at 37°C. After 16 h of incubation, colony 
counts were obtained for every library plate. 
 The next day, all colonies were scrapped off each library plate and pooled into 40 mL 
using LB-carbenicillin-D-Ala. The cell suspension of each library was concentrated by 
centrifuging at 2,500 ?g for 30 min, at 4°C. After decanting the supernatant, each cell pellet 
was resuspended in 5 mL LB-carbenicillin-D-Ala supplemented with 12.5% (v/v) glycerol. 
The OD600 readings of the cell suspensions ranged from 190–300, which corresponded to 
approximately 4.8 ? 1010 to 7.5 ? 1010 cfu/mL. Each cell suspension was divided into 10 
aliquots, and stored at ?80°C. 
3.4.8.3 SELECTION FOR METC VARIANTS WITH HIGHER RACEMASE ACTIVITY 
For every second-generation library [MetC(P113Q), MetC(P113A), MetC(P113T) and 
MetC(P113S)], a 10-μL aliquot of the thawed E. coli M2795 harbouring the MetC epPCR 
library was used to inoculate 50 mL LB-carbenicillin supplemented with 0.5 mM D-Ala. The 
culture was grown to OD600 of 0.4, at 37°C. The culture was diluted 25-fold using LB, 
followed by spreading an appropriate volume of the diluted culture (~0.8–2.0 mL) on the 
selective agar plate (24.5 cm ? 24.5 cm), LB-carbenicillin supplemented with arabinose to 
induce MetC expression. The arabinose concentrations used in the selection processes 
ranged from 0–0.8 mM (see Section 3.2.5.2 and 3.2.5.3 for details). Dilutions of the cultures 
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were also spread on the non-selective agar plates, LB-carbenicillin supplemented with 0.5 
mM D-Ala. The selective agar plate was incubated at 28°C, whereas the non-selective agar 
plates were incubated overnight at 37°C. 
 At the end of selection, each library plate was divided into 4 equal sections. Six 
colonies were randomly picked from each section, and used to inoculate 0.2 mL LB-
carbenicillin-D-Ala. The cultures were grown to saturation, and stored at ?80°C for 
posterity. A 1-μL aliquot of the saturated cultures was used for PCR screen to amplify the 
plasmid encoded metC gene. The vector-specific primers, pBAD-60 and pBAD.rev, were 
used. The resulting PCR products were then purified and sent for sequencing. 
3.4.8.4 RETRANSFORMATION/RECLONING AND RESTREAKING TESTS 
The plasmids from selected clones were extracted using commercial spin columns. The 
purified plasmids were used to transform a new batch of electrocompetent E. coli MB2795. 
The retransformed colonies were grown to saturation in 2 mL LB-carbenicillin-D-Ala at 
37°C. The saturated cultures were always PCR-screened to confirm the presence of the 
plasmid-encoded metC before being made as freezer stocks. 
 For several clones with genotypes similar to their first-generation parental clone (i.e., 
no extra mutation was introduced to the metC gene), their plasmid-encoded metC insert was 
amplified using the His-metC.for and His-metC.rev primers. The amplified insert was 
digested with PciI and XbaI to generate 3’ ends compatible with those of pBAD vector, 
which were produced by NcoI/XbaI digestion. The restricted insert and vector was ligated, 
and the ligated plasmid was electroporated into fresh E. coli MB2795. One retransformed 
colony was grown to saturation in 1 mL LB-carbenicillin-D-Ala at 37°C. The saturated 
culture was screened for the presence of the plasmid using PCR before being used for 
restreaking test. 
 For each restreaking test, the freezer stock of the selected clones was used to inoculate 
1 mL LB-carbenicillin supplemented with 0.5 mM D-Ala. After an overnight incubation at 
37°C, the saturated culture was pelleted at 12,000 ?g for 4 min. The cell pellet was washed 
twice with 1 mL LB, with a similar pelleting step (12,000 ?g for 4 min) after each wash. The 
cell pellet was finally resuspended in 1 mL LB. The cell resuspension was further diluted 
200-fold dilution using LB. A 2.5-μL aliquot of the cell dilution was streaked on two sets of 
agar, LB-carbenicillin with and without 0.1 mM arabinose. All agar plates were incubated at 
28°C for at least 1 week. 
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4.1 INTRODUCTION 
In Chapters 2 and 3, I used multicopy suppression experiments to identify promiscuous 
proteins (Alr and MetC) that could rescue conditionally auxotrophic strains of E. coli. This 
approach is a tractable — and therefore popular — way of demonstrating the connection 
between over-expression mutations, protein promiscuity and bacterial adaptation (Berg et 
al., 1988; Miller & Raines, 2004; Patrick et al., 2007; Christ & Chin, 2008; Morett et al., 2008; 
Patrick & Matsumura, 2008; Kim et al., 2010). 
 Two general conclusions can be drawn from these multicopy suppression experiments: 
(i) some fraction of proteins in modern proteomes are multifunctional and/or display broad 
substrate specificities; and (ii) their secondary functions can maintain metabolite fluxes in 
vivo, particularly when these fluxes are disrupted by deletion of metabolic enzymes (D'Ari 
& Casadesús, 1998; Kim et al., 2007). Utilization of a few novel nutrients (e.g. xylitol and 
amides) in bacteria has also been attributed to induced expression of proteins with 
secondary activities (Betz et al., 1974; Mortlock, 1984). However, at the outset of this study, 
the ability of proteome-wide promiscuity to drive an organism’s adaptation to new 
environments remained unknown.  
 Therefore, in this chapter, I attempted to survey the entire E. coli proteome for its latent 
ability to confer genuinely new phenotypes (rather than to re-create old ones). The aim was 
to gauge the extent to which a simple adaptive response — over-expression of a pre-existing 
protein — could impart new phenotypes on E. coli, when the cells were exposed to novel 
nutrients. In contrast to Chapters 2 and 3 where single examples of promiscuous enzymes 
were examined, the global search for promiscuous proteins in this chapter was designed to 
offer insights into the evolutionary potential of a contemporary proteome.  
4.1.1 THE GENETICS OF ADAPTIVE EVOLUTION 
All species must adapt to survive in changing environments. At the molecular level, the 
presence of novel nutrients and toxins can drive the evolution of proteins that recognize 
and/or metabolize them (Hegeman & Rosenberg, 1970; Mortlock, 1984). Duplicated copies 
of pre-existing genes provide the primary genetic source for functional innovation (Lewis, 
1951; Ohno, 1970). However, the relationship between duplication and the emergence of 
new biochemical functions is complicated because gene duplications are generally expected 
to be either selectively neutral (Lynch & Conery, 2003) or deleterious (Wagner, 2005).  
 Thus, numerous hypotheses have been proposed to explain the fates of duplicated 
genes within populations (Roth et al., 2007; Conant & Wolfe, 2008; Innan & Kondrashov, 
2010). A particularly appealing model identifies a mechanism by which selection can act 
continuously to favour both an increase in gene dosage, and divergence of one copy from 
the parental gene. This model, termed adaptive radiation (Francino, 2005) or the Innovation, 
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Amplification and Divergence (IAD) model (Bergthorsson et al., 2007) is rooted in the notion 
that many existing proteins display broad specificity and/or secondary activities, in 
addition to the function that they evolved to carry out (Khersonsky & Tawfik, 2010). In 
primordial times, this ‘promiscuity’ would have allowed many metabolic functions to be 
carried out by a minimal number of multi-tasking proteins (Jensen, 1976). In more 
specialized, modern day proteins, promiscuity is likely to be a product of contingency: 
active sites typically contain a variety of reactive groups (proton donors and acceptors, 
metal ions, etc.) that could (by chance) play roles in secondary reactions (O'Brien & 
Herschlag, 1999). These secondary activities are assumed to provide the necessary reservoir 
of novel and selectable functions. 
 In the IAD model, selection is imposed on a weak, promiscuous activity. In order to 
increase fitness, duplications (and higher-order amplifications) of the promiscuous gene are 
selected and maintained in the population. In turn, this increase in copy number improves 
the likelihood of point mutations that enhance the promiscuous activity, by increasing the 
number of mutational targets while allowing at least one copy to retain the parental activity 
(Bergthorsson et al., 2007). 
 Two central tenets of the IAD model are: (i) that gene amplification events are 
common; and (ii) that promiscuous activities are widespread, as well as being biochemically 
and mechanistically diverse. Experiments with unselected bacterial populations have 
shown the first point to be accurate (Anderson & Roth, 1981), with cells that bear 
duplications at any given locus reaching steady-state frequencies of ~10-3 (Reams et al., 
2010). In this chapter, I aimed to catalogue the proteome-wide promiscuity that could allow 
the evolution of new phenotypes, thereby addressing the second tenet and connecting 
protein biochemistry to the genetics of the IAD model. 
4.1.2 THE EVOLUTIONARY POTENTIAL OF A MODERN PROTEOME 
In the present study, the expression levels of E. coli proteins were increased artificially in an 
attempt to mimic the effects of the amplified gene copies, as described in the IAD model 
(Bergthorsson et al., 2007). After transforming the ASKA library into a common, laboratory 
E. coli strain, the plasmid-encoded protein in each clone was over-expressed. This E. coli 
pool with over-expressed proteins was then introduced into ~1,000 unique environments, 
where each contained a specific nutrient that needed to be either metabolized or tolerated if 
cells were to thrive. I demonstrated that E. coli could adapt to ~35% of these environments 
just by over-expressing one of its native proteins. Overall, the results imply that protein 
over-expression is a feasible biochemical route to cellular adaptation in novel environments. 
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4.2 RESULTS 
4.2.1 LIBRARY-ON-LIBRARY SCREEN (PM 1 TO PM 10) 
To search for promiscuous proteins that can impart new phenotypes on E. coli, two tools 
from functional genomics were utilized: the ASKA library and Biolog Phenotype 
Microarray (PM) plates (Bochner et al., 2001; Bochner, 2009). The PM plates are 96-well 
assays that were designed to test metabolic capabilities (Bochner et al., 2001), such as 
cellular utilization of carbon (PM 1 and PM 2), nitrogen and peptides (PM 3, PM 6 to PM 8), 
phosphorus and sulfur (PM 4), organic supplements (PM 5), as well as cell sensitivity to 
osmolytes and pH (PM 9, PM 10). However, in this study, I considered each well of the PM 
plates as an evolutionary scenario, where cells in both the test and control populations must 
either grow in the presence of a foreign nutrient, or face death. Every well contains a 
dehydrated base medium and a specific nutrient source. The base medium provides all the 
ingredients essential for cellular growth, except the assayed metabolic source. For instance, 
there is a different carbon source in every well of PM 1. A tetrazolium dye was also added 
to each well to monitor cell growth. When the cells grow, electrons generated from cellular 
respiration reduce the tetrazolium dye, which in turn leads to a colour change from 
colourless to purple in the well (Bochner, 2009).  
 First, the pooled plasmids of the ASKA library were used to transform E. coli strain 
DH5?-E. IPTG was added to this ASKA pool to induce over-expression (Figure 4.1A). The 
cells of the ASKA pool (each over-expressing a single E. coli ORF) were then used to 
inoculate every well of PM 1 to PM 10. The inoculum size was approximately 50,000 cells in 
each well to ensure that the entire ASKA pool of 5,272 clones was represented (an average 
of 9–10 copies of each ORF). Another set of PM plates was inoculated with E. coli DH5?-E 
containing the empty ASKA vector, pCA24N-NoIns (see Section 2.4.1). Both sets of 
inoculated PM plates were incubated in parallel at 37°C for 1 week (Figure 4.1B). The 
growth patterns between the ASKA and control clones were compared daily according to 
the tetrazolium colour intensities that had developed in the wells (Figure 4.1C). Two 
independent replicates of the entire screen were performed, and only wells that had been 
inoculated with the ASKA pool, and had showed darker shades of purple both times, were 
considered for subsequent steps (see Section 4.2.2). 
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Figure 4.1:  The library-on-library screen.   
(A) E. coli cells harbouring the pooled plasmids of the ASKA ORF collection (blue) and the negative control clone 
(grey) were grown to mid-log phase in parallel, and protein over-expression was induced by the addition of IPTG 
(50 μM). (B) Both cultures were used to inoculate every well of two sets of PM plates. A well was scored positive 
when the ASKA pool out-grew the negative control, as shown by more rapid tetrazolium colour development 
(Inset). (C) Examples of different tetrazolium colour intensities after incubation. 
 In two independent screens, the ASKA pool out-grew the negative control in 380 of the 
960 conditions screened (40%). The increased growth rates in the ASKA pool were noted in 
every type of environment: carbon (14% of wells); nitrogen and peptides (51%); phosphorus 
and sulfur (61%); biosynthetic supplements (90%); osmolytes and pH stresses (7%). The 
improved growth phenotypes of the ASKA pool (relative to the negative control) in the 
presence of various nutrient sources demonstrated the cells’ flexibility in metabolizing 
additional nutrients in defined, minimal environments. In comparison to the nutrient 
sources, the ASKA pool did poorly in conditions with different osmolarities or pH, 
suggesting that E. coli cells have limited metabolic capacity in tolerating changes in salt 
content and acidity of their environments. A more detailed analysis of each type of 
environment will be further described in Sections 4.2.3 to 4.2.7. 
4.2.2 ENRICHMENT OF THE FITTEST CLONE(S) 
In wells where the ASKA pool reproducibly out-grew the negative control, serial 
enrichment was employed to isolate the individual clones (out of 5,272 ASKA clones) that 
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were responsible for the overall improved growth phenotypes. The basis for the enrichment 
approach was that the ASKA pool in these selective environments would be dominated by 
populations of faster-growing clones, which harboured at least one type of ASKA ORF. As 
soon as the first sign of growth was detected, a small fraction of the ASKA pool was 
passaged into the same well of a new plate. Each passage represented a 50-fold dilution of 
the ASKA population in the well. This passage was repeated once in an identical fashion, 
prior to plating the clones on non-selective agar plates (Figure 4.2A). Colonies were 
screened using PCR with pCA24N-specific primers, and the amplified products were 
sequenced to determine the ASKA ORFs that were responsible for the enhanced phenotypes 
observed during the initial screens. Eight clones were screened from every enriched 
population. I considered an ASKA ORF as a positive hit only if it was isolated at least twice 
from the PCR screen (Figure 4.2B). By chance alone, it was highly unlikely that any two 
ORFs would be identical (P ? 0.005; refer to Section 4.4.4.1 for more details), unless a 
particular ORF had been positively enriched during the serial transfer. 
 
    
Figure 4.2:  Isolation of ASKA-encoded ORFs via a serial enrichment approach. 
(A) To enrich the populations of fitter clones, fresh aliquots of the ASKA pool (50,000 cells) were inoculated into a 
new set of PM plates. As soon as growth was detected (as indicated by light purple in the well), a 2-μL aliquot was 
transferred to the corresponding well of a new plate. This transfer was repeated once more before an aliquot of the 
enriched culture was plated on non-selective medium. (B) Eight random colonies that formed on the non-selective 
medium were screened using PCR with plasmid-specific primers. An ORF was considered as a positive hit only if 
it was isolated at least twice from a population (i.e., the amplified ASKA ORF showed up twice in the agarose gel). 
In the left gel image, no ORF was considered as a positive hit since no two PCR products were of identical sizes 
(Lanes 1 to 8). On the other hand, two enriched ORFs were apparent in the right gel image. PCR products from 
Lanes 1, 5 and 7 represented one ORF, whereas PCR products from Lanes 2 to 4, 6 and 8 represented another ORF. 
Lanes M, DNA ladders from Fermentas (left gel image) and New England Biolabs (right gel image). 
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 Using the serial enrichment approach, a total of 402 ASKA-encoded ORFs that were 
responsible for enhancing growth in 332 PM wells were isolated (Table 4.1 to Table 4.6). For 
a majority of the environments, only one ASKA ORF was identified. At maximum, three 
different ASKA ORFs were isolated from a single environment. The identities of the ASKA 
ORFs are grouped according to the types of environments from which they were isolated, 
and will be described in Section 4.2.3 to Section 4.2.7. The recurrence of several ASKA ORFs 
enriched in many different environments will also be discussed in subsequent sections. The 
EcoCyc (Keseler et al., 2009) and UniProt (The UniProt Consortium, 2010) databases were 
used to infer the functions of all isolated ASKA-encoded ORFs. 
4.2.3 CARBON SOURCES 
4.2.3.1 ASKA-ENCODED ORFS ISOLATED FROM PM 1 & PM 2  
The growth of the ASKA pool was compared to the negative control in a total of 192 wells, 
which contain a rich base medium and a unique carbon source in each well. According to 
Zhou et al. (2003), the base medium of PM 1 and PM 2 consists of 2.0 g/L of tryptone, 1.0 
g/L of yeast extract and 1.0 g/L of NaCl. This medium is a 5-fold dilution of LB-Lennox 
(Sambrook & Russell, 2001). 
 The ASKA pool displayed an enhanced growth phenotype in 27 of these 
environments. A total of 22 ASKA-encoded ORFs were isolated from 20 carbon-containing 
wells (Table 4.1). Hence, the hit rate (i.e., the percentage of environments where at least one 
ASKA-encoded ORF was enriched) for carbon sources was (20/192) = 10%. There were no 
wells in which the ASKA pool grew more poorly than the negative control.  
 Two ORFs were enriched from multiple wells containing different carbon sources: ycbS 
(6 times) and agaX (6 times). AgaX (a domain of an uncharacterized carbohydrate transport 
system) and YcbS (an uncharacterized outer membrane protein) appeared to be involved in 
the transport of a variety of sugar derivatives (Table 4.1). Another recurring ORF was bglA, 
which was isolated from two different wells (Table 4.1). E. coli BglA is a ?-glucosidase, 
which will be discussed further in Section 4.2.3.2. The remaining eight ORFs were isolated 
once (Table 4.1).   
 Along with AgaX and YcbS, other ORFs that code for membrane proteins were lacY (a 
lactose permease) and yedZ (an uncharacterized membrane protein), which were 
simultaneously enriched from the same carbon source (D-Mannitol). In two cases (?-D-
lactose and caproic acid), the isolated ORFs (ybcD and ymfL) code for uncharacterized, 
prophage-derived proteins (Table 4.1). The relationship between the expression of 
prophage-related proteins and carbon utilization in bacteria has not been investigated, 
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although activation of prophage genes in E. coli has been shown to mediate non-specific 
cellular responses against environmental stress (Wang et al., 2009) [also see Chapter 5].  
 
Table 4.1:  The complete list of over-expressed ORFs that conferred enhanced growth in 27 carbon-containing 
environments. 
Carbon source Days of inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) Product 
PM 1       
D-Mannitol 1 Dark Medium lacY 2 Lactose permease 
    yedZ 2 Uncharacterized 
inner membrane 
protein 
D-Ribose 1 Medium Light ycbS 8 Uncharacterized 
outer membrane ?-
barrel protein 
Tween 20 4 Medium Light agaX 8 Uncharacterized 
domain from a 
phosphotransferase 
system 
L-Rhamnose 1 Medium Light agaX 8 Uncharacterized 
domain from a 
phosphotransferase 
system 
Acetic acid 1 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Thymidine 1 Medium Light agaX 4 Uncharacterized 
domain from a 
phosphotransferase 
system 
Tween 40 5 Light Clear yjcF 2 Uncharacterized 
protein 
?-D-Lactose 2 Light Clear ybcD 3 Pseudogene from 
DLP12 prophage; 
predicted fragment 
of replication 
protein 
Lactulose 3 Medium Clear ydjO 2 Uncharacterized 
protein 
Uridine 1 Light Clear agaX 8 Uncharacterized 
domain from a 
phosphotransferase 
system 
m-Tartaric acid 3 Medium Light ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
?-methyl-D-
glucoside 
1 Light Clear bglA 4 6-phospho-?-
glucosidase A 
    ycbS 4 Uncharacterized 
outer membrane ?-
barrel protein 
Glycyl-L-aspartic 
acid 
3 Medium Light ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
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Carbon source Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
Bromosuccinic 
acid 
2 Light Clear None 
isolated 
N/A  
Glycolic acid 3 Light Clear ycbS 5 Uncharacterized 
outer membrane ?-
barrel protein 
Glyoxylic acid 2 Light Clear agaX 8 Uncharacterized 
domain from a 
phosphotransferase 
system 
N-acetyl-?-D-
mannosamine 
2 Medium Light agaX 2 Uncharacterized 
domain from a 
phosphotransferase 
system 
Mono-methyl-
succinate 
2 Light Clear None 
isolated 
N/A  
D-Malic acid 1 Light Clear wbbL_1 2 Putative 
lipopolysaccharide 
biosynthesis 
glycosyltransferase 
L-Lyxose 3 Medium Clear None 
isolated 
N/A  
Glucuronamide 3 Medium Light bglA 6 6-phospho-?-
glucosidase A 
L-Galactonic acid-
?-lactone 
2 Very dark Dark None 
isolated 
N/A  
PM 2       
3-O-?-D-
galactopyranosyl-
D-arabinose 
3 Light Clear cpdA 3 cAMP 
phosphodiesterase 
Caproic acid 5 Light Clear ymfL 5 Uncharacterized 
transcriptional 
regulator from e14 
prophage 
?-Hydroxy Butyric 
acid 
3 Light Clear None 
isolated 
N/A  
5-Keto-D-Gluconic 
acid 
3 Dark Light None 
isolated 
N/A  
Glycine 4 Medium Light None 
isolated  
N/A  
                           
* Days of incubation before a change in growth phenotype (i.e., tetrazolium colour intensity) was observed.         
Key for scoring growth phenotype (i.e., tetrazolium colour intensity):                        
 Very dark             Dark  Medium  Light        Clear          
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4.2.3.2 GLUCURONAMIDE UTILIZATION IN E. COLI 
Among the ASKA-encoded ORFs enriched from different carbon sources (Section 4.2.3.1), 
bglA is a particularly interesting case. BglA, a ?-glucosidase, was thought to hydrolyze only 
phosphorylated ?-glucosides (Prasad et al., 1973; Hall et al., 1983), such as 6-phospho-?-D-
glucosyl-(1,4)-D-glucose (also known as cellobiose-6-phosphate) and arbutin-6-phosphate 
(Figure 4.3A). One product of these reactions is glucose-6-phosphate, which can be utilized 
as the carbon source for cellular metabolism. ?-glucosides such as cellobiose and arbutin are 
phosphorylated during their uptake via a specific ?-glucoside transporter, BglF (Kricker & 
Hall, 1984; Kricker & Hall, 1987). Point mutations and insertions of transposable IS elements 
at the regulatory regions activate the expression of BglF (and BglB, another ?-glucosidase), 
which is otherwise cryptic under laboratory conditions (Prasad & Schaefler, 1974). In 
contrast, the expression of BglA is constitutive (Prasad et al., 1973; Hall et al., 1983). 
 The enrichment of the ASKA-encoded bglA from the well containing ?-methyl-D-
glucoside (Figure 4.3B; Table 4.1 in Section 4.2.3.1) also appeared to be reasonable. Unlike 
cellobiose and arbutin, phosphorylation of the aliphatic ?-methyl-D-glucoside in E. coli is 
carried out by the glucose permease (PtsG), instead of the cryptic BglF (Schaefler, 1967; 
Prasad et al., 1973). Hence, this phosphorylated form of ?-methyl-D-glucoside is also 
recognized as a substrate for BglA. The product of hydrolysis of the phosphorylated ?-
methyl-D-glucoside is glucose. 
 However, bglA was also enriched in another well containing glucuronamide (Figure 
4.3C; Table 4.1 in Section 4.2.3.1), implying that BglA may potentially recognize non-
phosphorylated substrates. In contrast to ?-glucosides, the C6 position of the 
glucuronamide is attached to an amide group, instead of a hydroxyl group. As a result, 
glucuronamide cannot be phosphorylated. Thus far, glucuronamide uptake and utilization 
in E. coli has not been described in the literature. 
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Figure 4.3:  The structures of the previously reported, and alternative, substrates of BglA. 
(A) Two reactions catalyzed by BglA. The enzyme was thought to recognize only phosphorylated glucosides. The 
phosphate groups are shown in red boxes. (B) The ASKA pool out-grew the negative control (NoInsert) in the well 
containing ?-methyl-D-glucoside after 1 day of incubation. (C) Similarly, the ASKA pool also out-grew the negative 
control in the well containing glucuronamide after 3 days of incubation.  
 The growth phenotypes of E. coli in glucuronamide were re-tested, in order to confirm 
that: (i) E. coli could utilize glucuronamide as the sole carbon source; and (ii) cells over-
expressing BglA could utilize glucuronamide better than the negative control. Wildtype E. 
coli strain K-12 (Section I.3 in Appendix I) was used for further testing, in order to eliminate 
the possibility that the growth phenotypes observed in the glucuronamide-containing well 
(during the initial screen) were specific to the DH5?-E strain. In the absence of pCA24N 
plasmid, E. coli K-12 was found to grow slowly in M9 media supplemented with 0.1% to 
0.5% glucuronamide as the sole carbon source (Figure 4.4). Although the overall growth of 
E. coli K-12 was low (maximum OD600 <0.2) for all glucuronamide concentrations, the 
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growth rates were correlated with glucuronamide concentrations — the higher the 
glucuronamide concentration, the higher the E. coli growth rate. Growth saturation, as 
normally shown as a plateau in a growth curve, was not present after 24 h of incubation. In 
comparison, the K-12 strain grown in a good carbon source (glycerol) reached saturation 
(OD600 ~0.8) after 16 h of incubation. 
  
  
Figure 4.4:  The growth of wildtype E. coli (strain K-12) in different glucuronamide concentrations. 
E. coli K-12 was grown in M9 supplemented with various concentrations of glucuronamide, for 24 h. For 
comparative purposes, M9-glycerol was used as the positive control (inset), whereas the M9 medium alone served 
as the negative control. Each growth curve is a mean representative of eight replicates. Abbreviation: gcm, 
glucuronamide. 
 The growth curves shown in Figure 4.4 suggested that E. coli K-12 could utilize 
glucuronamide, albeit poorly. Next, the effect of over-expressing BglA on E. coli growth was 
examined. The pCA24N-encoded bglA was introduced into E. coli K-12, and its growth in 
M9-glucuronamide was compared against the negative control used during the initial 
screen. The growth of the E. coli clones was tested in two glucuronamide concentrations, 
0.2% and 0.5%.  
 In both glucuronamide concentrations, cells over-expressing BglA appeared to grow 
faster than the negative control, especially after t = 11 h (Figures 4.5A and B). In the absence 
of IPTG, no differences were noted for the growth of the clone harbouring BglA and the 
negative control. The implication was that over-expressed levels of BglA could indeed 
impart improved growth phenotypes in E. coli by allowing better utilization of 
glucuronamide as the carbon source. The BglA activity towards glucuronamide is expected 
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to be low, as the plasmid-encoded bglA had to be over-expressed in order to elicit enhanced 
growth phenotypes (Figures 4.5A and B). Overall, the preliminary results presented in this 
section appear to support the initial enrichment of the ASKA-encoded bglA from the 
glucuronamide-containing well (Section 4.2.3.1). 
 
  
Figure 4.5:  E. coli growth in M9 medium supplemented with glucuronamide as the sole carbon source. 
(A) Growth of different strains in 0.2% glucuronamide. (B) Growth of different strains in 0.5% glucuronamide. 
Each growth curve is the mean of eight replicates. 
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4.2.4 NITROGEN SOURCES 
For PM 3, PM 6, PM 7 and PM 8, every well contains a base medium and a unique nitrogen 
source. The medium consists of 100 mM NaCl, 30 mM triethanolamine-HCl (pH 7.1), 2 mM 
NaH2PO4, 250 μM Na2SO4, 50 μM MgCl2 and 1 mM KCl (Zhou et al., 2003). The carbon 
sources were 20 mM sodium succinate and 2 μM ferric citrate (see Section 4.4.3 for more 
details).  
 Of the 384 conditions screened, the ASKA pool out-grew the negative control in 194 
conditions (with different nitrogen sources). A total of 206 ASKA-encoded ORFs that were 
responsible for the improved growth phenotypes in 169 conditions (Table 4.2) were 
isolated. The overall hit rate (i.e., the percentage of environments where at least one ASKA-
encoded ORF was enriched) for nitrogen sources was (169/384) = 44%. 
 In PM 3, the nitrogen source in every well is either an amino acid or its derivative. 
There were 31 wells, where the ASKA pool out-grew the negative control. At least one 
ASKA-encoded ORF was enriched from each of these wells. One particular ORF, cfa (which 
codes for cyclopropane fatty acyl phospholipid synthase), was over-represented and 
isolated from 30 of the 31 wells. The only well in which cfa was not isolated contained L-
tyrosine, and the enriched ORFs were glk (a glucokinase) and yhdZ (an ATP-binding 
component of a putative amino acid transporter). Other ORFs identified from the remaining 
wells of PM 3 were ylcG (an uncharacterized prophage protein), ybgA (an uncharacterized 
protein), grxA (a glutaredoxin), csiE (a stationary phase-inducible protein) and ymfL (an 
uncharacterized prophage protein). 
 In contrast, no well from PM 6 to PM 8 yielded clones that were over-expressing Cfa. 
Instead, the over-represented ORFs were ycbS (isolated from 81 wells) and ylcG (33 wells). 
These two ORFs constituted 70% of the total ORFs isolated from PM 6 to PM 8, in which 
each well contained a particular peptide as the sole nitrogen source. Out of 288 peptide-
containing wells, a total of 259 wells selected for clones over-expressing either YcbS or YlcG. 
Only nine ORFs were enriched once: ibpA (from the well containing Arg-Asp), yjjN (Gly-
Leu), mgsA (Leu-Asp), ubiX (Lys-Arg), pncA (Lys-Glu), yqcC (Lys-Leu), yciK (Lys-Phe), rfaS 
(Lys-Tyr) and yeaD (Leu-Pro).  
 Overall, the prevalence of multiple-occurring ORFs in Table 4.2 suggested that a non-
specific cellular response was elicited in E. coli cells upon nutrient starvation. These results 
were rather unexpected. The possible factors leading to this phenomenon, and its 
implications, will be discussed further in Section 4.3.3.1.  
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Table 4.2:  The complete list of over-expressed ORFs that conferred enhanced growth in 194 nitrogen- or 
peptide-containing environments. 
Nitrogen source Days of inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) Product 
PM 3       
Ammonia 2 Light Clear cfa 5 Cyclopropane fatty 
acyl phospholipid 
synthase 
Nitrite 3 Light Clear cfa 6 Cyclopropane fatty 
acyl phospholipid 
synthase 
L-Alanine 3 Very dark Medium cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
L-Arginine 3 Medium Light ylcG 4 Uncharacterized 
protein from DLP12 
prophage 
     cfa 4 Cyclopropane fatty 
acyl phospholipid 
synthase 
L-Asparagine 2 Light Clear cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
L-Aspartic acid 2 Light Clear cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
L-Glutamine 2 Light Clear cfa 6 Cyclopropane fatty 
acyl phospholipid 
synthase 
Glycine 2 Light Clear cfa 7 Cyclopropane fatty 
acyl phospholipid 
synthase 
L-Histidine 3 Light Clear cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
L-Phenylalanine 2 Light Clear cfa 7 Cyclopropane fatty 
acyl phospholipid 
synthase 
L-Serine 2 Medium Light cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
L-Threonine 2 Light Clear cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
L-Tryptophan 2 Medium Light cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
L-Tyrosine 5 Dark Medium glk 2 Glucokinase 
     yhdZ 5 Putative amino acid 
transporter 
D-Alanine 2 Medium Light cfa 4 Cyclopropane fatty 
acyl phospholipid 
synthase 
    ybgA 2 Uncharacterized 
protein 
    ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
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Nitrogen source Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
D-Serine 2 Medium Light cfa 7 Cyclopropane fatty 
acyl phospholipid 
synthase 
L-Citrulline 3 Light Clear cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
Glucuronamide 2 Medium Light cfa 7 Cyclopropane fatty 
acyl phospholipid 
synthase 
N-Acetyl-D-
glucosamine 
1 Light Clear cfa 3 Cyclopropane fatty 
acyl phospholipid 
synthase 
    grxA 2 Glutaredoxin 
Adenine 2 Light Clear cfa 7 Cyclopropane fatty 
acyl phospholipid 
synthase 
Cytidine 2 Dark Light cfa 4 Cyclopropane fatty 
acyl phospholipid 
synthase 
     csiE 3 Stationary phase-
inducible protein 
Guanine 3 Medium Light cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
Thymine 4 Light Clear cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
Uracil 4 Light Clear cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
Xanthine 3 Medium Light cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
Xanthosine 2 Light Clear cfa 7 Cyclopropane fatty 
acyl phospholipid 
synthase 
Uric acid 3 Medium Light cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
?-Amino-N-valeric 
acid 
2 Light Clear cfa 7 Cyclopropane fatty 
acyl phospholipid 
synthase 
Ala-His 2 Light Clear cfa 5 Cyclopropane fatty 
acyl phospholipid 
synthase 
     ymfL 2 Uncharacterized 
transcriptional 
regulator from e14 
prophage 
Ala-Leu 3 Light Clear cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
Gly-Glu 2 Light Clear cfa 7 Cyclopropane fatty 
acyl phospholipid 
synthase 
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Nitrogen source Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
PM 6       
Negative control 3 Light Clear ylcG 5 Uncharacterized 
protein from DLP12 
prophage 
Positive control:  
L-Glutamine 
3 Very dark Dark ylcG 6 Uncharacterized 
protein from DLP12 
prophage 
Ala-His 2 Light Clear None 
isolated 
N/A  
Ala-Leu 3 Light Clear ybgA 4 Uncharacterized 
protein 
Ala-Ser 2 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
Arg-Ala 2 Light Clear glk 3 Glucokinase 
Arg-Arg 2 Light Clear ylcG 5 Uncharacterized 
protein from DLP12 
prophage 
Arg-Asp 2 Light Clear ibpA 5 Small heat shock 
protein 
Arg-Gln 2 Light Clear csiE 4 Stationary phase-
inducible protein 
Arg-Glu 3 Dark Medium csiE 2 Stationary phase-
inducible protein 
    glk 2 Glucokinase 
     ylcG 3 Uncharacterized 
protein from DLP12 
prophage 
Arg-Ile 2 Light Clear None 
isolated 
N/A  
Arg-Leu 4 Light Clear ligT 2 2’-5’ RNA ligase 
     yjfN 2 Uncharacterized 
protein 
Arg-Met 2 Light Clear None 
isolated 
N/A  
Arg-Phe 2 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
    ymgC 2 Uncharacterized 
protein involved in 
biofilm formation 
Arg-Ser 2 Light Clear glk 2 Glucokinase 
Asn-Glu 2 Light Clear ycbS 4 Uncharacterized 
outer membrane ?-
barrel protein 
Asn-Val 5 Light Clear yjfN 4 Uncharacterized 
protein 
     ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
Asp-Leu 3 Light Clear ligT 2 2’-5’ RNA ligase 
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Nitrogen source Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
Asp-Val 5 Light Clear yjfN 3 Uncharacterized 
protein 
     ylcG 5 Uncharacterized 
protein from DLP12 
prophage 
Cys-Gly 2 Medium Light None 
isolated 
N/A  
Gln-Gly 2 Dark Medium csiE 2 Stationary phase-
inducible protein 
Glu-Gly 2 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
     ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
Glu-Trp 3 Dark Medium csiE 2 Stationary phase-
inducible protein 
Gly-Arg 2 Light Clear yjfN 2 Uncharacterized 
protein 
     ylcG 6 Uncharacterized 
protein from DLP12 
prophage 
Gly-Cys 2 Light Clear None 
isolated 
N/A  
Gly-His 2 Light Clear None 
isolated 
N/A  
Gly-Leu 4 Light Clear ligT 2 2’-5’ RNA ligase 
     yjjN 2 Uncharacterized 
oxidoreductase 
Gly-Met 2 Light Clear None 
isolated 
N/A  
Gly-Phe 2 Light Clear ybgA 3 Uncharacterized 
protein 
     ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
Gly-Thr 3 Medium Light ylcG 3 Uncharacterized 
protein from DLP12 
prophage 
Gly-Trp 2 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Gly-Val 7 Light Clear ilvB 3 Acetohydroxybutan-
oate synthase/ 
acetolactate 
synthase 
    yjfN 2 Uncharacterized 
protein 
     ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
His-Asp 3 Very dark Dark frvA 2 Uncharacterized 
domain of a 
phosphotransferase 
system 
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Nitrogen source Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
    ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
    ymgC 3 Uncharacterized 
protein involved in 
biofilm formation 
His-Gly 3 Dark Medium None 
isolated 
N/A  
His-Leu 3 Light Clear ylcG 4 Uncharacterized 
protein from DLP12 
prophage 
Ile-Arg 3 Medium Light yjfN 2 Uncharacterized 
protein 
Ile-Gln 3 Medium Light ylcG 5 Uncharacterized 
protein from DLP12 
prophage 
Ile-Gly 2 Light Clear yjfN 2 Uncharacterized 
protein 
Ile-His 3 Light Clear None 
isolated 
N/A  
Ile-Phe 2 Light Clear ylcG 3 Uncharacterized 
protein from DLP12 
prophage 
Ile-Ser 2 Light Clear ylcG 4 Uncharacterized 
protein from DLP12 
prophage 
Ile-Trp 3 Light Clear None 
isolated 
N/A  
Ile-Tyr 2 Light Clear ymfL 2 Uncharacterized 
transcriptional 
regulator from e14 
prophage 
Ile-Val 4 Light Clear None 
isolated 
N/A  
Leu-Ala 4 Light Clear ybgA 2 Uncharacterized 
protein 
Leu-Arg 2 Light Clear frvA 2 Uncharacterized 
domain of a 
phosphotransferase 
system 
Leu-Asp 2 Light Clear mgsA 4 Methylglyoxal 
synthase 
     ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
Leu-Glu 2 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
Leu-Leu 5 Light Clear csiE 3 Stationary phase-
inducible protein 
     ylcG 4 Uncharacterized 
protein from DLP12 
prophage 
Leu-Met 2 Light Clear ylcG 4 Uncharacterized 
protein from DLP12 
prophage 
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Nitrogen source Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
Leu-Phe 3 Light Clear None 
isolated 
N/A  
PM 7       
Leu-Trp 2 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Lys-Ala 3 Light Clear frvA 4 Uncharacterized 
domain of a 
phosphotransferase 
system 
     ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Lys-Arg 2 Light Clear ubiX 2 3-octaprenyl-4-
hydroxybenzoate 
decarboxylase 
Lys-Glu 3 Dark Medium pncA 2 Pyrazinamidase/ 
Nicotinamidase 
     ycbS 6 Uncharacterized 
outer membrane ?-
barrel protein 
Lys-Ile 3 Light Clear None 
isolated 
N/A  
Lys-Leu 3 Light Clear ligT 2 2’-5’ RNA ligase 
     yqcC 2 Uncharacterized 
protein 
Lys-Phe 2 Light Clear yciK 2 Uncharacterized 
oxidoreductase 
Lys-Pro 3 Dark Medium ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
     ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
Lys-Ser 2 Light Clear ycbS 8 Uncharacterized 
outer membrane ?-
barrel protein 
Lys-Thr 3 Medium Light ycbS 7 Uncharacterized 
outer membrane ?-
barrel protein 
Lys-Tyr 3 Medium Light rfaS 3 Lipopolysaccharide 
core biosynthesis 
protein 
Met-Arg 3 Medium Light frvA 5 Uncharacterized 
domain of a 
phosphotransferase 
system 
Met-Asp 3 Medium Light ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Met-Gln 2 Medium Light ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Met-Glu 2 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
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Nitrogen source Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
Met-Gly 2 Light Clear ycbS 4 Uncharacterized 
outer membrane ?-
barrel protein 
Met-Ile 3 Light Clear None 
isolated 
N/A  
Met-Leu 2 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
Met-Lys 2 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
Met-Met 2 Light Clear ylcG 4 Uncharacterized 
protein from DLP12 
prophage 
Met-Phe 2 Light Clear ycbS 6 Uncharacterized 
outer membrane ?-
barrel protein 
Met-Pro 2 Medium Light ycbS 6 Uncharacterized 
outer membrane ?-
barrel protein 
Met-Trp 2 Medium Light ycbS 5 Uncharacterized 
outer membrane ?-
barrel protein 
Phe-Ala 4 Dark Medium ylcG 4 Uncharacterized 
protein from DLP12 
prophage 
Phe-Gly 2 Light Clear ycbS 7 Uncharacterized 
outer membrane ?-
barrel protein 
Phe-Ile 3 Light Clear None 
isolated 
N/A  
Phe-Pro 3 Medium Light ycbS 8 Uncharacterized 
outer membrane ?-
barrel protein 
Phe-Ser 3 Medium Light ycbS 6 Uncharacterized 
outer membrane ?-
barrel protein 
Phe-Trp 3 Medium Light ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Pro-Asp 2 Light Clear higB 5 Toxin of the HigA-
HigB toxin-antitoxin 
system 
Pro-Gln 3 Very dark Medium None 
isolated 
N/A  
Pro-Hyp 4 Dark Medium ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
Pro-Leu 3 Medium Light higB 2 Toxin of the HigA-
HigB toxin-antitoxin 
system 
Pro-Pro 3 Very dark Medium csiE 2 Stationary phase-
inducible protein 
Ser-Ala 2 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
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Nitrogen source Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
Ser-Gly 2 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
Ser-His 4 Very dark Dark ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
Ser-Leu 3 Light Clear ycbS 6 Uncharacterized 
outer membrane ?-
barrel protein 
Ser-Met 3 Very dark Medium ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Ser-Phe 4 Dark Medium ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
Ser-Ser 3 Medium Clear ycbS 4 Uncharacterized 
outer membrane ?-
barrel protein 
Ser-Tyr 4 Dark Medium ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
Thr-Arg 3 Medium Light None 
isolated 
N/A  
Thr-Glu 4 Dark Medium ycbS 4 Uncharacterized 
outer membrane ?-
barrel protein 
Thr-Gly 2 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
Thr-Leu 2 Light Clear csiE 2 Stationary phase-
inducible protein 
Thr-Met 2 Light Clear ylcG 3 Uncharacterized 
protein from DLP12 
prophage 
Trp-Ala 3 Dark Medium ycbS 7 Uncharacterized 
outer membrane ?-
barrel protein 
Trp-Leu 3 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
Trp-Phe 2 Light Clear None 
isolated 
N/A  
Trp-Ser 2 Medium Light ycbS 8 Uncharacterized 
outer membrane ?-
barrel protein 
Tyr-Gly 2 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
Tyr-Leu 2 Light Clear ymfL 3 Uncharacterized 
transcriptional 
regulator from e14 
prophage 
Tyr-Lys 3 Medium Light ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
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Nitrogen source Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
Tyr-Phe 3 Medium Light ymfL 2 Uncharacterized 
transcriptional 
regulator from e14 
prophage 
Val-Ile 3 Light Clear None 
isolated 
N/A  
PM 8       
Negative control 3 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Asp-Ala 3 Dark Medium ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
Asp-Gly 2 Light Clear ycbS 5 Uncharacterized 
outer membrane ?-
barrel protein 
Gly-Asp 2 Light Clear ycbS 6 Uncharacterized 
outer membrane ?-
barrel protein 
Gly-Ile 3 Light Clear None 
isolated 
N/A  
His-Ala 2 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
    yciW 2 Uncharacterized 
oxidoreductase 
His-Glu 2 Light Clear ybgA 2 Uncharacterized 
protein 
     ycbS 5 Uncharacterized 
outer membrane ?-
barrel protein 
His-His 3 Light Clear ycbS 4 Uncharacterized 
outer membrane ?-
barrel protein 
Ile-Asn 3 Light Clear ylcG 6 Uncharacterized 
protein from DLP12 
prophage 
Ile-Leu 2 Light Clear None 
isolated 
N/A  
Leu-Asn 3 Light Clear ycbS 4 Uncharacterized 
outer membrane ?-
barrel protein 
Leu-His 3 Light Clear ycbS 5 Uncharacterized 
outer membrane ?-
barrel protein 
Leu-Pro 2 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
    yeaD 2 Putative mutarotase 
    yjbI 2 Uncharacterized 
protein 
Leu-Tyr 2 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
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Nitrogen source Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
Lys-Asp 2 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
    yjbI 2 Uncharacterized 
protein 
Lys-Gly  2 Light Clear None 
isolated 
N/A  
Lys-Met 3 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
Met-Thr 2 Light Clear None 
isolated 
N/A  
Met-Tyr 2 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Phe-Asp 2 Light Clear ycbS 6 Uncharacterized 
outer membrane ?-
barrel protein 
Phe-Met 2 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Phe-Tyr 2 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Pro-Ile 2 Light Clear ylcG 4 Uncharacterized 
protein from DLP12 
prophage 
Pro-Ser 2 Medium Light ycbS 5 Uncharacterized 
outer membrane ?-
barrel protein 
Pro-Val 5 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
    ylcG 4 Uncharacterized 
protein from DLP12 
prophage 
Ser-Asn 3 Dark Medium ycbS 6 Uncharacterized 
outer membrane ?-
barrel protein 
Ser-Asp 2 Light Clear ycbS 5 Uncharacterized 
outer membrane ?-
barrel protein 
Ser-Gln 2 Medium Light ycbS 7 Uncharacterized 
outer membrane ?-
barrel protein 
Ser-Glu 2 Medium Light ycbS 7 Uncharacterized 
outer membrane ?-
barrel protein 
Thr-Asp 3 Medium Light ycbS 4 Uncharacterized 
outer membrane ?-
barrel protein 
Thr-Phe 3 Light Clear ylcG 4 Uncharacterized 
protein from DLP12 
prophage 
Thr-Ser 4 Dark Medium ycbS 4 Uncharacterized 
outer membrane ?-
barrel protein 
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Nitrogen source Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
Tyr-Ile 3 Medium Light ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
Val-Ala 4 Light Clear ycbS 4 Uncharacterized 
outer membrane ?-
barrel protein 
    yciW 2 Uncharacterized 
oxidoreductase 
Val-Gln 4 Light Clear ilvB 3 Acetohydroxybutan-
oate synthase/ 
acetolactate 
synthase 
Val-Glu 6 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
     ylcG 5 Uncharacterized 
protein from DLP12 
prophage 
Val-Lys 6 Light Clear ilvB 6 Acetohydroxybutan-
oate synthase/ 
acetolactate 
synthase 
     ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
Val-Pro 6 Light Clear ycbS 6 Uncharacterized 
outer membrane ?-
barrel protein 
?-Ala-Phe 5 Light Clear ymfL 3 Uncharacterized 
transcriptional 
regulator from e14 
prophage 
D-Ala-D-Ala 2 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
D-Ala-Gly 2 Light Clear ycbS 6 Uncharacterized 
outer membrane ?-
barrel protein 
D-Leu-Gly 4 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
    ylcG 3 Uncharacterized 
protein from DLP12 
prophage 
?-Glu-Gly 4 Light Clear None 
isolated 
N/A  
Gly-D-Ala 2 Light Clear ycbS 4 Uncharacterized 
outer membrane ?-
barrel protein 
Gly-D-Ser 2 Light Clear ycbS 6 Uncharacterized 
outer membrane ?-
barrel protein 
Leu-?-Ala 5 Medium Light ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
Phe-?-Ala 3 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
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Nitrogen source Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
Ala-Ala-Ala 2 Medium Light None 
isolated 
N/A  
Gly-Gly-Gly 2 Light Clear ycbS 4 Uncharacterized 
outer membrane ?-
barrel protein 
Gly-Gly-Ile 2 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
Gly-Gly-Leu 2 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
Gly-Gly-Phe 2 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Leu-Gly-Gly 4 Light Clear frvA 2 Uncharacterized 
domain of a 
phosphotransferase 
system 
Leu-Leu-Leu 5 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
Phe-Gly-Gly 2 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Tyr-Gly-Gly 3 Medium Light ycbS 4 Uncharacterized 
outer membrane ?-
barrel protein 
                           
* Days of incubation before a change in growth phenotype (i.e., tetrazolium colour intensity) was observed.         
Key for scoring growth phenotype (i.e., tetrazolium colour intensity):                        
 Very dark             Dark                Medium                 Light        Clear           
4.2.5 PHOSPHORUS & SULFUR SOURCES 
The ASKA pool and the negative control were screened in a total of 60 phosphorus sources 
and 36 sulfur sources (found in PM 4). The base medium used for the wells containing 
phosphorus sources comprises 100 mM NaCl, 30 mM triethanolamine-HCl (pH 7.1), 5 mM 
NH4Cl, 250 μM Na2SO4, 50 μM MgCl2 and 1 mM KCl (Zhou et al., 2003). For the wells 
containing sulfur sources, the medium components are 100 mM NaCl, 30 mM 
triethanolamine-HCl (pH 7.1), 5 mM NH4Cl, 2 mM NaH2PO4, 50 μM MgCl2 and 1 mM KCl 
(Zhou et al., 2003). In both types of environment, 20 mM sodium succinate and 2 μM ferric 
citrate were used as the carbon sources (see Section 4.4.3 for more details).  
 The ASKA pool showed improved growth in 37 (out of 60) phosphorus-containing 
environments. A total of 38 ASKA-encoded ORFs were enriched from 34 of the phosphorus-
containing environments (Table 4.3). Hence, the overall hit rate (i.e., the percentage of 
environments where at least one ASKA-encoded ORF was enriched) for phosphorus 
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sources was (34/60) = 57%. Similar to the nitrogen sources (Section 4.2.4), the list of 
enriched ORFs was dominated by cfa (14 times), ylcG (9 times) and ycbS (6 times). The only 
ORFs that were isolated once were dgsA (from the well with 2-deoxy-D-glucose-6-
phosphate), yhdZ (guanosine-2’,3’-cyclic monophosphate), ybgA (cytidine-3’,5’-cyclic 
monophosphate) and glk (cytidine-2’-monophosphate).  
 
Table 4.3:  The complete list of over-expressed ORFs that conferred enhanced growth in 37 phosphorus-
containing environments. 
Phosphorus 
source 
Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) Product 
PM 4 
(Phosphorus) 
      
Phosphate 2 Light Clear ylcG 6 Uncharacterized 
protein from DLP12 
prophage 
Pyrophosphate 2 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
Trimetaphosphate 3 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
Tripolyphosphate 2 Light Clear cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
Adenosine-2’-
monophosphate 
2 Dark Medium cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
Adenosine-2’,3’-
cyclic 
monophosphate 
3  Dark Light cfa 7 Cyclopropane fatty 
acyl phospholipid 
synthase 
Thiophosphate 3 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Dithiophosphate 2 Light Clear cfa 4 Cyclopropane fatty 
acyl phospholipid 
synthase 
    ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
?-Glycerol 
phosphate 
2 Light Clear cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
Carbamyl 
phosphate 
2 Light Clear cfa 7 Cyclopropane fatty 
acyl phospholipid 
synthase 
D-3-Phospho-
glyceric acid 
5 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
Guanosine-2’-
monophosphate 
2 Light Clear cfa 5 Cyclopropane fatty 
acyl phospholipid 
synthase 
Guanosine-3’-
monophosphate 
2 Light Clear cfa 2 Cyclopropane fatty 
acyl phospholipid 
synthase 
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Phosphorus 
source 
Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
Guanosine-5’-
monophosphate 
2 Light Clear cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
Guanosine-2’,3’-
cyclic 
monophosphate 
5 Light Clear yhdZ 2 Putative amino acid 
transporter 
Phosphoenol 
pyruvate 
2 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
D-Glucose-1-
phosphate 
2 Medium Light cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
D-Glucose-6-
phosphate 
2 Medium Light cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
2-Deoxy-D-
glucose-6-
phosphate 
2 Light Clear dgsA 7 DgsA 
transcriptional 
repressor 
Cytidine-2’-
monophosphate 
2 Light Clear csiE 3 Stationary phase-
inducible protein 
     glk 2 Glucokinase 
Cytidine-5’-
monophosphate 
2 Light Clear csiE 6 Stationary phase-
inducible protein 
Cytidine-2’,3’-
cyclic 
monophosphate 
3 Light Clear ylcG 3 Uncharacterized 
protein from DLP12 
prophage 
Cytidine-3’,5’-
cyclic 
monophosphate 
2 Light Clear ybgA 5 Uncharacterized 
protein 
     ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
D-Mannose-1-
phosphate 
2 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
D-Mannose-6-
phosphate 
3 Medium Light cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
Cysteamine-S-
phosphate 
2 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
Phospho-L-
arginine 
2 Light Clear cfa 7 Cyclopropane fatty 
acyl phospholipid 
synthase 
O-Phospho-D-
serine 
5 Light Clear None 
isolated 
N/A  
O-Phospho-L-
serine 
2 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
Uridine-3’-
monophosphate 
2 Light Clear csiE 2 Stationary phase-
inducible protein 
Uridine-5’-
monophosphate 
3 Light Clear csiE 6 Stationary phase-
inducible protein 
Uridine-2’,3’-cyclic 
monophosphate 
5 Dark Medium ycbS 8 Uncharacterized 
outer membrane ?-
barrel protein 
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Phosphorus 
source 
Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
Phosphocreatine 2 Light Clear cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
O-Phosphoryl-
ethanolamide 
4 Light Clear None 
isolated 
N/A  
Thymidine-3’-
monophosphate 
2 Light Clear None 
isolated 
N/A  
Thymidine-5’-
monophosphate 
2 Light Clear ycbS 7 Uncharacterized 
outer membrane ?-
barrel protein 
Inositol 
hexaphosphate 
2 Light Clear csiE 2 Stationary phase-
inducible protein 
    ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
                           
* Days of incubation before a change in growth phenotype (i.e., tetrazolium colour intensity) was observed.         
Key for scoring growth phenotype (i.e., tetrazolium colour intensity):                        
 Very dark             Dark                Medium                 Light        Clear           
 Of the 36 environments with different sulfur sources, the ASKA pool out-grew the 
negative control in 22 of them. A total of 24 enriched ASKA-encoded ORFs were isolated 
from 20 environments (Table 4.4). The overall hit rate (i.e., the percentage of environments 
where at least one ASKA-encoded ORF was enriched) for sulfur sources was (20/36) = 56%. 
The ORFs that were isolated most frequently were ylcG (6 times) and ymfL (6 times), 
followed by ycbS (5 times) and cfa (4 times). Altogether, these ORFs represented >70% of the 
total ORFs enriched from sulfur-containing environments. 
 
Table 4.4:  The complete list of over-expressed ORFs that conferred enhanced growth in 22 sulfur-containing 
environments. 
Sulfur source Days of inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) Product 
PM 4 (Sulfur)       
Sulfate 2 Light Clear csiE 2 Stationary phase-
inducible protein 
     ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Thiosulfate 2 Light Clear ycbS 8 Uncharacterized 
outer membrane ?-
barrel protein 
Tetrathionate 2 Light Clear ycbS 4 Uncharacterized 
outer membrane ?-
barrel protein 
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Sulfur source Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
 Thiophosphate 2 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
    ymfL 5 Uncharacterized 
transcriptional 
regulator from e14 
prophage 
Dithiophosphate 2 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
L-Cysteine 2 Medium Clear cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
D-Cysteine 2 Light Clear cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
L-Cysteine-glycine 2 Light Clear None 
isolated 
N/A  
L-Cysteine sulfinic 
acid 
2 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Lanthionine 2 Light Clear cfa 7 Cyclopropane fatty 
acyl phospholipid 
synthase 
Glutathione 4 Medium Clear ylcG 4 Uncharacterized 
protein from DLP12 
prophage 
     ymfL 4 Uncharacterized 
transcriptional 
regulator from e14 
prophage 
L-Methionine 3 Light Clear cfa 8 Cyclopropane fatty 
acyl phospholipid 
synthase 
D-Methionine 4 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
Glycyl-L-
methionine 
2 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
N-Acetyl-D,L-
methionine 
2 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
L-Methionine 
sulfoxide 
3 Light Clear ymfL 3 Uncharacterized 
transcriptional 
regulator from e14 
prophage 
L-Djenkolic acid 3 Medium Light ylcG 3 Uncharacterized 
protein from DLP12 
prophage 
Taurine 2 Light Clear csiE 2 Stationary phase-
inducible protein 
     ymfL 4 Uncharacterized 
transcriptional 
regulator from e14 
prophage 
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Sulfur source Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
Hypotaurine 2 Light Clear ymfL 3 Uncharacterized 
transcriptional 
regulator from e14 
prophage 
Butane sulfonic 
acid 
2 Light Clear wbbL_1 2 Putative 
lipopolysaccharide 
biosynthesis 
glycosyltransferase 
2-Hydroxyethane 
sulfonic acid 
2 Light Clear None 
isolated 
N/A  
Methane sulfonic 
acid 
2 Light Clear ymfL 3 Uncharacterized 
transcriptional 
regulator from e14 
prophage 
                           
* Days of incubation before a change in growth phenotype (i.e., tetrazolium colour intensity) was observed.         
Key for scoring growth phenotype (i.e., tetrazolium colour intensity):                        
 Very dark             Dark                Medium                 Light        Clear           
4.2.6 BIOSYNTHETIC NUTRIENTS 
Instead of the nitrogen-free, phosphorus-free and sulfur-free versions of the minimal base 
medium used for PM 3, PM 4, PM 6, PM 7 and PM 8, every well of PM 5 contains the 
complete version of the minimal base medium as well as a biosynthetic nutrient. These 
nutrient supplements include various amino acids, vitamins and metabolic intermediates. 
The components of the base medium are 100 mM NaCl, 30 mM triethanolamine-HCl (pH 
7.1), 5 mM NH4Cl, 2 mM NaH2PO4, 250 μM Na2SO4, 50 μM MgCl2 and 1 mM KCl. Similar to 
PM 3, PM 4, PM6, PM 7 and PM 8, the carbon sources were 20 mM sodium succinate and 2 
μM ferric citrate (see Section 4.4.3 for more details).  
 Out of 96 conditions with different biosynthetic nutrients, the ASKA pool out-grew the 
negative control in 86 conditions. A total of 104 ASKA-encoded ORFs were enriched from 
84 conditions. The overall hit rate (i.e., the percentage of environments where at least one 
ASKA-encoded ORF was enriched) for biosynthetic nutrients was (84/96) = 88%. Similar to 
PM 1 and PM 2, there was no condition, in which the ASKA pool was out-grown by the 
negative control. 
 Two ORFs, ylcG and ycbS, dominated the pool of ORFs enriched from the 84 wells. 
YlcG-expressing clones were enriched 44 times, whereas YcbS-expressing clones were 
enriched 42 times. Other ORFs isolated multiple times were glk (9 times), yciI (3 times) and 
yhdZ (2 times). The only ORFs that were isolated once were thiE (from the well containing 
adenosine), ilvN (cytosine), csiE [(5)4-amino-imidazole-4(5)-carboxamide] and yjfN 
(pyridoxine). 
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Table 4.5:  The complete list of over-expressed ORFs that conferred enhanced growth in 86 environments, 
which contained different biosynthetic supplements. 
Biosynthetic 
nutrient 
Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) Product 
PM 5       
Negative control 3 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
    ylcG 3 Uncharacterized 
protein from DLP12 
prophage 
Positive control 
(LB) 
2 Very dark Dark ycbS 5 Uncharacterized 
outer membrane ?-
barrel protein 
L-Alanine 3 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
    ylcG 3 Uncharacterized 
protein from DLP12 
prophage 
L-Arginine 3 Light Clear glk 4 Glucokinase 
L-Asparagine 3 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
    ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
L-Aspartic acid 3 Light Clear glk 2 Glucokinase 
L-Glutamic acid 3 Light Clear ylcG 3 Uncharacterized 
protein from DLP12 
prophage 
Adenosine-3’,5’-
cyclic 
monophosphate 
3 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Adenine 3 Light Clear glk 8 Glucokinase 
Adenosine 3 Light Clear thiE 6 Thiamine phosphate 
synthase 
2’-
Deoxyadenosine 
3 Medium Light ycbS 4 Uncharacterized 
outer membrane ?-
barrel protein 
L-Glutamine 3 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Glycine 3 Light Clear ylcG 5 Uncharacterized 
protein from DLP12 
prophage 
L-Histidine 3 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
L-Isoleucine 3 Light Clear yciI 3 Uncharacterized 
protein 
L-Leucine 3 Light Clear ylcG 8 Uncharacterized 
protein from DLP12 
prophage 
L-Lysine 3 Light Clear ylcG 3 Uncharacterized 
protein from DLP12 
prophage 
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Biosynthetic 
nutrient 
Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
L-Methionine 3 Light Clear glk 2 Glucokinase 
    ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
L-Phenylalanine 3 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
Guanosine-3’,5’-
cyclic 
monophosphate 
   ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
 3 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
Guanine 3 Light Clear None 
isolated 
N/A  
Guanosine 3 Light Clear ylcG 8 Uncharacterized 
protein from DLP12 
prophage 
2’-
Deoxyguanosine 
3 Light Clear yhdZ 4 Putative amino acid 
transporter 
L-Serine 3 Light Clear glk 3 Glucokinase 
L-Threonine 3 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
    ylcG 3 Uncharacterized 
protein from DLP12 
prophage 
L-Tryptophan 3 Light Clear ylcG 4 Uncharacterized 
protein from DLP12 
prophage 
L-Tyrosine 3 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
L-Isoleucine + L-
Valine 
3 Light Clear glk 4 Glucokinase 
    ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
trans-4-Hydroxy-
L-proline 
3 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
(5)4-Amino-
imidazole-4(5)-
carboxamide 
3 Light Clear csiE 4 Stationary phase-
inducible protein 
Hypoxanthine 3 Medium Clear glk 2 Glucokinase 
    ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Inosine 3 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
2’-Deoxyinosine 3 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
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Biosynthetic 
nutrient 
Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
L-Ornithine 3 Light Clear ylcG 4 Uncharacterized 
protein from DLP12 
prophage 
L-Citrulline 3 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
    ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
L-Homoserine 
lactone 
3 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
    ylcG 6 Uncharacterized 
protein from DLP12 
prophage 
D-Alanine 3 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
    ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
D-Aspartic acid 3 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
D-Glutamic acid 3 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
D,L-?-
Diaminopimelic 
acid 
3 Light Clear ylcG 3 Uncharacterized 
protein from DLP12 
prophage 
Cytosine 3 Light Clear ilvN 2 Acetohydroxybutan-
oate synthase/ 
acetolactate 
synthase 
    ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
    ylcG 3 Uncharacterized 
protein from DLP12 
prophage 
Cytidine 3 Light Clear yciI 2 Uncharacterized 
protein 
2’-Deoxycytidine 3 Light Clear ylcG 3 Uncharacterized 
protein from DLP12 
prophage 
Putrescine 3 Light Clear ylcG 3 Uncharacterized 
protein from DLP12 
prophage 
Spermidine 3 Light Clear glk 2 Glucokinase 
Spermine 3 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
    ylcG 4 Uncharacterized 
protein from DLP12 
prophage 
Pyridoxine 4 Medium Light ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
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Biosynthetic 
nutrient 
Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
    yjfN 2 Uncharacterized 
protein 
Pyridoxal 3 Light Clear ylcG 4 Uncharacterized 
protein from DLP12 
prophage 
Pyridoxamine 4 Medium Light ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
?-Alanine 3 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
D-Pantothenic acid 3 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
    ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
Orotic acid 3 Light Clear ycbS 4 Uncharacterized 
outer membrane ?-
barrel protein 
Uracil 3 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
Uridine 3 Light Clear ycbS 4 Uncharacterized 
outer membrane ?-
barrel protein 
2’-Deoxyuridine 3 Light Clear yhdZ 2 Putative amino acid 
transporter 
Quinolinic acid 3 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
    ylcG 4 Uncharacterized 
protein from DLP12 
prophage 
Nicotinic acid 3 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Nicotinamide 3 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
    ylcG 4 Uncharacterized 
protein from DLP12 
prophage 
?-Nicotinamide 
adenine 
dinucleotide 
3 Medium Light ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
?-Amino-levulinic 
acid 
3 Light Clear ycbS 5 Uncharacterized 
outer membrane ?-
barrel protein 
Hematin 3 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
    ylcG 4 Uncharacterized 
protein from DLP12 
prophage 
Deferoxamine 
mesylate 
3 Light Clear ycbS 4 Uncharacterized 
outer membrane ?-
barrel protein 
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Biosynthetic 
nutrient 
Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
Thymine 3 Light Clear ylcG 4 Uncharacterized 
protein from DLP12 
prophage 
Glutathione 
(reduced) 
3 Light Clear ylcG 8 Uncharacterized 
protein from DLP12 
prophage 
Thymidine 3 Light Clear ylcG 6 Uncharacterized 
protein from DLP12 
prophage 
Oxaloacetic acid 3 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
D-Biotin 3 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
Cyano-cobalamine 3 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
p-Amino-benzoic 
acid 
3 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
Folic acid 3 Light Clear ylcG 3 Uncharacterized 
protein from DLP12 
prophage 
Riboflavin 3 Light Clear ycbS 4 Uncharacterized 
outer membrane ?-
barrel protein 
Pyrrolo-quinoline 
quinone 
3 Light Clear ycbS 4 Uncharacterized 
outer membrane ?-
barrel protein 
Menadione 3 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
Myo-inositol 3 Light Clear None 
isolated 
N/A  
Butyric acid 3 Light Clear ylcG 8 Uncharacterized 
protein from DLP12 
prophage 
D,L-?-
Hydroxybutyric 
acid 
3 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
?-Ketobutyric acid 3 Light Clear glk 8 Glucokinase 
Caprylic acid 3 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
D,L-?-Lipoic acid 
(oxidized) 
3 Light Clear ycbS 2 Uncharacterized 
outer membrane ?-
barrel protein 
    ylcG 6 Uncharacterized 
protein from DLP12 
prophage 
D,L-Mevalonic 
acid 
3 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
D,L-Carnithine 3 Light Clear ylcG 2 Uncharacterized 
protein from DLP12 
prophage 
- Chapter 4: Evolution of new phenotypes mediated by protein over-expression - 
165 
Biosynthetic 
nutrient 
Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
Choline 3 Light Clear ycbS 3 Uncharacterized 
outer membrane ?-
barrel protein 
Tween 20 3 Light Clear ycbS 4 Uncharacterized 
outer membrane ?-
barrel protein 
Tween 40 3 Light Clear ylcG 4 Uncharacterized 
protein from DLP12 
prophage 
Tween 60 3 Light Clear yciI 2 Uncharacterized 
protein 
Tween 80 3 Light Clear ylcG 8 Uncharacterized 
protein from DLP12 
prophage 
                           
* Days of incubation before a change in growth phenotype (i.e., tetrazolium colour intensity) was observed.         
Key for scoring growth phenotype (i.e., tetrazolium colour intensity):                        
 Very dark             Dark                Medium                 Light        Clear           
4.2.7 OSMOLYTES & pH STRESSES 
Similar to the rich base medium used in every well of PM 1 and 2, the base medium used 
for PM 9 and PM 10 consists of 2.0 g/L of tryptone, 1.0 g/L of yeast extract and 1.0 g/L of 
NaCl (Zhou et al., 2003).  
 As mentioned previously (Section 4.2.1), there were not many wells in PM 9 and PM 
10, where the ASKA pool out-grew the negative control. Out of 192 conditions screened, 
there were only 14 cases where the ASKA pool grew better than the negative control. 
However, only eight ASKA-encoded ORFs were isolated from five of these conditions 
(Table 4.6). Therefore, the hit rate (i.e., the percentage of environments where at least one 
ASKA-encoded ORF was enriched) for osmolyte and pH stresses was only (5/192) = 3%.   
 Among the ORFs isolated, cpdA (a cAMP phosphodiesterase) was isolated twice (from 
the wells with potassium chloride 5% and potassium chloride 6%). Two other ORFs were 
also enriched from each of these potassium chloride-containing wells: bdm (a biofilm-
dependent modulation protein) and acpP (an acyl carrier protein). Although it was not 
surprising that such similar environments yielded a clone (CpdA) in common, it is less clear 
why they also yielded different clones (Bdm versus AcpP). 
 For the alkaline environments (pH 9.5 supplemented with glycine and L-lysine, 
respectively), the ASKA pool out-grew the negative control. However, no ASKA-encoded 
ORF was enriched from these environments. In contrast, three ORFs were enriched 
successfully from two acidic environments: yhiS and yfjL (pH 4.5 + L-alanine) and frwB (pH 
4.5 + ?-hydroxyglutamate). 
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Table 4.6:  The complete list of over-expressed ORFs that conferred enhanced growth in 14 environments, 
which contained different osmolyte concentration and pH. 
Osmolyte and pH Days of 
inc.* 
ASKA 
growth 
NoInsert 
growth 
Enriched 
gene 
Freq. (n/8 
clones) 
Product 
PM 9       
NaCl 6% + 
Creatinine 
2 Light Clear None 
isolated 
N/A  
Potassium 
chloride 5% 
1 Medium Light bdm 3 Biofilm-dependent 
modulation protein 
    cpdA 5 cAMP 
phosphodiesterase 
Potassium 
chloride 6% 
5 Dark Medium acpP 5 Acyl carrier protein 
    cpdA 3 cAMP 
phosphodiesterase 
Sodium formate 
3% 
2 Medium Light tesB 2 Thioesterase II 
Sodium formate 
5% 
2 Light Clear None 
isolated 
N/A  
Urea 3% 2 Light Clear None 
isolated 
N/A  
Sodium nitrite   
100 mM 
2 Medium Light None 
isolated 
N/A  
PM 10       
pH 4.5 + L-Alanine 4 Medium Light yhiS 3 Uncharacterized 
protein 
    yfjL 2 Uncharacterized 
protein from CP4-57 
prophage 
pH 4.5 + 
Phenylalanine 
3 Light Clear None 
isolated 
N/A  
pH 4.5 + L-Serine 2 Light Clear None 
isolated 
N/A  
pH 4.5 + L-Valine 3 Light Clear None 
isolated 
N/A  
pH 4.5 + ?-
hydroxyglutamate 
2 Medium Clear frwB 7 Putative subunit of a 
phosphotransferase 
system 
pH 9.5 + Glycine 1 Dark Medium None 
isolated 
N/A  
pH 9.5 + L-Lysine 1 Light Clear None 
isolated  
N/A  
                           
* Days of incubation before a change in growth phenotype (i.e., tetrazolium colour intensity) was observed.         
Key for scoring growth phenotype (i.e., tetrazolium colour intensity):                        
 Very dark             Dark                Medium                 Light        Clear           
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4.2.8 CASES WHERE THE NEGATIVE CONTROL OUT-GREW THE ASKA 
POOL 
In total, the negative control grew better than the ASKA pool in 18 environments (2% of 960 
environments screened; Table 4.7). In particular, the negative control out-grew the ASKA 
pool in 9 wells with various osmolyte concentrations and pH values. In these 18 
environments, protein over-expression might have incurred a high fitness cost, compared to 
the negative control. Although the exact cause of the elevated cost was not clear, the overall 
slower growth of the ASKA pool (relative to the negative control) implied that E. coli would 
require a different adaptive approach (e.g. mutations in a nutrient transporter) rather than 
up-regulating its protein expression in these environments. A further investigation of the 
cost of protein over-expression under different conditions was outside the scope of this 
study, and therefore was not undertaken. The emphasis of this study was on finding E. coli 
proteins that, when over-expressed, were able to impart improved growth phenotypes in 
new environments. 
 
Table 4.7:  The 18 environments where the negative control out-grew the ASKA pool. 
Environment Days of incubation* ASKA growth NoInsert growth 
PM 3    
Thymidine 5 Clear Light 
Uridine 5 Clear Light 
PM 4    
O-Phospho-L-tyrosine 2 Clear Light 
PM 6    
His-Met 4 Light Medium 
His-Tyr 2 Clear Light 
Ile-Ala 3 Light Medium 
PM 7    
Negative control (No 
nitrogen source) 5 Clear Light 
Phe-Phe 5 Medium Dark 
Pro-Ala 2 Light Medium 
PM 9    
NaCl 1% 6 Dark Very dark 
NaCl 2% 6 Dark Very dark 
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Environment Days of incubation* ASKA growth NoInsert growth 
NaCl 3% 6 Dark Very dark 
NaCl 6% + L-Carnitine 2 Clear Light 
Sodium sulfate 4% 2 Medium Dark 
Sodium sulfate 5% 2 Medium Dark 
Urea 2% 1 Medium Dark 
Sodium benzoate pH 5.2, 20 
mM 1 Light Medium 
PM 10    
pH 9.5 + L-Leucine 2 Light Medium 
                           
* Days of incubation before a change in growth phenotype (i.e., tetrazolium colour intensity) was observed.         
Key for scoring growth phenotype (i.e., tetrazolium colour intensity):                        
 Very dark             Dark                Medium                 Light        Clear          
4.3 DISCUSSION 
4.3.1 AN OVERVIEW OF THE RESULTS 
The library-on-library screen described in this chapter was the first part of a comprehensive 
experiment to catalogue the evolutionary potential of the E. coli proteome. The emphasis 
was on finding E. coli proteins that are able to impart improved growth phenotypes in the 
presence of foreign compounds, when they are over-expressed. Although the screening 
methodology was initially conceived to discover enzymes with secondary activities, new 
phenotypes were also expected to be underpinned by gene regulatory effects and by 
metabolite influx via ambiguous transporter proteins. To date, this library-on-library screen 
is the most systematic screen conducted to probe the global phenotypic effects of protein 
over-expression in a variety of growth environments. 
 Over-expression from each ASKA plasmid is lac-controlled, and hence, is amenable to 
IPTG induction. Over-expression of the plasmid-encoded ORFs mirrored the effects of gene 
amplifications in the cells. The pCA24N backbone also encodes the lacIq repressor, for 
tightly controlling the expression of each ASKA ORF. The ASKA expression vector, 
pCA24N, has the same modified pMB1 replication origin as pQE30 (Qiagen), which gives it 
a copy number of 300–400 per cell (Qiagen, 2011). Therefore, this library-on-library screen 
was specifically aimed at examples where protein over-expression was essential for 
increased fitness. However, a previous study showed that induction with a high 
concentration of IPTG (1 mM) severely inhibits the growth of 51% of ASKA strains 
(including almost all that over-express membrane proteins), while another 28% show 
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moderate growth inhibition (Kitagawa et al., 2005). To avoid this source of bias, a 
significantly lower concentration of IPTG (50 μM) was used to induce protein expression. 
This is sufficient for derepression of the pCA24N T5-lacO promoter, but minimizes fitness 
differences associated with over-expression of different ORFs (Miller & Raines, 2004; Patrick 
et al., 2007). 
 In 335 of the 380 environments where the growth of ASKA pool was better than the 
negative control (Section 4.2.1), the colour differences between the two populations were 
observed within 1–3 days of incubation. I found that visual inspection was adequate for 
differentiating the intensity of the tetrazolium dye in each well. In a preliminary screen, I 
had attempted to quantify the A595 (as recommended by Biolog Inc.) of the colour intensities 
developed in the wells of PM 11 using a microtitre plate reader. However, the absorbance 
readings were not strictly correlated with the overall colour intensity in the wells, especially 
after 2 days of incubation (results not shown). This was because most of the intensely-
coloured cell clumps, which were formed after prolonged incubation (2–7 days), tend to 
sediment at the bottom of the wells. The presence of these cell clumps often interfered with 
the absorbance readings; manual resuspension of these cell clumps usually provided a more 
accurate representation of the colour intensity in each well. Furthermore, many wells 
inoculated with the ASKA pool were only a shade darker than the negative control (e.g. a 
“Light versus Clear” comparison, or a “Medium versus Light” comparison). In these cases, it 
was difficult to employ an absolute cut-off value for each colour shade, if the colour 
intensity of the PM wells was to be measured spectrophotometrically.  
  In many cases, the minimal colour differences between the ASKA pool and the 
negative control implied that the ASKA populations were only slightly fitter than the 
negative control. In order to isolate the ASKA clone that was responsible for each improved 
growth phenotype, the ASKA populations were serially enriched. Each serial transfer 
enabled a 50-fold enrichment, i.e., the numbers of each surviving ASKA clone in a well 
could be amplified 50 times. Accordingly, the ASKA clone(s) that propagated faster would 
outnumber other slow-growing clones, and thus, the final ASKA population would be 
dominated by the fitter ASKA clone(s) after 2 rounds of serial enrichment (50-fold ? 50-fold 
= 2,500-fold). Enrichment of the faster-growing clones in the ASKA population also 
manifested in growth improvements during each transfer. For example, the ASKA 
population from the well containing L-methionine as the sulfur source (Table 4.4 in Section 
4.2.5) took 3 days to develop a noticeable purple colour. After the first round of enrichment, 
the duration for colour development was reduced to 2 days. Finally, the colour 
development took only 1 day after the second round of enrichment.  Overall, this serial 
enrichment strategy yielded winner clones from 87% of the 380 environments (Section 
4.2.2). There were 41 environments a single ORF was enriched to apparent homogeneity, i.e. 
eight of eight sequenced ORFs were identical.  
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 In a minority of cases (~13%), serial transfer failed to enrich any individual ASKA 
clone to a frequency of two or more in the eight sequenced clones. One explanation is that 
there were many plasmid-encoded ORFs that all imparted fitness advantages (of similar 
magnitudes) in those conditions. It is also possible that chromosomal mutations were 
responsible for improved growth, although this is unlikely when the experimental design 
(two independent ASKA pools, both required to out-grow negative control populations) 
and the small size of each input population (~50,000 cells/well) are considered. 
Alternatively, further transfers may have been required to identify the fastest-growing 
clones in the ASKA pool. By imparting stringent criteria for identifying genes that imparted 
a growth advantage, the probability of isolating false positives was minimized.  
4.3.2 OVER-REPRESENTED ORFS 
The standout feature of the results for PM 3 to PM 8 (Section 4.2.4 to Section 4.2.6) was the 
dominance of three ASKA-encoded ORFs: cfa, ycbS and ylcG. This observation was 
unexpected, since the environments that yielded these multi-occurring ORFs were very 
different in their chemical composition. Each environment contained a unique nitrogen 
source (PM 3, PM 6, PM 7 and PM 8; Section 4.2.4), phosphorus source, sulfur source (both 
in PM 4; Section 4.2.5) or biosynthetic nutrient (PM 5; Section 4.2.6). In total, the cfa, ycbS 
and ylcG genes were isolated from 275 of the 576 wells in plates PM 3 to PM 8.  
 The literature contains little information about Cfa, YcbS and YlcG. Before speculating 
on their roles in enhancing the growth phenotypes in E. coli (Section 4.3.3.1), summaries of 
what is known about each are provided in Sections 4.3.2.1, 4.3.2.2 and 4.3.2.3.   
4.3.2.1 CFA 
One of the three ORFs isolated multiple times was cfa, which codes for cyclopropane fatty 
acyl phospholipid synthase (Keseler et al., 2009). The Cfa enzyme methylates an unsaturated 
fatty acyl chain to produce a cyclopropane derivative of the phospholipid fatty acid (PCFA), 
a component of the membrane lipid bilayer (Figure 4.6). In total, cfa was isolated from 47 
environments in PM 3 and PM 4 (in which the nitrogen source is varied).  
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Figure 4.6:  The reaction catalyzed by Cfa. 
The unsaturated bond of the acyl chain of phospholipid olefinic fatty acid is methylated via a methyl group 
donated by S-adenosyl-L-methionine, hence forming a cyclopropane derivative of the fatty acid (PCFA). 
 The physiological role of the product of Cfa catalysis (PCFA), and hence Cfa itself, has 
not been elucidated, although PCFAs are normally found in cells entering stationary phase, 
or growing in adverse conditions (Grogan & Cronan, 1997). Cfa catalyzes the methylation of 
mature phospholipid fatty acids found in membrane bilayers, but not free fatty acids nor 
intermediates of phospholipid biosynthesis. Previously, E. coli mutants lacking the cfa gene 
were shown to be more susceptible to acid shock (Chang & Cronan, 1999). E. coli cells over-
expressing Cfa did not appear to possess any growth defect (Grogan & Cronan, 1984). 
4.3.2.2 YCBS 
ASKA-encoded ycbS was the most over-represented ORF isolated from PM 3 to PM 8. The 
ycbS gene constituted 35% of all ASKA ORFs isolated, and was enriched from 136 
environments in PM 3 to 8. The YcbS protein is fairly large (866 amino acids), and is part of 
the ycbQRSTUVF operon in E. coli (Keseler et al., 2009). The operon codes for a set of 
putative chaperone-usher fimbrial proteins, which comprise a type of bacterial secretion 
system for transporting substrates across their cell membranes (Rêgo et al., 2010). The 
protein structure predicted for YcbS (Figure 4.7A) showed that it is likely to be an outer 
membrane ?-barrel protein. The closest homologue of YcbS is FimD, which shares 48% 
sequence identity. FimD, the usher protein for the fimbriae assembly complex (Figure 4.7B), 
forms a pore in the outer membrane to allow translocation of fimbrial subunits to the cell 
surface (Keseler et al., 2009).  
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Figure 4.7:  YcbS, and the Fim assembly protein complex in E. coli. 
(A) A predicted protein structure for YcbS. The structure was modelled using the Phyre2 server (Kelley & 
Sternberg, 2009), in October 2011. 773 residues of YcbS were modelled with 100% confidence based on the structure 
of the Fim outer membrane usher protein, FimD (PDB code: 3rfz; Chain B). (B) The Fim protein complex. FimD is 
an outer membrane usher protein that forms pore to allow the passage of the individual fimbrial subunits (FimA, 
FimF, FimG and FimH). The fimbrial subunits form the fimbrial rod on the surface of E. coli.  Figure B was adapted 
from Korea et al. (2011). 
 Under standard culturing conditions (i.e., LB as growth medium, 37°C incubation), 
Korea and her colleagues (2010) observed that the ycb operon in E. coli is cryptic. However, 
the insertion of a constitutive promoter in front of the ycb operon resulted in increased 
biofilm formation on abiotic surfaces (Korea et al., 2010). The conclusion was that the 
activated ycb operon codes for functional fimbriae. In the same study, the short and rigid 
Ycb fimbriae were proposed to function as adhesins, thereby allowing the Ycb-expressing 
cells to adhere to polysterene surfaces 7-fold more than cells that did not express the 
operon. 
4.3.2.3 YLCG 
Unlike Cfa and YcbS, YlcG is a prophage-derived protein. ASKA-encoded ylcG constituted 
25% of all the ASKA ORFs isolated from PM 3 to PM 8, and was isolated from 96 
environments. In contrast to YcbS, YlcG is a very small protein (46 amino acids) with 
unknown function. Predicting the structure (Figure 4.8) and function of YlcG were not 
possible, in light of the low sequence and structural homologies with existing proteins. A 
previous study demonstrated that YlcG was mildly expressed in E. coli during stationary 
phase (Hemm et al., 2008). The same study also predicted that YlcG is likely to contain a 
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single transmembrane helix. A lab member has attempted to express and purify the ASKA-
coded YlcG but the protein was largely insoluble (Ilana Gerber, personal communication). 
Recently, E. coli cells harbouring the ASKA-encoded ylcG were shown to have a reduced 
glycogen content (Eydallin et al., 2010), which led to a proposal that YlcG is involved in 
regulating carbon metabolism.  
 
     
Figure 4.8:  A predicted protein structure for YlcG. 
The structure was modelled using the Phyre2 server (Kelley & Sternberg, 2009), in October 2011. Only 14 residues 
of YlcG were modelled with 6.9% confidence based on the structure of a putative Blasticidin S deaminase from 
Bacillus anthracis (PDB code: 3b8f; Chain B).  
4.3.3 THIAMINE AUXOTROPHY IN E. COLI DH5?-E 
The over-representation of cfa, ycbS and ylcG in PM 3 to PM 8 hinted that there may be a 
drawback in the experimental design. The first clue to the drawback was offered by the 
overall growth patterns of the ASKA pool and the negative control in PM 5. This plate is 
normally used to test the nutrient requirements of auxotrophic strains. Three of the wells in 
PM 5 are supplemented with thiamine and its derivatives: well G6 contains thiamine and 
inosine; G7 contains thiamine; and G8 contains thiamine pyrophosphate. In duplicate 
screens, no difference was noted between the growth of the ASKA pool and the negative 
control in these three wells (Figure 4.9). In particular, the growth of both the ASKA and 
negative control populations was fairly rapid in all three thiamine-containing wells. The 
tetrazolium dye turned purple in these wells after only 1–2 days of incubation. In 
comparison, growth in other wells was undetectable until ?3 days of incubation (see Table 
4.5 in Section 4.2.6). These observations led me to postulate that the cells themselves — 
regardless of whether they were harbouring an ASKA plasmid or an empty vector — were 
starving from the lack of thiamine in their growth environment.  
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Figure 4.9:  The growth of the ASKA pool and the negative control in wells containing thiamine and its 
derivatives, after 2 days of incubation.  
Well 1 (G6) contained thiamine and inosine; Well 2 (G7) contained thiamine alone; Well 3 (G8) contained thiamine 
pyrophosphate. The growth patterns shown here were from one of the duplicate screens. 
 The host strain used for the entire library-on-library screen, and the serial enrichment 
experiment, was E. coli DH5?-E (Invitrogen), which has a thi?1 mutation (Section I.3 in 
Appendix I). Strains carrying this mutation do not require nutrient supplementation when 
grown in rich media, but their growth in minimal media must be supplemented with 
thiamine (Casali, 2003). However, at the outset of the screen, the formulations of the pre-
made base medium used in PM 3 to PM 8 were not known, as these were proprietary 
information (Biolog Inc., 2011). Throughout this study, the DH5?-E strain was grown 
without thiamine supplementation.  
 The manufacturer of the PM plates, Biolog Inc., has recently revealed that the base 
medium of PM 3 to PM 8 is similar — but not identical — to the defined medium 
previously reported by Zhou et al. (2003). The complete version of this medium is 100 mM 
NaCl, 30 mM triethanolamine HCl (pH 7.1), 5 mM NH4Cl, 2 mM NaH2PO4, 0.25 mM 
Na2SO4, 50 μM MgCl2 and 1 mM KCl. As recommended by Biolog Inc., a mixed carbon 
source (20 mM sodium succinate and 2 μM ferric citrate) was always added to the base 
medium to support cellular growth. Overall, the growth medium used for PM 3 to PM 8 
does not appear to contain any trace elements or vitamins, such as thiamine. Therefore, the 
absence of thiamine could be a major selective pressure for the repetitive enrichment of cfa, 
ycbS and ylcG. 
 The thiamine auxotrophy of the DH5?-E strain was not apparent when the screens and 
serial transfers were conducted. One would expect that the auxotrophy could be easily 
complemented by the over-expression of a thiamine transporter or enzymes involved in the 
thiamine biosynthesis. Yet, this was not observed. Only one thiamine-related ORF was 
isolated from the entire screen. The ORF for thiamine phosphate synthase [which catalyzes 
the penultimate step in thiamine biosynthesis (Keseler et al., 2009)], thiE, was enriched from 
a well containing adenosine (PM 5). Other ORFs that might encode for enzymes with low 
thiamine synthesis activity, such as YjbQ with promiscuous ThiE activity (Morett et al., 
2008), were not isolated either. Therefore, the under-represented thiamine-related ORFs 
implied that the over-expression of thiamine transporter proteins and thiamine biosynthetic 
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enzymes are likely to be costly in E. coli, especially in the presence of a poor carbon source 
(i.e., succinate) and the omission of crucial nutrient sources from the base medium (nitrogen 
in PM 3, PM 6, PM 7 and PM 8; phosphorus in PM 4; sulfur in PM 4).  
 The nature of the thi?1 mutation in the DH5?-E strain would be informative for 
predicting which ASKA-encoded ORF would complement the auxotrophy. However, no 
information is known about the thi?1 mutation (The Coli Genetic Stock Center). Since the 
DH5?-E strain in our lab had been commercially obtained from Invitrogen (Carlsbad, CA), 
it was difficult to trace the origins of the strain. According to the records provided by The 
Coli Genetic Stock Center, it is likely that the DH5?-E strain is a descendant of the MM294 
strain (Meselson & Yuan, 1968). The latter had been used to construct DH1 and DH5 
(Hanahan, 1983), which were presumably the ancestors for the DH5?-E strain. Notably, the 
thiamine auxotrophy (resulting from the thi?1 mutation) had been observed and reported 
for the MM294 strain (Meselson & Yuan, 1968). Similar to other bacterial gene operons, the 
expression of the thiamine operon (thiCEFSGH) in E. coli is tightly coordinated (Jurgenson et 
al., 2009). Therefore, over-expression of a single thi ORF, such as thiE, is unlikely to 
derepress the expression of other chromosomal genes in the thiamine operon.  
 In hindsight, thiamine should have been added to every well of PM 3 to PM 8, to 
complement the auxotrophy of the DH5?-E strain. A concentration of 1 μg/mL thiamine 
(Meselson & Yuan, 1968) should be sufficient to support growth of E. coli strains with the 
thi?1 mutation. Similarly, thiamine should have been added to the Inoculation Fluid (IF) 
media (Biolog Inc.), which were used to resuspend the ASKA pool and the negative control 
prior to inoculation in the PM wells (see Section 4.4.3 for details). Although the 
formulations of the IF media are proprietary (Biolog Inc., 2011), it is likely that thiamine is 
absent from the media.  
4.3.3.1 SPECULATION ON THE EFFECTS OF CFA, YCBS AND YLCG 
The repetitive enrichment of cfa, ycbS and ylcG from PM 3 to PM 8 implied that the over-
expression of these proteins was a generic fitness-enhancing response in E. coli when 
thiamine was absent. In particular, clones over-expressing either Cfa, YcbS or YlcG were 
isolated from several environments where no growth was expected (and indeed, no growth 
was observed in these PM wells that had been inoculated with the negative control clone). 
For instance, the ASKA-encoded ycbS was enriched from a peptide-less well in PM 8 
(termed the negative control well in Table 4.2 of Section 4.2.4); whereas ylcG was enriched 
from a peptide-less well in PM 6 (termed the negative control well in Table 4.2 of Section 
4.2.4). Taken together, the over-expression of Cfa, YcbS or YlcG appeared to confer new 
phenotypes on E. coli in the absence of not only thiamine, but also major nutrient sources, 
such as nitrogen. 
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 The information summarized in Sections 4.3.2.1 to 4.3.2.3 allowed me to speculate the 
roles of Cfa, YcbS and YlcG in improving the growth of E. coli in environments with 
minimal amounts of nutrients (e.g. the wells of PM 3 to PM 8). First, Cfa was likely to buffer 
E. coli from starvation of both thiamine and other nutrients, since the conditional formation 
of PCFAs, the products of Cfa catalysis (see Figure 4.6 in Section 4.3.2.1), has been proposed 
as a response to an exhausted metabolic state of the cells (Grogan & Cronan, 1997). On the 
other hand, increased levels of YcbS might promote the formation of fimbriae in E. coli by 
allowing more fimbrial subunits to traverse the outer membrane. Eventually, this might 
lead to increased cell adherence and biofilm formation in the PM wells. The ability of cells 
to withstand adverse conditions in the biofilms is well documented in the literature. For 
YlcG, its potential in regulating carbon metabolism (Eydallin et al., 2010) might translate as a 
fitness advantage, particularly when cells were struggling to adapt to a poor carbon source 
(i.e., succinate) and were starving from a lack of thiamine. Overall, the (known) functions of 
Cfa, YcbS and YlcG suggest they can act as general stress responses against nutrient 
starvation. The likelihood of any of these three ORF-expressing clones being enriched in a 
particular well (of PM 3 to PM 8) was probably determined by sampling biases, such as the 
degree of cell resuspension prior to serial transfers.   
 Alternatively, over-expression of Cfa, YcbS or YlcG might improve the scavenging 
capabilities of the E. coli clones. Recall that about ~50,000 cells were competing for nutrients 
against one another in every well. Apart from the possibility of being able to grow faster 
than the neighbouring clones, a clone could also scavenge nutrients, such as thiamine, from 
dead neighbours in order to survive. The ability to prolong survival would seem reasonable 
in a life-or-death situation. However, confirmation of such scavenging capabilities would 
require different approaches. The library-on-library screens and the serial enrichment 
described in this chapter were designed to only differentiate fit clones (such as those over-
expressing Cfa, YcbS and YlcG), from unfit clones.  
4.3.4 ORFS ENRICHED FROM THIAMINE-CONTAINING ENVIRONMENTS 
In spite of the issues around thiamine auxotrophy, the experiments described in this chapter 
still revealed many examples of apparent promiscuity. Enriched ORFs from PM 1, PM 2, 
PM 9 and PM 10 appeared to be more specific to individual environments. This was because 
the base medium used for PM 1, PM 2, PM 9 and PM 10 was derived from complex 
nutrients: tryptone and yeast extract [see Sections 4.2.3.1 and 4.2.7 for medium formulation; 
Zhou et al. (2003)]. In particular, thiamine could be derived from the yeast extract in the 
medium. Therefore, E. coli DH5?-E was not starved for thiamine in these plates.  
 In one case, E. coli cells over-expressing BglA appeared to grow more rapidly when 
glucuronamide was present as the sole carbon source (Table 4.1 in Section 4.2.3.1). 
Confirmation of the improved growth phenotype of the BglA-expressing clone was 
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subsequently demonstrated in Section 4.2.3.2. However, biphasic growth curves were 
observed for the BglA-expressing clones and the negative control grown using 
glucuronamide as the carbon source (Figure 4.5 in Section 4.2.3.2). These results suggested 
that trace amounts of a richer nutrient source were present. This was likely to be glycerol, 
which is a good carbon source for E. coli. Glycerol could have been carried over from the 
M9-glycerol media used to pre-condition the cells to the M9 medium, prior to growth in 
M9-glucuronamide (see Section 4.4.5 for details). However, the presence of mixed carbon 
sources in the M9-glucuronamide media was analogous to the growth environments where 
ASKA-encoded bglA was originally enriched. Recall that the base medium in every well of 
PM 1 consisted of tryptone and yeast extract. Carbon sources, such as glucose, are present 
in yeast extract and could contribute to basal levels of growth in PM wells. Thus, BglA 
appears to be a genuine example, where over-expression imparted a new growth phenotype 
in E. coli, i.e., the ability to grow using glucuronamide as a carbon source. The implication 
was that BglA, a glucosidase known to hydrolyze phosphorylated glucosides only (Prasad 
et al., 1973; Hall et al., 1983), could also recognize glucuronamide as a substrate. As 
glucuronamide does not contain a glycosidic bond (Figure 4.3C), BglA cannot be acting as a 
glucosidase. Instead, it is tempting to speculate that BglA could possess glycosyltransferase 
activity, and that this is the key reaction for allowing growth on glucuronamide. 
Glycosidases, an enzyme family to which glucosidase belongs, are known to catalyze the 
formation of glycosidic linkages using monosaccharides and an excess of acceptor molecule 
(Hancock et al., 2006). Glucuronamide could be used as an acceptor molecule in this case to 
form glycosides, which in turn could be metabolized. Further experiments will be required 
to confirm this tentative hypothesis. 
 In addition to BglA, AgaX also appeared to be an interesting case since E. coli that were 
over-expressing AgaX managed to out-grow the negative control in six different carbon 
sources (Table 4.1 in Section 4.2.3.1). Bioinformatic analysis of the agaX gene predicted that 
AgaX is a component of an uncharacterized phosphotransferase system (Keseler et al., 2009), 
which is normally involved in the uptake and phosphorylation of a variety of substrates. 
The enrichment of the ASKA-encoded agaX from six different carbon-containing 
environments suggests that AgaX is likely to show broad substrate specificities. Thus, it is 
appealing to hypothesize that AgaX is indeed part of the uncharacterized 
phosphotransferase system, which may also show broad substrate specificities. 
 Another interesting example isolated from an environment with moderately high 
osmolyte concentration (3% sodium formate) was TesB (Table 4.6 in Section 4.2.7). TesB is a 
thioesterase that cleaves long-chain acyl-CoA into coenzyme A and a carboxylate (Keseler et 
al., 2009). Nie and her colleagues (2008) recently reported that E. coli TesB also cleaves a 
variety of medium-chain (C6–C16) acyl-CoA substrates, which indicated that the enzyme 
does not seem to discriminate against the chain length of acyl-CoA. However, sodium 
formate (HCOONa) does not have a CoA, nor an aliphatic chain. One possible scenario that 
- Chapter 4: Evolution of new phenotypes mediated by protein over-expression - 
178 
could contribute to the enrichment of tesB was that E. coli could metabolize sodium formate 
into a compound that resembles a long/medium chain acyl-CoA. Therefore, TesB, which 
appears to show broad substrate specificities, may react with the compound derived from 
sodium formate. 
4.3.5 PROTEIN OVER-EXPRESSION CAN MEDIATE THE EMERGENCE OF NEW 
PHENOTYPES 
As shown in Chapter 2 and 3 (as well as several references therein), over-expression of pre-
existing proteins in E. coli can rescue auxotrophic strains. In this chapter, I demonstrated 
that over-expression of pre-existing proteins can also drive the emergence of new 
phenotypes in E. coli. For instance, an alternative carbon source, glucuronamide, could be 
utilized in cells that over-expressed BglA. This suggests that E. coli with increased levels of 
BglA could also utilize glucuronamide as the carbon source in natural settings. Instead of 
IPTG induction, gene amplifications or regulatory mutations could provide a means to 
increase enzyme levels in the cells. Similarly, the over-expression of Cfa, YcbS and YlcG 
could be a means for E. coli to adapt to thiamine starvation (and possibly, other nutrient 
starvation), since cells over-expressing these proteins displayed enhanced growth 
phenotypes. Taken together, the protein over-expression mechanism represents a viable 
solution for E. coli in the course of adapting to nutritionally challenging environments. 
Another common scenario for adaptive evolution is to evolve resistance to antibiotics and 
toxins. This will be explored further in Chapter 5.  
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4.4 MATERIALS AND METHODS 
All reagents were from Sigma, unless otherwise indicated. Specific materials and methods 
are described in the following subsections, while general molecular biology materials and 
techniques are explained in Appendix I. 
 Sodium succinate was prepared as a 2 M stock in water, and ferric citrate was 
prepared as a 0.2 mM stock in water. D-Glucuronamide (Chemos GmbH) was prepared as a 
10% (w/v) stock in water. All three reagents were filter-sterilized before use.  
4.4.1 CONSTRUCTION OF THE ASKA LIBRARY IN DH5?-E 
All 5,272 plasmids from the ASKA collection had been pooled previously (Patrick et al., 
2007). Approximately 10 ng of these pooled plasmids were used to transform an aliquot of 
E. coli DH5?-E. The transformed cells were grown on LB-chloramphenicol plates at 28°C. To 
enumerate the library size, dilutions of the transformed cells were plated on separate LB-
chloramphenicol plates. After 20 h of incubation, a total of ~723,600 cfu were obtained. The 
vast over-sampling ensured that >99% of the ASKA clones were represented [calculated by 
the library diversity and completeness programme, GLUE (Patrick et al., 2003)].  
 All clones were scraped off the agar plates, and pooled in 2.5 mL LB supplemented 
with chloramphenicol (34 μg/mL) and glycerol [12.5% (v/v)]. The pooled cell suspension 
was stored in aliquots at ?80°C. 
4.4.2 CONSTRUCTION OF THE CONTROL CLONE 
A negative control was constructed, for comparison with the ASKA pool (Section 4.4.1). The 
same host strain, E. coli DH5?-E, was transformed with pCA24N-NoIns (Section 2.4.1) to 
create the negative control. The plasmid pCA24N-NoIns shares the same vector backbone 
as all the ASKA plasmids, but lacks a gene insert. 
4.4.3 LIBRARY-ON-LIBRARY SCREEN 
Overnight cultures of the control clone and ASKA pool were prepared by inoculating 10 mL 
LB-chloramphenicol with 10 μL of the respective frozen stocks. A 1-mL aliquot of each 
overnight culture was used to inoculate 50 mL LB-chloramphenicol. Both cultures were 
grown at 37°C to mid-log phase (OD600 ~0.5) before adding 50 μM IPTG to induce protein 
over-expression. After induction for 2 h, cells were harvested by centrifugation (2,000 ?g, 15 
min, 4°C). The cell pellets were resuspended to OD600 ~0.2 in sterile water, and 100 μL of 
each cell suspension was added to the Inoculation Fluid (IF) medium (Biolog Inc.) 
supplemented with 50 μM IPTG. Assuming that OD600 corresponded to 2.5 ? 108 cells/mL 
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(Sambrook & Russell, 2001), the final  cell density in the IF medium was ~5 ? 105 cells/mL. 
The cell suspensions were starved by incubating at room temperature for 1 h. The starvation 
step was critical for two reasons: (i) to exhaust rich nutrient sources (carbon, nitrogen, 
phosphorus, sulfur, vitamins, etc.) carried over from the previous culture medium (LB), as 
well as any metabolite reserves in the cells; and (ii) to ensure brutal selection pressure for 
the cells to metabolize the exogenous compounds in each PM well.  
 After starvation, aliquots of each culture (100 μL) were used to inoculate the wells of 
PM 1 to PM 10 (Biolog Inc.). The PM plates were placed in airtight containers with 
moistened paper towels (to prevent evaporation), and incubated at 37°C for 7 days. Growth 
in each well, as indicated by purple colour development, was monitored visually and 
scored daily. Two independent replicates of the complete screen were performed. 
 According to Biolog Inc., the IF medium is a balanced salt solution with a gelling 
polysaccharide that keeps the microbial cells in suspension in the wells. As recommended, 
the IF-0 medium was used for PM 1 to PM 8, whereas the IF-10 medium was used for PM 9 
and PM 10. All IF media contained 1? IF and 1? Biolog Redox dye mix. 
 Another recommendation by Biolog Inc. was the addition of a mixed carbon source to 
the minimal, defined base medium of PM 3 to PM 8. Sodium succinate (final concentration, 
20 mM) and ferric citrate (final concentration, 2 μM) were added to the cell suspensions 
after the starvation step (and prior to PM well inoculation). Although E. coli does not 
normally utilize citrate as a carbon source (Blount et al., 2008), the low amount of citrate 
could potentially act as an anti-coagulant by chelating divalent ions, such as Ca2+, present in 
the well of the PM plates.  
4.4.4 ISOLATION OF WINNER GENES VIA SERIAL ENRICHMENT 
For conditions in which the ASKA pool had reproducibly out-grown the negative control, 
fresh aliquots of the pool were now used to inoculate the corresponding wells of new PM 
plates. At the first sign of purple colour development in a well (usually 1–5 days), a 2-μL 
aliquot of the culture from that well was mixed with 98 μL IF medium (supplemented with 
50 μM IPTG) and transferred to the corresponding well of a new plate. For PM 3 to PM 8, 
the IF medium was also supplemented with 20 mM sodium succinate and 2 μM ferric 
citrate. After a second transfer (carried out in an identical fashion), cells from the final 
passage were spread on LB-chloramphenicol plates. The universal pCA24N-specific 
primers, pCA24N.for and pCA24N.rev (Patrick et al., 2007), were used to amplify the ASKA 
ORFs (see Section I.10) from at least eight of the resulting colonies. The thermocycling 
parameters were as follows: 95°C for 5 min, 30 cycles of 95°C for 30 s, 50°C for 30 s, 72°C for 
2 min, and finally, 72°C for 5 min. PCR products were sequenced to reveal each ORF that 
was responsible for enhanced growth. 
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4.4.4.1 PROBABILITY OF SAMPLING THE SAME ORF TWICE OR MORE, BY CHANCE ALONE 
Given that there were 5,272 ORF variants in the ASKA collection, the probability of 
sampling the same ORF twice or more, in eight random clones is small.  
First, consider the probability that all eight clones are unique (i.e., different from each other): 
The first isolated clone is always unique, so   P = 1. 
The probability of the second clone being different from the first clone is:  
  
P = 5,271
5,272
 
Similarly, the probability of the third clone being different from both the first and second 
clones is: 
  
P = 5,270
5,272
 
Therefore, the overall probability of getting eight unique clones is: 
  
P = 1? 5,271
5,272
? 5,270
5,272
? 5,269
5,272
? 5,268
5,272
? 5,267
5,272
? 5,266
5,272
? 5,265
5,272
P = 0.9947
 
That is, there is a 99.47% chance that all eight clones, which are randomly sampled from the 
pool of 5,272 variants, carry different ASKA ORFs. Hence, the probability that all eight 
clones are not all different (i.e., two or more are the same) is: 
  
P = 1? 0.9947
P = 0.0053  
That is, by chance alone, the probability of isolating two clones harbouring identical ASKA-
encoded ORFs was only 0.53%. 
4.4.5 E. COLI GROWTH USING GLUCURONAMIDE AS A CARBON SOURCE 
As described in Section 2.4.4.1, the 1? M9 broth was diluted from a 5? M9 stock. The broth 
was also supplemented with 0.5% (v/v) carbon source (either glycerol or glucuronamide) 
and 34 μg/mL chloramphenicol. If necessary, IPTG (50 μM, final concentration) was added 
to the M9 medium to induce protein over-expression.   
 The growth of E. coli cells in every test condition was measured in eight replicates, in 
microtitre plates. First, freezer stocks of both the test strain and the negative control were 
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used to inoculate 1.5 mL LB-chloramphenicol, respectively. The cells were grown to 
saturation (~6.5 h), and were pelleted at 10,000 ?g for 5 min in a benchtop microcentrifuge. 
The cell pellets were washed once with 1 mL of 1? M9 broth, and resuspended in 1 mL of 
1? M9 broth. To pre-condition the cells to the M9 medium, 5 μL of each resuspended 
culture were used to inoculate 5 mL of M9-glycerol, and the cultures were grown at 37°C 
for 16 h. The overnight cultures were then diluted 10-fold, and 1 μL of each diluted culture 
was used to inoculate 200 μL M9 supplemented with either glycerol or glucuronamide as 
the sole carbon source. Cell growth was monitored at OD600 using a Synergy 2 plate reader 
(Biotek Instruments), which was programmed to agitate continuously at 37°C. The OD600 
readings were obtained every 10 min, for 24 h. 
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CHAPTER 5 
?
Toxin resistance mediated by 
protein over-expression 
Sections 5.2, 5.3 and 5.4 contain published materials from:  
 
 Soo, V. W. C., Hanson-Manful, P. & Patrick, W. M. (2011). Artificial gene 
 amplification reveals an abundance of promiscuous resistance determinants in 
 Escherichia coli. Proc Natl Acad Sci USA, 108:1484-1489. 
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5.1 INTRODUCTION 
The library-on-library screen described in Chapter 4 enabled a global search for 
promiscuous proteins that could mediate the evolution of novel phenotypes in E. coli, 
provided protein expression was up-regulated. This approach yielded many cases where 
over-expression of pre-existing proteins led to enhanced cellular growth in the presence of 
uncommon nutrients. However, the results were also dominated by a handful of proteins 
that appeared to mediate non-specific stress responses. In this chapter, I aimed to avoid 
some of the pitfalls encountered in Chapter 4. I utilized the same screening strategy to 
identify E. coli proteins that could impart resistance to the cells upon exposure to antibiotics 
and toxins. In contrast to common pathogenic bacteria, the laboratory strain of E. coli used 
for the screen has not been exposed to any clinical settings that may favour the evolution of 
resistance. Therefore, this library-on-library screen tested the ability of the E. coli proteome 
to mediate the de novo evolution of toxin resistance. 
5.1.1 MOLECULAR ORIGINS OF ANTIBIOTIC RESISTANCE 
Antibiotic resistance in bacterial populations is an outcome of successful adaptation to a 
toxic environment. From an evolutionary perspective, resistant clones are fitter than 
susceptible clones because they have gained an improved capacity for survival and 
reproduction in the presence of a toxin. This can be made possible by one or more of the 
following physiological alterations: (i) enzymatic inactivation or degradation of the 
antibiotic; (ii) reduction of intracellular antibiotic concentrations by drug transporters and 
pumps; (iii) mutating antibiotic targets in such a way that they are no longer inhibited by 
the antibiotic; and (iv) the appearance of compensatory mutations in response to costly 
resistance mechanisms. The genetics and biochemistry of these resistance mechanisms have 
been the subjects of extensive research for the past 70 years, and have been reviewed widely 
in the literature (Levy & Marshall, 2004; Courvalin, 2008; Sandegren & Andersson, 2009; 
Davies & Davies, 2010). 
 The need to understand the diverse nature of resistance, and its rapid spread, has 
spurred recent efforts to focus on the origins and evolution of resistance proteins. Protein 
structure and biochemical analyses have revealed that many modern resistance proteins are 
evolutionarily related to proteins that are not involved in drug resistance (Wright, 2007; 
Morar & Wright, 2010). For example, ?-lactamases (the penicillin-hydrolyzing enzymes) are 
likely to have evolved from bacterial DD-peptidases, which are involved in peptidoglycan 
biosynthesis and maintenance (Kelly et al., 1986; Urbach et al., 2008). One of the 
aminoglycoside-inactivating enzymes, aminoglycoside kinase (APH), shares high structural 
similarities with Ser/Thr/Tyr protein kinases, and this observation led to the hypothesis 
that both types of kinases share a common ancestor (Hon et al., 1997; Daigle et al., 1999; 
Fong et al., 2011). However, the origins of resistance proteins with broad substrate 
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specificities (also known clinically as “super” resistance proteins) are less clear. For instance, 
an aminoglycoside acetyltransferase (AAC) variant from clinical bacterial isolates was able 
to acetylate, and therefore reduce the activities of, both aminoglycosides and 
fluoroquinolones (Robicsek et al., 2006). The aminoglycosides and fluoroquinolones belong 
to two separate compound classes with distinctive functional groups and modes of 
inhibition. In a separate example, E. coli and Klebsiella pneumoniae strains that caused an 
epidemic outbreak in 2010 are now known to have been expressing the NDM-1 metallo-?-
lactamase, which shows activities for a broad range of ?-lactams, including the last-line 
antibiotic for ?-lactam-resistant infections, the carbapenems (King & Strynadka, 2011; 
Thomas et al., 2011). Resistance proteins with secondary activities are not only found in 
clinical variants, but also in environmental isolates. The discovery of a bifunctional ?-
lactamase from a remote Alaskan soil sample suggested that resistance proteins have been 
evolving in the environment for a long time (Allen et al., 2009). This notion was further 
supported by a study that unearthed several 30,000-year-old resistance genes from 
permafrost sediments (D'Costa et al., 2011). The evolution of resistance in the environment 
is a natural response to the diversity of antibiotics produced by antibiotic-producing 
microorganisms. Overall, these examples imply that resistance proteins with secondary 
activities are not uncommon.  
 Wright (2007) proposed that it is highly likely that modern resistance proteins have 
originated from ancestral metabolic proteins, which had fortuitous activities towards 
and/or affinities for antibiotics. Over time, these promiscuous activities evolved to provide 
robust resistance mechanisms as a result of antibiotic exposures from the clinical (Rice, 
2009) and environmental (Fajardo & Martínez, 2008; Martínez, 2008) reservoirs. This model 
is identical to the one discussed previously for the evolution of new biochemical functions 
from enzymes with secondary activities [Jensen (1976); Bergthorsson et al. (2007); see also 
Section 4.1.1 in Chapter 4]. Apart from allowing E. coli to grow better in environments 
containing new nutrients (Chapter 4), increases in gene dosage, or protein expression, could 
potentially confer new resistance phenotypes on bacteria. Therefore, in this chapter, I set out 
to catalogue all the possible resistance activities in an E. coli proteome using the library-on-
library screen described previously (Chapter 4). This experiment would offer insights into 
all the resistance pathways (towards all the antibiotics) that a modern proteome can 
facilitate. I provide experimental evidence that the over-expression of pre-existing E. coli 
proteins can provide resistance to >80 antibiotics and toxins, through a variety of proposed 
mechanisms. The results suggest that the evolution of resistance is surprisingly likely, and 
that even the proteome of a non-pathogenic bacterium harbours substantial reservoirs of 
latent resistance proteins. 
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5.2 RESULTS 
5.2.1 LIBRARY-ON-LIBRARY SCREEN (PM 11 TO PM 20) 
The library-on-library screen described in Chapter 4 was used to uncover latent resistance 
proteins in the E. coli proteome. The conceptual and methodological details of the screen has 
been described in Sections 4.2.1 and 4.4.3, respectively. Briefly, E. coli cells were transformed 
with the pooled plasmids of the ASKA library, and then used to inoculate every well of PM 
11 to PM 20 (Figure 4.1 in Section 4.2.1, Chapter 4). In total, these ten PM plates contained 
237 toxins (including anti-bacterial agents), with each toxin present at four concentrations 
(Bochner et al., 2001). Similar to PM 1 to PM 10 (Chapter 4), growth in each toxin-containing 
well was monitored by purple colour development, due to the presence of a tetrazolium 
indicator dye. The negative control (E. coli harbouring the empty ASKA vector, pCA24N-
NoIns) was used to inoculate a second set of PM plates. By comparing the growth of the 
ASKA pool and the control in parallel, I was able to screen for examples in which the over-
expression of ASKA-encoded ORFs conferred increased fitness (i.e., an improved capacity 
for survival and reproduction) in the presence of a toxin.  
5.2.1.1 CASES WHERE THE ASKA POOL OUT-GREW THE NEGATIVE CONTROL 
In duplicate screens, the ASKA pool out-grew the negative control in the presence of 99 
toxins (42% of those tested). In the majority of cases, these improved growth phenotypes 
manifested as small but reproducible changes in the intensity of tetrazolium colour 
development, within the first 48 h of incubation (Table 5.1). Specifically, the ASKA pool 
showed enhanced growth in 50 of the 78 anti-bacterial agents (64%) contained within the 
PM plates. The improved growth phenotypes was also noted for 49 of the other 159 toxins 
that were tested (31%). These included anti-fungal and anti-parasitic agents, inorganic salts 
and dyes (Table 5.1). 
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5.2.1.2 CASES WHERE THE NEGATIVE CONTROL OUT-GREW THE ASKA CLONE 
In contrast to the improved growth phenotypes shown by the ASKA pool (Section 5.2.1.1), 
there were four toxin-containing environments (2% of the all conditions screened) where 
the negative control out-grew the ASKA pool (Table 5.2) in two independent screens. A 
possible reason was that one or more ASKA clones were sensitizing the whole population to 
these compounds, e.g. by metabolizing the compounds into more toxic products. Unlike the 
99 cases described in Section 5.2.1.1, protein over-expression did not seem to be able to 
confer fitness to any member of the ASKA population. This was also noted previously 
(Section 4.2.8 in Chapter 4), where the ASKA pool was out-grown in 2% of the 960 
environments of PM 1 to PM 10. Since the number of such cases was small, and the 
difference in growth rates were slight, the exact reasons leading to this phenomenon were 
not investigated further.   
 
Table 5.2:  The four toxin-containing environments in which the negative control out-grew the ASKA pool. 
Compound PM well* Days of incubation† ASKA growth NoInsert growth 
?-Lactam     
Cefoxitin PM14, E4 3 Light Medium 
Anti-folate     
Sulfamethoxazole PM12, G7 3 Clear Light 
Polymyxin     
Polymyxin B PM12, B10 1 Dark Very dark 
Other toxins     
1-chloro-2,4-dinitrobenzene PM16, D2 2 Light Dark 
                      
* The toxin-containing PM well of which the difference of colour intensity was noted. † Days of incubation before a 
change in growth phenotype (i.e., tetrazolium colour intensity) was observed.                      
                            
Key for scoring growth phenotype (i.e., tetrazolium colour intensity):                            
 Very dark             Dark  Medium  Light        Clear          
5.2.2 IDENTIFICATION OF NOVEL RESISTANCE GENES 
To deconvolute the results of the library-on-library screen, the individual ASKA clones that 
were responsible for the observed improvements in growth rates were isolated. In each of 
the 99 conditions identified above, serial transfer was used to enrich for the fittest clone(s) 
within the ASKA pool (Figure 4.2 in Section 4.2.2, Chapter 4). After two transfers, cells from 
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the enriched population were plated under non-selective conditions. PCR and DNA 
sequencing revealed the plasmid-encoded genes that had imparted improved growth. 
 An ASKA ORF was scored as a hit if it occurred at least twice among the eight clones 
sequenced from a serially-passaged population. Given the large size of the ASKA pool 
(5,272 clones), it was highly unlikely (P ? 0.005; refer to Section 4.4.4.1 for more details) that 
any two of the eight randomly-chosen colonies would contain the same ASKA plasmid, 
unless that clone had been positively selected during serial transfer. This approach yielded 
hits from 86 of the 99 conditions tested, including representatives of all the compound 
classes that were tested (Table 5.3). For example, the PM plates contained 22 ?-lactam 
antibiotics, and ASKA clones that improved growth in 11 of them were isolated (Table 5.3, 
row 1). The serial enrichment strategy yielded a single hit from 60 of the 86 conditions. In 38 
of these, the ASKA clone was enriched to apparent homogeneity (i.e., eight of eight 
sequenced clones were identical). However, serial transfer gave two different hits in 23 
conditions, and three hits in another three cases (the ?-lactam, aztreonam; the antiseptic, 
benzethonium chloride; and the toxic alkaloid, sanguinarine). Overall, therefore, 115 
positively-selected hits were identified from 86 toxin-containing environments (Table 5.1 in 
Section 5.2.1.1; Table 5.3).  
 
Table 5.3:  Summary of hits obtained from the library-on-library screen for PM 11 to PM20. 
Class of toxic compound Number of positives* Number of ASKA hits† 
Anti-bacterials   
?-lactams 11 (of 22) 14 
Aminoglycosides  4 (of 14)  4 
Anti-folates 7 (of 9) 10 
Quinolones 4 (of 9)  6 
Tetracyclines 3 (of 8)  4 
Macrolide-Lincosamide-
Streptogramin (MLS) antibiotics 6 (of 7) 10 
Glycopeptides 1 (of 3)  1 
Nitrofurans 3 (of 3)  4 
Rifamycins 1 (of 2)  2 
Steroid anti-bacterial 1 (of 1)  1 
Other toxins 45 (of 159) 59 
Total 86 (of 237) 115 
 
* The number of toxic compounds for which screening and serial enrichment yielded at least one ASKA-encoded 
resistance gene. The total number of toxins that were screened in each class is listed in parentheses.       
† Total number of ASKA ORFs that were isolated from PM wells containing toxins of each compound class. 
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 In 13 cases, no individual ASKA clones were successfully enriched to a frequency of 
two or more in the eight sequenced clones (Table 5.1 in Section 5.2.1.1). The possible 
explanations for this phenomenon has been discussed previously (Section 4.3.1 in Chapter 
4). 
5.2.3 DIVERSE MECHANISMS OF RESISTANCE 
The initial focus was on identifying proteins — and particularly enzymes — that possessed 
weak secondary activities towards antibiotics and toxins. However, it rapidly became 
apparent that this library-on-library screen had uncovered many different classes of protein 
that were contributing to resistance. Therefore, I used the EcoCyc (Keseler et al., 2009) and 
UniProt (The UniProt Consortium, 2010) databases, in addition to the references cited in 
Table 5.1 (Section 5.2.1.1), to assign proposed modes of action for each of the 115 cases that 
had been positively selected and identified during the screen (Table 5.4).  
 
Table 5.4:  Proposed modes of action for 115 cases of resistance imparted by ASKA ORFs. 
Proposed mechanism of resistance Frequency 
Efflux pump/transporter 22 
Regulatory effect 19 
Catalytic promiscuity and/or substrate ambiguity 15 
Prophage gene 14 
Stress response 13 
Envelope/capsule synthesis  8 
Biofilm formation and regulation  5 
Over-expression of the drug’s target  1 
Maintenance of metabolic flux  1 
Unknown 17 
Total 115 
 
 Eighteen genes occurred multiple times, and were responsible for improving growth 
in a total of 72 toxin-containing environments (Table 5.5), suggesting broad and non-specific 
mechanisms. Consistent with previous results (Nishino & Yamaguchi, 2001; Breidenstein et 
al., 2008; Duo et al., 2008; Liu et al., 2010), the expression of efflux pumps and transporters 
was common among this subset of non-specific resistance determinants. For example, 
expression of the Bcr multidrug transporter increased growth in the presence of three anti-
folate antibiotics (sulfachloropyridazine, sulfathiazole and sulfisoxazole), two tetracyclines 
(oxytetracycline and rolitetracycline), and one ?-lactam (cefoperazone). An outer membrane 
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?-barrel, YcbS (see Section 4.3.2.2 of Chapter 4 for a summary of its function), improved 
growth in the presence of four toxic compounds: a mutagen, 9-aminoacridine; an 
uncoupling agent, FCCP; a herbicide, methyl viologen; and an alkaloid, sanguinarine. 
Similarly, the MdtM and Cmr efflux pumps improved growth in the presence of five and 
three toxins respectively (Table 5.5). The selection of these membrane proteins confirmed 
that any bias associated with IPTG-induced over-expression had been minimized (refer to 
Section 4.3.1 for the potential fitness bias associated with IPTG induction). 
 I also discovered transcriptional regulators, stress response proteins and proteins from 
capsule biosynthesis that each improved fitness in the presence of multiple toxins (Table 
5.5). The only readily predictable example was the transcriptional activator MarA, which 
was isolated from environments containing two quinolones (ciprofloxacin and ofloxacin), a 
tetracycline (penimepicycline), a macrolide (tylosin), and a mutagen (proflavine). MarA is 
known to mediate multidrug resistance by up-regulating the efflux system and down-
regulating membrane permeability (Cohen et al., 1993). In other cases, proteins that had not 
previously been associated with resistance were found, including the biofilm modulation 
protein, Bdm, the small stress response protein, YcgZ, and the global regulator of 
transcription, CpdA (cAMP phosphodiesterase). The likely pleiotropic effects of these in 
altering the expression of downstream resistance determinants can be rationalized. Another 
prominent hit was the UDP-glucose 4-epimerase (GalE) ASKA strain, which was isolated 
from seven PM wells. GalE is involved in a variety of galactose metabolic processes, 
including glycolysis and the biosynthesis of lipopolysaccharide and capsule components. 
The host strain, E. coli DH5?-E, is gal?, although the exact mutation(s) responsible for this 
phenotype are not known. It is possible that the fitness effects seen when GalE was over-
expressed were simply due to complementation of the gal? mutation. However, if this was 
the case, the GalE-expressing ASKA strain would have out-grown the negative control in 
many more than seven of the 237 environments that had been tested. Instead, GalE 
expression appears to mediate a suite of pleiotropic effects that are relevant for the 
evolution of resistance. Finally, other multiple-occurring ORFs hint at the functions of 
previously uncharacterized proteins (Table 5.5). For example, the YejG-expressing clone 
was isolated from PM wells containing apramycin, sisomicin and tobramycin, suggesting 
that it may possess broad enzymatic activity towards these aminoglycoside antibiotics. 
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Table 5.5:  Genes that conferred increased resistance to more than one toxic compound. 
Gene Gene product Freq.* Toxic compounds Proposed mechanism of resistance 
galE UDP-glucose 4-
epimerase 
7 Amitriptyline, Chlorpromazine, 
Nalidixic acid, Orphenadrine, 
Pridinol, Thioridazine, 
Trifluoperazine 
Envelope/capsule 
biosynthesis 
bcr Bcr multidrug 
transporter 
6 Cefoperazone, Oxytetracycline, 
Rolitetracycline, 
Sulfachloropyridazine, 
Sulfathiazole, Sulfisoxazole  
Efflux/transport 
ycgZ Small protein induced by 
YcgF 
6 Aztreonam, Cefmetazole, 
Cefuroxime, Moxalactam, 
Penimepicycline, Sulfamethazine 
Stress response 
ydaC Uncharacterized protein 
from Rac prophage 
6 Caffeine, Chelerythrine, 
Erythromycin, Phenethicillin, 
Plumbagin, Sanguinarine  
Prophage gene 
marA MarA transcriptional 
activator 
5 Ciprofloxacin, Ofloxacin, 
Penimepicycline, Proflavine, Tylosin  
Regulatory effect 
mdtM MdtM multidrug 
transporter 
5 5-Nitro-2-furaldehyde, Crystal 
violet, Furaltadone, Puromycin, 
Tinidazole  
Efflux/transport 
cpdA cAMP 
phosphodiesterase 
4 Dihydrostreptomycin, Hydroxyurea, 
Josamycin, L-Aspartic-b-
hydroxamate  
Regulatory effect 
csiE Stationary phase-
inducible protein 
4 3,4-Dimethoxybenzyl alcohol, 
Antimony (III) chloride, Blasticidin 
S, Guanidine hydrochloride,  
Stress response 
rbsR Ribose transcriptional 
repressor 
4 Aztreonam, Lincomycin, 
Sulfamethazine, 
Sulfamonomethoxine 
Regulatory effect 
ycbS Uncharacterized outer 
membrane ?-barrel 
protein 
4 9-Aminoacridine, FCCP, Methyl 
viologen, Sanguinarine  
Efflux/transport 
ydfW Uncharacterized protein 
from Qin prophage 
4 Chelerythrine, Erythromycin, 
Oleandomycin, Spiramycin,  
Prophage gene 
bdm Biofilm-dependent 
modulation protein 
3 Cefazolin, Cephalothin, Nafcillin Biofilm formation & 
regulation 
cmr MdfA/Cmr multidrug 
transporter 
3 Dodecyltrimethyl ammonium 
bromide, Lincomycin, Sodium 
dichromate 
Efflux/transport 
yejG Uncharacterized protein 3 Apramycin, Sisomicin, Tobramycin Unknown 
folA Dihydrofolate reductase 2 2,4-Diamino-6,7-diisopropyl-
pteridine, Trimethoprim 
Catalytic promiscuity 
and/or substrate 
ambiguity; over-
expression of drug 
target 
hcaR Hca operon 
transcriptional activator 
2 Fusidic acid, Sodium m-arsenite Regulatory effect 
tusE Sulfurtransferase 2 Rifampicin, Spiramycin Catalytic promiscuity 
and/or substrate 
ambiguity 
yfdO Uncharacterized protein 
from CPS-53 [KpLE1] 
prophage 
2 Lidocane, Nalidixic acid Prophage gene 
 
* The number of PM wells from which the ASKA-encoded gene was isolated. 
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 In 43 cases, an ASKA-encoded ORF improved growth in the presence of a single toxin 
(Table 5.6). These compound-specific responses included 12 cases in which metabolic 
enzymes appeared to display catalytic promiscuity and/or substrate ambiguity. Examples 
included the carbonic anhydrase, CynT, evincing growth in the presence of enoxacin 
(reminiscent of the human enzyme’s promiscuous esterase activity) (Gould & Tawfik, 2005)  
and the purine nucleotidase, YrfG, increasing fitness in the presence of a toxic analog (6-
mercaptopurine). Finally, 13 of the 17 instances in which I was unable to assign a proposed 
mechanism of action (Table 5.4) involved uncharacterized ASKA ORFs that were isolated 
from a single environment (Table 5.6). 
 
Table 5.6:  Genes that conferred increased resistance to one toxic compound only. 
Gene  Gene product Associated compound Proposed mechanism 
luxS S-ribosylhomocysteine lyase Sulfadiazine Biofilm formation & regulation 
tabA Toxin-antitoxin biofilm protein D-Serine Biofilm formation & regulation  
aroL Shikimate kinase II D,L-Methionine 
hydroxamate 
Catalytic promiscuity and/or 
substrate ambiguity 
cynT Carbonic anhydrase Enoxacin Catalytic promiscuity and/or 
substrate ambiguity 
elaD Deubiquitinase Sodium bromate Catalytic promiscuity and/or 
substrate ambiguity 
iaaA Isoaspartyl peptidase L-Aspartic-?-
hydroxamate 
Catalytic promiscuity and/or 
substrate ambiguity 
puuD ?-glutamyl-?-aminobutyrate hydrolase Benzethonium 
chloride 
Catalytic promiscuity and/or 
substrate ambiguity 
tehB Tellurite resistance protein Potassium tellurite Catalytic promiscuity and/or 
substrate ambiguity 
tmcA tRNAMet cytidine acetyltransferase  Sanguinarine Catalytic promiscuity and/or 
substrate ambiguity 
wrbA NAD(P)H:quinone oxidoreductase Tinidazole Catalytic promiscuity and/or 
substrate ambiguity 
yagT Aldehyde oxidoreductase, Fe-S subunit Furaltadone Catalytic promiscuity and/or 
substrate ambiguity 
yeaD Putative mutarotase Aztreonam Catalytic promiscuity and/or 
substrate ambiguity 
yrfG Purine nucleotidase 6-Mercaptopurine Catalytic promiscuity and/or 
substrate ambiguity 
ysgA Putative dienelactone hydrolase Patulin Catalytic promiscuity and/or 
substrate ambiguity 
phnC Alkylphosphonate ABC transporter, 
ATP-binding subunit 
Sulfathiazole Efflux/transport 
ugpC Glycerol-3-phosphate ABC transporter; 
ATP-binding subunit 
Piperacillin Efflux/transport 
yedA Uncharacterized inner membrane 
transporter 
Iodoacetate Efflux/transport 
yjeH Uncharacterized inner membrane 
transporter 
Sodium nitrite Efflux/transport 
wbbL_1 Putative lipopolysaccharide biosynthesis 
glycosyltransferase 
Lidocane Envelope/capsule biosynthesis 
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Gene  Gene product Associated 
compound 
Proposed mechanism 
nudB Dihydroneopterin triphosphate 
pyrophosphatase 
Sulfadiazine Maintaining metabolic flux 
tfaX Uncharacterized protein from DLP12 
prophage 
Nitrofurantoin Prophage gene 
ybcD Pseudogene from DLP12 prophage; 
predicted fragment of replication protein 
Benzethonium 
chloride 
Prophage gene 
feoC Transcriptional regulator of ferrous iron 
transport 
Rifampicin Regulatory effect 
hda Regulator of DnaA Guanazole Regulatory effect 
soxS SoxS transcriptional activator Enoxacin Regulatory effect 
yidF Uncharacterized protein; predicted 
transcriptional regulator 
D-Serine Regulatory effect 
bfd Bacterioferritin-associated ferredoxin Penicillin G Stress response 
gmr Cyclic-di-GMP phosphodiesterase 3,5-Dinitrobenzene Stress response 
mzrA Modulator of EnvZ and OmpR Vancomycin Stress response 
pheS Phenylalanyl-tRNA synthetase ?-chain Sodium nitrite Unknown 
yeeX Uncharacterized cytoplasmic protein Piperacillin Unknown 
yeiW Uncharacterized protein Potassium chromate Unknown 
ygeN Uncharacterized protein Niaproof Unknown 
yghW Uncharacterized protein Fusaric acid Unknown 
yhbT Uncharacterized protein Sodium dichromate Unknown 
yhfK Uncharacterized inner membrane 
protein 
Josamycin Unknown 
yhiK Uncharacterized protein Benzethonium 
chloride 
Unknown 
yjbI Uncharacterized protein Blasticidin S Unknown 
yjfK Uncharacterized protein Harmane Unknown 
ykiA Uncharacterized protein Antimony (III) 
chloride 
Unknown 
ymjB Uncharacterized protein Niaproof Unknown 
ypjC Uncharacterized protein Ornidazole Unknown 
yqjD Uncharacterized protein 2,2'-Dipyridyl Unknown 
 
5.2.4 THE INTERPLAY OF FITNESS AND RESISTANCE 
Mutations that confer antibiotic resistance can have a variety of effects on the fitness of the 
cell in the absence of drug (Andersson & Hughes, 2010). Resistance mutations often bear 
fitness costs, although examples of cost-free resistance (Sander et al., 2002) and mutual 
compensation (i.e., simultaneous increases in resistance and fitness) have also been 
described (Marcusson et al., 2009). The library-on-library screen revealed cases where 
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protein over-expression in the ASKA clones was responsible for enhancing fitness in the 
presence of a toxin.  
 It was unclear from the screen whether the plasmid-encoded ORFs were improving 
the general vigour of the host, or increasing resistance. To investigate this further, the 
relative fitness (W) for each of 25 strains relative to the negative control (i.e., E. coli DH5?-E 
with pCA24N-NoIns) was measured. Fitness tests were conducted in the absence of toxin, 
but in the presence of 50 μM IPTG (see Section 5.4.3 for details). Using the same set of 25 
strains, I also determined the minimum inhibitory concentrations (MICs) for 29 toxin/strain 
combinations (see Section 5.4.4 for details). The toxins were chosen based on their anti-
bacterial properties, and as examples of each mechanistic class (as defined in Table 5.4 of 
Section 5.2.3). MICs were determined by either plate-based measurements (see Section 
5.4.4.1 for details), or broth-based measurements (see Section 5.4.4.2 for details). An example 
of plate-based measurements is shown in Figure 5.1, where E-test strips containing 
cefuroxime were used to measure the MIC values of the negative control and the YcgZ-
expressing clone. 
 
   
Figure 5.1:  YcgZ over-expression conferred resistance to cefuroxime in E. coli. 
Cefuroxime susceptibility in E. coli was tested using E-test strips (Section 5.4.4). Clone over-expressing YcgZ 
showed a higher resistance to cefuroxime, as evident by the smaller zone of inhibition. 
 In the absence of toxin, only two of the 25 ASKA strains showed significantly reduced 
fitness (i.e. W < 1; P < 0.01) compared to the negative control (Table 5.7). Nine ASKA strains 
were not significantly different from the control (P > 0.01), and 14 of the strains out-
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competed it (W > 1; P < 0.01). In contrast, almost all of MICs determined for ASKA strains 
were increased compared to those that were measured for the negative control strain (Table 
5.7).  
 By far the largest increase in MIC was for trimethoprim, where over-expression of its 
intracellular target, dihydrofolate reductase (folA), effected very high levels of resistance (at 
least 500-fold greater than the negative control strain). The FolA-expressing strain was also 
one of the least fit in the absence of antibiotic (W = 0.84). Expression of the multidrug 
transporters MdtM and Cmr led to 16-fold and 8-fold increases in the MICs for puromycin 
and lincomycin respectively, without imparting fitness costs in a toxin-free environment. 
The remainder of the selected ASKA strains exhibited modest increases (<8-fold) in MICs 
compared to the negative control (Table 5.7).  
 In general, there was a poor correlation between resistance, and fitness in the absence 
of toxin. In some cases, fitter clones were also more resistant. For example, the YcgZ-
expressing clone had the highest relative fitness of the 25 that we measured (W = 1.72), and 
it also showed a greater increase in aztreonam resistance (5.9-fold) than the other two clones 
that were isolated from the aztreonam-containing PM well (Table 5.7). However, there were 
also cases where the opposite was true. For example, over-expression of YdaC imparted a 4-
fold increase in erythromycin resistance and a small increase in fitness (W = 1.33), while 
YdfW over-expression gave a smaller increase in resistance (3-fold) but a larger increase in 
fitness (W = 1.51). Similarly, over-expressing NudB gave a higher MIC for sulfadiazine than 
LuxS over-expression (32 μg/mL versus 24 μg/mL), yet the NudB-expressing strain was 
considerably less fit (W = 0.68 versus W = 1.11).  
 
Table 5.7:  Relative fitness and drug resistance data for E. coli cells over-expressing ORFs from the ASKA 
library. 
ASKA 
ORF    W ± SE* Compound 
MIC (μg/mL) with 
ASKA ORF 
MIC (μg/mL) with 
pCA24N-NoIns 
Fold 
increase 
in MIC 
1. ?-lactams     
bdm 1.47 ± 0.04† Cephalothin 16 8 2.0 
bfd 1.16 ± 0.03† Penicillin G 48 32 1.5 
rbsR 1.40 ± 0.04† Aztreonam 0.19 0.064 3.0 
yeaD 1.20 ± 0.03† Aztreonam 0.094 0.064 1.5 
ycgZ 1.72 ± 0.05† Aztreonam 0.38 0.064 5.9 
ycgZ See above Cefuroxime 16 6 2.7 
2. Aminoglycosides     
yejG 0.94 ± 0.04 Sisomicin 0.19 0.125 1.5 
yejG See above Tobramycin 1.5 0.5 3.0 
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ASKA 
ORF 
   W ± SE* Compound MIC (μg/mL) with 
ASKA ORF 
MIC (μg/mL) with 
pCA24N-NoIns 
Fold 
increase 
in MIC 
3. Anti-folates     
folA 0.84 ± 0.03† Trimethoprim >32 0.064 >500 
luxS 1.11 ± 0.02† Sulfadiazine 24 16 1.5 
nudB 0.68 ± 0.04† Sulfadiazine 32 16 2.0 
4. Quinolones     
cynT 1.17 ± 0.04† Enoxacin 0.25 0.19 1.3 
marA 1.08 ± 0.02 Ciprofloxacin 0.125 0.032 3.9 
galE 1.16 ± 0.01† Nalidixic acid 96 32 3.0 
yfdO 1.03 ± 0.02 Nalidixic acid 48 32 1.5 
5. Tetracyclines     
bcr 1.03 ± 0.04 Oxytetracycline 6 2 3.0 
6. Macrolide-Lincosamide-Streptogramin    
cmr 1.45 ± 0.02† Lincomycin 1536 192 8.0 
rbsR See above Lincomycin 384 192 2.0 
ydfW 1.51 ± 0.12† Spiramycin 36 24 1.5 
ydfW See above Erythromycin 96 32 3.0 
ydaC 1.33 ± 0.03† Erythromycin 128 32 4.0 
7. Glycopeptides     
mzrA 1.23 ± 0.07 Vancomycin 256 128 2.0 
8. Nitrofurans     
tfaX 1.18 ± 0.02† Nitrofurantoin 0.094 0.19 0.5 
9. Rifamycins     
feoC 0.78 ± 0.07 Rifampicin 6 4 1.5 
tusE 0.87 ± 0.04 Rifampicin 6 4 1.5 
10. Other toxins     
mdtM 1.07 ± 0.03 Puromycin 128 8 16.0 
puuD 1.12 ± 0.03† Benzethonium chloride 6 6 1.0 
ybcD 1.02 ± 0.02 Benzethonium chloride 8 6 1.3 
yhiK 1.19 ± 0.01† Benzethonium chloride 12 6 2.0 
 
* Fitness (W) of the ASKA strain, in the absence of toxin, relative to a neutrally-marked negative control that 
harbours pCA24N-NoIns. Values are expressed as mean ± S.E.M. (n = 8).         
† Significance level of P < 0.01 for a two-tailed test with the null hypothesis that W = 1, calculated using the t 
distribution and 7 degrees of freedom. 
 The host strain, E. coli DH5?-E, contains a chromosomal gyrA mutation. The gyrA gene 
encodes DNA gyrase, and mutations at this locus are known to give rise to nalidixic acid 
resistance. Unexpectedly, two genes, galE and yfdO, were identified in this study. Over-
expression of GalE and YfdO further increased the MIC for nalidixic acid, by 3-fold and 1.5-
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fold respectively (Table 5.7). In the absence of nalidixic acid, the GalE-expressing strain was 
slightly fitter than the control strain (W = 1.16), whereas the YfdO-expressing strain was 
nearly as fit as the control strain (W = 1.03). The implication is that there are alternate routes 
to nalidixic acid resistance in E. coli, and/or novel ways (possibly mediated by GalE and/or 
YfdO) to compensate for fitness costs that are associated with gyrA mutations. 
 In a single case, expression of an ASKA ORF (an uncharacterized prophage gene, tfaX) 
decreased the MIC for the antibiotic (nitrofurantoin) in which it was selected. The TfaX-
expressing strain showed a small but statistically significant fitness improvement in the 
absence of nitrofurantoin (W = 1.18). This suggests that increased fitness in the absence of an 
antibiotic can translate into a selective advantage when the drug is introduced; however, 
this appears to be uncommon. It is noteworthy that no single ASKA gene was isolated from 
more than seven PM wells (see Table 5.5 for genes that conferred resistance to more than 
one toxic compound). It might be expected that one (or a handful) of general, growth-
enhancing genes would have been isolated from a majority of the 237 toxin-containing 
environments, were such a gene present in the ASKA pool. Instead, this approach has 
revealed many latent resistance determinants in the E. coli genome. 
5.3 DISCUSSION 
5.3.1 AN OVERVIEW OF THE RESULTS 
In contrast to Chapter 4 where the ability to grow better in novel nutrients was selected, in 
this chapter I used resistance to antibiotics and toxins as a readily selectable trait. This 
approach is different from previous studies where roles in resistance have been inferred 
indirectly, based on the increased sensitivity of mutants produced by transposon 
inactivation or gene knockouts (Breidenstein et al., 2008; Duo et al., 2008; Liu et al., 2010). In 
the first part of the experiment, I identified toxin-containing environments where the 
pooled ASKA clones out-grew the negative control. In those PM wells, at least one member 
of the pool had gained an improved ability to survive and reproduce, through the over-
expression of a single, wild-type ORF. Next, serial transfer was used to identify the fittest 
strain(s) in the ASKA pool. This experimental design precluded the identification of ASKA 
clones with increased susceptibility to toxins, although these are likely to have been present 
in many (and perhaps all) of the PM wells.  
 In Chapter 4, thiamine starvation appeared to be an issue for the biased gene 
enrichments from the wells of PM 3 to PM 8 (Section 4.3.3). However, thiamine was not a 
factor in selecting ASKA ORFs from the toxin-containing environments. This was because 
the base medium in the wells of PM 11 to PM 20 was derived from rich nutrients (2.0 g/L of 
tryptone, 1.0 g/L of yeast extract and 1.0 g/L of NaCl). This formulation is identical to that 
- Chapter 5: Toxin resistance mediated by protein over-expression - 
210
of PM 1, PM 2, PM 9 and PM 10 [(Zhou et al., 2003); also see Sections 4.2.3.1 and 4.2.7], and 
provides a source of thiamine through yeast extract. 
 In total, I identified 61 different ASKA ORFs that improved fitness in 86 of 237 toxin-
containing environments. Eighteen of these ORFs were hits in multiple wells (Table 5.5 in 
Section 5.2.3); overall, I identified 115 examples of resistance. Hits were obtained from every 
class of toxic compound tested (Table 5.3 in Section 5.2.2). The hit rate (resistance to 36% of 
all toxins) was comparable with the study conducted in Chapter 4, where 35% of the 
environments yielded at least an enriched ASKA ORF. Consistent with the results obtained 
in Chapter 4, this study emphasizes just how likely evolutionary innovation can be. The 
results of this chapter imply that the over-expression of a randomly chosen E. coli protein 
will impart resistance to a novel toxin with a probability of (61/5,272) ? (86/237) ? 0.4%. 
 On the whole, the results supported the hypothesis that a bacterium from a non-
clinical environment (in this case, a laboratory strain of E. coli) can nevertheless possess a 
significant reservoir of latent resistance proteins (Martínez, 2008). More generally, the 
identification of many E. coli proteins that have not been previously associated with 
antibiotic resistance suggests that resistance activities can be evolved from pre-existing 
proteins (Wright, 2007). Protein over-expression can provide an effective initial adaptive 
response for populations that are exposed to antimicrobial compounds.  
5.3.2 A RESERVOIR OF UNEXPLORED TOXIN RESISTANCE 
The PM plates contained four concentrations of each toxin. Therefore, a hit could have been 
due to an increase in resistance (i.e., a strain undergoing division at a toxin concentration 
that was inhibitory to the other strains, including the negative control), or due to 
particularly rapid growth in a sub-inhibitory concentration of the toxin (i.e., dividing faster 
than the other strains in the pool). In this respect, the library-on-library screen in this 
chapter mimics the dynamics of a clinical setting (Martínez et al., 2007; Marcusson et al., 
2009). At an infection site, the ability to out-grow the neighbouring cells is as important as 
the ability to resist the actions of antibiotics. Therefore, the fitness values and the MICs of 25 
ASKA strains were determined in order to elucidate the correlation between their growth 
rates and resistance activities (Table 5.7 in Section 5.2.4). 
 Almost exclusively, the proteins that were identified from the screen did facilitate 
increased resistance (Table 5.7 in Section 5.2.4). The majority of the measured MIC increases 
were modest (<8-fold); nevertheless, theoretical models have shown that even small 
changes such as these can be responsible for increasing the severity of bacterial infections 
(Drusano, 2004). In one case — cefuroxime — the expression of a small stress response 
protein, YcgZ, increased the MIC from 6 μg/mL to 16 μg/mL (Table 5.7 and Figure 5.1 in 
Section 5.2.4). The clinical breakpoint for resistance to this ?-lactam is 8 μg/mL (The 
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European Committee on Antimicrobial Susceptibility Testing [EUCAST], 2011); that is, the 
non-pathogenic host strain used in this study attained clinically relevant levels of resistance, 
simply through over-expression of a previously uncharacterized protein. Furthermore, most 
strains showed no fitness cost associated with expressing an ASKA ORF in the absence of 
toxin (and indeed, many out-competed the negative control; Table 5.7). Strong selection 
pressure for cost-free resistance mutations has been observed in clinical isolates of M. 
tuberculosis (Sander et al., 2002). Together, the MIC and fitness data suggest that up-
regulating the expression of pre-existing, latent resistance determinants may play an 
important role in the emergence of drug-resistant pathogens. 
 Quinolone antibiotics are of particular interest in clinical settings because these drugs 
are fully synthetic (Heeb et al., 2011). For this reason, the development of quinolone 
resistance in bacteria is generally assumed to be a lengthy process due to the lack of 
intrinsic resistance. However, almost half of the quinolone antibiotics tested in this screen 
yielded at least one ASKA-encoded resistance gene (Table 5.1 in Section 5.2.1.1; Table 5.3 in 
Section 5.2.2). In one case, E. coli cells over-expressing MarA were ~4-fold more resistant to 
ciprofloxacin than the control clone, and no biological cost was associated with MarA over-
expression in the absence of the antibiotic (W = 1.08; P > 0.01). Protein over-expression has 
successfully provided a basal level of resistance to the cells, which could pave the way to 
full-blown resistance. There is only an 8-fold difference between the clinical breakpoint for 
ciprofloxacin resistance (1.0 μg/mL; The European Committee on Antimicrobial 
Susceptibility Testing [EUCAST], 2011) and the MIC of the MarA-expressing clone in this 
study (0.125 μg/mL). 
 Ciprofloxacin-resistant E. coli mutants were recently isolated from a microenvironment 
that mimicked an infected host (Zhang et al., 2011). All isolates contained three single amino 
acid changes, and one of the substitutions was located in the transcriptional repressor of the 
marRAB operon, MarR (Cohen et al., 1993). MarA, the transcriptional activator for the same 
operon, is an antagonist of MarR. Hence, the results of this study (based on MarA over-
expression) suggested that the marR mutation was likely to increase the expression of the 
operon (including marA), and eventually result in bacterial resistance to ciprofloxacin. This 
specific example confirms that the resistance determinants (such as marA) isolated from the 
library-on-library screen can be informative in explaining the molecular origins of antibiotic 
resistance. 
 Other proteins identified from the screen were found to act through a variety of 
mechanisms to effect resistance (Table 5.4 in Section 5.2.3). Many of these mechanisms — 
such as toxin efflux/transport, stress responses and biofilm formation — were unsurprising, 
even if the identities of the individual resistance genes were less predictable. In 15 of 115 
cases, over-expressed enzymes appeared to be acting promiscuously to impart resistance. In 
addition to these mechanisms, there was a prevalence of (i) prophage genes; and (ii) genes 
of unknown function in the list. Prophage genes are usually assumed to be cryptic and/or 
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defective remnants of temperate bacteriophage genomes, although a recent study has 
shown that genes from the CP4-57 and DLP12 prophages can play roles in biofilm 
development (Wang et al., 2009). Here, I have reported 14 cases in which the over-
expression of prophage genes (including two from DLP12) can improve growth in the 
presence of toxins. Twelve of these cases arose from the over-expression of only three 
prophage genes: ydaC, ydfW and yfdO (Table 5.5 in Section 5.2.3). This extends the previous 
finding (Wang et al., 2009), demonstrating that prophage genes can modulate broad, 
compound non-specific cellular responses when they are activated from latency. 
 In contrast, 20 uncharacterized, non-prophage genes that showed specificity in their 
actions were identified; that is, they each imparted a growth advantage in the presence of a 
single toxin. These included genes for putative enzymes (wbbL_1, yeaD, ysgA), predicted 
transporters (yedA, yjeH) and a predicted transcriptional regulator (yidF), as well as 14 genes 
for which functional annotation was impossible due to insufficient homology with any gene 
of known function (Table 5.6 in Section 5.2.3). These results provide experimental evidence 
for the importance of cryptic genes as a reservoir of evolutionarily-accessible functions (Hall 
et al., 1983). 
5.3.3 PROTEIN OVER-EXPRESSION: A POSSIBLE ADAPTIVE MECHANISM 
In summary, I have used two tools from functional genomics (PM plates and the ASKA 
collection) to conduct a comprehensive search for E. coli proteins that can impart improved 
growth phenotypes in the presence of novel nutrients (Chapter 4) or toxic compounds 
(Chapter 5). The hit rates of Chapter 4 (improved growth in 35% of all environments) and 
Chapter 5 (resistance to 36% of all toxins) were considerably higher than a previous 
multicopy suppression screen (Patrick et al., 2007), where only 20% of single-gene knockout 
strains were rescued by non-cognate ASKA ORFs. Hence, the catalogue of proteins 
identified from the library-on-library screen provides a unique picture of a bacterium’s 
latent evolutionary potential and emphasizes the high frequency at which novel traits can 
evolve.  
 By cataloguing sources of phenotypic innovation, I have revealed the diversity of 
adaptive mechanisms that can be underpinned by over-expression mutations such as gene 
amplification. Every plasmid-carrying ASKA clone approximated a non-plasmid-containing 
strain in which a single chromosomal locus had been amplified. Growth under selection 
began when the pooled ASKA clones were used to inoculate each PM well. In order to be 
scored positive, a PM well had to contain cells that out-grew the negative control, in which 
no ASKA ORF was being expressed. Therefore, I was specifically looking for cases in which 
proteins possessed activities that were valuable in the presence of either a novel nutrient or 
a toxin, and cases in which increases in their dosage were required to uncover the latent 
activities. However, the library-on-library screen was not designed to consider mutations 
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beyond protein over-expression (or gene amplification). The next logical step will be to 
determine feasible mutational routes after protein over-expression, by applying selection 
continuously. This approach, which is underpinned by the Innovation, Amplification and 
Divergence (IAD) model (Bergthorsson et al., 2007), can potentially demonstrate the 
emergence of new activities from pre-existing protein scaffolds. Related questions, such as 
the nature of the trade-off between new and old biochemical functions, can also be 
addressed.  
 In Chapters 2 and 3, I examined the mutational routes for evolving one pre-existing 
protein scaffold to have the activity of another. In contrast, Chapters 4 and 5 allowed me to 
identify pre-exising scaffolds that could mediate the evolution of novel phenotypes. 
Overall, the prevalence of promiscuity in the E. coli proteome, as described in Chapters 4 
and 5, appears to confirm that the second tenet of the IAD model (Bergthorsson et al., 2007) 
is correct. Hence, the IAD model is a feasible, likely-to-be-widespread model for the 
evolution of new traits. 
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5.4 MATERIALS AND METHODS 
All reagents were from Sigma, unless otherwise specified. The following subsections 
describe materials and methods specific to this chapter. Common molecular biology 
materials and techniques are described in Appendix I. 
 Powdered X-gal (5-bromo-4-chloro-3-indolyl-?-D-galactopyranoside; ForMedium) was 
dissolved in DMSO (dimethyl sulfoxide), and was always prepared as 20 mg/mL stocks. 
Benzethonium chloride, lincomycin (Duchefa Biochemie), puromycin (Melford), sisomicin 
and vancomycin (Duchefa Biochemie) were dissolved in water. Enoxacin and sulfadiazine 
were dissolved in 1 N NaOH. Oxytetracycline (Duchefa Biochemie) was dissolved in water : 
ethanol (2 : 1). Spiramycin was dissolved in ethanol. The concentrations of the antibiotic 
stocks were: benzethonium chloride, 20 mg/mL; enoxacin, 8 mg/mL; lincomycin, 100 
mg/mL; oxytetracycline, 20 mg/mL; puromycin, 20 mg/mL; sisomicin, 20 mg/mL; 
spiramycin, 20 mg/mL; sulfadiazine, 100 mg/mL; vancomycin, 50 mg/mL. 
5.4.1 IDENTIFICATION OF LATENT RESISTANCE GENES 
The library-on-library screen and serial enrichment method (described in Section 4.4.3 and 
4.4.4, respectively) were used to identify latent resistance genes from the ASKA collection. 
PM 11 to PM 20 plates (Biolog Inc.) were inoculated with both the ASKA pool and the 
control clone, in parallel. IF-10 medium (Biolog Inc.) was used throughout the experiment 
(see Section 4.4.3 for more information). Two independent repeats of the complete screen 
were carried out. 
5.4.2 NEUTRALLY MARKED E. COLI STRAIN 
E. coli DH5?-E carries the lacZ?M15 mutation. In order to distinguish the two competing 
strains in each fitness assay (which will be further described in Section 5.4.3), a mini-Tn7 
system (Choi et al., 2005) was used to mark the negative control strain (E. coli DH5?-E 
harbouring pCA24N-NoIns) with a functional copy of lacZ (and a gentamicin resistance 
cassette, GmR). The marker genes were integrated at the attTn7 site downstream of the 
chromosomal glmS gene. The presence of a functional copy of lacZ allowed blue/white 
colony screening, where blue colonies were the marked negative control and white colonies 
were the competitor.  
5.4.2.1 CONSTRUCTION OF A SUICIDE PLASMID  
A suicide plasmid that carries a lacZ fragment and does not replicate in E. coli was 
constructed. This was achieved by reassembling suitable fragments from two available 
plasmids, pUC18R6K-mini-Tn7T-Gm and pUC18-mini-Tn7T-Gm-lacZ (Section I.4 in 
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Appendix I). Both plasmids carry GmR and the Tn7 mini-transposons. The R6K origin of 
replication in the plasmid pUC18R6K-mini-Tn7T-Gm ensures no replication in E. coli strains 
without the pir gene, but the plasmid lacks a lacZ gene (Figure 5.2A). Replication of the 
pUC18R6K-mini-Tn7T-Gm depends on the presence of the pir gene. On the other hand, the 
pUC18-mini-Tn7T-Gm-lacZ plasmid carries a lacZ gene, but it replicates in E. coli due to its 
compatible ColE1 origin of replication (Figure 5.2A). 
 Therefore, a fragment containing lacZ (and Tn7L) was excised from pUC18-mini-Tn7T-
Gm-lacZ by SpeI/SapI digestion. This fragment was ligated to the pUC18R6K-mini-Tn7T-Gm 
backbone that had been digested similarly. The resulting plasmid was termed pUC18R6K-
mini-Tn7T-Gm-lacZ (Figure 5.2A), and was maintained in E. coli DH5?–?pir (Section I.3 in 
Appendix I). 
5.4.2.2 LACZ-TAGGED CONTROL CLONE  
An aliquot of E. coli DH5?-E was transformed with equal amounts (250 ng) of pUC18R6K-
mini-Tn7T-Gm-lacZ and the helper plasmid, pUX-BF13 (Section I.4 in Appendix I). 
Expression of the transposase genes from pUX-BF13 was essential for Tn7 transposition. 
The transformed cells were recovered at 37°C for 3 h, before being plated on selective LB 
agar plates [supplemented with 15 μg/mL gentamicin and 40 μg/mL X-gal]. The prolonged 
recovery time was to allow expression of the transposition functions from the helper 
plasmid, and eventually, the transposition event. Colonies that turned blue indicated the 
presence of a functional lacZ gene. Successful integration of the ~5.2-kb lacZ/GmR fragment 
in the bacterial chromosome was verified by sequencing the PCR product amplified using a 
Tn7R-specific primer (ecTn7R.for) and a glmS-specific primer (ecGlmS.rev) (Figure 5.2B; 
Section I.6 in Appendix I). 
 The lacZ/GmR-tagged strain (DH5?-E::lacZ) was made electrocompetent, and finally 
transformed with pCA24N-NoIns to create a marked negative control clone. The lacZ-
marked negative control strain and the unmarked negative control strain were equally fit 
(W = 1.00 ± 0.01, mean ± S.E.M.; n = 8 replicates; P = 0.93). Therefore, the lacZ-marked strain 
was used as the negative control for the pairwise fitness assays (Section 5.4.3). 
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Figure 5.2:  Schematic diagram of pUC18R6K-mini-Tn7T-Gm-lacZ and the integration region of the lacZ/GmR 
genes in E. coli chromosome. 
(A) The 4.0-kb vector backbone of pUC18R6K-mini-Tn7T-Gm-lacZ was obtained by digesting pUC18R7K-mini-
Tn7T-Gm with SpeI and SapI. The Tn7L element was removed during vector linearization. The 3.6-kb fragment 
containing lacZ and Tn7L was excised from pUC18-mini-Tn7T-Gm-lacZ by digesting with the same combination of 
restriction endonucleases. The lacZ/Tn7L fragment was inserted into the pUC18R6K vector backbone, thereby 
forming a suitable suicide plasmid for E. coli. (B) Transposition mediated by the Tn7 elements was site- and 
orientation-specific. The Tn7 elements were inserted at the attTn7 site (in the presence of a helper plasmid) located 
in the intergenic region between the pstS and glmS genes. Amplification of the intergenic region between the Tn7R 
element and glmS gene using the ecTn7R.for and ecGlmS.rev primers yielded a 700-bp PCR product. 
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5.4.3 RELATIVE FITNESS ASSAYS 
Twenty-five ASKA plasmids that conferred increased growth in the presence of antibiotics 
were purified from individual clones and used to transform fresh aliquots of E. coli DH5?-E. 
The fitness of each of these IPTG-induced strains, in the absence of antibiotics and in 
competition with the lacZ-marked negative control (which carried pCA24N-NoIns; Section 
5.4.2), was measured using Lenski’s protocol (Lenski et al., 1991).  
 In each experiment, single colonies of the ASKA strain and of the negative control 
were used to inoculate separate 5 mL aliquots of the competition medium [2.0 g/L tryptone 
(Acumedia), 1.0 g/L yeast extract (HiMedia), 1.0 g/L NaCl, 34 μg/mL chloramphenicol, 
and 50 μM IPTG]. This medium was used because it accurately represents growth 
conditions in the PM plates (Zhou et al., 2003). The cultures were grown at 37°C for 24 h, so 
that the two competing strains were pre-conditioned to the medium (Lenski et al., 1991). 
Equal amounts of the two competing strains (?106 cfu per strain) were then mixed together 
in a fresh aliquot of the competition medium (5 mL), and the strains were grown in 
competition for another 24 h. The initial (t = 0 h) and final (t = 24 h) densities of each 
competitor were measured by spreading diluted aliquots of the culture on LB-
chloramphenicol agar plates supplemented with X-gal (40 μg/mL). The relative fitness, W, 
of the ASKA strain was estimated as the ratio of its number of doublings in 24 h, divided by 
the number of doublings of the lacZ-marked negative control (Lenski et al., 1991). Eight 
replicates were carried out to estimate the mean relative fitness of each ASKA strain. 
5.4.4 ANTIBIOTIC SUSCEPTIBILITY TESTING 
The retransformed ASKA strains and the unmarked negative control strain from the fitness 
assays were grown in 10 mL LB-chloramphenicol to mid-log phase before IPTG (final 
concentration, 50 μM) was added to induce protein over-expression for 2 h. The cells were 
harvested by centrifugation (2,000 ?g, 15 min, 4°C), and the pellets were resuspended to 
OD600 ~0.2 in sterile water. These cell suspensions were used for MIC determination (see 
below). Reported MICs values were the average of at least two independent experiments. 
5.4.4.1 E-TESTS 
MICs for aztreonam, cefuroxime, cephalothin, ciprofloxacin, erythromycin, nalidixic acid, 
nitrofurantoin, penicillin G, rifampicin, tobramycin and trimethoprim were determined 
using E-test strips (AB bioMérieux). E-test strips are impregnated antibiotic gradients, 
which are depicted on each strip (for examples, see Figure 5.1 in Section 5.2.4). A lawn of 
?106 cells was spread on Mueller-Hinton agar plates (BD Difco™; 2 g/L beef heart infusion, 
17.5 g/L acid hydrolysate of casein, 1.5 g/L starch, 17 g/L agar) supplemented with 
chloramphenicol and IPTG (50 μM). The relevant E-test strip was placed on top of the lawn 
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and the agar plates were incubated at 37°C for 24 h. The MIC was read off the E-test strip 
based on the size of the clearance zone on the bacterial lawn.  
5.4.4.2 BROTH MICRODILUTIONS 
MICs for benzethonium chloride, enoxacin, lincomycin, oxytetracycline, puromycin, 
sisomicin, spiramycin, sulfadiazine, and vancomycin were determined using the broth 
microdilution method (Wiegand et al., 2008). Two-fold serial dilutions of an antibiotic were 
set up in 96-well microtiter plate. Each well was inoculated with ~105 cells in Mueller-
Hinton broth (BD Difco™) supplemented with chloramphenicol and IPTG (50 μM). All wells 
contained a final volume of 100 μL. Cell growth was monitored at OD600 using a Synergy 2 
plate reader (Biotek Instruments). The MIC was defined as the lowest concentration of an 
antibiotic that prevented cell growth (i.e., OD600 <0.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
?
219 
CHAPTER 6 
?
Concluding remarks 
6.1 A LOOK BACKWARDS IN ENZYME EVOLUTION 
In Chapters 2 and 3, I investigated a novel example of reciprocal promiscuity. The PLP 
cofactor that Alr and MetC have in common allowed the enzymes to catalyze each other’s 
reaction (in addition to their native reaction), despite the fact that they are not homologues. 
These findings emphasize that promiscuity is usually a product of contingency, rather than 
being indicative of shared ancestry. After all, only a few key components or residues are 
critical for catalysis, and they are usually in the active site. For example, the promiscuous 
Kemp elimination activities of human serum albumin and a catalytic antibody were 
attributed to catalytic lysines in rudimentary active sites that were hydrophobic overall 
(James & Tawfik, 2001). For PurF, its promiscuous TrpF activity appeared to stem from its 
affinity for phosphoribosylated substrates, including 5-phosphoribosyl-1-pyrophosphate 
[the substrate for PurF’s native reaction] and phosphoribosylanthranilate [the substrate for 
TrpF reaction] (Patrick & Matsumura, 2008).  
 In the absence of an enzyme scaffold, it is believed that the PLP cofactor can catalyze 
all of the enzymatic PLP-dependent reactions weakly (Eliot & Kirsch, 2004; Vacca et al., 
2008), due to the electrophilicity of the pyridine ring (Richard et al., 2009). Recruitment of a 
protein scaffold would have enhanced this catalytic potential of PLP, as well as stabilizing 
the aldehyde group at position C4’ of PLP by forming a covalent bond to a lysine in the 
active site. Simply put, once PLP is recruited into an active site, it can endow a protein 
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scaffold with new activities. It appears that at least five scaffolds have successfully recruited 
PLP, throughout evolutionary history (Christen & Mehta, 2001; Eliot & Kirsch, 2004). With 
PLP bound in their active sites, these scaffolds could evolve further into the PLP-dependent 
enzymes that we observe today. 
 However, it seems unlikely that all five scaffolds recruited PLP simultaneously. 
Instead, I propose that there was a single, most ancient PLP-dependent enzyme that was 
able to recognize a broad range of substrates and catalyze many different reactions. 
Presumably, this key evolutionary innovation (protein-PLP binding) would have been 
strongly selected, once it arose. As the primordial protein repertoire expanded, different 
protein scaffolds emerged. Some of these new scaffolds could also bind PLP, and this would 
have allowed subsequent specialization of each lineage, towards different substrate and 
reaction specificities. The MetC variants that I characterized in Chapter 3 provide evidence 
for my model. Any one of several mutations at position 113 improved the enzyme’s 
promiscuous alanine racemase activity, while having modest effect on its native activity. 
Therefore, a protein such as MetC(P113S) mimics a viable, bifunctional ancestor from a time 
before (?/?)8-barrel proteins such as Alr had evolved to bind PLP. 
 In the context of longstanding evolutionary models (Section 1.1), the PLP-mediated 
promiscuity in Alr and MetC is not consistent with Horowitz’s theory of retrogade 
evolution. Alr and MetC do not have the most important feature of enzymes that obey this 
evolutionary model — homology. Is reciprocal promiscuity in non-homologous enzymes 
consistent with Jensen’s model? In this case, the answer is yes, and no. Consistent with his 
model, the promiscuous activities of Alr and MetC are analogous to the fortuitous activities 
of primitive enzymes. However, Jensen (as well as Horowitz) did not take the role of 
cofactors into account in his explanations for enzyme evolution. In his original arguments, 
Jensen assumed only that promiscuity is inherent in (primitive) enzymes. In light of the 
results presented in Chapters 2 and 3, it is apparent that the reactivity of smaller 
biomolecules, such as PLP, is also important to consider in evolutionary models. Indeed, 
these small biomolecules might have withstood harsh environments in the primitive world 
better than proteins, whose three-dimensional shapes must be maintained for their 
activities. Taken together, I propose a “cofactor-first” model for the very early evolution of 
metabolic networks, in which PLP (as well as other enzyme cofactors) played significant 
roles in driving the evolution of new enzymes. 
 My model is partly supported by a very recent study, which used a structural census 
analysis to conclude that the oldest aerobic enzyme was PLP synthase (Kim et al., 2012). PLP 
synthase produces PLP from either pyridoxine 5’-phosphate (PNP) or pyridoxamine 5’-
phosphate (PMP). The authors proposed that this enzyme appeared ~2.9 billion years ago. 
However, PLP-dependent enzymes are present in all three kingdoms of life, and archaea are 
proposed to have diverged from bacteria more than 4 billion years ago (Battistuzzi et al., 
2004). These results support my proposal that PLP was recruited by different scaffolds at 
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different times during evolution — and that horizontal gene transfer led to the widespread 
adoption of the resulting PLP-dependent enzymes. However, the timeline also implies that 
it may have been one of the PLP precursors (PNP or PMP) that was important as a 
promiscuous cofactor in the most ancient cells. Alternatively, PLP may have been 
synthesized via a different route before PLP synthase evolved. 
 A major question that follows from this discussion is, which lineage of PLP-dependent 
enzymes is the oldest? Furthermore, how would the biophysical and kinetic behaviours of 
this ancestral protein compare to extant PLP-dependent enzymes? A combination of 
phylogenetic and directed evolution studies will be useful in shedding light on the 
emergence of the very first PLP-dependent enzyme(s). Ancestral proteins inferred from 
phylogenetics analysis can be reconstructed in the laboratory, and their biochemical 
functions can be investigated accordingly. Recently, a 1 billion year-old dehydrogenase 
enzyme (Hobbs et al., 2012) and a 4 billion year-old thioredoxin (Perez-Jimenez et al., 2011) 
have been successfully reconstructed, suggesting that it may be possible to study very 
ancient PLP-dependent enzymes in the same way.  
6.2 LOOKING FORWARDS IN ENZYME EVOLUTION 
In Chapters 4 and 5, I used a library-on-library screen to probe the effects of protein over-
expression on bacterial phenotypes, on a proteome-wide scale. This screen was developed 
to demonstrate that protein promiscuity and increased expression — the two tenets of the 
IAD model (Section 1.2) — could drive cellular adaptation. I found that many proteins, 
when over-expressed, could impart improved growth on E. coli that had been placed in 
environments containing either a novel nutrient or toxin. These findings demonstrate that 
protein over-expression may be a common, de novo adaptive response. 
 Protein over-expression also appears to be a feasible mechanism for cells to circumvent 
thiamine starvation (Chapter 4). In hindsight, this should not be too surprising, considering 
that promiscuous proteins can rescue many auxotrophies when they are expressed in high 
levels (Chapters 2 and 3). Protein over-expression did not only buffer against physiological 
perturbances, but also facilitate cellular adaptation to foreign environments (Chapters 4 and 
5), via the (promiscuous) activities of a variety of proteins, including membrane 
transporters, prophage-derived proteins and regulatory elements. My overall findings 
demonstrated the diversity of functional innovations in a contemporary cell, and 
promiscuity is only a subset of this pool of innovations. 
 In many cases, the growth improvement conferred by each over-expressed protein was 
marginal. Nevertheless, it seems reasonable to suggest that these small increases in fitness 
can play significant roles during the initial stages of adaptation. Any increase in fitness 
means that a cell can produce greater numbers of viable descendants than its competitors in 
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a population. This improves the likelihood that descendants of that cell will acquire (rare) 
mutations that further increase their fitness.  
 Increased expression of promiscuous proteins underpins the IAD model for the 
evolution of new functions from pre-existing ones. Although protein over-expression was 
induced artificially (i.e., regulated by a strong promoter) in this study, I argued that this 
approach mimics bona fide over-expression resulted from gene amplification events. For 
example, a recent study showed that two gene promoters were part of large amplicons 
(ranging from 18 to 271 kb) in Acinetobacter baylyi (Seaton et al., 2012). Increased expression 
of the benzoate- and catechol-degrading enzymes resulting from these amplifications 
allowed the organism to grow on benzoate. Furthermore, the copy numbers of genes that 
are under selection can reach greater than 100 (Gaines et al., 2010; Seaton et al., 2012). This is 
comparable to the copy number of the pCA24N plasmid of the ASKA library. 
 Overall, the prevalence of promiscuity and its ability to drive cellular adaptation 
implies that the IAD model is biochemically feasible. To further demonstrate the connection 
between promiscuity, gene amplification and the emergence of new function, non-plasmid-
containing bacterial populations could be evolved experimentally by serial passage, with 
increasing selection pressure. I predict that the ASKA clones identified in this thesis will be 
the genes that are amplified in the serial passage experiments, because of their fitness-
enhancing effects.  
6.3 FINAL COMMENTS 
In summary, I have used both single gene/protein analyses and genome-/proteome-wide 
screens to address the two themes of this thesis (looking backwards and forwards in 
enzyme evolution). I have shown that promiscuity is common, and that proteins often have 
promiscuous activities that are the primary functions of non-homologous enzymes. 
However, a priori, promiscuity is mostly unpredictable. High-throughput experiments such 
as those I described remain an ideal way to gain broadly relevant insights into enzyme 
evolution. 
 The bacterium used throughout this work, E. coli, is one of the most well-studied 
organisms in science. Its proteome consists of over four thousand proteins, and a majority of 
their primary functions have been studied. However, the work described in this thesis 
emphasizes that much remains to be discovered, both about the primary functions of 
previously uncharacterized proteins, and the promiscuous activities of proteins that we 
thought we had already characterized. The evolutionary potential of E. coli appears to be 
vast, and this will undoubtedly be the same for other organisms on Earth. 
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APPENDIX I 
?
General materials and methods 
I.1 REAGENTS 
Chemicals used throughout this research were purchased from Sigma-Aldrich, unless 
otherwise specified. Reagent purity was always analytical grade or higher. All solutions 
were prepared using autoclaved MilliQ® water. 
I.2 GROWTH MEDIA AND ANTIBIOTICS 
All E. coli strains were routinely grown in LB medium (ForMedium; 10 g/L tryptone, 5 g/L 
yeast extract, 10 g/L NaCl) at 37°C (Bertani, 1951), with agitation at 180 rpm. Agar plates 
were prepared by adding bacteriological agar (ForMedium) to a final concentration of 1.5% 
(w/v). All growth media were supplemented with antibiotics and/or nutrients where 
necessary.  
 All general antibiotics, except chloramphenicol (Duchefa Biochemie), were bought 
from Melford. To make stock solutions, chloramphenicol was dissolved in ethanol, while all 
other antibiotics were dissolved in water. The final concentrations used were: ampicillin, 
100 μg/mL; carbenicillin, 50 μg/mL; chloramphenicol, 34 μg/mL; gentamicin, 15 μg/mL; 
kanamycin, 30 μg/mL. All antibiotics were stored at ?20°C. 
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I.3 BACTERIAL STRAINS 
For long term storage, a single bacterial colony was propagated overnight in selective LB. 
Glycerol was added to a 300-μL aliquot of the saturated culture to 12.5% (v/v) final 
concentration, and the culture was stored at ?80°C. Agar plates with cultured bacteria were 
stored at 4°C for no longer than one week.  
Table I.1:  Characteristics of E. coli strains used in this study. 
Strain Genotype Reference(s) 
BW25113 ?metC F?  ?(araD–araB)567  ?lacZ4787(::rrnB?3)  ??  rph?1                
?(rhaD–rhaB)568  hsdR514  ?metC::KanR 
(Baba et al., 2006) 
BW25113 ?metE F?  ?(araD–araB)567  ?lacZ4787(::rrnB?3)  ??  rph?1                
?(rhaD–rhaB)568  hsdR514  ?metE::KanR 
(Baba et al., 2006) 
DH5?–?pir F?  ?80lacZ??15  ?(lacZYA–argF)U169  recA1  endA1        
hsdR17(rk?, mk+)  supE44  thi?1  gyrA96  relA1  ?pir 
Dr. Xue-Xian Zhang 
(Massey University) 
DH5?-E F?  ?80lacZ??15  ?(lacZYA–argF)U169  recA1  endA1         
hsdR17(rk?, mk+)  gal?  phoA  supE44  ??  thi?1  gyrA96  relA1 
Invitrogen 
DH5?-E::lacZ DH5?-E with a GmR-lacZ marker inserted at the attTn7 site. This study 
K-12 Wildtype E. coli; F+  ?+ American Type 
Culture Collection 
(ATCC) 10798 
MB2795 araD139  ?(araA–leu)7697  galU  galK  ?(lac)174  rpsL  thi?1  
?dadX::frt ?alr::frt  
Prof. Kurt Krause 
(University of Otago) 
WMP001.1 MB2795 ?metC::KanR    This study 
 
I.4 PLASMIDS 
All purified plasmid DNA was kept at ?20°C. 
Table I.2:  Designation and characteristics of plasmids used in this study. 
Plasmid Description Reference 
pUC19 AmpR; 2.7-kb control plasmid for transformation Invitrogen 
pBAD-epMetC(P113A) AmpR; plasmid-encoded metC variants with random 
mutations; used to construct a second-generation MetC 
library. 
This study 
pBAD-epMetC(P113Q) AmpR; plasmid-encoded metC variants with random 
mutations; used to construct a second-generation MetC 
library. 
This study 
pBAD-epMetC(P113S) AmpR; plasmid-encoded metC variants with random 
mutations; used to construct a second-generation MetC 
library. 
This study 
pBAD-epMetC(P113T) AmpR; plasmid-encoded metC variants with random 
mutations; used to construct a second-generation MetC 
library. 
This study 
pBAD-metC AmpR; plasmid-encoded wildtype metC from E. coli. This study 
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Plasmid Description Reference 
pBAD-metC(P113A) AmpR; plasmid-encoded metC with P113A mutation.  This study 
pBAD-metC(P113A-9) AmpR; second-generation winner from the MetC(P113A) 
library; carried a A113P mutation. 
This study 
pBAD-metC(P113Q) AmpR; plasmid-encoded metC with P113Q mutation. This study 
pBAD-metC(P113Q-12) AmpR; second-generation winner from the MetC(P113Q) 
library; no additional mutation apart from its parental 
P113Q mutation.  
This study 
pBAD-metC(P113S) AmpR; plasmid-encoded metC with P113S mutation. This study 
pBAD-metC(P113S-2) AmpR; plasmid-encoded metC with P113S, P156L and 
A227T mutations; second-generation MetC winners. 
This study 
pBAD-metC(P113S-14) AmpR; plasmid-encoded metC with P113S and I251M 
mutations; second-generation MetC winners. 
This study 
pBAD-metC(P113S-16) AmpR; plasmid-encoded metC with P113S, K120N and 
P352A mutations; second-generation MetC winners. 
This study 
pBAD-metC(P113S-18) AmpR; second-generation winner from the MetC(P113S) 
library; no additional mutation apart from its parental 
P113S mutation.  
This study 
pBAD-metC(P113T) AmpR; plasmid-encoded metC with P113T mutation. This study 
pBAD-metC(P113T-20) AmpR; second-generation winner from the MetC(P113T) 
library; no additional mutation apart from its parental 
P113T mutation.  
This study 
pBAD/Myc-His-B AmpR; pBR322-derived expression vector with the PBAD 
promoter. 
Invitrogen 
pBAD/Myc-His-lacZ AmpR; a pBAD plasmid carrying the lacZ gene. Invitrogen 
pCA24N-alr CamR; an ASKA plasmid carrying the alr gene. (Kitagawa et al., 2005) 
pCA24N-alr(GFP?) CamR; pCA24N-alr without the GFP tag. This study 
pCA24N-alr(R209E) CamR; a codon mutation (R209E) in the alr gene; plasmid 
lacks the GFP tag. 
This study 
pCA24N-bglA CamR; an ASKA plasmid carrying the bglA gene. (Kitagawa et al., 2005) 
pCA24N-cycA CamR; an ASKA plasmid carrying the cycA gene. (Kitagawa et al., 2005) 
pCA24N-dadX CamR; an ASKA plasmid carrying the dadX gene. (Kitagawa et al., 2005) 
pCA24N-epAlr-1 CamR; selected winner from the Alr library; no mutation in 
the alr gene. 
This study 
pCA24N-epAlr-2 CamR; selected winner from the Alr library; no mutation in 
the alr gene. 
This study 
pCA24N-epAlr-3 CamR; plasmid-encoded alr with Y274F mutation; selected 
winner from the Alr library. 
This study 
pCA24N-epAlr-11 CamR; plasmid-encoded alr with Y274F and A335T 
mutations; selected winner from the Alr library. 
This study 
pCA24N-epAlr-14 CamR; plasmid-encoded alr with R266S and Y274F 
mutations; selected winner from the Alr library. 
This study 
pCA24N-epAlr-19 CamR; plasmid-encoded alr with M29I and Y274F 
mutations; selected winner from the Alr library. 
This study 
pCA24N-epAlr-22 CamR; plasmid-encoded alr with L241M, R263H and Y274F 
mutations; selected winner from the Alr library. 
This study 
pCA24N-epAlr-24 CamR; plasmid-encoded alr with T97S, P252R and Y274F 
mutations; selected winner from the Alr library. 
This study 
pCA24N-epAlr-28 CamR; plasmid-encoded alr with I242V and Y274F 
mutations; selected winner from the Alr library. 
This study 
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Plasmid Description Reference 
pCA24N-epAlr-41 CamR; plasmid-encoded alr with V150I and Y274F 
mutations; selected winner from the Alr library. 
This study 
pCA24N(KanR)-
epMetC 
KanR; plasmid-encoded metC variants with random 
mutations; used to construct first-generation MetC library. 
This study 
pCA24N(KanR)-
metC(P113Q) 
KanR; plasmid-encoded metC with P113Q mutation; first-
generation MetC winners. 
This study 
pCA24N(KanR)-
metC(P113A) 
KanR; plasmid-encoded metC with P113A mutation; first-
generation MetC winners. 
This study 
pCA24N(KanR)-
metC(P113T) 
KanR; plasmid-encoded metC with P113T mutation; first-
generation MetC winners. 
This study 
pCA24N(KanR)-
metC(P113S) 
KanR; plasmid-encoded metC with P113S mutation; first-
generation MetC winners. 
This study 
pCA24N(KanR)-tS1 KanR; derived from pCA24N-tS1(no-ext). Dr. Monica Gerth 
(Massey University) 
pCA24N-metC CamR; an ASKA plasmid carrying the metC gene. (Kitagawa et al., 2005) 
pCA24N-metC(GFP?) CamR; pCA24N-metC without the GFP tag. This study 
pCA24N-metE CamR; the ASKA plasmid carrying the metE gene. (Kitagawa et al., 2005) 
pCA24N-NoIns CamR; pCA24N plasmid without any gene insert; 5.2 kb. This study 
pCA24N-trpD(GFP?) CamR; an ASKA plasmid carrying the trpD gene; GFP tag 
removed. 
Dr. Wayne Patrick/ 
Lab stock 
pCA24N-tS1(no-ext) CamR; an ASKA plasmid carrying a mutated purF gene; 
GFP tag removed. 
Dr. Wayne Patrick/ 
Lab stock 
pCA24N-tS1-corr CamR; an ASKA plasmid carrying the wildtype purF gene. (Patrick & Matsumura, 
2008) 
pCA24N-wcaL CamR; an ASKA plasmid carrying the wcaL gene. (Kitagawa et al., 2005) 
pKD46 AmpR; temperature-sensitive plasmid expressing the 
arabinose-induced ? Red recombinase. 
Lab stock (from the 
The Coli Genetics 
Stock Centre, Yale) 
pUC18T-mini-Tn7T-
Gm-lacZ 
AmpR, GmR on mini-Tn7T suicide vector; oriColE1; lacZ 
transcriptional fusion vector. 
Dr. Xue-Xian Zhang 
(Massey University) 
pUC18R6K-mini-
Tn7T-Gm 
AmpR, GmR on mini-Tn7T suicide vector; oriR6K. Dr. Monica Gerth 
pUC18R6K-mini-
Tn7T-Gm-lacZ 
AmpR, GmR on mini-Tn7T suicide vector; oriR6K; lacZ 
transcriptional fusion vector. 
This study 
pUX-BF13 AmpR; oriR6K; helper plasmid encoding the TnsABC+D. Dr. Monica Gerth  
 
I.5 ANALYTICAL SOFTWARE 
MacVector (MacVector, Inc.) was used to view, align, annotate, modify and design all DNA 
and protein sequences. It was also used to import sequencing chromatograms for further 
analyses. Molecular structures were visualized and manipulated using MacPymol 
(Schrödinger LLC).  
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I.6 OLIGONUCLEOTIDES 
All primers were custom synthesized by Integrated DNA Technologies (Coralville, Iowa). 
Upon arrival, TE buffer (10 mM Tris-HCl, pH 8.0; 1 mM EDTA) was used to resuspend 
lyophilized primers to a final concentration of 100 μM. Aliquots of 10 μM working stock 
were prepared by diluting the 100 μM master stock with sterile MilliQ® water. All primers 
were stored at ?20°C.  
Table I.3:  Primers used in this study. 
Primer Sequence (5’ ?  3’) Reference 
Alr.rev GCGGCCGCATAGGCCTTAATCCACGTATTTC This study 
Alr-R209E.for TGACTGGGTGGAACCGGGCATC This study 
Alr-R209E.rev GATGCCCGGTTCCACCCAGTCA This study 
ecGlmS.rev CAGTTAACTGTGCTGTTGATGC This study 
ecTn7R.for CAGCATAACTGGACTGATTTCAG This study 
His-metC.for ATGAACATGTCTCACCATCACCATCACCAT This study 
His-metC.rev CGCATCTAGATTATACAATTCGCGCAAAAC This study 
KeioKanR.out CGGTGCCCTGAATGAACTGC Lab stock 
metC877.rev ATGCCCAACCAGATATTTGGTG This study 
MetC(GFP?).rev GCGGCCGCATAGGCCTTATACAATTCGCGCA This study 
metC-dwnstr.rev GACTTTTCACAATAAAATGTCTGCAAAATTGTCCAAAAG This study 
metC-upstr.for CGCGAATATTCATGCTAGTTTAGACATCCAGAC This study 
pBAD-60 ATCGCAACTCTCTACTGTTTCTCCATAC Lab stock 
pBAD.rev GAAAATCTTCTCTCATCCGCCAAAAC This study 
pCA24N.for GATAACAATTTCACACAGAATTCATTAAAGAG (Patrick et al., 2007) 
pCA24N.rev CCCATTAACATCACCATCTAATTCAAC (Patrick et al., 2007) 
pCA24N.rev2 CAAATCCAGATGGAGTTCTGAGG (Patrick & 
Matsumura, 2008) 
pCA24N-NoIns.for* Phos-GGCCTATGCGGCCGCAGTAAAG This study 
pCA24N-NoIns.rev* Phos-GGCCCTCAGGGCCGGATCCGTAT This study 
pUCrev+120 GCAGTGAGCGCAACGCAATTA Lab stock 
Rev+270 TAACCGTATTACCGCCTTTGAGTGAGC Lab stock 
Univ-70 ATGTGCTGCAAGGCGATTAAGTTGGGT Lab stock 
                    
*Primers were phosphorylated at the 5’ terminus.  
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I.7 AGAROSE GEL ELECTROPHORESIS 
Depending on the size of DNA, gels were prepared with 0.8% (w/v) agarose for 1–10 kb, or 
1.5% (w/v) agarose for 100–1000 bp. Agarose powder (Axygen) was dissolved in 1? TAE 
buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA, pH 8.0). The nucleic acid stain, 
ethidium bromide (Bio-Rad), was added to a final concentration 0.5 μg/mL. Four volumes 
of each DNA sample were mixed with one volume of 5? GelPilot DNA Loading Dye 
(Qiagen) prior to loading into the well, except when samples were pre-mixed with special 
reaction buffer (see Section I.10). The samples were run alongside appropriate DNA ladders 
at 100 V until the bottom tracking dye had migrated through ? of the gel. Agarose gels 
were viewed using a UV transilluminator (part of the Gel Doc™ 2000 Gel Documentation 
System, Bio-Rad).  
 When DNA was to be purified from the gel (see Section I.8), 1? SYBR Safe™ Gel DNA 
stain (supplied as 10,000? concentrate by Invitrogen) was used instead of ethidium 
bromide. Such gels were viewed using a Safe Imager™ Blue Light Transilluminator 
(Invitrogen) to eliminate DNA exposure to UV light.  
I.8 DNA EXTRACTION AND CLEAN-UP 
Genomic DNA was extracted using the Wizard® Genomic DNA Purification Kit (Promega), 
according to the manufacturer’s instructions. Plasmid DNA was routinely purified using 
the QIAprep Spin Miniprep kit (Qiagen). DNA from PCRs, agarose gels and ligation 
reactions was cleaned up with the QIAquick purification kit series (Qiagen). When a 
concentrated DNA sample was desired (e.g. a 10-μL DNA eluate), MinElute Spin columns 
(Qiagen) were used in place of the usual QIAprep or QIAquick Spin columns. 
I.9 DNA QUANTIFICATION 
Each DNA sample was diluted to 50 μL in a UVette (Eppendorf), and its concentration was 
determined spectrophotometrically in an Eppendorf Biophotometer. Alternatively, the 
amount of DNA could be estimated by comparing its band intensity with that of a known 
DNA marker on an agarose gel.   
I.10 PCR SCREENING 
Each routine PCR screen was performed as a 20-μL reaction, in 0.2 mL thin-walled tubes. 
Each reaction contained 1? Green GoTaq® Reaction buffer (pre-mixed with two tracking 
dyes; Promega), 0.25 mM dNTP mix (iNtRON Biotechnology), 1.25 U i-Taq™ DNA 
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polymerase (iNtRON Biotechnology), 0.5 μM of the forward and reverse primers, and DNA 
template (either 1 μL of saturated bacterial culture or plasmid DNA, or one colony from a 
cultured agar plate).  
 The standard thermocycling parameters were as follows: 95°C for 5 min, 35 cycles of 
95°C for 1 min, annealing temperature for 30–60 s, 72°C for 1 min/kb, and finally, 72°C for 1 
min. The annealing temperature was usually 3°C below the lower Tm of the two primers. All 
PCR reactions were carried out in an MJ Mini Thermal Cycler (Bio-Rad).  
I.11 RESTRICTION DIGEST AND LIGATION 
All restriction endonucleases were obtained from New England Biolabs. A typical digestion 
contained 1? reaction buffer, 0.1–2 μg of DNA and 2-10 U restriction endonuclease per 10 
μL reaction. Unless otherwise stated, DNA was digested for 1–16 h, depending on different 
endonuclease stabilities as reported by the manufacturer. Other recommendations from the 
manufacturer included incubation temperature, buffer compatibilities (especially for double 
digestion), bovine serum albumin supplementation and heat inactivation. 
 All ligation reactions were performed in 0.2 mL thin-walled tubes. Normally, a ligation 
reaction contained 1? T4 DNA Ligase Buffer, 2.5 Weiss units of T4 DNA Ligase (Fermentas) 
per 10 μL reaction, appropriate amounts of linearized vector and digested gene insert (in 3-
fold molar excess than vector). The ligation reaction was incubated at 16°C for 4–16 h, 
before heat-inactivation at 65°C for 10 min. Ligated products were either cleaned up (see 
Section I.8), or diluted at least 5-fold using sterile MilliQ® water before being used to 
transform E. coli.  
I.12 ELECTROCOMPETENT CELLS 
Electrocompetent cells were prepared as described (Sambrook & Russell, 2001). An E. coli 
strain (from either freezer stock or a single colony) was grown overnight in 4 mL LB 
supplemented with the appropriate nutrients or antibiotics. The saturated culture was used 
to inoculate 250 mL SOB medium (20 g/L tryptone, 5 g/L yeast extract, 10 mM NaCl, 2.5 
mM KCl) (Hanahan, 1983), supplemented with the appropriate nutrients or antibiotics. The 
culture was incubated at 37°C to an OD600 ~0.4. The cells were evenly divided into 6 ? 50 
mL pre-chilled centrifuge tubes, and allowed to incubate on ice for another 1 h. All 
following steps were carried out at 4°C.  
 The cells were pelleted at 2,200 ?g for 17 min, at 4°C (Heraeus Multifuge 1S-R), 
washed with 40 mL of pre-chilled 10% (v/v) glycerol, and re-pelleted as described. The six 
cell pellets were resuspended with 10% glycerol and pooled into 4 ? 40 mL. The pelleting 
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step was repeated. The four pellets were resuspended using 10% glycerol and further 
pooled into 2 ? 40 mL. The cells were spun down similarly, and the resulting two pellets 
were resuspended with 10% glycerol and pooled into 1 ? 40 mL. The cells were pelleted for 
the final time. 
 The final cell pellet was weighed, and resuspended with 0.1 mL of 10% glycerol per 0.1 
g of wet cell weight. The OD600 of the resulting suspension was usually in the range of 100–
150. The cell resuspension was dispensed as 50 μL aliquots, and either used immediately for 
electroporation (see Section I.13), or stored at ?80°C until use.  
I.13 TRANSFORMATION 
For library construction, electrocompetent cells were prepared on the same day that they 
were transformed. Otherwise, frozen electrocompetent cells were thawed on ice and used 
for general cloning purposes.  
 Electroporation was carried out according to standard procedures (Sambrook & 
Russell, 2001). Generally, plasmid DNA or ligated products was added to a 50-μL aliquot of 
electrocompetent cells, and allowed to incubate on ice for 1 min. The cells were transferred 
to a sterile, pre-chilled electroporation cuvette with 0.1 cm gap (Bio-Rad). The cuvette was 
placed in the shocking chamber, and pulsed at 1.8 kV (Bio-Rad Gene Pulser II; other 
settings: 200 ? and 25 μF). Specifically, the MB2795 and WMP001.1 strains of E. coli (Table 
I.1 in Section I.3) were always pulsed at 2.5 kV in electroporation cuvette with 0.2 cm gap 
(Bio-Rad). Time constants typically ranged from 4.5–5.5 ms for all electroporations. The 
electroporated cells were resuspended in 0.5 mL of pre-warmed SOC medium (SOB + 20 
mM glucose) (Hanahan, 1983), and transferred to a sterile glass test tube. The cells were 
incubated at 37°C for 1 h. Recovered cells were then spread on selective LB agar plates 
containing the appropriate antibiotics and/or nutrients. Agar plates were incubated 
overnight at 37°C. Most E. coli strains (except strains MB2795 and WMP001.1; see Section 
I.3) prepared using the methods from Section I.12 and I.13 typically yielded transformation 
efficiencies of ?108 cfu/μg of pUC19 (Invitrogen).  
I.14 DNA SEQUENCING 
All amplicon and plasmid sequencing was carried out by either the Massey Genome Service 
(Palmerston North), or Macrogen Inc. (South Korea). Both companies utilize automated 
capillary-based ABI3730 DNA Analyzers (Applied Biosystems) for routine dye-terminator 
sequencing. 
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I.15 SDS-PAGE 
The discontinuous buffer system (Laemmli, 1970) was used for all SDS-PAGE carried out in 
this study. The stock solutions for making polyacrylamide gels were 40% acrylamide : N,N’-
methylene-bis-acrylamide (29 : 1) solution (Bio-Rad), 1.5 M Tris-HCl (pH 8.8), 0.5 M Tris-
HCl (pH 6.8), 10% (w/v) sodium dodecyl sulfate, 10% (w/v) ammonium persulfate and 
N,N,N’,N’-tetramethylethylenediamine (~6.67 M).  
 All resolving gel mixtures consisted of 12% acrylamide : N,N’-methylene-bis-
acrylamide (29 : 1) solution, 375 mM Tris-HCl (pH 8.8), 0.1% sodium dodecyl sulfate, 0.05% 
ammonium persulfate and 6.67 mM N,N,N’,N’-tetramethylethylenediamine.  
 All stacking gel mixtures consisted of 4% acrylamide : N,N’-methylene-bis-acrylamide 
(29 : 1) solution, 125 mM Tris-HCl (pH 6.8), 0.1% sodium dodecyl sulfate, 0.05% ammonium 
persulfate and 6.67 mM N,N,N’,N’-tetramethylethylenediamine. 
 Polyacrylamide gels of 1 mm thickness were prepared using the Mini-PROTEAN gel 
casting assembly (Bio-Rad). The resolving gel mixture was added between the glass plates 
until it was ~3.5 cm from the top of the plates. The gel mixture was then layered with 1 cm 
of 70% (v/v) ethanol, and gel polymerization was allowed to take place. After ~30 min, the 
ethanol was removed, and the polymerized resolving gel was rinsed with 1 mL of 1.5 M 
Tris-HCl (pH 8.8). The stacking gel mixture was poured on top of the resolving gel before 
inserting a clean 10-well comb. Similarly, the stacking gel was allowed to polymerize for 
~30 min. The polymerized gel was either used immediately, or wrapped in moistened 
paper towels and stored at 4ºC. Stored gels were usually used within two weeks. 
 Protein samples were mixed with an equal volume of 2? Loading Buffer [100 mM Tris-
HCl (pH 8.8), 4% (w/v) sodium dodecyl sulfate, 20% (v/v) glycerol, 0.2% (w/v) 
bromophenol blue, 200 mM ?-mercaptoethanol]. The mixtures were heated at 95°C for 5 
min prior to electrophoresis. In the meantime, the polyacrylamide gel was assembled into 
the Mini-PROTEAN Tetra Cell electrophoresis tank (Bio-Rad). After removing the comb 
from the gel, the heated samples were loaded into each well. The gel was run in 1? SDS-
PAGE buffer [25 mM Tris, 250 mM glycine (pH 8.3), 0.1% (w/v) sodium dodecyl sulfate], at 
200 V until the tracking dye was 0.5 cm from the bottom of the gel. The gel was removed 
from the glass plates, and stained in Coomassie Blue [2.5 g/L (w/v) Coomassie R250 (Bio-
Rad) in 4 volumes of water : 5 volumes of methanol : 1 volume of acetic acid] with gentle 
rocking for 30 min. The stained gel was then washed extensively with water. The gel was 
destained with Destaining Solution (6 volumes of water : 3 volumes of methanol : 1 volume 
of acetic acid) for at least 1 h with gentle rocking.  
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Artiﬁcial gene ampliﬁcation reveals an abundance of
promiscuous resistance determinants in
Escherichia coli
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Duplicated genes provide an important raw material for adaptive
evolution. However, the relationship between gene duplication
and the emergence of new biochemical functions is complicated,
and it has been difﬁcult to quantify the likelihood of evolving
novelty in any systematic manner. Here, we describe a compre-
hensive search for artiﬁcially ampliﬁed genes that are able to
impart new phenotypes on Escherichia coli, provided their expres-
sion is up-regulated. We used a high-throughput, library-on-library
strategy to screen for resistance to antibiotics and toxins. Cells
containing a complete E. coli ORF library were exposed to 237
toxin-containing environments. From 86 of these environments,
we identiﬁed a total of 115 cases where overexpressed ORFs
imparted improved growth. Of the overexpressed ORFs that we
tested, most conferred small but reproducible increases in mini-
mum inhibitory concentration (≤16-fold) for their corresponding
antibiotics. In many cases, proteins were acting promiscuously to
impart resistance. In the absence of toxins, most strains bore no
ﬁtness cost associated with ORF overexpression. Our results show
that even the genome of a nonpathogenic bacterium harbors a
substantial reservoir of resistance genes, which can be readily
accessed through overexpression mutations. During the growth
of a population under selection, these mutations are most likely
to be gene ampliﬁcations. Therefore, our work provides validation
and biochemical insight into the innovation, ampliﬁcation, and
divergence model of gene evolution under continuous selection
[Bergthorsson U, Andersson DI, Roth JR (2007) Proc Natl Acad Sci
USA 104:17004–17009], and also illustrates the high frequency at
which novel traits can evolve in bacterial populations.
antibiotic resistance | evolutionary innovation | molecular evolution |
protein promiscuity | phenotype microarray
All species must adapt to survive in changing environments.At the molecular level, the presence of novel nutrients and
toxins can drive the evolution of proteins that recognize or me-
tabolize them (1, 2). Duplicated copies of preexisting genes
provide the primary genetic source for functional innovation (3,
4). However, the relationship between duplication and the
emergence of new biochemical functions is complicated because
gene duplications are generally expected to be either selectively
neutral (5) or deleterious (6). Therefore, it has been difﬁcult to
systematically assess the likelihood of evolving novel traits. In the
present study, we have sought to address this gap in the Dar-
winian paradigm.
Numerous hypotheses have been proposed to explain the fates
of duplicated genes within populations (7–9). A particularly ap-
pealing model identiﬁes a mechanism by which selection can act
continuously to favor both an increase in gene dosage, and di-
vergence of one copy from the parental gene. This model, termed
adaptive radiation (10) or the innovation, ampliﬁcation, and di-
vergence (IAD) model (11), is rooted in the notion that many
existing proteins display broad speciﬁcity and secondary activities
in addition to the function that they evolved to carry out (12). In
primordial times, this “promiscuity” would have allowed many
metabolic functions to be carried out by a minimal number of
multitasking proteins (13). In more specialized, modern-day
proteins, promiscuity is likely to be a product of contingency: ac-
tive sites typically contain a variety of reactive groups (proton
donors and acceptors, metal ions, and so forth) that could (by
chance) play roles in secondary reactions (14). These secondary
activities are assumed to provide the necessary reservoir of se-
lectable functions.
In the IAD model, selection is imposed on a weak, promis-
cuous activity. To increase ﬁtness, duplications (and higher-order
ampliﬁcations) of the promiscuous gene are selected and main-
tained in the population. In turn, this increase in copy number
improves the likelihood of point mutations that enhance the
promiscuous activity, by increasing the number of mutational
targets yet still allowing at least one copy to retain the parental
activity (11).
Two central tenets of the IAD model are: (i) that gene ampli-
ﬁcation events are common; and (ii) that promiscuous activities
are widespread, as well as being biochemically and mechanis-
tically diverse. Experiments with unselected bacterial populations
have shown the ﬁrst point to be accurate (15), with cells that bear
duplications at any given locus reaching steady-state frequencies
of ∼10−3 (16). We are interested in cataloguing the promiscuous
activities within an entire proteome to understand the protein
biochemistry that underlies the evolution of new phenotypes.
Multicopy suppression experiments are a powerful and trac-
table way of demonstrating that adaptation can begin with the
increased expression of promiscuous proteins. In these experi-
ments, conditionally auxotrophic bacterial strains are trans-
formed with plasmid-encoded libraries of ORFs. The libraries are
screened for genes that can suppress the phenotype of the original
mutation, provided they are present in high copy number (17–19)
or overexpressed (20, 21). Previously, we used the multicopy
suppression approach in an attempt to assess the prevalence of
promiscuity, on a proteome-wide scale. We made use of the
ASKA (A Complete Set of Escherichia coli K-12 ORF Archive)
library, which comprises every E. coli ORF cloned into the ex-
pression vector pCA24N (22). The plasmids of the library were
pooled and used to transform 104 conditionally auxotrophic,
single-gene deletion strains. Twenty-one of the auxotrophies were
speciﬁcally suppressed by the overexpression of noncognate
E. coli genes (23). The implication was that many proteins are
multifunctional; however, the ability of proteome-wide promiscuity
to drive an organism’s adaptation to new environments remained
unknown. The next logical step was to survey the entire E. coli
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proteome for its latent ability to confer genuinely new phenotypes
(rather than to recreate old ones).
Here, we describe a comprehensive search for promiscuous
proteins that can impart new phenotypes on E. coli. We provide
experimental evidence that the overexpression of preexisting
E. coli proteins can provide resistance to>80 antibiotics and toxins.
Our results suggest that the evolution of novel traits is surprisingly
likely, and that even the genomes of well-characterized bacteria
harbor substantial reservoirs of latent resistance determinants.
Results
Library-on-Library Screen. We have conducted a global survey to
uncover latent resistance genes in the E. coli genome. E. coli cells
were transformed with the pooled plasmids of the ASKA ORF
library and then used to inoculate every well of 10 phenotype
microarray (PM) plates (Fig. 1 A and B). In total, these 10 PM
plates contained 237 toxins (including antibacterial agents), with
each toxin present at four concentrations (24). Growth in each
toxin-containing well could be monitored by purple color de-
velopment because of the presence of a tetrazolium indicator dye
(25). A negative control (E. coli harboring the empty ASKA
vector, pCA24N-NoIns) was used to inoculate a second set of
PM plates in parallel. By comparing the growth rates of the ASKA
pool and the control, we were able to screen for examples in which
the isopropyl-β-D-thiogalactopyranoside (IPTG)-induced over-
expression of ASKA-encoded genes conferred increased ﬁtness
(i.e., an improved capacity for survival and reproduction) in the
presence of a toxin.
The ASKA expression vector, pCA24N, has the same modiﬁed
pMB1 replication origin as pQE30 (Qiagen), which gives it a copy
number of 300 to 400 per cell. The pCA24N backbone also enc-
odes the lacIq repressor, for tightly controlling the expression of
each ASKA ORF. Therefore, we were speciﬁcally seeking
examples where protein overexpression was essential for in-
creased ﬁtness. However, induction with a high concentration of
IPTG (1 mM) severely inhibits the growth of 51% of ASKA
strains (including almost all that overexpress membrane pro-
teins), and in addition, another 28% show moderate growth in-
hibition (22). To avoid this source of bias, we used a signiﬁcantly
lower concentration of IPTG (50 μM) to induce protein expres-
sion. This amount is sufﬁcient for derepression of the pCA24N
T5-lacO promoter, but minimizes ﬁtness differences associated
with overexpression of different ORFs (20, 23).
In duplicate screens, the ASKA pool out-grew the negative
control in the presence of 99 toxins (42% of those tested). In the
majority of cases, these improved growth phenotypes manifested
as small but reproducible changes in the intensity of tetrazolium
color development within the ﬁrst 48 h of incubation (Dataset S1).
The ASKA pool showed enhanced growth in 50 of the 78 anti-
bacterial agents (64%) contained within the PM plates. We also
noted increased growth rates in the presence of 49 of the other 159
toxins that were tested (31%), which included antifungal and
antiparasitic agents, inorganic salts, and dyes (Dataset S1).
Identiﬁcation of Novel Resistance Genes. Next we sought to
deconvolute the results of our library-on-library screen by iso-
lating individual ASKA clones that were responsible for the ob-
served improvements in growth rates. In each of the 99 conditions
identiﬁed above, we used serial transfer to enrich for the ﬁttest
clones within the ASKA pool (Fig. 1C). After two transfers, cells
from the enriched population were plated under nonselective
conditions. PCR and DNA sequencing revealed the plasmid-
encoded genes that had imparted improved growth.
An ASKA ORF was scored as a hit if it occurred at least twice
among the eight clones sequenced from a serially passaged
population. Given the large size of the ASKA pool (5,272 clones),
it was highly unlikely (P ≈ 0.005) that any two of the eight ran-
domly chosen colonies would contain the same ASKA plasmid,
unless that clone had been positively selected during serial
transfer. Our approach yielded hits from 86 of the 99 conditions
tested, including representatives of all of the compound classes
that were tested (Table 1). For example, the PM plates contained
22 β-lactam antibiotics, and we isolated ASKA clones that im-
proved growth in 11 of them (Table 1, row 1). Our serial en-
richment strategy yielded a single hit from 60 of the 86 conditions.
In 38 of these, the ASKA clone was enriched to apparent ho-
mogeneity (i.e., eight of eight sequenced clones were identical).
However, serial transfer gave two different hits in 23 conditions,
Fig. 1. The library-on-library screen and subsequent isolation of ASKA-
encoded resistance genes. (A) E. coli cells harboring the pooled plasmids of
the ASKA ORF collection (blue) and the negative control clone (gray) were
grown to midlog phase in parallel, and protein overexpression was induced
by the addition of IPTG (50 μM). (B) Both cultures were used to inoculate
every well of two sets of PM plates. A well was scored positive when the
ASKA pool out-grew the negative control, as shown by more rapid tetra-
zolium color development (Inset). (C) For each positive PM well, the ﬁttest
ASKA clone (or clones) was isolated by two rounds of serial transfer before
an aliquot of the enriched culture was plated on nonselective medium to
allow identiﬁcation of the ASKA ORF (or ORFs).
Table 1. Summary of hits obtained from the library-on-library
screen
Class of toxic compound
Number of
positives*
Number of
ASKA hits†
Antibacterials
β-Lactams 11 (of 22) 14
Aminoglycosides 4 (of 14) 4
Anti-folates 7 (of 9) 10
Quinolones 4 (of 9) 6
Tetracyclines 3 (of 8) 4
MLS antibiotics 6 (of 7) 10
Glycopeptides 1 (of 3) 1
Nitrofurans 3 (of 3) 4
Rifamycins 1 (of 2) 2
Steroid antibacterial 1 (of 1) 1
Other toxins 45 (of 159) 59
Total 86 (of 237) 115
*The number of toxic compounds for which screening and serial enrichment
yielded at least one ASKA-encoded resistance gene. The total number of
toxins that were screened in each class is listed in parentheses.
†Total number of ASKA ORFs that were isolated from PM wells containing
toxins of each compound class.
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and three hits in another three cases (the β-lactam, aztreonam;
the antiseptic, benzethonium chloride; and the toxic alkaloid,
sanguinarine). Overall, therefore, we identiﬁed 115 positively
selected hits from 86 toxin-containing environments (Table 1 and
Dataset S1).
In 13 cases, serial transfer failed to enrich any individual
ASKA clone to a frequency of two or more in the eight se-
quenced clones (Dataset S1). One explanation is that there were
many plasmid-encoded ORFs that all imparted ﬁtness advan-
tages (of similar magnitudes) in those conditions. It is also pos-
sible that chromosomal mutations were responsible for improved
growth, although this is unlikely when the experimental design
(two independent ASKA pools, both required to out-grow neg-
ative control populations) and the small size of each input pop-
ulation (∼50,000 cells) are considered. Alternatively, further
transfers may have been required to identify the fastest-growing
clones in the ASKA pool. By imparting stringent criteria for
identifying novel resistance genes, we minimized the probability
of isolating false-positives.
Diverse Mechanisms of Resistance. Our initial focus was on iden-
tifying proteins—and particularly enzymes—that possessed weak
secondary activities. However, it rapidly became apparent that
our library-on-library screen had uncovered many different clas-
ses of protein that were contributing to resistance. Therefore, we
used the EcoCyc (26) and UniProt (27) databases, in addition to
the references cited in Dataset S1, to assign proposed modes of
action for each of the 115 cases that we had identiﬁed (Table 2).
Eighteen genes occurred multiple times and were responsible
for improving growth in a total of 72 toxin-containing environ-
ments (Table S1), suggesting broad and nonspeciﬁc mechanisms.
Consistent with previous results (28–31), the expression of efﬂux
pumps and transporters was common among this subset of com-
pound nonspeciﬁc resistance determinants. For example, expres-
sion of the Bcr multidrug transporter increased growth in the
presence of three antifolate antibiotics (sulfachloropyridazine,
sulfathiazole, and sulﬁsoxazole), two tetracyclines (oxytetracycline
and rolitetracycline), and one β-lactam (cefoperazone). An unchar-
acterized outer-membrane β-barrel, YcbS, improved growth in the
presence of four toxic compounds: a mutagen, 9-aminoacridine; an
uncoupling agent, FCCP; a herbicide, methyl viologen; and an al-
kaloid, sanguinarine. Similarly, the MdtM and Cmr efﬂux pumps
improved growth in the presence ofﬁve and three toxins, respectively
(Table S1).The selectionof thesemembraneproteins conﬁrmed that
we had minimized any bias associated with IPTG-induced over-
expression.
We also discovered regulators, stress-response proteins, and
proteins from capsule biosynthesis that each improved ﬁtness
in the presence of multiple toxins (Table S1). The only readily
predictable example was the transcriptional activator MarA,
which we isolated from environments containing two quinolones
(ciproﬂoxacin and oﬂoxacin), a tetracycline (penimepicycline), a
macrolide (tylosin), and a mutagen (proﬂavine). MarA is known
to mediate multidrug resistance by up-regulating the efﬂux system
and down-regulating membrane permeability (32, 33). In other
cases, we found genes that had not previously been associated
with resistance, including the bioﬁlm modulation protein, Bdm,
the small stress response protein, YcgZ, and the global regulator
of transcription, CpdA (cAMP phosphodiesterase). The likely
pleiotropic effects of these in altering the expression of down-
stream resistance determinants can be rationalized. Another pro-
minent hit was the UDP-glucose 4-epimerase (GalE) ASKA
strain, which was isolated from seven PM wells. GalE is involved
in a variety of galactose metabolic processes, including glycolysis
and the biosynthesis of lipopolysaccharide and capsule compo-
nents. The host strain, E. coliDH5α-E, is gal−, although the exact
mutations responsible for this phenotype are not known. It is
possible that the ﬁtness effects seen whenGalEwas overexpressed
were simply a result of complementation of the gal− mutation.
However, if this was the case, we would have expected the GalE-
expressing ASKA strain to out-grow the negative control in many
more than seven of the 237 environments that we tested. Instead,
GalE expression appears to mediate a suite of pleiotropic effects
that are relevant for the evolution of resistance. Finally, other
multiple-occurring ORFs hint at the functions of previously
uncharacterized proteins (Table S1). For example, the YejG-
expressing clone was isolated from PM wells containing apramy-
cin, sisomicin, and tobramycin, suggesting that it may possess
broad enzymatic activity toward these aminoglycoside antibiotics.
In 43 cases, an ASKA-encoded gene improved growth in the
presence of a single toxin (Dataset S2). These compound-speciﬁc
responses included 12 cases in whichmetabolic enzymes appeared
to display catalytic promiscuity or substrate ambiguity. Examples
included the carbonic anhydrase, CynT, evincing growth in the
presence of enoxacin [reminiscent of the human enzyme’s pro-
miscuous esterase activity (34)] and the purine nucleotidase,
YrfG, increasing ﬁtness in the presence of a toxic analog (6-
mercaptopurine). Finally, 13 of the 17 instances in which we were
unable to assign a mechanism of action (Table 2) involved un-
characterized ASKA ORFs that were isolated from a single
environment (Dataset S2).
Interplay of Fitness and Resistance. Mutations that confer antibi-
otic resistance can have a variety of effects on the ﬁtness of the
cell in the absence of drug (35). Resistance mutations often bear
ﬁtness costs, although examples of cost-free resistance (36) and
mutual compensation (i.e., simultaneous increases in resistance
and ﬁtness) have also been described (37). Our library-on-library
screen revealed cases where ASKA clones were responsible for
enhancing ﬁtness in the presence of a toxin. It was unclear from
our screen whether the plasmid-encoded ORFs were improving
the general vigor of the host or increasing resistance. To in-
vestigate this further, we measured the ﬁtness value (W) for each
of 25 strains relative to the negative-control strain (i.e., E. coli
DH5α-E with pCA24N-NoIns). Fitness tests were conducted in
the absence of toxin, but the presence of 50 μM IPTG. Using the
same set of 25 strains, we also determined the minimum in-
hibitory concentrations (MICs) for 29 toxin/strain combinations.
We chose to focus on anti-bacterial compounds and to test
examples of each mechanistic class (as deﬁned in Table 2).
In the absence of toxin, only two of the 25 ASKA strains
showed signiﬁcantly reduced ﬁtness (i.e., W < 1; P < 0.01) com-
pared with the negative control (Table 3). Nine ASKA strains
were not signiﬁcantly different from the control (P > 0.01), and 14
of the strains out-competed it (W > 1; P < 0.01). In contrast, al-
most all of MICs determined for ASKA strains were increased
compared with those that were measured for the negative-control
strain (Table 3).
Table 2. Proposed modes of action for 115 cases of resistance
imparted by ASKA ORFs
Mechanism of resistance Frequency
Efﬂux pump/transporter 22
Regulatory effect 19
Catalytic promiscuity and/or substrate ambiguity 15
Prophage gene 14
Stress response 13
Envelope/capsule synthesis 8
Bioﬁlm formation and regulation 5
Overexpression of the drug’s target 1
Maintenance of metabolic ﬂux 1
Unknown 17
Total 115
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By far the largest increase in MIC was for trimethoprim, where
overexpression of its intracellular target, dihydrofolate reductase
(folA), effected very high levels of resistance (at least 500-fold
greater than the negative control strain). The FolA-expressing
strain was also one of the least ﬁt in the absence of antibiotic
(W = 0.84). Expression of the multidrug transporters MdtM and
Cmr led to 16-fold and 8-fold increases in the MICs for puro-
mycin and lincomycin, respectively, without imparting ﬁtness
costs in a toxin-free environment. The remainder of the selected
ASKA strains exhibited modest increases (<8-fold) in MICs
compared with the negative control (Table 3).
In general, there was a poor correlation between resistance
and ﬁtness in the absence of toxin. In some cases, ﬁtter clones
were also more resistant. For example, the YcgZ-expressing
clone had the highest relative ﬁtness of the 25 that we measured
(W = 1.72), and it also showed a greater increase in aztreonam
resistance (5.9-fold) than the other two clones that were isolated
from the aztreonam-containing PM well (Table 3). However,
there were also cases where the opposite was true. For example,
overexpression of YdaC imparted a fourfold increase in eryth-
romycin resistance and a small increase in ﬁtness (W = 1.33);
YdfW overexpression gave a smaller increase in resistance (three-
fold) but a larger increase in ﬁtness (W = 1.51). Similarly, over-
expressing NudB gave a higher MIC for sulfadiazine than LuxS
overexpression (32 vs. 24 μg·mL−1), yet the NudB-expressing
strain was considerably less ﬁt (W = 0.68 vs. W = 1.11).
In a single case, expression of an ASKA ORF (an uncharac-
terized prophage gene, tfaX) decreased theMIC for the antibiotic
(nitrofurantoin) in which it was selected. The TfaX-expressing
strain showed a small but statistically signiﬁcant ﬁtness im-
provement in the absence of nitrofurantoin (W = 1.18). This
suggests that increased ﬁtness in the absence of an antibiotic can
translate into a selective advantage when the drug is introduced;
however, this appears to be uncommon. It is noteworthy that no
single ASKA gene was isolated from more than seven PM wells
(vide supra) (Table S1). It might be expected that one (or a
handful) of general, growth-enhancing genes would have been
isolated from a majority of the 237 toxin-containing environ-
Table 3. Relative ﬁtness and drug resistance data for E. coli cells overexpressing ORFs from the ASKA library
ASKA ORF W ± SE* Compound
MIC (μg/mL) with
ASKA ORF
MIC (μg/mL) with
pCA24N-NoIns
Fold-increase
in MIC
β-Lactams
bdm 1.47 ± 0.04† Cephalothin 16 8 2.0
bfd 1.16 ± 0.03† Penicillin G 48 32 1.5
rbsR 1.40 ± 0.04† Aztreonam 0.19 0.064 3.0
yeaD 1.20 ± 0.03† Aztreonam 0.094 0.064 1.5
ycgZ 1.72 ± 0.05† Aztreonam 0.38 0.064 5.9
ycgZ See above Cefuroxime 16 6 2.7
Aminoglycosides
yejG 0.94 ± 0.04 Sisomicin 0.19 0.125 1.5
yejG See above Tobramycin 1.5 0.5 3.0
Anti-folates
folA 0.84 ± 0.03† Trimethoprim >32 0.064 >500
luxS 1.11 ± 0.02† Sulfadiazine 24 16 1.5
nudB 0.68 ± 0.04† Sulfadiazine 32 16 2.0
Quinolones
cynT 1.17 ± 0.04† Enoxacin 0.25 0.19 1.3
marA 1.08 ± 0.02 Ciproﬂoxacin 0.125 0.032 3.9
galE 1.16 ± 0.01† Nalidixic acid 96 32 3.0
yfdO 1.03 ± 0.02 Nalidixic acid 48 32 1.5
Tetracyclines
bcr 1.03 ± 0.04 Oxytetracycline 6 2 3.0
Macrolide-Lincosamide-Streptogramin
cmr 1.45 ± 0.02† Lincomycin 1,536 192 8.0
rbsR See above Lincomycin 384 192 2.0
ydfW 1.51 ± 0.12† Spiramycin 36 24 1.5
ydfW See above Erythromycin 96 32 3.0
ydaC 1.33 ± 0.03† Erythromycin 128 32 4.0
Glycopeptides
mzrA 1.23 ± 0.07 Vancomycin 256 128 2.0
Nitrofurans
tfaX 1.18 ± 0.02† Nitrofurantoin 0.094 0.19 0.5
Rifamycins
feoC 0.78 ± 0.07 Rifampicin 6 4 1.5
tusE 0.87 ± 0.04 Rifampicin 6 4 1.5
Other toxins
mdtM 1.07 ± 0.03 Puromycin 128 8 16.0
puuD 1.12 ± 0.03† Benzethonium chloride 6 6 1.0
ybcD 1.02 ± 0.02 Benzethonium chloride 8 6 1.3
yhiK 1.19 ± 0.01† Benzethonium chloride 12 6 2.0
*Fitness (W) of the ASKA strain, in the absence of toxin, relative to a neutrally-marked negative control that harbors pCA24N-NoIns. Values are expressed as
mean ± SE (n = 8).
†Signiﬁcance level of P < 0.01 for a two-tailed test with the null hypothesis that W = 1, calculated using the t distribution and 7 df.
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ments, were such a gene present in the ASKA pool. Instead, our
approach has revealed many latent resistance determinants in the
E. coli genome.
Discussion
The aim of this study was to gauge the extent to which a simple
adaptive response—overexpression of a preexisting protein—
could impart new phenotypes on E. coli. A handful of analogous
examples have been discovered adventitiously (2), but at the
outset of this study the likelihood (and therefore relevance) of
this route to evolutionary innovation was unclear. We used re-
sistance to antibiotics and toxins as a readily selectable trait. Our
survey was the most comprehensive to date, because we used the
wells of 10 PM plates as our toxin-containing environments. We
also used the ASKA ORF collection to directly identify proteins
that could impart resistance. This process contrasts with previous
studies where roles in resistance have been inferred indirectly,
based on the increased sensitivity of mutants produced by
transposon inactivation or gene knockouts (28, 30, 31).
In the ﬁrst part of our experiment, we identiﬁed toxin-
containing conditions where the pooled ASKA clones out-grew
the negative control. In those PM wells, at least one member of
the pool had gained an improved ability to survive and re-
produce, through the overexpression of a single, wild-type ORF.
Next, serial transfer was used to identify the ﬁttest strains in the
ASKA pool. Our approach was designed to focus on monogenic
examples, and to exclude multicell phenomena (such as cross-
feeding between members of the pool). Our experimental design
also precluded the identiﬁcation of ASKA clones with increased
susceptibility to toxins, although these are likely to have been
present in many (and perhaps all) of the PM wells. In total, we
identiﬁed 61 ASKA ORFs that improved ﬁtness in 86 of 237
toxin-containing environments. Eighteen of these ORFs were
hits in multiple wells (Table S1); overall, we identiﬁed 115
examples of resistance. Hits were obtained from every class of
toxic compound tested (Table 1). The hit rate (resistance to 36%
of all toxins) was even higher than in our previous study (23),
where only 20% of single-gene knockout strains were rescued by
noncognate ASKA ORFs. As hypothesized previously (38), we
have shown that a bacterium from a nonclinical environment (in
this case, a laboratory strain of E. coli) can nevertheless possess
a signiﬁcant reservoir of latent resistance determinants. More
generally, our study emphasizes just how likely evolutionary in-
novation can be. Our results imply that the overexpression of
a randomly chosen E. coli protein will impart resistance to a novel
toxin with a probability of (61/5,272) × (86/237) ≈ 0.4%.
The PM plates contained four concentrations of each toxin.
Therefore, a hit could have been because of an increase in re-
sistance (i.e., a strain undergoing division at a toxin concentration
that was inhibitory to the other strains, including the negative
control), or because of particularly rapid growth in a subinhibitory
concentration of the toxin (i.e., dividing faster than the other
strains in the pool). In this respect, our experiment mimics the
dynamics of a clinical setting (37, 39). Almost exclusively, the
proteins that we identiﬁed did facilitate increased resistance
(Table 3). The majority of the measured MIC increases were
modest (<8-fold); nevertheless, even small changes such as these
can be responsible for increasing the severity of bacterial infec-
tions (40). In one case—cefuroxime—we showed that expression
of a small stress response protein, YcgZ, increased the MIC from
6 to 16 μg·mL−1. The clinical breakpoint for resistance to this
β-lactam is 8 μg·mL−1 (41); that is, our nonpathogenic host strain
attained clinically relevant levels of resistance, simply through
overexpression of a previously uncharacterized protein. Fur-
thermore, most strains showed no ﬁtness cost associated with
expressing an ASKA ORF in the absence of toxin (and indeed,
many out-competed the negative control) (Table 3). Strong se-
lection pressure for cost-free resistance mutations has been ob-
served in clinical isolates of Mycobacterium tuberculosis (36).
Together, our MIC and ﬁtness data suggest that up-regulating the
expression of preexisting, latent resistance determinants may play
an important role in the emergence of drug-resistant pathogens.
We discovered proteins acting through a variety of mechanisms
to effect resistance (Table 2). Many of these mechanisms—such
as toxin efﬂux/transport, stress responses and bioﬁlm formation—
were unsurprising, even if the identities of the individual re-
sistance genes were less predictable. In 15 of 115 cases, overex-
pressed enzymes appeared to be acting promiscuously to impart
resistance. In addition to these mechanisms, there was a preva-
lence of prophage genes and genes of unknown function in our
list. Prophage genes are usually assumed to be cryptic or defective
remnants of temperate bacteriophage genomes, although a recent
study has shown that genes from the CP4-57 and DLP12 proph-
ages can play roles in bioﬁlm development (42). Here, we have
reported 14 cases in which the overexpression of prophage genes
(including two from DLP12) can improve growth in the presence
of toxins. Twelve of these cases arose from the overexpression of
only three prophage genes: ydaC, ydfW, and yfdO (Table S1). This
result extends the previous ﬁnding (42), demonstrating that pro-
phage genes can modulate broad, compound nonspeciﬁc cellular
responses when they are activated from latency.
In contrast, we identiﬁed 20 uncharacterized, nonprophage
genes that showed speciﬁcity in their actions; that is, they each
imparted a growth advantage in the presence of a single toxin.
These included genes for putative enzymes (wbbL_1, yeaD, ysgA),
predicted transporters (yedA, yjeH), and a predicted transcrip-
tional regulator (yidF), as well as 14 genes for which functional
annotation was impossible due to insufﬁcient homology with any
gene of known function (Dataset S2). These results provide ex-
perimental evidence for the importance of cryptic genes as a res-
ervoir of evolutionarily-accessible functions (43).
Our experiments have demonstrated the biochemical feasi-
bility of the IAD model for the origins of new genes (11). Every
plasmid-carrying ASKA clone approximated a nonplasmid-
containing strain in which a single chromosomal locus had been
ampliﬁed. Growth under selection began when the pooled ASKA
clones were used to inoculate each PMwell. To be scored positive,
a PM well had to contain cells that out-grew the negative control,
in which no ASKAORF was being expressed. Therefore, we were
speciﬁcally looking for cases in which proteins possessed activities
that were valuable in the presence of a toxin and cases in which
increases in their dosage were required to uncover the latent ac-
tivities. We halted our selection experiments at this stage; that is,
we applied selection, but we did not consider mutation beyond
(artiﬁcial) gene ampliﬁcation. The next step will be to determine
feasible mutational routes for the divergence of ampliﬁed copies
from their original function toward their new role in antibiotic
resistance. These studies are on-going in our laboratory, and will
allow related questions, such as the nature of the tradeoff between
new and old enzymatic functions, to be addressed.
Concluding Remarks. We have used two tools from functional
genomics (PM plates and the ASKA collection) to conduct a
comprehensive search for E. coli proteins that can impart im-
proved growth in the presence of toxic compounds. The resulting
catalog provides a unique picture of a bacterium’s latent evolu-
tionary potential and emphasizes the high frequency at which
novel traits can evolve. By cataloguing sources of phenotypic in-
novation, we have revealed the diversity of adaptive mechanisms
that can be underpinned by overexpression mutations such as
gene ampliﬁcation. Our results suggest that the IAD model (11)
is a biochemically and evolutionarily feasible—and perhaps
dominant—mechanism for the birth of new genes under selection.
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Materials and Methods
Experimental methods are summarized below. Detailed protocols are pro-
vided in the SI Materials and Methods.
Library-on-Library Screen. The library-on-library screening protocol is outlined
in Fig. 1. Plates PM11 to PM20 were from Biolog Inc. After inoculation, the
PM plates were incubated at 37 °C for 7 d and the growth in each well was
scored daily. Two independent replicates of the screen were performed.
Serial Enrichment to Identify Resistance Genes. For conditions in which the
ASKA pool reproducibly out-grew the negative control, fresh aliquots of the
pool were now used to inoculate the corresponding wells of new PM plates.
At the ﬁrst sign of growth (i.e., purple color development), the culture in that
well was diluted 50-fold with fresh medium and transferred to the corre-
spondingwell of a newplate. After a second transfer, cells were spread on LB-
chloramphenicol plates. PCR ampliﬁcation and sequencing of the ASKA ORFs
from at least eight of the resulting colonies revealed each ORF that was
responsible for enhanced growth.
Relative Fitness Assays. Twenty-ﬁve ASKA plasmids that conferred increased
growth in the presence of antibiotics were puriﬁed from individual clones
and used to transform fresh aliquots of E. coli DH5α-E. The ﬁtness of each
IPTG-induced strain, in the absence of antibiotics and in competition with
the negative control harboring pCA24N-NoIns, was measured using Lenski’s
protocol (44). E. coli DH5α-E carries the lacZΔM15 mutation. To distinguish
the two strains in each ﬁtness assay, a mini-Tn7 system (45) was used to mark
the negative control with a functional copy of lacZ. Control experiments
showed that marking the strain had no effect on its ﬁtness in the con-
ditions used. The initial (t = 0 h) and ﬁnal (t = 24 h) densities of each com-
petitor could then be measured by spreading them on LB agar plates
supplemented with X-gal. Each relative ﬁtness value (W) in Table 3 is the
mean of eight replicates.
Antibiotic Susceptibility Testing. MICs were determined using either E-test
strips (AB bioMérieux) or a broth microdilution method (46). Reported values
are the mean of at least two independent experiments.
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